CA3214904A1 - Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses - Google Patents
Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses Download PDFInfo
- Publication number
- CA3214904A1 CA3214904A1 CA3214904A CA3214904A CA3214904A1 CA 3214904 A1 CA3214904 A1 CA 3214904A1 CA 3214904 A CA3214904 A CA 3214904A CA 3214904 A CA3214904 A CA 3214904A CA 3214904 A1 CA3214904 A1 CA 3214904A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- unsubstituted
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims description 74
- 125000003835 nucleoside group Chemical group 0.000 title claims description 26
- 125000003729 nucleotide group Chemical group 0.000 title description 10
- 239000003443 antiviral agent Substances 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 363
- 238000000034 method Methods 0.000 claims abstract description 197
- 239000000203 mixture Substances 0.000 claims abstract description 116
- 208000015181 infectious disease Diseases 0.000 claims abstract description 59
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 23
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 21
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 11
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims abstract description 9
- -1 R5 is 0 Chemical group 0.000 claims description 124
- 125000000217 alkyl group Chemical group 0.000 claims description 88
- 239000003112 inhibitor Substances 0.000 claims description 81
- 239000003814 drug Substances 0.000 claims description 79
- 239000002777 nucleoside Substances 0.000 claims description 70
- 229940002612 prodrug Drugs 0.000 claims description 65
- 239000000651 prodrug Substances 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 58
- 241000711573 Coronaviridae Species 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000000304 alkynyl group Chemical group 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 241000150350 Peribunyaviridae Species 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 230000000840 anti-viral effect Effects 0.000 claims description 30
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000001153 fluoro group Chemical group F* 0.000 claims description 26
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 22
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 241000709664 Picornaviridae Species 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- 241000710781 Flaviviridae Species 0.000 claims description 17
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- 150000002191 fatty alcohols Chemical class 0.000 claims description 13
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 12
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 12
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 150000001336 alkenes Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 150000001345 alkine derivatives Chemical class 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 10
- 125000001769 aryl amino group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 9
- 125000001475 halogen functional group Chemical group 0.000 claims description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 9
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 9
- 235000011178 triphosphate Nutrition 0.000 claims description 9
- 239000001226 triphosphate Substances 0.000 claims description 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 229940127218 antiplatelet drug Drugs 0.000 claims description 7
- 125000005335 azido alkyl group Chemical group 0.000 claims description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 7
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 150000008575 L-amino acids Chemical class 0.000 claims description 6
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims description 6
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 6
- 229940118555 Viral entry inhibitor Drugs 0.000 claims description 6
- 229950000971 baricitinib Drugs 0.000 claims description 6
- 125000002346 iodo group Chemical group I* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000029302 virus maturation Effects 0.000 claims description 6
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 5
- 239000004012 Tofacitinib Substances 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 229940045773 jakafi Drugs 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical group OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 5
- 229960001350 tofacitinib Drugs 0.000 claims description 5
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 3
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 208000008371 Bunyaviridae Infections Diseases 0.000 claims 17
- 208000000255 Togaviridae Infections Diseases 0.000 claims 17
- 208000004576 Flaviviridae Infections Diseases 0.000 claims 16
- 208000005155 Picornaviridae Infections Diseases 0.000 claims 16
- 208000025935 Picornaviridae infectious disease Diseases 0.000 claims 16
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 4
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 4
- 241000027294 Fusi Species 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241001678559 COVID-19 virus Species 0.000 abstract description 7
- 241000710831 Flavivirus Species 0.000 abstract description 5
- 241000713112 Orthobunyavirus Species 0.000 abstract description 5
- 241000711467 Human coronavirus 229E Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 133
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- 238000003556 assay Methods 0.000 description 52
- 229940079593 drug Drugs 0.000 description 45
- 238000003786 synthesis reaction Methods 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- 239000002105 nanoparticle Substances 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- 239000002585 base Substances 0.000 description 32
- 238000009472 formulation Methods 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000002245 particle Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 150000003833 nucleoside derivatives Chemical class 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- ZASCXWTVGGZQIZ-UHFFFAOYSA-N thieno[3,2-d]pyrimidin-2-amine Chemical compound NC1=NC=C2SC=CC2=N1 ZASCXWTVGGZQIZ-UHFFFAOYSA-N 0.000 description 22
- 238000006722 reduction reaction Methods 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 19
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- 238000010348 incorporation Methods 0.000 description 18
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 241000725619 Dengue virus Species 0.000 description 16
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- ICZVBOAABXHPSZ-UHFFFAOYSA-N piperidine-2,5-dione Chemical compound O=C1CCC(=O)NC1 ICZVBOAABXHPSZ-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 235000000346 sugar Nutrition 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 241000907316 Zika virus Species 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 239000003381 stabilizer Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 229910052805 deuterium Inorganic materials 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 239000003039 volatile agent Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 241000608292 Mayaro virus Species 0.000 description 12
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 11
- 108060004795 Methyltransferase Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 239000002872 contrast media Substances 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 10
- 241000710772 Yellow fever virus Species 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 10
- 235000011089 carbon dioxide Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 229940051021 yellow-fever virus Drugs 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010019233 Headaches Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 208000025721 COVID-19 Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102000016903 DNA Polymerase gamma Human genes 0.000 description 8
- 108010014080 DNA Polymerase gamma Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 241000710960 Sindbis virus Species 0.000 description 8
- 241000710924 Togaviridae Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000007758 minimum essential medium Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 241000710929 Alphavirus Species 0.000 description 7
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 7
- 206010050685 Cytokine storm Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000000112 Myalgia Diseases 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 206010052015 cytokine release syndrome Diseases 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- HMXQIFUGFZEJEO-UHFFFAOYSA-N 1,2-dihydropyrrol-3-one Chemical compound O=C1CNC=C1 HMXQIFUGFZEJEO-UHFFFAOYSA-N 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 241000713124 Rift Valley fever virus Species 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000004679 31P NMR spectroscopy Methods 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 102000016397 Methyltransferase Human genes 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 206010014599 encephalitis Diseases 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000004324 lymphatic system Anatomy 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002047 solid lipid nanoparticle Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- 229940125673 3C-like protease inhibitor Drugs 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 208000006339 Caliciviridae Infections Diseases 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 4
- 206010012310 Dengue fever Diseases 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- IJMWOMHMDSDKGK-UHFFFAOYSA-N Isopropyl propionate Chemical compound CCC(=O)OC(C)C IJMWOMHMDSDKGK-UHFFFAOYSA-N 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 4
- 108020005196 Mitochondrial DNA Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 208000000705 Rift Valley Fever Diseases 0.000 description 4
- 241000710801 Rubivirus Species 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 4
- 201000005806 Western equine encephalitis Diseases 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000025729 dengue disease Diseases 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BHIWKHZACMWKOJ-UHFFFAOYSA-N methyl isobutyrate Chemical compound COC(=O)C(C)C BHIWKHZACMWKOJ-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012354 sodium borodeuteride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 4
- 229960004626 umifenovir Drugs 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000009182 Chikungunya Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 102000003849 Cytochrome P450 Human genes 0.000 description 3
- 108020001019 DNA Primers Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 231100000491 EC50 Toxicity 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010022004 Influenza like illness Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000713137 Phlebovirus Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 208000011361 Severe Fever with Thrombocytopenia Syndrome Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940048053 acrylate Drugs 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229950008454 favipiravir Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000021760 high fever Diseases 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 3
- 230000004682 mucosal barrier function Effects 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- GQIXFHWAAHPMSO-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=C=C[N]1 GQIXFHWAAHPMSO-UHFFFAOYSA-N 0.000 description 3
- 108700022487 rRNA Genes Proteins 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229960004274 stearic acid Drugs 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000002723 toxicity assay Methods 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- DLPIYBKBHMZCJI-WBVHZDCISA-N (2r,3s)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)[C@@H](C)O)=NC=1NCC1=CN=C(C)C=C1C DLPIYBKBHMZCJI-WBVHZDCISA-N 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- HETYCUMIILTHSZ-UHFFFAOYSA-N 1,2-selenazol-3-one Chemical compound O=C1C=C[se]N1 HETYCUMIILTHSZ-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DUFFEAYSMVMWOC-UHFFFAOYSA-N 2-acetyloxybenzoic acid;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.N1C2=CC(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C DUFFEAYSMVMWOC-UHFFFAOYSA-N 0.000 description 2
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 description 2
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical class C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 description 2
- MQUYTXDAVCOCMX-UHFFFAOYSA-N 6-phenyl-2-imidazo[2,1-b][1,3,4]thiadiazolesulfonamide Chemical compound N1=C2SC(S(=O)(=O)N)=NN2C=C1C1=CC=CC=C1 MQUYTXDAVCOCMX-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000710946 Barmah Forest virus Species 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000150523 Black Creek Canal orthohantavirus Species 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000008889 California Encephalitis Diseases 0.000 description 2
- 241001493160 California encephalitis virus Species 0.000 description 2
- 241000711506 Canine coronavirus Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 241001502567 Chikungunya virus Species 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102100024745 DNA-directed RNA polymerase, mitochondrial Human genes 0.000 description 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 2
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000725579 Feline coronavirus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108700010013 HMGB1 Proteins 0.000 description 2
- 101150021904 HMGB1 gene Proteins 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 101000902539 Homo sapiens DNA polymerase beta Proteins 0.000 description 2
- 101000686765 Homo sapiens DNA-directed RNA polymerase, mitochondrial Proteins 0.000 description 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000168432 New York hantavirus Species 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 241000150218 Orthonairovirus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 241000150288 Sin Nombre orthohantavirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000608278 Una virus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- HVQDOKDLGGYIOY-RITPCOANSA-N [(1r,3s)-3-aminocyclopentyl]methanol Chemical compound N[C@H]1CC[C@@H](CO)C1 HVQDOKDLGGYIOY-RITPCOANSA-N 0.000 description 2
- MNLVCBKWEVXHGE-UHFFFAOYSA-N [CH]1[CH]CC[CH]1 Chemical group [CH]1[CH]CC[CH]1 MNLVCBKWEVXHGE-UHFFFAOYSA-N 0.000 description 2
- WIEOLFZNMKSGEX-RITPCOANSA-N [[(2s,5r)-5-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical class C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC1 WIEOLFZNMKSGEX-RITPCOANSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229940119059 actemra Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960003116 amyl nitrite Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 2
- 229960000772 camostat Drugs 0.000 description 2
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 2
- 229960005025 cilazapril Drugs 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000002247 constant time method Methods 0.000 description 2
- 238000011437 continuous method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- ZVTDLPBHTSMEJZ-JSZLBQEHSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-JSZLBQEHSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229950008639 dociparstat sodium Drugs 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 208000005098 feline infectious peritonitis Diseases 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920005669 high impact polystyrene Polymers 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 239000004797 high-impact polystyrene Substances 0.000 description 2
- 102000047799 human POLB Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 229960001195 imidapril Drugs 0.000 description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940047889 isobutyramide Drugs 0.000 description 2
- WDAXFOBOLVPGLV-UHFFFAOYSA-N isobutyric acid ethyl ester Natural products CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 229940121292 leronlimab Drugs 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 229960004644 moclobemide Drugs 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 2
- 229950008814 momelotinib Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- XYWHZUCZNRMJGO-UHFFFAOYSA-N n-(2-amino-4,6-dichloropyrimidin-5-yl)formamide Chemical compound NC1=NC(Cl)=C(NC=O)C(Cl)=N1 XYWHZUCZNRMJGO-UHFFFAOYSA-N 0.000 description 2
- IGLNXKVGKIFNBQ-UHFFFAOYSA-N n-[5-[[5-fluoro-4-(4-prop-2-ynoxyanilino)pyrimidin-2-yl]amino]-2-methylphenyl]sulfonylpropanamide Chemical compound C1=C(C)C(S(=O)(=O)NC(=O)CC)=CC(NC=2N=C(NC=3C=CC(OCC#C)=CC=3)C(F)=CN=2)=C1 IGLNXKVGKIFNBQ-UHFFFAOYSA-N 0.000 description 2
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
- 229960001920 niclosamide Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229950011410 pacritinib Drugs 0.000 description 2
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 2
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical group CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229940020573 plavix Drugs 0.000 description 2
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 description 2
- 229920001987 poloxamine Polymers 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- LMXOHSDXUQEUSF-YECHIGJVSA-N sinefungin Chemical compound O[C@@H]1[C@H](O)[C@@H](C[C@H](CC[C@H](N)C(O)=O)N)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LMXOHSDXUQEUSF-YECHIGJVSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 2
- 229960002063 sofosbuvir Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
- 229960000488 tizanidine Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- DBGVGMSCBYYSLD-RCUQKECRSA-N tributyl(deuterio)stannane Chemical compound CCCC[Sn]([2H])(CCCC)CCCC DBGVGMSCBYYSLD-RCUQKECRSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- KHPCBZYTDJCPHW-GITKWUPZSA-N (2r,3r,4r,5r)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(N)=C2N=C1 KHPCBZYTDJCPHW-GITKWUPZSA-N 0.000 description 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OIRDTQYFTABQOQ-XQLZWXLASA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[deuterio(hydroxy)methyl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)[2H])O[C@H]1N1C2=NC=NC(N)=C2N=C1 OIRDTQYFTABQOQ-XQLZWXLASA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- JVAZJLFFSJARQM-RMPHRYRLSA-N (2r,3r,4s,5s,6r)-2-hexoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-RMPHRYRLSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-ARQDHWQXSA-N (2r,3s,4r,5r)-2-methoxyoxane-3,4,5-triol Chemical group CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1O ZBDGHWFPLXXWRD-ARQDHWQXSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- MUQWDYYIYNYBQD-OFHININYSA-N (2s,3s,4s,5r,6r)-3-[(2r,3r,4r,5s,6r)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]-4,5-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxy-4,5-dimethoxy- Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS(O)(=O)=O)O4)NC(=O)CCCCCNC(=O)CCCC[C@H]4[C@H]5NC(=O)N[C@H]5CS4)[C@H](O3)C(O)=O)OC)[C@@H](COS(O)(=O)=O)O2)OS(O)(=O)=O)[C@H](C(O)=O)O1 MUQWDYYIYNYBQD-OFHININYSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- LKVFMOMQYXIFRK-KSVAIKAXSA-N (3S,6S,9S,12S,18S,21S,27S,30S,33S,36S,42R,47R,50S,53S,56S)-42-amino-3-(4-aminobutyl)-36-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-9,18,30-tris(2-carboxyethyl)-27-[(1R)-1-hydroxyethyl]-50-[(4-hydroxyphenyl)methyl]-53-(1H-indol-3-ylmethyl)-6,12-dimethyl-2,5,8,11,14,17,20,26,29,32,35,38,41,49,52,55-hexadecaoxo-44,45-dithia-1,4,7,10,13,16,19,25,28,31,34,37,40,48,51,54-hexadecazatricyclo[54.3.0.021,25]nonapentacontane-47-carboxylic acid Chemical compound C[C@@H](O)[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]2CCCN2C1=O)C(O)=O LKVFMOMQYXIFRK-KSVAIKAXSA-N 0.000 description 1
- JDRSMPFHFNXQRB-IWQYDBTJSA-N (3r,4s,5s,6r)-2-decoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IWQYDBTJSA-N 0.000 description 1
- CCEFMUBVSUDRLG-KXUCPTDWSA-N (4R)-limonene 1,2-epoxide Natural products C1[C@H](C(=C)C)CC[C@@]2(C)O[C@H]21 CCEFMUBVSUDRLG-KXUCPTDWSA-N 0.000 description 1
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 1
- JHLIGYPHPBLDDL-UHFFFAOYSA-N (5-pyridin-3-ylthiophen-2-yl)methanamine Chemical compound S1C(CN)=CC=C1C1=CC=CN=C1 JHLIGYPHPBLDDL-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- RYSXWUYLAWPLES-MTOQALJVSA-N (Z)-4-hydroxypent-3-en-2-one titanium Chemical compound [Ti].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O RYSXWUYLAWPLES-MTOQALJVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- JWGBOHJGWOPYCL-UHFFFAOYSA-N 1-(10H-phenothiazin-2-yl)ethanone Chemical compound C1=CC=C2NC3=CC(C(=O)C)=CC=C3SC2=C1 JWGBOHJGWOPYCL-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- JILKVTMRFKOGDW-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-methoxypyrimidin-2-one Chemical compound O=C1N=C(OC)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JILKVTMRFKOGDW-ZOQUXTDFSA-N 0.000 description 1
- MXHRCPNRJAMMIM-GBCLWAKPSA-N 1-[(2r,3s,4s,5r)-3-deuterio-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound [2H][C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-GBCLWAKPSA-N 0.000 description 1
- HLNDPICGHQGWSU-UHFFFAOYSA-N 1-[3-(5-acetyl-2-hydroxy-3-methoxyphenyl)-4-hydroxy-5-methoxyphenyl]ethanone Chemical compound COC1=CC(C(C)=O)=CC(C=2C(=C(OC)C=C(C=2)C(C)=O)O)=C1O HLNDPICGHQGWSU-UHFFFAOYSA-N 0.000 description 1
- YGEIMSMISRCBFF-UHFFFAOYSA-M 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium;chloride Chemical compound [Cl-].C1=CC(Cl)=CC=C1C([N+]1=CN(CC(OCC=2C(=CC(Cl)=CC=2)Cl)C=2C(=CC(Cl)=CC=2)Cl)C=C1)C1=CC=C(Cl)C=C1 YGEIMSMISRCBFF-UHFFFAOYSA-M 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- KTQUQXNSBOKXEV-UHFFFAOYSA-N 1-methyl-2-phenylindazol-3-one Chemical compound O=C1C2=CC=CC=C2N(C)N1C1=CC=CC=C1 KTQUQXNSBOKXEV-UHFFFAOYSA-N 0.000 description 1
- YGGSSUISOYLCBF-UHFFFAOYSA-N 1-nitroso-1-propylurea Chemical compound CCCN(N=O)C(N)=O YGGSSUISOYLCBF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical class C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- NQFUSWIGRKFAHK-UHFFFAOYSA-N 2,3-epoxypinane Chemical compound CC12OC1CC1C(C)(C)C2C1 NQFUSWIGRKFAHK-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- XDLJIIILKATPAQ-UHFFFAOYSA-N 2,8-dichloro-7h-purine Chemical compound ClC1=NC=C2NC(Cl)=NC2=N1 XDLJIIILKATPAQ-UHFFFAOYSA-N 0.000 description 1
- LEELWLKZRKDMAS-UHFFFAOYSA-N 2-(2,4-dimethoxy-3-methylsulfanylphenyl)ethanamine Chemical compound COC1=CC=C(CCN)C(OC)=C1SC LEELWLKZRKDMAS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HZSOKHVVANONPV-UHFFFAOYSA-N 2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole Chemical compound N1=NC2=C(SC=3OC4=CC=CC=C4N=3)N=CN=C2N1CC1=CC=CC=C1 HZSOKHVVANONPV-UHFFFAOYSA-N 0.000 description 1
- JVZDLDFNSCFLPM-UHFFFAOYSA-N 2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-oxazole Chemical compound N1=NC2=C(SC=3OC=CN=3)N=CN=C2N1CC1=CC=CC=C1 JVZDLDFNSCFLPM-UHFFFAOYSA-N 0.000 description 1
- SLUOSAOMRMURFW-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-1,2-benzothiazol-3-one Chemical compound C1=CC(O)=CC=C1N1C(=O)C2=CC=CC=C2S1 SLUOSAOMRMURFW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- WFZFMHDDZRBTFH-CZEFNJPISA-N 2-[(e)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-1-benzofuran-5-carboximidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)C1=CC=C2OC(/C=C/C=3OC4=CC=C(C=C4C=3)C(=N)N)=CC2=C1 WFZFMHDDZRBTFH-CZEFNJPISA-N 0.000 description 1
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-HZROVQDNSA-N 2-amino-9-[(2R,4S,5R)-3,3-dideuterio-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one Chemical compound [2H]C1([C@@H](O[C@@H]([C@H]1O)CO)N1C=NC=2C(=O)NC(N)=NC1=2)[2H] YKBGVTZYEHREMT-HZROVQDNSA-N 0.000 description 1
- YKBGVTZYEHREMT-KYJCUMGHSA-N 2-amino-9-[(2r,4s,5r)-5-deuterio-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1[C@H](O)[C@@]([2H])(CO)O[C@H]1N1C(NC(N)=NC2=O)=C2N=C1 YKBGVTZYEHREMT-KYJCUMGHSA-N 0.000 description 1
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- IFAQTUPIBHAALX-UHFFFAOYSA-N 2-cyano-n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound N#CCC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 IFAQTUPIBHAALX-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- KIHAGWUUUHJRMS-JOCHJYFZSA-N 2-octadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CO)COP(O)(=O)OCCN KIHAGWUUUHJRMS-JOCHJYFZSA-N 0.000 description 1
- KDMQSUUXKLZVNU-UHFFFAOYSA-N 2-phenyl-1,2-benzothiazol-3-one Chemical compound S1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 KDMQSUUXKLZVNU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- XBIUWALDKXACEA-UHFFFAOYSA-N 3-[bis(2,4-dioxopentan-3-yl)alumanyl]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)[Al](C(C(C)=O)C(C)=O)C(C(C)=O)C(C)=O XBIUWALDKXACEA-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- RTTBBADOMOOPTQ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-b]pyridine Chemical class C1CCNC2=C1NN=C2 RTTBBADOMOOPTQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- NCZFXISZNVYLCF-UHFFFAOYSA-N 4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 NCZFXISZNVYLCF-UHFFFAOYSA-N 0.000 description 1
- JWEQLWMZHJSMEC-AFJTUFCWSA-N 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12 JWEQLWMZHJSMEC-AFJTUFCWSA-N 0.000 description 1
- PPUDLEUZKVJXSZ-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical class C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 PPUDLEUZKVJXSZ-VPCXQMTMSA-N 0.000 description 1
- KTOLOIKYVCHRJW-XZMZPDFPSA-N 4-amino-1-[(2r,3s,4r,5r)-5-azido-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](F)[C@H](O)[C@](CO)(N=[N+]=[N-])O1 KTOLOIKYVCHRJW-XZMZPDFPSA-N 0.000 description 1
- OOBICGOWICFMIX-POYBYMJQSA-N 4-amino-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical class O=C1N=C(N)C=CN1[C@H]1C=C[C@@H](CO)O1 OOBICGOWICFMIX-POYBYMJQSA-N 0.000 description 1
- JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 1
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- FJPUXMVNLPHRCZ-UHFFFAOYSA-N 4-methyl-2-(2-methylphenyl)-5-(pyridin-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)N(CC=3N=CC=CC=3)C(=O)C=C2N1 FJPUXMVNLPHRCZ-UHFFFAOYSA-N 0.000 description 1
- YNWUIBSEOAWSHW-HIQWKFPQSA-N 5-[(e)-2-bromoethenyl]-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidine-2,4-dione Chemical compound O1[C@@H](CO)OC[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 YNWUIBSEOAWSHW-HIQWKFPQSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- LLPOBYGXVLYIJR-UHFFFAOYSA-N 5-methylidene-1,4,2,3-dioxadithiolane Chemical class C=C1OSSO1 LLPOBYGXVLYIJR-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- UAXLIAFJSCHPKS-UHFFFAOYSA-N 7-bromo-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2Br)C2=N1 UAXLIAFJSCHPKS-UHFFFAOYSA-N 0.000 description 1
- KTXBGBIBFVAPBD-UHFFFAOYSA-N 7-bromo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(Br)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 KTXBGBIBFVAPBD-UHFFFAOYSA-N 0.000 description 1
- FZLPMBULBHSJGD-UHFFFAOYSA-N 7-bromo-n-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1=NC=C(SC=C2Br)C2=N1 FZLPMBULBHSJGD-UHFFFAOYSA-N 0.000 description 1
- CRVCMLQVHOKQBS-UHFFFAOYSA-N 7-iodo-n-(3-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=1)=CC=CC=1N1CCOCC1 CRVCMLQVHOKQBS-UHFFFAOYSA-N 0.000 description 1
- MOAKLJKOGYJRNX-UHFFFAOYSA-N 7-iodo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 MOAKLJKOGYJRNX-UHFFFAOYSA-N 0.000 description 1
- BIUXMWARCYGKBI-UHFFFAOYSA-N 7-iodo-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 BIUXMWARCYGKBI-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150046889 ADORA3 gene Proteins 0.000 description 1
- 108010049501 AP301 peptide Proteins 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 108010049298 Antithrombin Proteins Proteins 0.000 description 1
- 102000009064 Antithrombin Proteins Human genes 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 240000006063 Averrhoa carambola Species 0.000 description 1
- 235000010082 Averrhoa carambola Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 241000150347 Bunyavirales Species 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 101150086475 COXII gene Proteins 0.000 description 1
- DNJVYWXIDISQRD-UHFFFAOYSA-N Cafestol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-UHFFFAOYSA-N 0.000 description 1
- 102000020167 Calcium release-activated calcium channel Human genes 0.000 description 1
- 108091022898 Calcium release-activated calcium channel Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 229940094918 Cathepsin L inhibitor Drugs 0.000 description 1
- 241001428800 Cell fusing agent virus Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RSENJWVCZBIONW-UHFFFAOYSA-N Cl.NP(N)(N)=O Chemical compound Cl.NP(N)(N)=O RSENJWVCZBIONW-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000004175 Coronavirinae Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241001464430 Cyanobacterium Species 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000150528 Dobrava-Belgrade orthohantavirus Species 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical group [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101800001768 Exoribonuclease Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 208000021727 Hantavirus hemorrhagic fever with renal syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000932213 Homo sapiens Dipeptidase 1 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000009617 Inorganic Pyrophosphatase Human genes 0.000 description 1
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 description 1
- JDNLPKCAXICMBW-UHFFFAOYSA-N JWH 018 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=CC=C12 JDNLPKCAXICMBW-UHFFFAOYSA-N 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CCEFMUBVSUDRLG-XNWIYYODSA-N Limonene-1,2-epoxide Chemical compound C1[C@H](C(=C)C)CCC2(C)OC21 CCEFMUBVSUDRLG-XNWIYYODSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010072930 Mucolipidosis type IV Diseases 0.000 description 1
- 102100026502 Mucolipin-1 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- XYQHCMDVGIJOTA-UHFFFAOYSA-N N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyl-1,3-oxazole-5-carboxamide Chemical compound NC(C(C(CC1=CC=CC=C1)NC(=O)C1=C(N=C(O1)C)C1=C(C=CC=C1)F)=O)=O XYQHCMDVGIJOTA-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000532183 Norovirus GI Species 0.000 description 1
- 241000532184 Norovirus GII Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000712894 Orthotospovirus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108700028865 Pam2CSK4 acetate and ODN M362 combination Proteins 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 108091000106 RNA cap binding Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 101800004575 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical class [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 108700038445 SARS coronavirus papain-like protease Proteins 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 241000057035 Saaremaa hantavirus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 229940078053 Sphingosine kinase 2 inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 241000192117 Trichodesmium erythraeum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010071362 Viral sepsis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-DRLMQTGJSA-N [2H]C(=O)[C@H]([C@H](O)[C@H](O)CO)[2H] Chemical compound [2H]C(=O)[C@H]([C@H](O)[C@H](O)CO)[2H] ASJSAQIRZKANQN-DRLMQTGJSA-N 0.000 description 1
- ASJSAQIRZKANQN-RVIOXEJYSA-N [2H][C@H](C=O)[C@H](O)[C@H](O)CO Chemical compound [2H][C@H](C=O)[C@H](O)[C@H](O)CO ASJSAQIRZKANQN-RVIOXEJYSA-N 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- LYFQKBYNAGDVHO-UHFFFAOYSA-N [3-[(7-iodothieno[3,2-d]pyrimidin-2-yl)amino]phenyl]methanol Chemical compound OCC1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 LYFQKBYNAGDVHO-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- VBAPMKXSHRDSCJ-UHFFFAOYSA-N [4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 VBAPMKXSHRDSCJ-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- 229940077422 accupril Drugs 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 229940000279 aggrastat Drugs 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003441 anti-flavivirus Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229930188866 apocynin Natural products 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229950000586 aviptadil Drugs 0.000 description 1
- 108010006060 aviptadil Proteins 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229950009568 bemcentinib Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- DBMJZOMNXBSRED-OQLLNIDSSA-N bergomottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CCC=C(C)C DBMJZOMNXBSRED-OQLLNIDSSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229950011103 betrixaban Drugs 0.000 description 1
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- AEXFXNFMSAAELR-RXVVDRJESA-N brensocatib Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 description 1
- 229940010847 brensocatib Drugs 0.000 description 1
- 229940086777 brilinta Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNJVYWXIDISQRD-JTSSGKSMSA-N cafestol Chemical compound C([C@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1CC2 DNJVYWXIDISQRD-JTSSGKSMSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 108010007877 calpain inhibitor III Proteins 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229960001080 cangrelor Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 108010023376 caplacizumab Proteins 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- AYOCQODSVOEOHO-UHFFFAOYSA-N carbamoyl carbamate Chemical class NC(=O)OC(N)=O AYOCQODSVOEOHO-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000027448 caveolin-mediated endocytosis Effects 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 1
- 229950001684 cinanserin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003958 clopidogrel bisulfate Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
- 229960002402 cobicistat Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229950002891 danoprevir Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YNKCTZQHSHSLNN-PINRYBIZSA-N dehydrosinefungin Natural products N[C@@H](CC[C@H](N)C(=O)O)C=C1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)ncnc23 YNKCTZQHSHSLNN-PINRYBIZSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- FCFZKAVCDNTYID-UHFFFAOYSA-M dibenziodolium chloride Chemical compound [Cl-].C1=CC=C2[I+]C3=CC=CC=C3C2=C1 FCFZKAVCDNTYID-UHFFFAOYSA-M 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 230000003438 effect on compound Effects 0.000 description 1
- 229940101638 effient Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950004645 emapalumab Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- NDZWEWJSWYERNF-UHFFFAOYSA-N ethyl 3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 NDZWEWJSWYERNF-UHFFFAOYSA-N 0.000 description 1
- YICDSLBAVQXFOF-UHFFFAOYSA-N ethyl 4-(3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1C(=O)C2=CC=CC=C2S1 YICDSLBAVQXFOF-UHFFFAOYSA-N 0.000 description 1
- CYCFEEXTLQGJEL-XEOXDSMQSA-N ethyl 4-[(2s)-3-[3-[(e)-(hydroxyhydrazinylidene)methyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NS(=O)(=O)C=1C(=CC(=CC=1C(C)C)C(C)C)C(C)C)CC1=CC=CC(\C=N\NO)=C1 CYCFEEXTLQGJEL-XEOXDSMQSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 229940013204 fadraciclib Drugs 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229940110266 farxiga Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229950002031 galidesivir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229950009614 gimsilumab Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940071829 ilaris Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- 229940101712 kengreal Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 230000005577 local transmission Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940103179 mavik Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WVJUCAJCGQVMCE-UHFFFAOYSA-N methyl 2-(3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1N1C(=O)C2=CC=CC=C2S1 WVJUCAJCGQVMCE-UHFFFAOYSA-N 0.000 description 1
- SWXOJCVNZZWISE-UHFFFAOYSA-N methyl 2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidine-7-carboxylate Chemical compound N1=C2C(C(=O)OC)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 SWXOJCVNZZWISE-UHFFFAOYSA-N 0.000 description 1
- XNMVTFSHIKCJHF-UHFFFAOYSA-N methyl 2-methoxy-4-(3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC=C1N1C(=O)C2=CC=CC=C2S1 XNMVTFSHIKCJHF-UHFFFAOYSA-N 0.000 description 1
- ZIFJJRRCTKAIGB-UHFFFAOYSA-N methyl 4-(3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1N1C(=O)C2=CC=CC=C2S1 ZIFJJRRCTKAIGB-UHFFFAOYSA-N 0.000 description 1
- UKRSXMOECUNKDX-UHFFFAOYSA-N methyl 4-(5-fluoro-3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1N1C(=O)C2=CC(F)=CC=C2S1 UKRSXMOECUNKDX-UHFFFAOYSA-N 0.000 description 1
- JQMWOYHBTMMJDR-UHFFFAOYSA-N methyl 6-(3-oxo-1,2-benzothiazol-2-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1N1C(=O)C2=CC=CC=C2S1 JQMWOYHBTMMJDR-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 229960001094 midodrine Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 229940118178 monopril Drugs 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000002365 multiple layer Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- POTVAILTNPOQJH-UHFFFAOYSA-N n,n-dimethyl-1-(5-phenylmethoxy-1h-indol-3-yl)methanamine Chemical compound C1=C2C(CN(C)C)=CNC2=CC=C1OCC1=CC=CC=C1 POTVAILTNPOQJH-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- XBDUZBHKKUFFRH-UHFFFAOYSA-N n-(2-oxo-1h-pyrimidin-6-yl)benzamide Chemical compound OC1=NC=CC(NC(=O)C=2C=CC=CC=2)=N1 XBDUZBHKKUFFRH-UHFFFAOYSA-N 0.000 description 1
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
- SIGATAYQAZTAOH-UHFFFAOYSA-N n-(9,10-dioxoanthracen-2-yl)benzamide Chemical compound C=1C=C2C(=O)C3=CC=CC=C3C(=O)C2=CC=1NC(=O)C1=CC=CC=C1 SIGATAYQAZTAOH-UHFFFAOYSA-N 0.000 description 1
- JMINZMMVUOMWOD-UHFFFAOYSA-N n-(cyanomethyl)-2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=C2C(C(NCC#N)=O)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 JMINZMMVUOMWOD-UHFFFAOYSA-N 0.000 description 1
- RESVYOGEFUDMLA-UHFFFAOYSA-N n-(cyanomethyl)-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound N#CCNC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 RESVYOGEFUDMLA-UHFFFAOYSA-N 0.000 description 1
- ODAXMGKPEIAQSX-UHFFFAOYSA-N n-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ODAXMGKPEIAQSX-UHFFFAOYSA-N 0.000 description 1
- OFTCFZMUPWWHQB-UHFFFAOYSA-N n-(cyanomethyl)-n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N#CCN(S(=O)(=O)C)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 OFTCFZMUPWWHQB-UHFFFAOYSA-N 0.000 description 1
- LYGWVDVUGFARKL-UHFFFAOYSA-N n-(cyanomethyl)-n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC(N(CC#N)S(=O)(=O)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 LYGWVDVUGFARKL-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JJVAPHYEOZSKJZ-JGCGQSQUSA-N n-[(2r)-3-(7-methyl-1h-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxamide Chemical compound C1CN(C)CCC1N1CCN(C(=O)[C@@H](CC=2C=C3C=NNC3=C(C)C=2)NC(=O)N2CCC(CC2)C=2C(NC3=CC=CC=C3C=2)=O)CC1 JJVAPHYEOZSKJZ-JGCGQSQUSA-N 0.000 description 1
- QAORNCIDWJJIAL-UHFFFAOYSA-N n-[2-methoxy-4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound C1=C(NC(C)=O)C(OC)=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 QAORNCIDWJJIAL-UHFFFAOYSA-N 0.000 description 1
- QYHLZBUMTADYQI-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 QYHLZBUMTADYQI-UHFFFAOYSA-N 0.000 description 1
- LGTMIYZVEVWGHI-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C=CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 LGTMIYZVEVWGHI-UHFFFAOYSA-N 0.000 description 1
- QWJOIOCEITWYGW-UHFFFAOYSA-N n-[3-[2-[4-(2-pyrrolidin-1-ylethoxy)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(OCCN5CCCC5)=CC=4)=NC=C3SC=2)=C1 QWJOIOCEITWYGW-UHFFFAOYSA-N 0.000 description 1
- OFKYPJFPTVMPEQ-UHFFFAOYSA-N n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C1=CC(NC(=O)C=C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 OFKYPJFPTVMPEQ-UHFFFAOYSA-N 0.000 description 1
- PLGIIOKXCKDKEU-VXLYETTFSA-N n-[4-chloro-3-[(e)-(2-methylpropan-2-yl)oxyiminomethyl]phenyl]-2-methylfuran-3-carbothioamide Chemical compound O1C=CC(C(=S)NC=2C=C(\C=N\OC(C)(C)C)C(Cl)=CC=2)=C1C PLGIIOKXCKDKEU-VXLYETTFSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- OMRXBNSVRJWWAZ-UHFFFAOYSA-N n-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-1,2-oxazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1CNC(=O)C1=CC=NO1 OMRXBNSVRJWWAZ-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 1
- VHYYJWLKCODCNM-OIMNJJJWSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]heptanamide Chemical compound CCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO VHYYJWLKCODCNM-OIMNJJJWSA-N 0.000 description 1
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000037971 neglected tropical disease Diseases 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 229940020452 neupro Drugs 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- UPWHZOYYXHKXLQ-BGPJRJDNSA-N nucleoside triphosphate Chemical class C[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O UPWHZOYYXHKXLQ-BGPJRJDNSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229950007074 opaganib Drugs 0.000 description 1
- 108700013356 oplunofusp Proteins 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 229940121480 otilimab Drugs 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical class C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940072273 pepcid Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229940090007 persantine Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950001448 piclidenoson Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940095638 pletal Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940073281 prezcobix Drugs 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 208000012327 purpuric rash Diseases 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 150000005229 pyrazolopyridines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- FGHMGRXAHIXTBM-TWFJNEQDSA-N s-[2-[[(2r,3r,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate Chemical compound C([C@@H]1[C@H]([C@@](C)(O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1)O)OP(=O)(OCCSC(=O)C(C)(CO)C)NCC1=CC=CC=C1 FGHMGRXAHIXTBM-TWFJNEQDSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950010613 selinexor Drugs 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- RGYQPQARIQKJKH-UHFFFAOYSA-N setanaxib Chemical compound CN(C)C1=CC=CC(C2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2C)=C1 RGYQPQARIQKJKH-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950008974 sinefungin Drugs 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- RTVVXRKGQRRXFJ-UHFFFAOYSA-N sodium;2-sulfobutanedioic acid Chemical compound [Na].OC(=O)CC(C(O)=O)S(O)(=O)=O RTVVXRKGQRRXFJ-UHFFFAOYSA-N 0.000 description 1
- 229950008127 solnatide Drugs 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011916 stereoselective reduction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 229940053017 sylvant Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- QSEABWLABRBFSM-UHFFFAOYSA-N tert-butyl 4-(3-oxo-1,2-benzothiazol-2-yl)benzoate Chemical compound C1=CC(C(=O)OC(C)(C)C)=CC=C1N1C(=O)C2=CC=CC=C2S1 QSEABWLABRBFSM-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- DZGQZNRJDFZFLV-UHFFFAOYSA-N theaflavin 3,3'-digallate Natural products OC1=CC(=Cc2cc(C3Oc4cc(O)cc(O)c4CC3OC(=O)c5cc(O)c(O)c(O)c5)c(O)c(O)c2C1=O)C6Oc7cc(O)cc(O)c7CC6OC(=O)c8cc(O)c(O)c(O)c8 DZGQZNRJDFZFLV-UHFFFAOYSA-N 0.000 description 1
- 235000008230 theaflavin-3,3'-digallate Nutrition 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229940028869 ticlid Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229950011232 tradipitant Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- FTNWXGFYRHWUKG-UHFFFAOYSA-N triflupromazine hydrochloride Chemical compound [H+].[Cl-].C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FTNWXGFYRHWUKG-UHFFFAOYSA-N 0.000 description 1
- 229960004312 triflupromazine hydrochloride Drugs 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GQMVAUFIUVHMBB-UHFFFAOYSA-K trinaphthalen-2-yloxybismuthane Chemical compound C1=CC=CC2=CC(O[Bi](OC=3C=C4C=CC=CC4=CC=3)OC=3C=C4C=CC=CC4=CC=3)=CC=C21 GQMVAUFIUVHMBB-UHFFFAOYSA-K 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 229940008349 truvada Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229950008529 upamostat Drugs 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- DDUFYKNOXPZZIW-CRCLSJGQSA-N vince lactam Chemical compound C1[C@H]2C(=O)N[C@@H]1C=C2 DDUFYKNOXPZZIW-CRCLSJGQSA-N 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Abstract
Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
Description
MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS
ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES
Field The present disclosure is directed to compounds, methods and compositions for treating or preventing coronavirus infections. More specifically, the disclosure describes certain nucleoside and nucleotide analogs, pharmaceutically acceptable salts, or other derivatives thereof, and the use thereof in the treatment of coronaviruses, especially SARS-CoV-2.
Background Coronaviruses are a species of virus belonging to the subfamily Coronavirinae in the family Coronaviridae, and are enveloped viruses with a positive-sense single-stranded RNA
genome and with a nucleocapsid of helical symmetry.
Coronaviruses primarily infect the upper respiratory and gastrointestinal tract of mammals and birds, though several known strains infect humans as well.
Coronaviruses are believed to cause a significant percentage of all common colds in human adults and children.
Coronaviruses cause colds in humans, primarily in the winter and early spring seasons.
Coronaviruses can also cause pneumonia, either direct viral pneumonia or a secondary bacterial pneumonia, bronchitis, either direct viral bronchitis or a secondary bacterial bronchitis, and severe acute respiratory syndrome (SARS).
Coronaviruses also cause a range of diseases in farm animals and domesticated pets, some of which can be serious and are a threat to the farming industry. In chickens, the infectious bronchitis virus (IBV), a coronavirus, targets not only the respiratory tract but also the uro-genital tract. The virus can spread to different organs throughout the chicken.
Economically significant coronaviruses of farm animals include porcine coronavirus (transmissible gastroenteritis coronavirus, TGE) and bovine coronavirus, which both result in diarrhea in young animals. Feline Coronavirus: two forms, Feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.
There are two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MLIV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.
Some strains of MIIV cause a progressive demyelinating encephalitis in mice which has been used as a murine model for multiple sclerosis.
More recently a coronavirus pandemic has caused a dual threat to the health and the economy of the U.S. and the world. COVID-19 was first identified in December 2019 in Wuhan, Hubei province, China, resulting in the ongoing 2019-2020 pandemic.
COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Common symptoms of the disease include fever (88%), dry cough (68%), shortness of breath (19%), and loss of smell (15 to 30%). Complications may include pneumonia, viral sepsis, acute respiratory distress syndrome, diarrhea, renal disease, cardiac issues and encephalitis.
As of June, 2020, the total number of infected worldwide stood at over 4 million and at least 102,753 had died, and, according to the Johns Hopkins University Coronavirus Resource Center, almost two million people had tested positive for coronavirus in the U.S. and over one hundred thousand people had died of the disease. Local transmission of the disease has been recorded in over 200 countries. Risk factors include travel and viral exposure, and prevention is assisted by social distancing and quarantine.
Current treatments for these infections are mainly supportive, minimizing the symptoms rather than treating the underlying viral infection. For example, patients may be treated with analgesics to relieve pain, and patients with enteroviral carditis can be treated for complications such as arrhythmias, pericardial effusion, and cardiac failure.
It would be advantageous to provide new antiviral agents, compositions including these agents, and methods of treatment using these agents to treat coronaviruses.
The present disclosure provides such agents, compositions and methods.
Summary The present disclosure relates to compounds, methods and compositions for treating or preventing coronaviruses and/or other viral infections in a host. The methods involve administering a therapeutically or prophylactically-effective amount of at least one compound described herein to treat or prevent an infection by, or an amount sufficient to reduce the biological activity of, coronaviruses or other viral infections including, but not limited to,
ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES
Field The present disclosure is directed to compounds, methods and compositions for treating or preventing coronavirus infections. More specifically, the disclosure describes certain nucleoside and nucleotide analogs, pharmaceutically acceptable salts, or other derivatives thereof, and the use thereof in the treatment of coronaviruses, especially SARS-CoV-2.
Background Coronaviruses are a species of virus belonging to the subfamily Coronavirinae in the family Coronaviridae, and are enveloped viruses with a positive-sense single-stranded RNA
genome and with a nucleocapsid of helical symmetry.
Coronaviruses primarily infect the upper respiratory and gastrointestinal tract of mammals and birds, though several known strains infect humans as well.
Coronaviruses are believed to cause a significant percentage of all common colds in human adults and children.
Coronaviruses cause colds in humans, primarily in the winter and early spring seasons.
Coronaviruses can also cause pneumonia, either direct viral pneumonia or a secondary bacterial pneumonia, bronchitis, either direct viral bronchitis or a secondary bacterial bronchitis, and severe acute respiratory syndrome (SARS).
Coronaviruses also cause a range of diseases in farm animals and domesticated pets, some of which can be serious and are a threat to the farming industry. In chickens, the infectious bronchitis virus (IBV), a coronavirus, targets not only the respiratory tract but also the uro-genital tract. The virus can spread to different organs throughout the chicken.
Economically significant coronaviruses of farm animals include porcine coronavirus (transmissible gastroenteritis coronavirus, TGE) and bovine coronavirus, which both result in diarrhea in young animals. Feline Coronavirus: two forms, Feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.
There are two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MLIV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.
Some strains of MIIV cause a progressive demyelinating encephalitis in mice which has been used as a murine model for multiple sclerosis.
More recently a coronavirus pandemic has caused a dual threat to the health and the economy of the U.S. and the world. COVID-19 was first identified in December 2019 in Wuhan, Hubei province, China, resulting in the ongoing 2019-2020 pandemic.
COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Common symptoms of the disease include fever (88%), dry cough (68%), shortness of breath (19%), and loss of smell (15 to 30%). Complications may include pneumonia, viral sepsis, acute respiratory distress syndrome, diarrhea, renal disease, cardiac issues and encephalitis.
As of June, 2020, the total number of infected worldwide stood at over 4 million and at least 102,753 had died, and, according to the Johns Hopkins University Coronavirus Resource Center, almost two million people had tested positive for coronavirus in the U.S. and over one hundred thousand people had died of the disease. Local transmission of the disease has been recorded in over 200 countries. Risk factors include travel and viral exposure, and prevention is assisted by social distancing and quarantine.
Current treatments for these infections are mainly supportive, minimizing the symptoms rather than treating the underlying viral infection. For example, patients may be treated with analgesics to relieve pain, and patients with enteroviral carditis can be treated for complications such as arrhythmias, pericardial effusion, and cardiac failure.
It would be advantageous to provide new antiviral agents, compositions including these agents, and methods of treatment using these agents to treat coronaviruses.
The present disclosure provides such agents, compositions and methods.
Summary The present disclosure relates to compounds, methods and compositions for treating or preventing coronaviruses and/or other viral infections in a host. The methods involve administering a therapeutically or prophylactically-effective amount of at least one compound described herein to treat or prevent an infection by, or an amount sufficient to reduce the biological activity of, coronaviruses or other viral infections including, but not limited to,
2 SARS-CoV-2, MERS, SARS, and OC-43. In other embodiments, the compounds described herein can be used for treating or preventing infections by Flaviviruses, Picornaviridae, Togavirodae and Bunyaviridae.
In one embodiment, methods of using potent, selective antiviral agents to target coronaviruses and other viral infections and thus help eliminate and/or treat infection in patients infected by these viruses are disclosed.
In one aspect of this embodiment, the compounds used include one or more of the specific nucleoside inhibitors described herein.
In another embodiment, pharmaceutical compositions including one or more of the compounds described herein are disclosed, which in one embodiment comprises a combination of a cytidine and a uridine analog, in combination with a pharmaceutically acceptable carrier or excipient. These compositions can be used to treat a host infected with a coronavirus or other viral infections, to prevent one of these infections, and/or to reduce the biological activity of one of these viruses. The compositions can include a combination of one or more of the compounds described herein, optionally with other antiviral compounds or biological agents, including anti-SARS-CoV2 compounds and biological agents, fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, such as remdesivir, GS-441524, N4-hydroxycytidine, and other compounds disclosed in U.S. Patent No.
9,809,616, and their prodrugs, viral entry inhibitors, viral maturation inhibitors, JAK
inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, NS5A inhibitors, such as daclastavir, and agents of distinct or unknown mechanism.
In yet another embodiment, the present disclosure relates to processes for preparing the specific nucleoside compounds described herein In some embodiments, the compounds described herein are deuterated at one or more positions. Where the compounds are nucleosides, deuteration can be present in one or more positions on the sugar moiety of the compounds, the base portion of the compounds, and/or the prodrug portion of the compounds, at any position.
In some embodiments, ester prodrugs were prepared to allow more drug, when given orally, to reach the plasma and not be trapped in the gut as a triphosphate.
In one embodiment, methods of using potent, selective antiviral agents to target coronaviruses and other viral infections and thus help eliminate and/or treat infection in patients infected by these viruses are disclosed.
In one aspect of this embodiment, the compounds used include one or more of the specific nucleoside inhibitors described herein.
In another embodiment, pharmaceutical compositions including one or more of the compounds described herein are disclosed, which in one embodiment comprises a combination of a cytidine and a uridine analog, in combination with a pharmaceutically acceptable carrier or excipient. These compositions can be used to treat a host infected with a coronavirus or other viral infections, to prevent one of these infections, and/or to reduce the biological activity of one of these viruses. The compositions can include a combination of one or more of the compounds described herein, optionally with other antiviral compounds or biological agents, including anti-SARS-CoV2 compounds and biological agents, fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, such as remdesivir, GS-441524, N4-hydroxycytidine, and other compounds disclosed in U.S. Patent No.
9,809,616, and their prodrugs, viral entry inhibitors, viral maturation inhibitors, JAK
inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, NS5A inhibitors, such as daclastavir, and agents of distinct or unknown mechanism.
In yet another embodiment, the present disclosure relates to processes for preparing the specific nucleoside compounds described herein In some embodiments, the compounds described herein are deuterated at one or more positions. Where the compounds are nucleosides, deuteration can be present in one or more positions on the sugar moiety of the compounds, the base portion of the compounds, and/or the prodrug portion of the compounds, at any position.
In some embodiments, ester prodrugs were prepared to allow more drug, when given orally, to reach the plasma and not be trapped in the gut as a triphosphate.
3
4 In another embodiment, ester prodrugs were prepared to improve the oral bioavailability of drugs.
The present disclosure will be better understood with reference to the following Detailed Description.
Brief Description of the Drawings Fig. 1 shows the structure of the COV1D-19 virus nsp12-nsp7-nsp8 complex, including the domain organization of COVID-19 virus nsp12.
Fig. 2 is a schematic illustration of the structure of the N-terminal NiRAN
domain and p hairpin of RdRp. The interacting residues in the palm and fingers subdornain of the RdRp domain and the NiRAN domain are identified by the labels.
Fig. 3 is a schematic illustration showing one embodiment of how an inhibitor triphosphate can interfere with RNA synthesis.
Fig. 4 is a photograph showing the degree of polymerase inhibition when Remdesivir, or a specific nucleotide inhibitor as described herein, is added, in a dose-dependent manner (1, 10, 100, 250, or 500 uM) to a mixture including an RdRp complex and nucleoside triphosphates, and one of water (control), Remdesivir, or an inhibitor compound is added.
Detailed Description The compounds described herein show inhibitory activity against Coronaviridae in cell-based assays. Therefore, the compounds can be used to treat or prevent a Coronaviridae infection in a host, or reduce the biological activity of the virus. The host can be a mammal, and in particular, a human, infected with Coronaviridae virus. The compounds are also effective against Flaviviridae, Picornaviridae, Togavirodae and Bunyaviridae viruses. The methods involve administering an effective amount of one or more of the compounds described herein.
Pharmaceutical formulations including one or more compounds described herein, in combination with a pharmaceutically acceptable carrier or excipient, are also disclosed. In one embodiment, the formulations include at least one compound described herein and at least one further therapeutic agent.
The present disclosure will be better understood with reference to the following definitions:
I. Definitions The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
Thus, in a compound such as R"XYR", wherein R" is "independently carbon or nitrogen,"
both R" can be carbon, both R" can be nitrogen, or one R" can be carbon and the other R"
nitrogen.
As used herein, the term "enantiomerically pure" refers to a compound composition that comprises at least approximately 95%, and, preferably, approximately 97%, 98%, 99%
or 100% of a single enantiomer of that compound.
As used herein, the term "substantially free of' or "substantially in the absence of' refers to a compound composition that includes at least 85 to 90% by weight, preferably 95% to 98 % by weight, and, even more preferably, 99% to 100% by weight, of the designated enantiomer of that compound. In a preferred embodiment, the compounds described herein are substantially free of enantiomers.
Similarly, the term "isolated- refers to a compound composition that includes at least 85 to 90% by weight, preferably 95% to 98% by weight, and, even more preferably, 99% to 100% by weight, of the compound, the remainder comprising other chemical species or en anti om ers.
The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbons, including both substituted and unsubstituted alkyl groups. The alkyl group can be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included are CF3 and CH2CF3.
In the text, whenever the term C(alkyl range) is used, the term independently includes each member of that class as if specifically and separately set out. The term "alkyl"
includes C1.22 alkyl moieties, and the term "lower alkyl" includes C 1.6 alkyl moieties. It is understood to those of ordinary skill in the art that the relevant alkyl radical is named by replacing the suffix "-ane" with the suffix "-yl".
As used herein, a "bridged alkyl" refers to a bicyclo- or tricyclo alkane, for example, a 2:1:1 bicyclohexane.
As used herein, a "Spiro alkyl" refers to two rings that are attached at a single (quaternary) carbon atom.
The term "alkenyl" refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds. The alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to those described for sub stituents on alkyl moieties.
Non-limiting examples of alkenyl groups include ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane- diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
The term "alkynyl- refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds. The alkynyl group can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to those described above for alkyl moeities. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1 -yl, butyn-2-yl, pentyn-l-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3 -m ethylbutyn-l-yl, hexyn-l-yl, hexyn-2-yl, and hexyn-3-yl, 3,3 -dim ethyl butyn-l-yl radicals.
The term -alkylamino" or "arylamino" refers to an amino group that has one or two alkyl or aryl substituents, respectively.
The term "fatty alcohol" as used herein refers to straight-chain primary alcohols with between 4 and 26 carbons in the chain, preferably between 8 and 26 carbons in the chain, and most preferably, between 10 and 22 carbons in the chain. The precise chain length varies with the source. Representative fatty alcohols include lauryl, stearyl, and oleyl alcohols. They are colourless oily liquids (for smaller carbon numbers) or waxy solids, although impure samples may appear yellow. Fatty alcohols usually have an even number of carbon atoms and a single alcohol group (-OH) attached to the terminal carbon. Some are unsaturated and some are branched. They are widely used in industry. As with fatty acids, they are often referred to generically by the number of carbon atoms in the molecule, such as "a C12 alcohol", that is an alcohol having 12 carbons, for example dodecanol.
The term "protected" as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis, and are described, for example, in Greene et al., Protective Groups in Organic Synthesis, supra.
The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings can be attached together in a pendent manner or can be fused. Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or other aromatic groups that remain after the removal of a hydrogen from an aromatic ring. The term aryl includes both substituted and unsubstituted moieties. The aryl group can be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to those described above for alkyl moieties. Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N- alkylamino, N-h eteroaryl am i n o-N-al kyl amino, h eteroaral koxy, aryl amino, aral kyl amino, aryl thi o, monoarylamidosulfonyl, aryl sulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, aryl sulfinyl, aryl sulfonyl, heteroarylthio, heteroaryl sulfinyl, heteroaryl sulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, hal oal koxyal kyl , aryl, aral kyl , aryl oxy, aral koxy, aryl oxyal kyl , saturated heterocycl yl, partially saturated heterocyclyl, heteroaryl, heteroaryl oxy, heteroaryl oxy al kyl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, carboaralkoxy.
The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.
The term -halo," as used herein, includes chloro, bromo, iodo and fluoro.
The term "acyl- refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from the group consisting of straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl, including, but not limited to methoxymethyl, aralkyl, including, but not limited to, benzyl, aryloxyalkyl, such as phenoxymethyl, aryl, including, but not limited to, phenyl, optionally substituted with halogen (F, Cl, Br, or I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4), sulfonate esters such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g., dimethyl-t-butylsily1) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term "lower acyl" refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form m on oal koxyal kyl and di al koxyal kyl radicals. The " al koxy" radicals can be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy"
radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
The term "alkyl amino" denotes "monoalkylamino" and "dialkylamino" containing one or two alkyl radicals, respectively, attached to an amino radical The terms arylamino denotes "monoarylamino" and "diarylamino" containing one or two aryl radicals, respectively, attached to an amino radical. The term "aralkylamino", embraces aralkyl radicals attached to an amino radical. The term aralkylamino denotes "monoaralkylamino" and "diaralkylamino"
containing one or two aralkyl radicals, respectively, attached to an amino radical. The term aralkylamino further denotes "monoaralkyl monoalkylamino- containing one aralkyl radical and one alkyl radical attached to an amino radical.
The term "heteroatom," as used herein, refers to oxygen, sulfur, nitrogen and phosphorus.
The terms "heteroaryl" or "heteroaromatic," as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
The term "heterocyclic," "heterocyclyl," and cycloheteroalkyl refer to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl , thi enyl, i sothi az olyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thi adi azolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3 -triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, pyrimidine or pyridazine, and pteridinyl, aziridines, thiazole, isothiazole, 1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine, oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-az auracilyl , tri az ol opyri di nyl, imi daz olopyri di nyl , pyrrolopyrimidinyl, pyraz ol opyrimi di nyl , adenine, N6-alkylpurines, N6-benzylpurine, N6-halopurine, N6-vinypurine, N6-acetylenic purine, N6-acyl purine,N6-hydroxyalkyl purine, N6-thioalkyl purine, thymine, cytosine, 6-.
azapyrimidine, 2-mercaptopyrmidine, N5 -alkylpyrimidines, N5-benzylpyrimidines, N5-halopyrimi dines, N5-vinylpyrimidine, N5-acetylenic pyrimidine, N5-acyl pyrimidine, N5-hydroxyalkyl purine, and N6-thioalkyl purine, and isoxazolyl. The heteroaromatic group can be optionally substituted as described above for aryl. The heterocyclic or heteroaromatic group can be optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, and dialkylamino. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexyl silyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl. The heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
The term "host," as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and, preferably, humans. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds described herein. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications described herein, the host is a human being.
Veterinary applications, in certain indications, however, are clearly contemplated (such as for use in treating chimpanzees).
The term nucleoside also includes ribonucleosides, and representative ribonucleosides are disclosed, for example, in the Journal of Medicinal Chemistry, 43(23), 4516-4525 (2000), Antimicrobial Agents and Chemotherapy, 45(5), 1539-1546(2001), and PCT WO
2000069876.
The term "peptide" refers to a natural or synthetic compound containing two to one hundred amino acids linked by the carboxyl group of one amino acid to the amino group of another.
The term "pharmaceutically acceptable salt or prodrug" is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester) compound which, upon administration to a patient, provides the compound.
Pharmaceutically-acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art.
Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound described herein. Typical examples of prodrugs include compounds that have biologically labile protecting groups on functional moieties of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. The prodrug forms of the compounds described herein can possess antiviral activity, can be metabolized to form a compound that exhibits such activity, or both.
II. Active Compounds The nucleoside compounds described herein are of one of the following formulas. In one embodiment, the compounds are compounds of Formula (A) or Formula (Al):
R4R1 R1A Base R8 R8' Formula A
Base RiA
R3 ____________________________________ RE3' R8 Formula Al or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI is and R1A are, independently, H, CH3, CH?F, CHF2, or CF3, wherein, when RI
is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or R1 and RA can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl;
R3 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H, F , N 3, substituted or unsubstituted (C1-8)alkyl, substituted or unsubstituted (C2-8)alkenyl, substituted or unsubstituted (C2-8)alkynyl, 0-(C1-8) alkyl and N3 when R5 is Se, CH2, CHF, CF2, -C(CH3)-, -C(cyclopropy1)-, C=CF2 or C=CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropy1)-, C=CF2 or C=CH2, R8 and R8' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R' is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, cyano, R4 is OH, an optionally substituted 0-linked amino acid, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of R4, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
II OH
+-K
(a) OR15 where 105 selected from the group consisting of H, OH
,1OH
R. -' 1 0 OH
OH
, Li, Na, K, substituted or unsubstituted C1-20a1ky1, substituted or unsubstituted C3-6cyc10a1ky1, CI-4(alkyl)aryl, benzyl, C1-6 haloalkyl, C2-3(alky1)0C1.20alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2R16 and (CH2)0.6 CON(R16)2, where le6 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3.10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1,5 alkyl, or C1,5 alkyl substituted with a C1-6 alkyl, alkoxy, di (C1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
J .0 (b) the ester of a D- or L-amino acid R17 and R18 are independently H, C1.20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(Ci-oalkyl)- amino, fluoro, C3-10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycl oh etero al kyl , aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a CI-6a1ky1, alkoxy, di(C1-6alkyl)-amino, fluoro, C3.10 cycloalkyl, or cycloalkyl;
In one embodiment, Base is selected from the group consisting of:
N N
N N
N Xi X2 NX2 , µ1.1.1,1õ, N
N
NI/
X2 , and \NI x2 W
*nris and in another embodiment, Base is:
HN N
sjITIP
Xl is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cyc1oa1kyl, C-(CI-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-OR22, C-N(R22)2, C-halo, C-CN or N, X" is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH2, halo (i.e., F, Cl, Br, or I), SH, NHOH, 1_10)al kyl , 0(C2_10)alkene, O(C210)al kyne, 0(C3_7)cycloalkyl , -0-C(0)-alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-CI-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, S(Ci.
io)alkyl, S(C2.10)alkene, S(C2.10)alkyne, S(C37)cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((Ci_10)alky1)2, NH(C37)cycloalkyl, an optionally unsaturated NH(C0)(C1_20)alkyl, an optionally unsaturated NH(C0)0(C1_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(Ci_20)alkyl, or an optionally unsaturated NHO(CO)NH(Ci_ 20)alkyl, (C1-3)a1ky1, R9' is OH, NH2, SH, NHOH, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Rth is II or F, X2' is N or CH, and W is 0 or S
In one embodiment, IV is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H
In another embodiment, R3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In another embodiment, le is and RA are H.
In another embodiment, R8 and R8' are OH.
In another embodiment, R4 is OH or 0-P(0)R6R7.
R9' R o X2' N W
In another embodiment, Base is In one aspect of this embodiment, R9 is OH, NH2, or NHOH
X N
N x2 In another embodiment, Base is 4/jv In one aspect of this embodiment, X2 is NH2, OH or SH.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (B) or (B1):
o R1 A
Base A
p R8' Formula B
Base RiA 0 R3 ____________________________________________________________ A
R /
R8' Formula B1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RA, R2, R3, 5, _lc ¨and Rware as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR15 where R15 is selected from the group consisting of H, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, CI-4(alkyl)aryl, benzyl, Cl-6 haloalkyl, C2_3(alky1)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)()-6CO2R16 and (CH2)0_6 CON(R16)2 ,.0 N"
(b) the ester of a D- or L-amino acid , 7 and Ri8 are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6a1ky1)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1_6a1ky1, alkoxy, di(C1-6a1ky1)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl, and S., ,..R30 (C) where R3 is selected from the group consisting of substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2_10)alkene, substituted or unsubstituted (C2_10)alkyne, C1-4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
In one embodiment, R5 is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl In another embodiment, R3 is H.
In another embodiment, It3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H
In another embodiment, Rg. is OH.
In another embodiment, Y is H.
In another embodiment, R1 and RA are H.
In another embodiment, A is 0 These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (C) or (Cl):
X
R1 pp 1 A N
=N
R2 I.TX
R8 Rgi Formula C
X
/LW
RiA
_________________________________________________________ R2 R8' R8 Formula CI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, RA, ¨2, K R3, R5, R8, R8' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
In one embodiment, R5 is 0.
In another embodiment, R2 is N3 or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H.
In another embodiment, R3 is N3 or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In one embodiment, R8 and R8' are OH.
In one embodiment, Y is H.
In one embodiment, R is H.
In one embodiment, Z is H.
In one embodiment, X is OH, NH2 or NHOH.
In one embodiment, W is 0.
In one embodiment, R and R' A are H.
In one embodiment, R4 is OH or 0-P(0)R6R7.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (D) or (D1):
X
0 R1 R1 A N, __________________________________________________ ...1714 p 0 ID' Formula D
X
RiA R1 NN
R5 \\.,...õ.0\
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, RA, R2, R3, R5, Rs' and Y are as defined in Formula A, and A and D are as defined in Formula C.
In one embodiment, R5 is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H.
In another embodiment, R3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In another embodiment, R8. is OH
In another embodiment, Y is H.
In another embodiment, R is H.
In another embodiment, Z is H.
In another embodiment, X is OH, NH2 or NHOH.
In another embodiment, W is 0.
In another embodiment, Rl and RA are H.
In another embodiment, R4 is OH or 0-P(0)R6R7.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (E) or (El):
R4 pp . .
R A
Base¨
R2 4_ __ R3 R¨ R32 Formula E
RIA
Base R
Formula El or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Rl, RA, R2, _I( ¨ 3, and R4 are as defined in Formula A, R3 is 0 or CH2, R31 is 0 or S when R3 is 0 or CH2, R32 and R33 are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
In one embodiment, R3 is 0.
In another embodiment, R31 is 0.
In another embodiment, le2 and R33 are, independently, H or F.
In another embodiment, R2 is N3 or substituted or unsubstituted C2-8alkynyl.
In another embodiment, le is N3 or substituted or unsubstituted C2-8alkynyl.
In another embodiment, R2 is CN
In another embodiment, Rl and RA are H.
In another embodiment, R4 is OH or or 0-P(0)R6R7.
In another embodiment, Base is /
In another embodiment, Xl is N
These subfeatures can be present in any combination in any compound described herein In another embodiment, the compounds are compounds of Formula (F) or (F1).
R
R .4 RiA
Base Formula F
Base R3 ____________________________________ cç
Formula Fl or a pharmaceutically acceptable salt or prodnig thereof, wherein:
Base, RA, R2, lc ¨3, and R4 are as defined in Formula A, R34 is 0 or CH2, and R" and R36 are independently H, F or CH3 In embodiment, R35 and R36 are H.
In one embodiment, R34 is CH2.
In one embodiment, R4 is OH or or 0-P(0)R6R7.
In one embodiment, R3 is H.
In one embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In one embodiment, R2 is CN or N3.
In one embodiment, le is substituted or unsubstituted C2-8 alkynyl.
In one embodiment, le and RA are H.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds have one of the following formulas:
)¨ 0 rj(NH ?L.-NH
________________________________________ 0 HO ,0 \
0 HNI-P-0, N,N0 HO,N
S'LCL; 1 SI24 S-LCL;
OPh OH OH OH OH OH OH
OH
frILNH
HO-- HO,N s HO--or) OH OH OH OH OH OH
HN-OH
?y ri)LNH
?LNH
HO, N,N--,S HO, N, N,-.0 HO, N,N0 _--0--,_ c-- _____________________________________________________________________ F
OH OH OH F OH F
, NH fri(NH NH
HO, NN 0 HO
, ,.. N- -- HO
-N 0 ---14 0 HaisN-N0 OH OH OH OH OH
OH OH
rjLNH ry 0 HO-N-LO HO N ri)LNH
HO, N,N_.L0 OH OH OH OH
OH
N N
Nz-,..r.-N
C------r-L
HO __-NI,N
/1c24 N
/ HO OH
OH
Cr.)-'N N__.--r--k-N
HO
C-A-N
\ r\1-N--1-,NH2 HO,- ._..-N,NNH2 )c_HO \ N,NNH2 //lc2_ HO OH - HO OH
)LI ""
ANH
HO-- -NO Bz0., -.N0 HO, NO
SH
NH
N--.._.,--N
>'N
NõAN IN0 N----HHON
HO_0_; 0 HOIcLO__Me OH OH HO OH HO OH
, CI
/
HO N---r\ij //' N
-,k :,=;.k 14 No 19- N..-Nci Me HO HO j HO OH
ei 0 , 0 W tie CI
, \...- 0 i , CI
N,--1-- ' N CI
I
CI
HO
)--0 I NN CI
0 , ----101 s...õ...-CI
N-,,---- 1, ---.:-,,N
[ N ----"N
-g-cl___ ,..õ.>-, -0 ----, ¨1 HO----ic V--....
,and 0 , or a pharmaceutically acceptable salt or prodrug thereof.
Tn one embodiment, the compounds have one of the following formulas:
SH
N,....õ---LN
NH N-_,}--. N
1 -,IN I
- HO ,--,...õ -;...-IN
OH OH OH OH HO OH
-/L
I 1 h..A:..-=
/ I N
HO N 0 Ho N---N--) -.
CcL4Me Me HO OH HO OH ,and , CI
N---....----LN
I
___.----......r0.,.... N---1=1 CI
In another embodiment, the compounds have one of the following formulas:
t'' NH2)..'N --)LNH
0 = 0 t -N- -II'0 N 0 )---s-')7--- 91 ii HN--0 PN0 HO --- o 0 I
OH OH OH OH OH OH
NHOH
0 -ANH HO \NH N
I I
'N ---N )1' NH
'''' 0 HO 0 N H(i) ,s1 I
HO ''''N''0 HO., '.'N 0 CI
OH OH OH OH , \ __ / 8 ....Ø) ,or , , 26 HO
In any of these embodiments, the compounds can be present in the I3-D or I3-L
configuration.
III Stereoisomerism and Polymorphism The compounds described herein can have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present disclosure. Compounds described hereinhaving a chiral center can exist in and be isolated in optically active and racemic forms. Some compounds can exhibit polymorphism. The present disclosure encompasses racemic, optically-active, polymorphic, or stereoisomeric forms, or mixtures thereof, of a compound described herein, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution. One can either purify the respective compound, then derivatize the compound to form the compounds described herein, or purify the compound themselves.
Optically active forms of the compounds can be prepared using any method known in the art, including but not limited to by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase.
Examples of methods to obtain optically active materials include at least the following.
i) physical separation of crystals: a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;
ii) simultaneous crystallization: a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;
iii) enzymatic resolutions: a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;
iv) enzymatic asymmetric synthesis: a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;
v) chemical asymmetric synthesis: a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which can be achieved using chiral catalysts or chiral auxiliaries;
vi) diastereomer separations: a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;
vii) first- and second-order asymmetric transformations: a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer;
viii) kinetic resolutions: this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;
ix) enantiospecific synthesis from non-racemic precursors: a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;
x) chiral liquid chromatography: a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including but not limited to via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
xi) chiral gas chromatography: a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;
xii) extraction with chiral solvents: a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;
xiii) transport across chiral membranes: a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier.
Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
Chiral chromatography, including but not limited to simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
IV. Salt or Prodrug Formulations In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate and a-glycerophosphate. Suitable inorganic salts can also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts. For certain transdermal applications, it can be preferred to use fatty acid salts of the compounds described herein. The fatty acid salts can help penetrate the stratum comeum. Examples of suitable salts include salts of the compounds with stearic acid, oleic acid, lineoleic acid, palmitic acid, caprylic acid, and capric acid.
Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion. In those cases where a compound includes multiple amine groups, the salts can be formed with any number of the amine groups.
Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.
A prodrug is a pharmacological substance that is administered in an inactive (or significantly less active) form and subsequently metabolized in vivo to an active metabolite.
Getting more drug to the desired target at a lower dose is often the rationale behind the use of a prodrug and is generally attributed to better absorption, distribution, metabolism, and/or excretion (ADME) properties. Prodrugs are usually designed to improve oral bioavailability, with poor absorption from the gastrointestinal tract usually being the limiting factor.
Additionally, the use of a prodrug strategy can increase the selectivity of the drug for its intended target thus reducing the potential for off target effects.
V. Methods of Treatment In one embodiment, the compounds described herein can be used to prevent, treat or cure coronavirus infections, specifically including SARS-CoV2 infections, such as SARS-CoV-2, MERS, SARS, and OC-43. In other embodiments, the compounds described herein can be used to prevent, treat or cure infections by Flaviviruses, Picornaviridae, Togavirodae and Bunyaviridae.
The methods involve administering a therapeutically or prophylactically-effective amount of at least one compound as described herein to treat, cure or prevent an infection by, or an amount sufficient to reduce the biological activity of, a coronavirus infection, or an infection caused by a Flavivirus, Picomavus, Togavirus, or Bunyavirus, or other RNA virus.
In another embodiment, the compounds described herein can be used to inhibit a coronoviral, flaviviral, picomaviral, togaviral, or bunyaviral protease, or protease associated with another RNA virus, in a cell. The method includes contacting the cell with an effective amount of a compound described herein, Hosts, including but not limited to humans infected with a coronavirus, flavivirus, picornavirus, togavirus, or bunyavirus, or other RNA virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, transdermally, subcutaneously, or topically, in liquid or solid form.
There are several species within the Coronavirus genus including, but not limited to, Middle East respiratory syndrome coronavirus (MERS-CoV), SARS coronavirus (SARS-CoV) and SARS-Cov2. In some embodiments, a compound described herein can ameliorate and/or treat a MERS-CoV infection, SARS-CoV infection, or SARS-Cov2 infection. An effective amount of a compound described herein can be administered to a subject infected with these viruses, and/or by contacting a cell infected with these viruses with an effective amount of a compound described herein. In some embodiments, a compound described herein can inhibit replication of these viruses. In some embodiments, a compound described herein can ameliorate one or more symptoms of these infections. Symptoms include, but are not limited to, extreme fatigue, malaise, headache, high fever (e.g., >100.4 F.), lethargy, confusion, rash, loss of appetite, myalgia, chills, diarrhea, dry cough, runny nose, sore throat, shortness of breath, breathing problems, gradual fall in blood-oxygen levels (such as, hypoxia) and pneumonia.
Some embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Togaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein. Some embodiments described herein relate to using one or more compounds described herein in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Togaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein.
Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Togaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Togaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s).
In some embodiments, the Togaviridae virus can be an Alphavirus. One species of an Alphavirus is a Venezuelan equine encephalitis virus (VEEV). In some embodiments, a compound described herein can ameliorate and/or treat a VEEV infection. In other embodiments, one or more compounds described herein, can be manufactured into a medicament for ameliorating and/or treating an infection caused by a VEEV that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by a VEEV that can include contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiment, the VEEV can be an epizootic subtype. In some embodiment, the VEEV can be an enzootic subtype. As described herein, the Venezuelan equine encephalitis complex of viruses includes multiple subtypes that are further divided by antigenic variants. In some embodiments, a compound described herein can be effective against more than one subtype of a VEEV, such as 2, 3, 4, 5 or 6 subtypes. In some embodiments, a compound can be used to treat, ameliorate and/or prevent VEEV subtype I. In some embodiments, a compound described herein can be effective against more than one antigenic variants of a VEEV. In some embodiments, a compound can ameliorate one or more symptoms of a VEEV infection. Examples of symptoms manifested by a subject infected with VEEV include flu-like symptoms, such as high fever, headache, myalgia, fatigue, vomiting, nausea, diarrhea, and pharyngitis. Subjects with encephalitis show one or more of the following symptoms: somnolence, convulsions, confusion, photophobia, coma and bleeding of the brain, lung(s) and/or gastrointestinal tract. In some embodiments, the subject can be human. In other embodiments, the subject can be a horse.
Chikungunya (CHIKV) is another Alphavirus species. In some embodiments, a compound described herein can ameliorate and/or treat a CHIKV infection. In other embodiments, one or more compounds described herein can be manufactured into a medicament for ameliorating and/or treating an infection caused by a CHIKV
that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by a CHIKV that can include contacting a cell infected with the virus with an effective amount of said compound(s) In some embodiments, one or more symptoms of a CHIKV infection can be ameliorated by administering an effective amount of a compound to a subject infected with CHIKV and/or by contacting an CHIKV
infected cell with an effective amount of a compound described herein. Clinical symptoms of a CHIKV infection include fever, rash (such as petechial and/or maculopapular rash), muscle pain, joint pain, fatigue, headache, nausea, vomiting, conjunctivitis, loss of taste, photophobia, insomnia, incapacitating joint pain and arthritis Other species of Alphaviruses include Barmah Forest virus, Mayaro virus (MAYV), O'nyong'nyong virus, Ross River virus (RRV), Semliki Forest virus, Sindbis virus (SINV), Una virus, Eastern equine encephalitis virus (EEE) and Western equine encephalomyelitis (WEE).
In some embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by an Alphavirus that can include contacting a cell infected with the virus with an effective amount of one or more of said compound(s) and/or administering to a subject (such as, a subject infected with the virus) an effective amount of one or more of said compound(s), wherein the Alphavirus can be selected from Barmah Forest virus, Mayaro virus (MAYV), O'nyong'nyong virus, Ross River virus (RRV), Semliki Forest virus, Sindbis virus (SINV), Una virus, Eastern equine encephalitis virus (EEE) and Western equine encephalomyelitis (WEE).
Another genus of a Coronaviridae virus is a Rubivirus. Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Rubivirus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Rubivirus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, that can be used for ameliorating and/or treating an infection caused by a Rubivirus by contacting a cell infected with the virus with an effective amount of said compound(s).
Some embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Bunyaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein. Other embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Bunyaviridae virus that can include administering to a subject identified as suffering from the viral infection an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, that can be used for ameliorating and/or treating an infection caused by a Bunyaviridae virus by contacting a cell infected with the virus with an effective amount of said compound(s).
Some embodiments disclosed herein relate to methods of inhibiting replication of a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for inhibiting replication of a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to a compound described herein, that can be used for inhibiting replication of a Bunyaviridae virus by contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, a compound described herein can inhibit a RNA
dependent RNA polymerase of a Bunyaviridae virus, and thereby, inhibit the replication of RNA. In some embodiments, a polymerase of a Bunyaviridae virus can be inhibited by contacting a cell infected with the Bunyaviridae virus with a compound described herein.
In some embodiments, the Bunyaviridae virus can be a Bunyavirus. In other embodiments, the Bunyaviridae virus can be a Hantavirus. In still other embodiments, the Bunyaviridae virus can be a Nairovirus. In yet still other embodiments, the Bunyaviridae virus can be a Phlebovirus. In some embodiments, the Bunyaviridae virus can be an Orthobunyavirus.
In other embodiments, the Bunyaviridae virus can be a Tospovirus.
A species of the Phlebovirus genus is Rift Valley Fever virus. In some embodiments, a compound described herein can ameliorate and/or treat a Rift Valley Fever virus infection. In other embodiments, one or more compounds described herein, can be manufactured into a medicament for ameliorating and/or treating an infection caused by a Rift Valley Fever virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein can be used for ameliorating and/or treating an infection caused by a Rift Valley Fever virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, a compound described herein can inhibit replication of Rift Valley Fever virus, wherein said compound is administering to a subject infected with Rift Valley Fever virus and/or wherein said compound contacts a cell infected with Rift Valley Fever.
In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of one or more of the ocular form, the meningoencephalitis form, or the hemorrhagic fever form of Rift Valley Fever virus. In some embodiments, one or more symptoms of a Rift Valley Fever virus infection can be ameliorated. Examples of symptoms of a Rift Valley Fever viral infection include headache, muscle pain, joint pain, neck stiffness, sensitivity to light, loss of appetite, vomiting, myalgia, fever, fatigue, back pain, dizziness, weight loss, ocular form symptoms (for example, retinal lesions, blurred vision, decreased vision and/or permanent loss of vision), meningoencephalitis form symptoms (such as, intense headache, loss of memory, hallucinations, confusion, disorientation, vertigo, convulsions, lethargy and coma) and hemorrhagic fever form symptoms (for example, jaundice, vomiting blood, passing blood in the feces, a purpuric rash, ecchymoses, bleeding from the nose and/or gums, menorrhagia and bleeding from a venepuncture site).
Another species of the Phlebovirus genus is thrombocytopenia syndrome virus.
In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication thrombocytopenia syndrome virus. In some embodiments, a compound can ameliorate and/or treat severe fever with thrombocytopenia syndrome (SFTS). In some embodiments, a compound described herein can ameliorate one or more symptoms of SFTS.
Clinical symptoms of include the following: fever, vomiting, diarrhea, multiple organ failure, thrombocytopenia, leucopenia, and elevated liver enzyme levels.
Crimean-Congo hemorrhagic fever virus (CCHF) is a species within the Nairovirus genus. In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of Crimean-Congo hemorrhagic fever virus. Subjects infected with CCEIF have one or more of the following symptoms: flu-like symptoms (such as high fever, headache, myalgia, fatigue, vomiting, nausea, diarrhea, and/or pharyngitis), hemorrhage, mood instability, agitation, mental confusion, throat petechiae, nosebleeds, bloody urine, vomiting, black stools, swollen and/or painful liver, disseminated intravascular coagulation, acute kidney failure, shock and acute respiratory distress syndrome. In some embodiments, a compound described herein can ameliorate one or more symptoms of CCHF.
California encephalitis virus is another virus of the Bunyaviridae family, and is a member of the Orthobunavirus genus. Symptoms of a California encephalitis virus infection include, but are not limited to fever, chills, nausea, vomiting, headache, abdominal pain, lethargy, focal neurologic findings, focal motor abnormalities, paralysis, drowsiness, lack of mental alertness and orientation and seizures. In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of California encephalitis virus. In some embodiments, a compound described herein can ameliorate one or more symptoms of a California encephalitis viral infection.
Viruses within the Hantavirus genus can cause hantavirus hemorrhagic fever with renal syndrome (HFRS) (caused by viruses such as Hantaan River virus, Dobrava-Belgrade virus, Saaremaa virus, Seoul virus, and Puumala virus) and hantavirus pulmonary syndrome (HPS).
Viruses that can cause LIPS include, but are not limited to, Black Creek Canal virus (BCCV), New York virus (NYV), Sin Nombre virus (SNV). In some embodiments, a compound described herein can ameliorate and/or treat HFRS or HIPS. Clinical symptoms of HFRS include redness of cheeks and/or nose, fever, chills, sweaty palms, diarrhea, malaise, headaches, nausea, abdominal and back pain, respiratory problems, gastro-intestinal problems, tachycardia, hypoxemia, renal failure, proteinuria and diuresis. Clinical symptoms of HIPS
include flu-like symptoms (for example, cough, myalgia, headache, lethargy and shortness-of-breath that can deteriorate into acute respiratory failure). In some embodiments, a compound described herein can ameliorate one or more symptoms of HFRS or HPS.
Various indicators for determining the effectiveness of a method for treating and/or ameliorating a Coronaviridae, a Togaviridae, a Hepeviridae and/or a Bunyaviridae viral infection are known to those skilled in the art. Example of suitable indicators include, but are not limited to, a reduction in viral load, a reduction in viral replication, a reduction in time to seroconversion (virus undetectable in patient serum), a reduction of morbidity or mortality in clinical outcomes, and/or other indicator(s) of disease response. Further indicators include one or more overall quality of life health indicators, such as reduced illness duration, reduced illness severity, reduced time to return to normal health and normal activity, and reduced time to alleviation of one or more symptoms. In some embodiments, a compound described herein can result in the reduction, alleviation or positive indication of one or more of the aforementioned indicators compared to a subject who is untreated subject.
VI. Combination or Alternation Therapy In one embodiment, the compounds described herein can be employed together with at least one other active agent, which can be an antiviral agent. In one aspect of this embodiment, the at least one other active agent is selected from the group consisting of fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, such as remdesivir, GS-441524, N4-hydroxycytidine, and other compounds disclosed in U.S. Patent No. 9,809,616, and their prodrugs, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, NS5A inhibitors such as daclastavir, and agents of distinct or unknown mechanism.
Umifenovir (also known as Arbidol) is a representative fusion inhibitor.
Representative entry inhibitors include Camostat, luteolin, MDL28170, SSAA09E2, SSAA09E1 (which acts as a cathepsin L inhibitor), SSAA09E3, and tetra-0-galloy1-13-D-glucose (TGG). The chemical formulae of certain of these compounds are provided below:
II:
1::le /N
HN
IC '7 w Other entry inhibitors include the following:
= 1 i j AN , I oft om ' # 1 . µ'''''*4-.'' 1.. 04 , ..:, P$9.- 0- ;:r-7,,. .
11 -1 ...........................................................
.. .,..--z,,,.- ."-.0 ..=$!-----i 1 ii R.6: bii HO' . ' .
&14 A itti P 1 ti -----.,::..0 I
Remdesivir, Sofosbuvir, ribavirin, IDX-184 and GS-441524 have the following formulas:
, \\
mai (6).
ts1 H2 ii a 1 ikr N
''s\*Nµ' ., a HC.i bli ,,---Remdesivir HO F
Sofosbuvir C\) HO
0, " 7 7'0 NH r\L NH
HO OH
--)LN114 HO
OH OH
Ribavirin N
Hd =
HO
)1e "kJ
Additionally, one can administer compounds which inhibit the cytokine storm, anti-coagulants and/or platelet aggregation inhibitors that address blood clots, compounds which chelate iron ions released from hemoglobin by viruses such as COVID-19, cytochrome P-450 (CYP450) inhibitors and/or NOX inhibitors.
Representative NOX inhibitors are disclosed in PCT/US2018/067674, and include AEBSF, Apocyanin, DPI, GK-136901, ML171, Plumbagin, S17834, VAS2870, VAS3947, GKT-831, GKT771, GTL003 or amido thiadiazole derivatives thereof, as described in AU2015365465, EP20140198597; and W02015/59659, Schisandrin B, as described in CN104147001 and CN20131179455), bi-aromatic and tri-aromatic compounds described in U.S. Publication No. 2015045387, GB 20110016017, and W0201200725, methoxyflavone derivatives described in JP 2015227329, JP 20140097875, and JP 20150093939, peptides, such as NOX2ds-tat and PR-39, as described in U.S. Publication No. 2015368301, TN
2015000295, U.S. Publication No. 201514689803, U.S. Publication No. 201462013916, PCT WO
201450063, and EP 20130150187, piperazine derivatives described in U.S.
Publication No.
2014194422, U.S. Patent No. 9428478, U.S. Publication No. 201214123877, U.S.
Publication No. 201161496161, and PCT WO 2012US41988, pyrazole derivatives disclosed in KR101280198, KR20110025151, and KR20090082518, pyrazoline di one derivatives disclosed in HK1171748, PCT W0201054329, and EP 20090171466, pyrazolo piperidine derivatives disclosed in KR20130010109, KR20130002317, EP20100153927, PCT W0201150667, EP20100153929, and PCT W020111B50668, pyrazolo pyridine derivatives described in KR20170026643, HK1158948, HK1141734, HK1159096, 11K1159092, EP20080164857, PCT
W0200954156, PCT W0200954150, EP20080164853, PCT W0200853390, U.S. Publication No. 20070896284, EP20070109555, PCT WO 200954148, EP20080164847, PCT
W0200954155, and EP20080164849, quinazoline and quinoline derivatives disclosed in EP2886120, U.S. Publication No. 2014018384, U.S. Publication No. 20100407925, EP20110836947, GB20110004600, and PCT WO 201250586, tetrahydroindole derivatives disclosed in U.S. Publication No. 2010120749, U.S. Patent No. 8,288,432, U.S.
Publication No.
20080532567, EP20070109561, U.S. Publication No. 20070908414, and PCT WO
200853704, tetrahydroisoquinoline derivatives disclosed in U.S. Publication No.
2016083351, U.S.
Publication No. 201414888390, U.S. Publication No. 201361818726, and PCT WO
201436402, Scopoletin, described in TW201325588 and TW20110147671, and 2,5-disubstituted benzoxazole and benzothiazole derivatives disclosed in TW201713650 and PCT
WO 201554662. Representative NOX inhibitors also include those disclosed in PCT
W02011062864.
Exemplary Nox inhibitors also include 2-phenylbenzo[d]isothiazol-3(2H)-one, 2-(4-methoxyphenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(benzo[d][1,3]dioxo1-5-yl)b enzo[d]i sothiazol-3 (2H)-one, 2-(2,4-dimethylphenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(4-fluorophenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(2,4-dimethylpheny1)-5-fluorob enz o [d] i sothi az 01-3 (2H)-one,
The present disclosure will be better understood with reference to the following Detailed Description.
Brief Description of the Drawings Fig. 1 shows the structure of the COV1D-19 virus nsp12-nsp7-nsp8 complex, including the domain organization of COVID-19 virus nsp12.
Fig. 2 is a schematic illustration of the structure of the N-terminal NiRAN
domain and p hairpin of RdRp. The interacting residues in the palm and fingers subdornain of the RdRp domain and the NiRAN domain are identified by the labels.
Fig. 3 is a schematic illustration showing one embodiment of how an inhibitor triphosphate can interfere with RNA synthesis.
Fig. 4 is a photograph showing the degree of polymerase inhibition when Remdesivir, or a specific nucleotide inhibitor as described herein, is added, in a dose-dependent manner (1, 10, 100, 250, or 500 uM) to a mixture including an RdRp complex and nucleoside triphosphates, and one of water (control), Remdesivir, or an inhibitor compound is added.
Detailed Description The compounds described herein show inhibitory activity against Coronaviridae in cell-based assays. Therefore, the compounds can be used to treat or prevent a Coronaviridae infection in a host, or reduce the biological activity of the virus. The host can be a mammal, and in particular, a human, infected with Coronaviridae virus. The compounds are also effective against Flaviviridae, Picornaviridae, Togavirodae and Bunyaviridae viruses. The methods involve administering an effective amount of one or more of the compounds described herein.
Pharmaceutical formulations including one or more compounds described herein, in combination with a pharmaceutically acceptable carrier or excipient, are also disclosed. In one embodiment, the formulations include at least one compound described herein and at least one further therapeutic agent.
The present disclosure will be better understood with reference to the following definitions:
I. Definitions The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
Thus, in a compound such as R"XYR", wherein R" is "independently carbon or nitrogen,"
both R" can be carbon, both R" can be nitrogen, or one R" can be carbon and the other R"
nitrogen.
As used herein, the term "enantiomerically pure" refers to a compound composition that comprises at least approximately 95%, and, preferably, approximately 97%, 98%, 99%
or 100% of a single enantiomer of that compound.
As used herein, the term "substantially free of' or "substantially in the absence of' refers to a compound composition that includes at least 85 to 90% by weight, preferably 95% to 98 % by weight, and, even more preferably, 99% to 100% by weight, of the designated enantiomer of that compound. In a preferred embodiment, the compounds described herein are substantially free of enantiomers.
Similarly, the term "isolated- refers to a compound composition that includes at least 85 to 90% by weight, preferably 95% to 98% by weight, and, even more preferably, 99% to 100% by weight, of the compound, the remainder comprising other chemical species or en anti om ers.
The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbons, including both substituted and unsubstituted alkyl groups. The alkyl group can be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included are CF3 and CH2CF3.
In the text, whenever the term C(alkyl range) is used, the term independently includes each member of that class as if specifically and separately set out. The term "alkyl"
includes C1.22 alkyl moieties, and the term "lower alkyl" includes C 1.6 alkyl moieties. It is understood to those of ordinary skill in the art that the relevant alkyl radical is named by replacing the suffix "-ane" with the suffix "-yl".
As used herein, a "bridged alkyl" refers to a bicyclo- or tricyclo alkane, for example, a 2:1:1 bicyclohexane.
As used herein, a "Spiro alkyl" refers to two rings that are attached at a single (quaternary) carbon atom.
The term "alkenyl" refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds. The alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to those described for sub stituents on alkyl moieties.
Non-limiting examples of alkenyl groups include ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane- diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
The term "alkynyl- refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds. The alkynyl group can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to those described above for alkyl moeities. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1 -yl, butyn-2-yl, pentyn-l-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3 -m ethylbutyn-l-yl, hexyn-l-yl, hexyn-2-yl, and hexyn-3-yl, 3,3 -dim ethyl butyn-l-yl radicals.
The term -alkylamino" or "arylamino" refers to an amino group that has one or two alkyl or aryl substituents, respectively.
The term "fatty alcohol" as used herein refers to straight-chain primary alcohols with between 4 and 26 carbons in the chain, preferably between 8 and 26 carbons in the chain, and most preferably, between 10 and 22 carbons in the chain. The precise chain length varies with the source. Representative fatty alcohols include lauryl, stearyl, and oleyl alcohols. They are colourless oily liquids (for smaller carbon numbers) or waxy solids, although impure samples may appear yellow. Fatty alcohols usually have an even number of carbon atoms and a single alcohol group (-OH) attached to the terminal carbon. Some are unsaturated and some are branched. They are widely used in industry. As with fatty acids, they are often referred to generically by the number of carbon atoms in the molecule, such as "a C12 alcohol", that is an alcohol having 12 carbons, for example dodecanol.
The term "protected" as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis, and are described, for example, in Greene et al., Protective Groups in Organic Synthesis, supra.
The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings can be attached together in a pendent manner or can be fused. Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or other aromatic groups that remain after the removal of a hydrogen from an aromatic ring. The term aryl includes both substituted and unsubstituted moieties. The aryl group can be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to those described above for alkyl moieties. Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N- alkylamino, N-h eteroaryl am i n o-N-al kyl amino, h eteroaral koxy, aryl amino, aral kyl amino, aryl thi o, monoarylamidosulfonyl, aryl sulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, aryl sulfinyl, aryl sulfonyl, heteroarylthio, heteroaryl sulfinyl, heteroaryl sulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, hal oal koxyal kyl , aryl, aral kyl , aryl oxy, aral koxy, aryl oxyal kyl , saturated heterocycl yl, partially saturated heterocyclyl, heteroaryl, heteroaryl oxy, heteroaryl oxy al kyl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, carboaralkoxy.
The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.
The term -halo," as used herein, includes chloro, bromo, iodo and fluoro.
The term "acyl- refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from the group consisting of straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl, including, but not limited to methoxymethyl, aralkyl, including, but not limited to, benzyl, aryloxyalkyl, such as phenoxymethyl, aryl, including, but not limited to, phenyl, optionally substituted with halogen (F, Cl, Br, or I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4), sulfonate esters such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g., dimethyl-t-butylsily1) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term "lower acyl" refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form m on oal koxyal kyl and di al koxyal kyl radicals. The " al koxy" radicals can be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy"
radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
The term "alkyl amino" denotes "monoalkylamino" and "dialkylamino" containing one or two alkyl radicals, respectively, attached to an amino radical The terms arylamino denotes "monoarylamino" and "diarylamino" containing one or two aryl radicals, respectively, attached to an amino radical. The term "aralkylamino", embraces aralkyl radicals attached to an amino radical. The term aralkylamino denotes "monoaralkylamino" and "diaralkylamino"
containing one or two aralkyl radicals, respectively, attached to an amino radical. The term aralkylamino further denotes "monoaralkyl monoalkylamino- containing one aralkyl radical and one alkyl radical attached to an amino radical.
The term "heteroatom," as used herein, refers to oxygen, sulfur, nitrogen and phosphorus.
The terms "heteroaryl" or "heteroaromatic," as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
The term "heterocyclic," "heterocyclyl," and cycloheteroalkyl refer to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl , thi enyl, i sothi az olyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thi adi azolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3 -triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, pyrimidine or pyridazine, and pteridinyl, aziridines, thiazole, isothiazole, 1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine, oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-az auracilyl , tri az ol opyri di nyl, imi daz olopyri di nyl , pyrrolopyrimidinyl, pyraz ol opyrimi di nyl , adenine, N6-alkylpurines, N6-benzylpurine, N6-halopurine, N6-vinypurine, N6-acetylenic purine, N6-acyl purine,N6-hydroxyalkyl purine, N6-thioalkyl purine, thymine, cytosine, 6-.
azapyrimidine, 2-mercaptopyrmidine, N5 -alkylpyrimidines, N5-benzylpyrimidines, N5-halopyrimi dines, N5-vinylpyrimidine, N5-acetylenic pyrimidine, N5-acyl pyrimidine, N5-hydroxyalkyl purine, and N6-thioalkyl purine, and isoxazolyl. The heteroaromatic group can be optionally substituted as described above for aryl. The heterocyclic or heteroaromatic group can be optionally substituted with one or more substituents selected from the group consisting of halogen, haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, and dialkylamino. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexyl silyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl. The heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
The term "host," as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and, preferably, humans. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds described herein. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications described herein, the host is a human being.
Veterinary applications, in certain indications, however, are clearly contemplated (such as for use in treating chimpanzees).
The term nucleoside also includes ribonucleosides, and representative ribonucleosides are disclosed, for example, in the Journal of Medicinal Chemistry, 43(23), 4516-4525 (2000), Antimicrobial Agents and Chemotherapy, 45(5), 1539-1546(2001), and PCT WO
2000069876.
The term "peptide" refers to a natural or synthetic compound containing two to one hundred amino acids linked by the carboxyl group of one amino acid to the amino group of another.
The term "pharmaceutically acceptable salt or prodrug" is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester) compound which, upon administration to a patient, provides the compound.
Pharmaceutically-acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art.
Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound described herein. Typical examples of prodrugs include compounds that have biologically labile protecting groups on functional moieties of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. The prodrug forms of the compounds described herein can possess antiviral activity, can be metabolized to form a compound that exhibits such activity, or both.
II. Active Compounds The nucleoside compounds described herein are of one of the following formulas. In one embodiment, the compounds are compounds of Formula (A) or Formula (Al):
R4R1 R1A Base R8 R8' Formula A
Base RiA
R3 ____________________________________ RE3' R8 Formula Al or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI is and R1A are, independently, H, CH3, CH?F, CHF2, or CF3, wherein, when RI
is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or R1 and RA can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl;
R3 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H, F , N 3, substituted or unsubstituted (C1-8)alkyl, substituted or unsubstituted (C2-8)alkenyl, substituted or unsubstituted (C2-8)alkynyl, 0-(C1-8) alkyl and N3 when R5 is Se, CH2, CHF, CF2, -C(CH3)-, -C(cyclopropy1)-, C=CF2 or C=CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropy1)-, C=CF2 or C=CH2, R8 and R8' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R' is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, cyano, R4 is OH, an optionally substituted 0-linked amino acid, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of R4, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
II OH
+-K
(a) OR15 where 105 selected from the group consisting of H, OH
,1OH
R. -' 1 0 OH
OH
, Li, Na, K, substituted or unsubstituted C1-20a1ky1, substituted or unsubstituted C3-6cyc10a1ky1, CI-4(alkyl)aryl, benzyl, C1-6 haloalkyl, C2-3(alky1)0C1.20alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2R16 and (CH2)0.6 CON(R16)2, where le6 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3.10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1,5 alkyl, or C1,5 alkyl substituted with a C1-6 alkyl, alkoxy, di (C1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
J .0 (b) the ester of a D- or L-amino acid R17 and R18 are independently H, C1.20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(Ci-oalkyl)- amino, fluoro, C3-10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycl oh etero al kyl , aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a CI-6a1ky1, alkoxy, di(C1-6alkyl)-amino, fluoro, C3.10 cycloalkyl, or cycloalkyl;
In one embodiment, Base is selected from the group consisting of:
N N
N N
N Xi X2 NX2 , µ1.1.1,1õ, N
N
NI/
X2 , and \NI x2 W
*nris and in another embodiment, Base is:
HN N
sjITIP
Xl is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cyc1oa1kyl, C-(CI-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-OR22, C-N(R22)2, C-halo, C-CN or N, X" is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH2, halo (i.e., F, Cl, Br, or I), SH, NHOH, 1_10)al kyl , 0(C2_10)alkene, O(C210)al kyne, 0(C3_7)cycloalkyl , -0-C(0)-alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-CI-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, S(Ci.
io)alkyl, S(C2.10)alkene, S(C2.10)alkyne, S(C37)cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((Ci_10)alky1)2, NH(C37)cycloalkyl, an optionally unsaturated NH(C0)(C1_20)alkyl, an optionally unsaturated NH(C0)0(C1_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(Ci_20)alkyl, or an optionally unsaturated NHO(CO)NH(Ci_ 20)alkyl, (C1-3)a1ky1, R9' is OH, NH2, SH, NHOH, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Rth is II or F, X2' is N or CH, and W is 0 or S
In one embodiment, IV is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H
In another embodiment, R3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In another embodiment, le is and RA are H.
In another embodiment, R8 and R8' are OH.
In another embodiment, R4 is OH or 0-P(0)R6R7.
R9' R o X2' N W
In another embodiment, Base is In one aspect of this embodiment, R9 is OH, NH2, or NHOH
X N
N x2 In another embodiment, Base is 4/jv In one aspect of this embodiment, X2 is NH2, OH or SH.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (B) or (B1):
o R1 A
Base A
p R8' Formula B
Base RiA 0 R3 ____________________________________________________________ A
R /
R8' Formula B1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RA, R2, R3, 5, _lc ¨and Rware as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR15 where R15 is selected from the group consisting of H, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, CI-4(alkyl)aryl, benzyl, Cl-6 haloalkyl, C2_3(alky1)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)()-6CO2R16 and (CH2)0_6 CON(R16)2 ,.0 N"
(b) the ester of a D- or L-amino acid , 7 and Ri8 are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6a1ky1)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1_6a1ky1, alkoxy, di(C1-6a1ky1)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl, and S., ,..R30 (C) where R3 is selected from the group consisting of substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2_10)alkene, substituted or unsubstituted (C2_10)alkyne, C1-4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
In one embodiment, R5 is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl In another embodiment, R3 is H.
In another embodiment, It3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H
In another embodiment, Rg. is OH.
In another embodiment, Y is H.
In another embodiment, R1 and RA are H.
In another embodiment, A is 0 These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (C) or (Cl):
X
R1 pp 1 A N
=N
R2 I.TX
R8 Rgi Formula C
X
/LW
RiA
_________________________________________________________ R2 R8' R8 Formula CI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, RA, ¨2, K R3, R5, R8, R8' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
In one embodiment, R5 is 0.
In another embodiment, R2 is N3 or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H.
In another embodiment, R3 is N3 or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In one embodiment, R8 and R8' are OH.
In one embodiment, Y is H.
In one embodiment, R is H.
In one embodiment, Z is H.
In one embodiment, X is OH, NH2 or NHOH.
In one embodiment, W is 0.
In one embodiment, R and R' A are H.
In one embodiment, R4 is OH or 0-P(0)R6R7.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (D) or (D1):
X
0 R1 R1 A N, __________________________________________________ ...1714 p 0 ID' Formula D
X
RiA R1 NN
R5 \\.,...õ.0\
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, RA, R2, R3, R5, Rs' and Y are as defined in Formula A, and A and D are as defined in Formula C.
In one embodiment, R5 is 0.
In another embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R3 is H.
In another embodiment, R3 is H or substituted or unsubstituted C2-8 alkynyl.
In another embodiment, R2 is CN or H.
In another embodiment, R8. is OH
In another embodiment, Y is H.
In another embodiment, R is H.
In another embodiment, Z is H.
In another embodiment, X is OH, NH2 or NHOH.
In another embodiment, W is 0.
In another embodiment, Rl and RA are H.
In another embodiment, R4 is OH or 0-P(0)R6R7.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds are compounds of Formula (E) or (El):
R4 pp . .
R A
Base¨
R2 4_ __ R3 R¨ R32 Formula E
RIA
Base R
Formula El or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Rl, RA, R2, _I( ¨ 3, and R4 are as defined in Formula A, R3 is 0 or CH2, R31 is 0 or S when R3 is 0 or CH2, R32 and R33 are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
In one embodiment, R3 is 0.
In another embodiment, R31 is 0.
In another embodiment, le2 and R33 are, independently, H or F.
In another embodiment, R2 is N3 or substituted or unsubstituted C2-8alkynyl.
In another embodiment, le is N3 or substituted or unsubstituted C2-8alkynyl.
In another embodiment, R2 is CN
In another embodiment, Rl and RA are H.
In another embodiment, R4 is OH or or 0-P(0)R6R7.
In another embodiment, Base is /
In another embodiment, Xl is N
These subfeatures can be present in any combination in any compound described herein In another embodiment, the compounds are compounds of Formula (F) or (F1).
R
R .4 RiA
Base Formula F
Base R3 ____________________________________ cç
Formula Fl or a pharmaceutically acceptable salt or prodnig thereof, wherein:
Base, RA, R2, lc ¨3, and R4 are as defined in Formula A, R34 is 0 or CH2, and R" and R36 are independently H, F or CH3 In embodiment, R35 and R36 are H.
In one embodiment, R34 is CH2.
In one embodiment, R4 is OH or or 0-P(0)R6R7.
In one embodiment, R3 is H.
In one embodiment, R2 is H or substituted or unsubstituted C2-8 alkynyl.
In one embodiment, R2 is CN or N3.
In one embodiment, le is substituted or unsubstituted C2-8 alkynyl.
In one embodiment, le and RA are H.
These subfeatures can be present in any combination in any compound described herein.
In another embodiment, the compounds have one of the following formulas:
)¨ 0 rj(NH ?L.-NH
________________________________________ 0 HO ,0 \
0 HNI-P-0, N,N0 HO,N
S'LCL; 1 SI24 S-LCL;
OPh OH OH OH OH OH OH
OH
frILNH
HO-- HO,N s HO--or) OH OH OH OH OH OH
HN-OH
?y ri)LNH
?LNH
HO, N,N--,S HO, N, N,-.0 HO, N,N0 _--0--,_ c-- _____________________________________________________________________ F
OH OH OH F OH F
, NH fri(NH NH
HO, NN 0 HO
, ,.. N- -- HO
-N 0 ---14 0 HaisN-N0 OH OH OH OH OH
OH OH
rjLNH ry 0 HO-N-LO HO N ri)LNH
HO, N,N_.L0 OH OH OH OH
OH
N N
Nz-,..r.-N
C------r-L
HO __-NI,N
/1c24 N
/ HO OH
OH
Cr.)-'N N__.--r--k-N
HO
C-A-N
\ r\1-N--1-,NH2 HO,- ._..-N,NNH2 )c_HO \ N,NNH2 //lc2_ HO OH - HO OH
)LI ""
ANH
HO-- -NO Bz0., -.N0 HO, NO
SH
NH
N--.._.,--N
>'N
NõAN IN0 N----HHON
HO_0_; 0 HOIcLO__Me OH OH HO OH HO OH
, CI
/
HO N---r\ij //' N
-,k :,=;.k 14 No 19- N..-Nci Me HO HO j HO OH
ei 0 , 0 W tie CI
, \...- 0 i , CI
N,--1-- ' N CI
I
CI
HO
)--0 I NN CI
0 , ----101 s...õ...-CI
N-,,---- 1, ---.:-,,N
[ N ----"N
-g-cl___ ,..õ.>-, -0 ----, ¨1 HO----ic V--....
,and 0 , or a pharmaceutically acceptable salt or prodrug thereof.
Tn one embodiment, the compounds have one of the following formulas:
SH
N,....õ---LN
NH N-_,}--. N
1 -,IN I
- HO ,--,...õ -;...-IN
OH OH OH OH HO OH
-/L
I 1 h..A:..-=
/ I N
HO N 0 Ho N---N--) -.
CcL4Me Me HO OH HO OH ,and , CI
N---....----LN
I
___.----......r0.,.... N---1=1 CI
In another embodiment, the compounds have one of the following formulas:
t'' NH2)..'N --)LNH
0 = 0 t -N- -II'0 N 0 )---s-')7--- 91 ii HN--0 PN0 HO --- o 0 I
OH OH OH OH OH OH
NHOH
0 -ANH HO \NH N
I I
'N ---N )1' NH
'''' 0 HO 0 N H(i) ,s1 I
HO ''''N''0 HO., '.'N 0 CI
OH OH OH OH , \ __ / 8 ....Ø) ,or , , 26 HO
In any of these embodiments, the compounds can be present in the I3-D or I3-L
configuration.
III Stereoisomerism and Polymorphism The compounds described herein can have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present disclosure. Compounds described hereinhaving a chiral center can exist in and be isolated in optically active and racemic forms. Some compounds can exhibit polymorphism. The present disclosure encompasses racemic, optically-active, polymorphic, or stereoisomeric forms, or mixtures thereof, of a compound described herein, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution. One can either purify the respective compound, then derivatize the compound to form the compounds described herein, or purify the compound themselves.
Optically active forms of the compounds can be prepared using any method known in the art, including but not limited to by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase.
Examples of methods to obtain optically active materials include at least the following.
i) physical separation of crystals: a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;
ii) simultaneous crystallization: a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;
iii) enzymatic resolutions: a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;
iv) enzymatic asymmetric synthesis: a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;
v) chemical asymmetric synthesis: a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which can be achieved using chiral catalysts or chiral auxiliaries;
vi) diastereomer separations: a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;
vii) first- and second-order asymmetric transformations: a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer;
viii) kinetic resolutions: this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;
ix) enantiospecific synthesis from non-racemic precursors: a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;
x) chiral liquid chromatography: a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including but not limited to via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
xi) chiral gas chromatography: a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;
xii) extraction with chiral solvents: a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;
xiii) transport across chiral membranes: a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier.
Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
Chiral chromatography, including but not limited to simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
IV. Salt or Prodrug Formulations In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate and a-glycerophosphate. Suitable inorganic salts can also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts. For certain transdermal applications, it can be preferred to use fatty acid salts of the compounds described herein. The fatty acid salts can help penetrate the stratum comeum. Examples of suitable salts include salts of the compounds with stearic acid, oleic acid, lineoleic acid, palmitic acid, caprylic acid, and capric acid.
Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion. In those cases where a compound includes multiple amine groups, the salts can be formed with any number of the amine groups.
Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.
A prodrug is a pharmacological substance that is administered in an inactive (or significantly less active) form and subsequently metabolized in vivo to an active metabolite.
Getting more drug to the desired target at a lower dose is often the rationale behind the use of a prodrug and is generally attributed to better absorption, distribution, metabolism, and/or excretion (ADME) properties. Prodrugs are usually designed to improve oral bioavailability, with poor absorption from the gastrointestinal tract usually being the limiting factor.
Additionally, the use of a prodrug strategy can increase the selectivity of the drug for its intended target thus reducing the potential for off target effects.
V. Methods of Treatment In one embodiment, the compounds described herein can be used to prevent, treat or cure coronavirus infections, specifically including SARS-CoV2 infections, such as SARS-CoV-2, MERS, SARS, and OC-43. In other embodiments, the compounds described herein can be used to prevent, treat or cure infections by Flaviviruses, Picornaviridae, Togavirodae and Bunyaviridae.
The methods involve administering a therapeutically or prophylactically-effective amount of at least one compound as described herein to treat, cure or prevent an infection by, or an amount sufficient to reduce the biological activity of, a coronavirus infection, or an infection caused by a Flavivirus, Picomavus, Togavirus, or Bunyavirus, or other RNA virus.
In another embodiment, the compounds described herein can be used to inhibit a coronoviral, flaviviral, picomaviral, togaviral, or bunyaviral protease, or protease associated with another RNA virus, in a cell. The method includes contacting the cell with an effective amount of a compound described herein, Hosts, including but not limited to humans infected with a coronavirus, flavivirus, picornavirus, togavirus, or bunyavirus, or other RNA virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, transdermally, subcutaneously, or topically, in liquid or solid form.
There are several species within the Coronavirus genus including, but not limited to, Middle East respiratory syndrome coronavirus (MERS-CoV), SARS coronavirus (SARS-CoV) and SARS-Cov2. In some embodiments, a compound described herein can ameliorate and/or treat a MERS-CoV infection, SARS-CoV infection, or SARS-Cov2 infection. An effective amount of a compound described herein can be administered to a subject infected with these viruses, and/or by contacting a cell infected with these viruses with an effective amount of a compound described herein. In some embodiments, a compound described herein can inhibit replication of these viruses. In some embodiments, a compound described herein can ameliorate one or more symptoms of these infections. Symptoms include, but are not limited to, extreme fatigue, malaise, headache, high fever (e.g., >100.4 F.), lethargy, confusion, rash, loss of appetite, myalgia, chills, diarrhea, dry cough, runny nose, sore throat, shortness of breath, breathing problems, gradual fall in blood-oxygen levels (such as, hypoxia) and pneumonia.
Some embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Togaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein. Some embodiments described herein relate to using one or more compounds described herein in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Togaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein.
Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Togaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Togaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s).
In some embodiments, the Togaviridae virus can be an Alphavirus. One species of an Alphavirus is a Venezuelan equine encephalitis virus (VEEV). In some embodiments, a compound described herein can ameliorate and/or treat a VEEV infection. In other embodiments, one or more compounds described herein, can be manufactured into a medicament for ameliorating and/or treating an infection caused by a VEEV that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by a VEEV that can include contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiment, the VEEV can be an epizootic subtype. In some embodiment, the VEEV can be an enzootic subtype. As described herein, the Venezuelan equine encephalitis complex of viruses includes multiple subtypes that are further divided by antigenic variants. In some embodiments, a compound described herein can be effective against more than one subtype of a VEEV, such as 2, 3, 4, 5 or 6 subtypes. In some embodiments, a compound can be used to treat, ameliorate and/or prevent VEEV subtype I. In some embodiments, a compound described herein can be effective against more than one antigenic variants of a VEEV. In some embodiments, a compound can ameliorate one or more symptoms of a VEEV infection. Examples of symptoms manifested by a subject infected with VEEV include flu-like symptoms, such as high fever, headache, myalgia, fatigue, vomiting, nausea, diarrhea, and pharyngitis. Subjects with encephalitis show one or more of the following symptoms: somnolence, convulsions, confusion, photophobia, coma and bleeding of the brain, lung(s) and/or gastrointestinal tract. In some embodiments, the subject can be human. In other embodiments, the subject can be a horse.
Chikungunya (CHIKV) is another Alphavirus species. In some embodiments, a compound described herein can ameliorate and/or treat a CHIKV infection. In other embodiments, one or more compounds described herein can be manufactured into a medicament for ameliorating and/or treating an infection caused by a CHIKV
that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by a CHIKV that can include contacting a cell infected with the virus with an effective amount of said compound(s) In some embodiments, one or more symptoms of a CHIKV infection can be ameliorated by administering an effective amount of a compound to a subject infected with CHIKV and/or by contacting an CHIKV
infected cell with an effective amount of a compound described herein. Clinical symptoms of a CHIKV infection include fever, rash (such as petechial and/or maculopapular rash), muscle pain, joint pain, fatigue, headache, nausea, vomiting, conjunctivitis, loss of taste, photophobia, insomnia, incapacitating joint pain and arthritis Other species of Alphaviruses include Barmah Forest virus, Mayaro virus (MAYV), O'nyong'nyong virus, Ross River virus (RRV), Semliki Forest virus, Sindbis virus (SINV), Una virus, Eastern equine encephalitis virus (EEE) and Western equine encephalomyelitis (WEE).
In some embodiments, one or more compounds described herein, can be used for ameliorating and/or treating an infection caused by an Alphavirus that can include contacting a cell infected with the virus with an effective amount of one or more of said compound(s) and/or administering to a subject (such as, a subject infected with the virus) an effective amount of one or more of said compound(s), wherein the Alphavirus can be selected from Barmah Forest virus, Mayaro virus (MAYV), O'nyong'nyong virus, Ross River virus (RRV), Semliki Forest virus, Sindbis virus (SINV), Una virus, Eastern equine encephalitis virus (EEE) and Western equine encephalomyelitis (WEE).
Another genus of a Coronaviridae virus is a Rubivirus. Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Rubivirus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Rubivirus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, that can be used for ameliorating and/or treating an infection caused by a Rubivirus by contacting a cell infected with the virus with an effective amount of said compound(s).
Some embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Bunyaviridae virus that can include administering to a subject an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein. Other embodiments disclosed herein relate to a method of treating and/or ameliorating an infection caused by a Bunyaviridae virus that can include administering to a subject identified as suffering from the viral infection an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes a compound described herein Some embodiments disclosed herein relate to methods of ameliorating and/or treating an infection caused by a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein. Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating an infection caused by a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, that can be used for ameliorating and/or treating an infection caused by a Bunyaviridae virus by contacting a cell infected with the virus with an effective amount of said compound(s).
Some embodiments disclosed herein relate to methods of inhibiting replication of a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein Other embodiments described herein relate to using one or more compounds described herein, in the manufacture of a medicament for inhibiting replication of a Bunyaviridae virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to a compound described herein, that can be used for inhibiting replication of a Bunyaviridae virus by contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, a compound described herein can inhibit a RNA
dependent RNA polymerase of a Bunyaviridae virus, and thereby, inhibit the replication of RNA. In some embodiments, a polymerase of a Bunyaviridae virus can be inhibited by contacting a cell infected with the Bunyaviridae virus with a compound described herein.
In some embodiments, the Bunyaviridae virus can be a Bunyavirus. In other embodiments, the Bunyaviridae virus can be a Hantavirus. In still other embodiments, the Bunyaviridae virus can be a Nairovirus. In yet still other embodiments, the Bunyaviridae virus can be a Phlebovirus. In some embodiments, the Bunyaviridae virus can be an Orthobunyavirus.
In other embodiments, the Bunyaviridae virus can be a Tospovirus.
A species of the Phlebovirus genus is Rift Valley Fever virus. In some embodiments, a compound described herein can ameliorate and/or treat a Rift Valley Fever virus infection. In other embodiments, one or more compounds described herein, can be manufactured into a medicament for ameliorating and/or treating an infection caused by a Rift Valley Fever virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). In still other embodiments, one or more compounds described herein can be used for ameliorating and/or treating an infection caused by a Rift Valley Fever virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, a compound described herein can inhibit replication of Rift Valley Fever virus, wherein said compound is administering to a subject infected with Rift Valley Fever virus and/or wherein said compound contacts a cell infected with Rift Valley Fever.
In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of one or more of the ocular form, the meningoencephalitis form, or the hemorrhagic fever form of Rift Valley Fever virus. In some embodiments, one or more symptoms of a Rift Valley Fever virus infection can be ameliorated. Examples of symptoms of a Rift Valley Fever viral infection include headache, muscle pain, joint pain, neck stiffness, sensitivity to light, loss of appetite, vomiting, myalgia, fever, fatigue, back pain, dizziness, weight loss, ocular form symptoms (for example, retinal lesions, blurred vision, decreased vision and/or permanent loss of vision), meningoencephalitis form symptoms (such as, intense headache, loss of memory, hallucinations, confusion, disorientation, vertigo, convulsions, lethargy and coma) and hemorrhagic fever form symptoms (for example, jaundice, vomiting blood, passing blood in the feces, a purpuric rash, ecchymoses, bleeding from the nose and/or gums, menorrhagia and bleeding from a venepuncture site).
Another species of the Phlebovirus genus is thrombocytopenia syndrome virus.
In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication thrombocytopenia syndrome virus. In some embodiments, a compound can ameliorate and/or treat severe fever with thrombocytopenia syndrome (SFTS). In some embodiments, a compound described herein can ameliorate one or more symptoms of SFTS.
Clinical symptoms of include the following: fever, vomiting, diarrhea, multiple organ failure, thrombocytopenia, leucopenia, and elevated liver enzyme levels.
Crimean-Congo hemorrhagic fever virus (CCHF) is a species within the Nairovirus genus. In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of Crimean-Congo hemorrhagic fever virus. Subjects infected with CCEIF have one or more of the following symptoms: flu-like symptoms (such as high fever, headache, myalgia, fatigue, vomiting, nausea, diarrhea, and/or pharyngitis), hemorrhage, mood instability, agitation, mental confusion, throat petechiae, nosebleeds, bloody urine, vomiting, black stools, swollen and/or painful liver, disseminated intravascular coagulation, acute kidney failure, shock and acute respiratory distress syndrome. In some embodiments, a compound described herein can ameliorate one or more symptoms of CCHF.
California encephalitis virus is another virus of the Bunyaviridae family, and is a member of the Orthobunavirus genus. Symptoms of a California encephalitis virus infection include, but are not limited to fever, chills, nausea, vomiting, headache, abdominal pain, lethargy, focal neurologic findings, focal motor abnormalities, paralysis, drowsiness, lack of mental alertness and orientation and seizures. In some embodiments, a compound described herein can ameliorate, treat, and/or inhibit replication of California encephalitis virus. In some embodiments, a compound described herein can ameliorate one or more symptoms of a California encephalitis viral infection.
Viruses within the Hantavirus genus can cause hantavirus hemorrhagic fever with renal syndrome (HFRS) (caused by viruses such as Hantaan River virus, Dobrava-Belgrade virus, Saaremaa virus, Seoul virus, and Puumala virus) and hantavirus pulmonary syndrome (HPS).
Viruses that can cause LIPS include, but are not limited to, Black Creek Canal virus (BCCV), New York virus (NYV), Sin Nombre virus (SNV). In some embodiments, a compound described herein can ameliorate and/or treat HFRS or HIPS. Clinical symptoms of HFRS include redness of cheeks and/or nose, fever, chills, sweaty palms, diarrhea, malaise, headaches, nausea, abdominal and back pain, respiratory problems, gastro-intestinal problems, tachycardia, hypoxemia, renal failure, proteinuria and diuresis. Clinical symptoms of HIPS
include flu-like symptoms (for example, cough, myalgia, headache, lethargy and shortness-of-breath that can deteriorate into acute respiratory failure). In some embodiments, a compound described herein can ameliorate one or more symptoms of HFRS or HPS.
Various indicators for determining the effectiveness of a method for treating and/or ameliorating a Coronaviridae, a Togaviridae, a Hepeviridae and/or a Bunyaviridae viral infection are known to those skilled in the art. Example of suitable indicators include, but are not limited to, a reduction in viral load, a reduction in viral replication, a reduction in time to seroconversion (virus undetectable in patient serum), a reduction of morbidity or mortality in clinical outcomes, and/or other indicator(s) of disease response. Further indicators include one or more overall quality of life health indicators, such as reduced illness duration, reduced illness severity, reduced time to return to normal health and normal activity, and reduced time to alleviation of one or more symptoms. In some embodiments, a compound described herein can result in the reduction, alleviation or positive indication of one or more of the aforementioned indicators compared to a subject who is untreated subject.
VI. Combination or Alternation Therapy In one embodiment, the compounds described herein can be employed together with at least one other active agent, which can be an antiviral agent. In one aspect of this embodiment, the at least one other active agent is selected from the group consisting of fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, such as remdesivir, GS-441524, N4-hydroxycytidine, and other compounds disclosed in U.S. Patent No. 9,809,616, and their prodrugs, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, NS5A inhibitors such as daclastavir, and agents of distinct or unknown mechanism.
Umifenovir (also known as Arbidol) is a representative fusion inhibitor.
Representative entry inhibitors include Camostat, luteolin, MDL28170, SSAA09E2, SSAA09E1 (which acts as a cathepsin L inhibitor), SSAA09E3, and tetra-0-galloy1-13-D-glucose (TGG). The chemical formulae of certain of these compounds are provided below:
II:
1::le /N
HN
IC '7 w Other entry inhibitors include the following:
= 1 i j AN , I oft om ' # 1 . µ'''''*4-.'' 1.. 04 , ..:, P$9.- 0- ;:r-7,,. .
11 -1 ...........................................................
.. .,..--z,,,.- ."-.0 ..=$!-----i 1 ii R.6: bii HO' . ' .
&14 A itti P 1 ti -----.,::..0 I
Remdesivir, Sofosbuvir, ribavirin, IDX-184 and GS-441524 have the following formulas:
, \\
mai (6).
ts1 H2 ii a 1 ikr N
''s\*Nµ' ., a HC.i bli ,,---Remdesivir HO F
Sofosbuvir C\) HO
0, " 7 7'0 NH r\L NH
HO OH
--)LN114 HO
OH OH
Ribavirin N
Hd =
HO
)1e "kJ
Additionally, one can administer compounds which inhibit the cytokine storm, anti-coagulants and/or platelet aggregation inhibitors that address blood clots, compounds which chelate iron ions released from hemoglobin by viruses such as COVID-19, cytochrome P-450 (CYP450) inhibitors and/or NOX inhibitors.
Representative NOX inhibitors are disclosed in PCT/US2018/067674, and include AEBSF, Apocyanin, DPI, GK-136901, ML171, Plumbagin, S17834, VAS2870, VAS3947, GKT-831, GKT771, GTL003 or amido thiadiazole derivatives thereof, as described in AU2015365465, EP20140198597; and W02015/59659, Schisandrin B, as described in CN104147001 and CN20131179455), bi-aromatic and tri-aromatic compounds described in U.S. Publication No. 2015045387, GB 20110016017, and W0201200725, methoxyflavone derivatives described in JP 2015227329, JP 20140097875, and JP 20150093939, peptides, such as NOX2ds-tat and PR-39, as described in U.S. Publication No. 2015368301, TN
2015000295, U.S. Publication No. 201514689803, U.S. Publication No. 201462013916, PCT WO
201450063, and EP 20130150187, piperazine derivatives described in U.S.
Publication No.
2014194422, U.S. Patent No. 9428478, U.S. Publication No. 201214123877, U.S.
Publication No. 201161496161, and PCT WO 2012US41988, pyrazole derivatives disclosed in KR101280198, KR20110025151, and KR20090082518, pyrazoline di one derivatives disclosed in HK1171748, PCT W0201054329, and EP 20090171466, pyrazolo piperidine derivatives disclosed in KR20130010109, KR20130002317, EP20100153927, PCT W0201150667, EP20100153929, and PCT W020111B50668, pyrazolo pyridine derivatives described in KR20170026643, HK1158948, HK1141734, HK1159096, 11K1159092, EP20080164857, PCT
W0200954156, PCT W0200954150, EP20080164853, PCT W0200853390, U.S. Publication No. 20070896284, EP20070109555, PCT WO 200954148, EP20080164847, PCT
W0200954155, and EP20080164849, quinazoline and quinoline derivatives disclosed in EP2886120, U.S. Publication No. 2014018384, U.S. Publication No. 20100407925, EP20110836947, GB20110004600, and PCT WO 201250586, tetrahydroindole derivatives disclosed in U.S. Publication No. 2010120749, U.S. Patent No. 8,288,432, U.S.
Publication No.
20080532567, EP20070109561, U.S. Publication No. 20070908414, and PCT WO
200853704, tetrahydroisoquinoline derivatives disclosed in U.S. Publication No.
2016083351, U.S.
Publication No. 201414888390, U.S. Publication No. 201361818726, and PCT WO
201436402, Scopoletin, described in TW201325588 and TW20110147671, and 2,5-disubstituted benzoxazole and benzothiazole derivatives disclosed in TW201713650 and PCT
WO 201554662. Representative NOX inhibitors also include those disclosed in PCT
W02011062864.
Exemplary Nox inhibitors also include 2-phenylbenzo[d]isothiazol-3(2H)-one, 2-(4-methoxyphenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(benzo[d][1,3]dioxo1-5-yl)b enzo[d]i sothiazol-3 (2H)-one, 2-(2,4-dimethylphenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(4-fluorophenyl)b enzo[d]i sothiazol-3 (2H)-one, 2-(2,4-dimethylpheny1)-5-fluorob enz o [d] i sothi az 01-3 (2H)-one,
5 -fluoro-2-(4-fluorophenyl)b enz o [d] i sothi azol-3 (2H)-one, 2-(2-chloro-6-methylpheny1)-5-fluorobenzo[d]isothiazol-3(2H)-one, 5-fluoro-2-phenylbenzo[d]i sothiazol-3 (2H)-one, 2-(benzo[d] [1,3] dioxo1-5 -y1)-5 -fluorobenzo[d]i sothiazol-3(2H)-one, methyl 4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl 4-(5-fluoro-3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, ethyl 4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, tert-butyl 4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl 2-methoxy-4-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, methyl 3 -chloro-4-(3 -oxob enzo[d]i sothiazol-2(3H)-yl)benzoate, 4-(3-oxobenzo[d]i sothi azol -2(3H)-yl)benzonitrile, methyl 2-(3-oxobenzo[d]isothiazol-2(3H)-yl)benzoate, 2-(4-acetylphenyl)benzo[d]i sothiazol-3 (2H)-one, 2-(4-nitrophenyl)b enzo[d]i sothi azol-3 (2H)-one, 2-(4-hydroxyphenyl)benzo[d]i sothiazol-3 (2H)-one, methyl 6-(3-oxobenzo[d]isothiazol-2(3H)-yl)nicotinate, 6-(3 -oxobenzo[d]i sothiazol-2(3H)-yl)nicotinonitrile, 2-(4-(hydroxymethyl)phenyl)benzo[d]i sothiazol-3 (2H)-one, 2-b enzylb enzo[d]i sothi azol-3 (2H)-one, N-m ethy1-4-(3 -oxob enzo [d] i sothi azol-2(3H)-yl)benzamide, 2-(4-hydroxyphenyl)benzo[d]isothiazol-3(2H)-one, 2-(2,4-dimethylpheny1)-1-methy1-1H-indazol-3(2H)-one, 2-(4-fluoropheny1)- 1 -methyl- 1 H-indazol-3 (2H)-one, 2-(2,4-dimethylpheny1)-1H-indazol-3(2H)-one, 1 -methyl-2-phenyl- 1 H-indazol-3 (2H)-one, 241,3,4-thi adi azol-2-yl)b enz o [d] i sothi azol-3 (2H)-one, 245 -phenyl-1, 3 ,4 -thi adi azol -2-yl)b enzo [d] i sothi az I-3 (2H)-one, 2-(5 -(ethyl thi o)-1, 3 ,4-thi adi azol-2-yl)b enzo [d]i s othi azol-3 (2H)-one, 245 -(rn ethylthi o)-1,3,4-thi adi azol -2-yl)b enzo[d]i sothi azol -3 (211)-one, 5 -fluoro-2-(1,3 ,4-thi adi azol-2-yl)b enz o [d] i sothi az ol-3 (2H)-one, 2-(5 -(tert-butyl)-1, 3 ,4-thi adi azol -2-yl)b enzo[d]i sothiazol-3 (2H)-one, 245 -(4 -bromopheny1)-1,3 ,4-thi adi azol-2-yl)b enzo [d] i s othi azol-3 (2H)-one 2-(4-methylthi azol-2-yl)b enzo [d]i s othi az 01-3 (2H)-one, 2-(4,5 -dimethylthiazol-2-yl)b enzo[d]i sothiazol-3 (2H)-one, 2-(b enzo[d] [1,3 ] di oxo1-5 -y1)-4, 5-difluorob enzo[d] [1,2] sel enazol-3 (2H)-one, 2-(benzo[d] [1,3] di oxo1-5 -y1)-5-fluorob enzo[d] [1,2] selenazol-3 (2H)-one, 242,3 -dihydrobenzo[b] [1,4] di oxin-6-y1)-5-fluorob enzo[d] [1,2] selenazol-3 (2H)-2-(4-(1, 3 -di oxolan-2-yl)phenyl)b enzo[d] [1,2] selenazol-3 (2H)-one, 2-(benzo[d] [1,3] di oxo1-5 -y1)-6, 7-dimethoxyb enzo[d] [1,2] sel enazol-3 (2H)-one, methyl 443 -oxob enzo[d] [1,2] selenazol-2(3 H)-yl)b enzoate, methyl 4-(3 -oxoi sothiazolo[5,4-b]pyridin-2(3H)-yl)benzoate, and ethyl 443-oxoisothiazol-2(3H)-yl)benzoate, and pharmaceutically acceptable salts and prodrugs thereof.
Additional representative NOX inhibitors include:
ri..,.,,../-=,õzz.., ,,..2-...,,_(z)n<---- ci 1 _g)n .,/1 ..,,.,...sõ,.,...,1 (Z)n ' \
Pn H H (Z)n Me0 \ Pn ...e,...V i .... ....... -'\',,,..õ,,.., /
e s- ...,.....=0 , .. /;?.õ = 4,,:;<=,-,...¨ .
.................................. I 4,41 0 FL'Il.
'' H!
.,,,,w wherein Z is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl, heterocyclic, alkylaryl, arylalkyl, hydroxyl, nitro, cyano, cyanoalkyl, azido, azidoalkyl, formyl, hydrazino, halo (F, Cl, Br, or 1), OR', MTh, SR', S (0)R' , S (0)2R' , S(0)2NEER' , S(0)2N(R' )R' , SF5, C 0 OR' , C OR', OC OR', NHCOR', N(COR')COR', SCOR', OCOOR', and NHCOOR', wherein each R' is independently H, a C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl , al kyl aryl , or aryl al kyl , wherein the groups can be substituted with one or more substituents as defined above, and n is an integer from 0-4, or a pharmaceutically acceptable salt or prodrug thereof Specific examples of these compounds include H
Ail N
I
:1 .....
.,, Ou H H
,.... N N
õC----\ 14µ''' . -.'''' .14."-' Nsk,:, ===. , _.,,,,, N. , i. ,,,,,L, )_._ il 11 Pi a meo-' ..-*
a toi2, ., -F, F
P 0,s A ir-,=< -1 F ..õ,,,,. fi sN,,,,-- '"\\,N.----\
11 1 =N'-- ?"¨*:) its,,,,, 1 N'ss".% is deuterated analogs thereof, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the NOX inhibitor is Ebselen, Neopterin, APBA, Diapocynin, or a deuterated analog thereof, or a pharmaceutically-acceptable salt or prodrug thereof.
In another embodiment, the NOX compounds are those disclosed in PCT WO
In still another embodiment, the compounds are NOX inhibitors disclosed in PCT
WO
2013/068972, which are selected from the group consisting of:
4-(2-fluoro-4-methoxypheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyri dine-3,6(2H,5H)-di one;
4-(4-chloropheny1)-2-(2-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoro-4-methoxypheny1)-5-[(1-methyl-1H-pyrazol-3 -y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-[(2-methoxypyridin-4-yl)methyl] -4-methyl-1H-pyrazo lo [4,3 -c]
pyridine-3,6(2H,5H)-dione, 2-(2-methoxypheny1)-4-methyl-5 -(pyridin-3-ylmethyl)-1H-pyrazo lo [4,3 -c]pyridine-3,6(2H,5H)-dione;
4-(4-chloro-2-fluoropheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c] pyridine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3 -ylmethyl)- 1 H-pyrazo lo [4,3 -c]pyri dine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-[(6-methoxypyridin-3 -yl)methy1]-4-methyl-1H-pyrazolo[4,3 -c]
pyridine-3,6 (2H,5H)-di one;
4-(4-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3,6(2H,5H)-di one;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-[(1-methyl-lH-pyrazo-1-3 -y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c] pyridine-3,6(2H,5H)-dione, 2-(2-chloropheny1)-4-methyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6 (2H,5H)-dione;
2-(2-chl oropheny1)-4-(4-chl oropheny1)-5 -(pyrazin-2-y1 methyl)-1H-pyrazol o[4, 3-c]
pyridine-3,6 (2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazol o[4, 3-c]
pyri dine-3 ,6(2H,5H)-di one;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3 ,6(2H,5H)-dione;
4-(4-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazo lo [4,3 -c]pyri dine-3 ,6(2H, 5H)-dione;
2-(2-methoxypheny1)-4-(3 -methoxypheny1)-5 -[(1 -methyl- 1H-pyrazo- 1-3 -yl)methy1]-1 H-pyrazolo[4, 3 -c]pyridine-3 , 6(2H, 5H)-dione;
2-(2-chloropheny1)-4-(2-fluoro-4-methoxypheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-dione, 4-(2-fluoro-4-methoxypheny1)-2-(2-methoxypheny1)-5 -[( 1 -methyl- 1H-pyrazo- 1-3 -y1) methyl]-1H-pyrazolo[4,3 -c]pyridine-3,6(2H,5H)-dione;
2-(2-methoxypheny1)-4-(4-methoxypheny1)-5 -[(1 -methyl- 1H-pyrazo- 1-3 -yl)methy1]-1 H-pyrazolo[4, 3 -cipyridine-3 , 6(2H, 5H)-dione;
2-(2-methoxypheny1)-4-(3 -methoxypheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo[4, 3-c]
pyridine-3 ,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo[4,3-c]
pyri dine-3 ,6(2H,5H)-di one;
4-(4-chl oro-2-fluoropheny1)-2-(2-chl oropheny1)-5 - [(2-methoxypyri din-4-yl)methyl] -1H-pyrazol o [4, 3 -c]pyri dine-3 , 6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2-tluoro-4-methoxypheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2,6-difluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]
pyridine-3 ,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazol o[4, 3-c]
pyridine-3 ,6(2H,5H)-dione, 2-(2-chloropheny1)-4-methyl-5-[(1-methyl-1H-pyrazol-3 -yl)methy1]-1H-pyrazolo [4, 3-c]
pyridine-3 ,6(2H,5H)-dione;
4-(3-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-methyl-443-(methylamino)pheny1]-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-di one;
2-(2-methoxypheny1)-4-(4-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2,5-ditluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(1,3-thiazol-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, 2-(2-chloropheny1)-4-[3-(dimethylamino)pheny1]-5-[(1-methyl-1H-pyrazol-3-y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(3,5-dichloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
4-(3-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-443-(dimethylamino)pheny1]-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2,6-difluoropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazol o[4,3-c]pyri dine-3,6(2H,5H)-di one;
2-(2-chloropheny1)-4-(2,5-difluoropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione; and 2-(2-chloropheny1)-443-(dimethylamino)pheny1]-5-[(1-methyl-1H-pyrazol-3-y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione.
Representative CYP450 inhibitors include, but are not limited to, amiodarone, amlodipine, apigenin, aprepitant, bergamottin (grapefruit), buprenorphine, bupropion, caffeine, cafestol, cannabidiol, celecoxib, chloramphenicol, chlorphenamine, chlorpromazine, cimetidine, cinacalcet, ciprofloxacin, citalopram, clarithromycin, clemastine, clofibrate, clomipramine, clotrimazole, cobicistat, cocaine, curcumin (turmeric), cyclizine, delavirdine, desipramine, disulfiram, diltiazem, diphenhydramine, dithiocarbamate, domperidone, doxepin, doxorubicin, duloxetine, echinacea, entacapone, erythromycin, escitalopram, felbam ate, fenofibrate, flavonoids (grapefruit), fluoroquinolones (e.g., ciprofloxacin), fluoxetine, fluvoxamine, fluconazole, fluvastatin, gabapentin, gemfibrozil, gestodene, halofantrine, haloperidol, hydroxyzine, imatinib, indomethacin, indinavir, interferon, isoniazid, itraconazole, JWH-018, ketoconazole, letrozole, lovastatin, levomepromazine, memantine, methylphenidate, metoclopramide, methadone, methimazole, methoxsalen, metyrapone, mibefradil, miconazole, midodrine, mifepristone, milk thistle, moclobemide, modafinil, montelukast, moclobemide, naringenin (grapefruit), nefazodone, nelfinavir, niacin, niacinamide, nicotine, nicotinamide,nilutamide, norfloxacin, orphenadrine, paroxetine, perphenazine, pilocarpine, piperine, phenylbutazone, probenecid, promethazine, proton pump inhibitors (e.g., lansoprazole, omeprazole, pantoprazole, rabeprazole), quercetin, quinidine, ranitidine, risperidone, ritonavir, saquinavir, selegiline, sertraline, star fruit, St.
John's wort, sulconazole, sulfamethoxazole, sulfaphenazole, telithromycin, teniposide, terbinafine, thiazolidinediones, thioridazine, ticlopidine, tioconazole, thiotepa, trimethoprim, topiramate, tranylcypromine, tripelennamine, valerian, valproic acid, verapamil, voriconazole, zafirlukast, and zuclopenthixol.
Representative ACE-2 inhibitors include sulfhydryl-containing agents, such as alacepril, captopril (capoten), and zefnopril, dicarboxylate-containing agents, such as enalapril (vasotec), ramipril (altace), quinapril (accupril), perindopril (coversyl), lisinopril (listril), benazepril (lotensin), imidapril (tanatril), trandolapril (mavik), and cilazapril (inhibace), and phosphonate-containing agents, such as fosinopril (fositen/monopril) For example, when used to treat or prevent infection, the active compound or its prodrug or pharmaceutically acceptable salt can be administered in combination or alternation with another antiviral agent including, but not limited to, those of the formulae above. In general, in combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially.
The dosage will depend on absorption, inactivation and excretion rates of the drug, as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
A number of agents for combination with the compounds described herein are disclosed in Ghosh et al., "Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics," ChemMedChem 10.1002/cmdc.202000223.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include those listed below.
Compounds for Inhibiting the Cytokine Storm Throughout its activation, the inflammatory response must be regulated to prevent a damaging systemic inflammation, also known as a "cytokine storm." A number of cytokines with anti-inflammatory properties are responsible for this, such as IL-10 and transforming growth factor 13 (TGF-13). Each cytokine acts on a different part of the inflammatory response.
For example, products of the Th2 immune response suppress the Thl immune response and vice versa.
By resolving inflammation, one can minimize collateral damage to surrounding cells, with little or no long-term damage to the patient. Accordingly, in addition to using the compounds described herein to inhibit the viral infection, one or more compounds which inhibit the cytokine storm can be co-administered.
Compounds which inhibit the cytokine storm include compounds that target fundamental immune pathways, such as the chemokine network and the cholinergic anti-inflammatory pathway.
JAK inhibitors, such as JAK 1 and JAK 2 inhibitors, can inhibit the cytokine storm, and in some cases, are also antiviral. Representative JAK inhibitors include those disclosed in U.S.
Patent No. 10,022,378, such as Jakafi, Tofacitinib, and Baricitinib, as well as LY3009104/INCB28050, Pacritinib/SB1518, VX-509, GLPG0634, INC424, R-348, CYT387, TG 10138, AEG 3482, and pharmaceutically acceptable salts and prodrugs thereof.
Still further examples include CEP-701 (Lestaurtinib), AZD1480, INC424, R-348, CYT387, TG 10138, AEG 3482, 7-iodo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-aminopheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl) acrylamide, aminopheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl) acrylamide, N-(4-m orpholi n oph enyl )thi en o [3 ,2-d]pyri mi di n -2- am i ne, methyl 2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxylate, N-(4-morpholinopheny1)-5H-pyrrolo[3,2-d]pyrimidin-2-amine, 7-(4-amino-3-methoxypheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzene- sulfonamide, N,N-dimethy1-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 1-ethy1-3-(2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyOurea, N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)metha-nesulfonami de, 2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)pheno- 1, 2-cyano-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, N-(cyanomethyl)-2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxamide, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, 1-ethy1-3-(4-(2-(4-morpholinophenylamino)thieno[3,2-dipyrimidin-7-y1)-2-(trifluoromethoxy)phenyl)urea, N-(3-nitropheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, 7-i odo-N-(3 -nitrophenyl)thieno[3 ,2-d]pyrimi din-2 -amine, N 1 -(7-(2-ethylphenyl)thi eno [3 ,2-d]pyrimidin-2-yl)benzene-1,3-diamine, N-tert-buty1-3-(2-(4-m orphol inophenyl ami no)thi en o [3 ,2-d]pyri mi di n -7-y1 )b enzen e sul fon ami de, N1-(7-i odothi eno [3 ,2-d]pyrimidin-2-yl)benzene- 1,3 -di amine, 7-(4-amino-3-(trifluoromethoxy)pheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(2-ethylpheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)aceta- mi de, N-(cyanom ethyl )-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, N-(cyanomethyl)-N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, N-(3-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, 4-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)b-enzenesulfonamide, N-(4-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-y-l)phenyl)methanesulfonamide, 7-iodo-N-(4-morpholinopheny1)-5H-pyrrolo[3,2-d]pyrimidin-2-amine, 7-(2-isopropylpheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-bromo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N7-(2-isopropylpheny1)-N2-(4-morpholinophenyl)thieno[3 ,2-d]pyri mi di n e-2, 7-di amine, N7-(4-isopropylpheny1)-N2-(4-morpholinophenyl)thieno[3,2-d]pyrimidine-2,7-diamine, 745 -amino-2-methylpheny1)-N- (4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide, 7-iodo-N-(3-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-amino-3-nitropheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(2-methoxypyridin-3-y1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, (3 -(7-i odothi eno [3 ,2-d]pyrimidin-2-ylamino)phenyl)methanol, N-tert-butyl-3 -(2-(3 -morpholinophenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)benzenesulfonamide, N-tert-buty1-3-(2-(3-(hydroxymethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, N-(4-morpholinopheny1)-7-(4-nitrophenylthio)-5H-pyrrolo[3,2-d]pyrimidin-2- -amine, N-tert-butyl-3 -(2-(3 ,4, 5 -tri m ethoxyphenyl ami no)thi en o [3 ,2-d]pyrimi- di n-7 -yl)b enzene sul fonami de, 7-(4-amino-3 -nitropheny1)-N-(3 ,4-dimethoxyphenyl)thi eno [3 ,2-d]pyrimidin-2-amine, N-(3,4-dimethoxypheny1)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine, N-tert-buty1-3-(2-(3,4-dimethoxyphenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 7-(2-aminopyri mi din- 5 -y1)-N-(3 , 4-dimethoxyphenyl)thi eno [ 3 ,2-d]pyrimidin-2-amine, N-(3,4-di methoxypheny1)-7-(2,6-di methoxypyri din-3 -yl )thi en o [3 , 2- d]-pyri mi di n-2-ami n e, N-(3 , 4-dimethoxypheny1)-7-(2,4-dimethoxypyrimidin-5 -yl)thieno[3,2-d]pyrim- idin-2-amine, 7-iodo-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine, N-tert-buty1-3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 2-cyano-N-(4-m ethyl -3 -(2-(4-m orpholi nophenyl ami no)thi en o [3 ,2-d]pyri m i di n -7-y1 )ph enyl )acetami de, ethyl 3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzoate, 7-bromo-N-(4-(2-(pyrroli din- 1 -yl)ethoxy)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, N-(3 -(2-(4-(2-(pyrroli din-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, N-(cyanomethyl)-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide, N-tert-butyl-3 morpholinophenyl amino)thi eno [3 ,2- d]pyrimi din-7-yl)b enz amide, N-tert-butyl-3 -(24441 -ethylpiperidin-4-yloxy)phenylamino)thieno- [3 ,2-d]pyrimidin-7-yl)b enzenesulfonami de, tert-buty1-4-(2-(4-(morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimidin- 7- -y1)- 1 H-pyrazol e- 1-carboxylate, 7-bromo-N-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)thieno[3,2-d]pyrimidin- -2-amine, N-tert-butyl-3-(2-(44(4-ethylpiperazin-1-yl)methyl)phenylamino)- thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, N-(444-ethylpiperazin-1-yl)methyl)pheny1)-7-(1H-pyrazol-4-y1)thi en o [3 ,2-d]pyrimi di n -2-am i ne, N-(cy an om ethyl )-3 (morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimi- din-7-yl)benzamide, N-tert-butyl-3 -(2-(4-(2-(pyrroli din- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d] -pyrimi din-7-yl)b enzenesulfonami de, tert-butyl pyrroli din- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)benzylcarb- amate, 3 -(2-(4-(2-(pyrrolidin- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d]pyrimi din-yl)benzenesulfonamide, 7-(3 -chl oro-4-fluoropheny1)-N-(4-(2-(py rrol i di n - 1 -yl)ethoxy)phenyl)thi eno- [3,2-d]pyrimidin-2-amine, tert-butyl 4-(2-(4-(1-ethylpiperidin-4-yloxy)phenylamino)thieno[3 ,2-d]pyrimidin-7-y1-)- 1H-pyrazole- 1 -carb oxyl ate, 7(b enzo [d] [ 1 , 3 ]di oxo1-5-y1)-N-(4-(morphol inomethyl)phenyl)thi eno [3 ,2-d]pyrimi din-2-amine, tert-butyl 5 -(2-(4-(morpholinomethy 1)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-y1)- 1H-indol e- 1 -carb oxyl ate, 7-(2-aminopyrimi din-5 -y1)-N-(4-(morpholinomethyl)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, tert-butyl 4-(2-(-4-(morpholinomethyl)phenylamino)thieno[3,2-dipyrimidin-7-y1)-5 , 6-di-hydropyri dine- 1 (2H)-carboxylate, tert-butyl morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)benzylcarbamate, N-(3 -(2-(4-(morpholinomethyl)phenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)phen- yl)acetami de, N-(4-(2-(4-(morpholinomethyl)phenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)phen- yl)acetami de, N-(3 -(2-(4-(morphol i n om ethyl )ph enyl ami no)thi en o [3 ,2-d]pyrimi di n -7-y1 )ph en - yl)methanesul fon ami de, 7-(4-(4-methylpiperazin- 1 -yl)pheny1)-N-(4-(morpholinomethyl)phenyl)thi eno-[3 ,2-d]pyrimidin-2-amine, N-(2-methoxy-4-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, 7-bromo-N-(3 ,4, 5 -trim ethoxyphenyl)thi eno [3 ,2-d]pyrimi di n -2-am i ne, (3 -(243 ,4, 5-trim ethoxyphenyl ami no)thi en o [3 ,2-d]pyrimi di n -7-yl)phenyl)met- hanol, (4-(2-(3 ,4, 5 -trimethoxyphenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)phen-yl)methanol, (3 -(2-(4-morpholinophenyl amino)thi eno [3 ,2-d]pyrimi din-7-yl)phenyl)methano-1, (4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanol, N-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzyl)methanesulfonamide, tert-butyl morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzylcarbamate, N-(4 -(morpholinomethyl)pheny1)-7-(3 -(piperazin-1 -yl)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, 7-(6-(2-morpholinoethyl amino)pyri din-3 -y1)-N-(3,4,5 -trimethoxyphenyl)thieno[3 ,2-d]pyrimidin-2 -amine, 7-(2-ethylpheny1)-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-(aminomethyl)pheny1)-N-(4-(morpholinomethyl)phenyl)thieno[3 ,2-d]pyrimidin-2-amine, N-(4-(1-ethylpiperidin-4-yl oxy)pheny1)-7-(1H-pyrazol -4 -yl )thi eno[3,2-d]pyri mi di n-2-am in e, N-(2,4-dimethoxypheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, 7-bromo-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3 ,4-dimethoxypheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, and pharmaceutically acceptable salts and prodrugs thereof.
HMGB1 antibodies and COX-2 inhibitors can be used, which downregulate the cytokine storm. Examples of such compounds include Actemra (Roche). Celebrex (celecoxib), a COX-2 inhibitor, can be used. IL-8 (CXCL8) inhibitors can also be used.
Chemokine receptor CCR2 antagonists, such as PF-04178903 can reduce pulmonary immune pathology.
Selective a7Ach receptor agonists, such as GTS-21 (DMXB-A) and CNI-1495, can be used. These compounds reduce TNF-a. The late mediator of sepsis, HMGB1, downregulates IFN-y pathways, and prevents the LPS-induced suppression of IL-10 and STAT 3 mechanisms.
Compounds for Treating or Preventing Blood Clots Viruses that cause respiratory infections, including Coronaviruses such as Covid-19, can be associated with pulmonary blood clots, and blood clots that can also do damage to the heart.
The compounds described herein can be co-administered with compounds that inhibit blood clot formation, such as blood thinners, or compounds that break up existing blood clots, such as tissue plasminogen activator (TPA), Integrilin (eptifibatide), abciximab (ReoPro) or tirofiban (Aggrastat).
Blood thinners prevent blood clots from forming, and keep existing blood clots from getting larger. There are two main types of blood thinners. Anticoagulants, such as heparin or warfarin (also called Coumadin), slow down biological processes for producing clots, and antiplatelet aggregation drugs, such as Plavix, aspirin, prevent blood cells called platelets from clumping together to form a clot.
By way of example, Integriling is typically administered at a dosage of 180 mcg/kg intravenous bolus administered as soon as possible following diagnosis, with 2 mcg/kg/min continuous infusion (following the initial bolus) for up to 96 hours of therapy.
Representative platelet aggregation inhibitors include glycoprotein IIB/IIIA
inhibitors, phosphodiesterase inhibitors, adenosine reuptake inhibitors, and adenosine diphosphate (ADP) receptor inhibitors. These can optionally be administered in combination with an anticoagulant.
Representative anti-coagulants include coumarins (vitamin K antagonists), heparin and derivatives thereof, including unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra-low-molecular weight heparin (ULMWH), synthetic pentasaccharide inhibitors of factor Xa, including Fondaparinux, Idraparinux, and Idrabiotaparinux, directly acting oral anticoagulants (DA0Cs), such as dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, and antithrombin protein therapeutics/thrombin inhibitors, such as bivalent drugs hirudin, lepirudin, and bivalirudin and monovalent argatroban.
Representative platelet aggregation inhibitors include pravastatin, Plavix (clopidogrel bisulfate), Pletal (cilostazol), Effient (prasugrel), Aggrenox (aspirin and dipyridamole), Brilinta (ticagrelor), caplacizumab, Kengreal (cangrelor), Persantine (dipyridamole), Ticlid (ticlopidine), Yosprala (aspirin and omeprazole).
Small Molecule Covalent CoV 3CLpro Inhibitors Representative small molecule covalent CoV 3CLpro inhibitors include the following compounds:
CI
'CI 0 , and Non-Covalent CoV 3CLpro Inhibitors Representative non-covalent CoV 3CLpro inhibitors include the following:
1. \
,..,I...
t".
'A
M A:
.:
...:
, ...,..:' se : $ ..
:. .......................................
N, .. ".
, r,.. k , ,. NS
1 x -0 (k,. e .4 e :
0\ 0 ,---- 4 ! N: :- . s si g I 4 s ... , -.--,..
:. .......... 1.. . H. ?I Pi N..",' : `. \.,-:==`' ' \
:t.4.''''' .1( N...,,,"'s ::N:....'" \y-. .. . . .. .. . . .. . .. N¨. : i rs' . 1>=741 \---,, 1 .. . . . . . . .
N., ..,i= e >
...WM, .
f OH 0=
HO-tt ¨
.=:: :.= :7 :,:. .z,:f ........ :. 43-0H
.-,,..." b 4,40 ozNi:,:
' and rt' .:: ..... NMe2:
I., .........,,,z.,::::,.
[1,..Ø<1õ,.,,..,,O...... 4 .. ..
. ,...õ:11,.: ...õ1:,...,..õ...:...õ, il -11... ti t F
)-----SARS-CoV PLpro Inhibitors Representative SARS-Cov PLpro inhibitors include the following:
S--... :::='::":.: :: .:::...,:.: R.:= .
.,?= A= :::: . :::: - .A.- .---,,,l, flii: =.'N = 0g:=''''',..
' ,;$ ...= .1 ;L:::4]: .i! .V*:.
s... ......... = 'No..N. ne A
=,,,,:: .: . =,,,' .::..t,'". :--- '=,õ::,õõ
.,:,...p.õ.. ...,,.ri:,.: = ...,:.:..,. ...:1.i:. ).,..
.... i M.õ.fir' tY == õ... ....
Ni:41. .i ....044.-...,). ...1 ,,,,t.
..
tr- --4 ,.. I
It 1 1 0.
.
8J iM
41,-. :.=z.::-.------'.-II ..'1 "I
,,.,:.:,..,..:05:
Ii and I
L4 .1, L.1 Additional compounds include the following:
.JI" I 0 e N KAU' i 11 1 ,and Additional Compounds that can be Used Additional compounds and compound classes that can be used in combination therapy include the following: Antibodies, including monoclonal antibodies (mAb), Arbidol (umifenovir), Actemra (tocilizumab), APNO1 (Aperion Biologics), ARMS-1 (which includes Cetylpyridinium chloride (CPC)), ASCO9 (Ascletis Pharma), AT-001 (Applied Therapeutics Inc.) and other aldose reductase inhibitors (ART), ATYR1923 (aTyr Pharma, Inc.), Aviptadil (Relief Therapeutics), Azvudine, Bemcentinib, BLD-2660 (Blade Therapeutics), Bevacizumab, Brensocatib, Calquence (acalabrutinib), Camostat mesylate (a TMPRSS2 inhibitor), Camrelizumab, CAP-1002 (Capricor Therapeutics), CD24Fcm, Clevudine, (OncoImmune), CM4620-IE (CalciMedica Inc., CRAC channel inhibitor), Colchicine, convalescent plasma, CYNK-001 (Sorrento Therapeutics), DAS181 (Ansun Pharma), Desferal, Dipyridamole (Persantine), Dociparstat sodium (DSTAT), Duvelisib, Eculizumab, EIDD-2801 (Ridgeback Biotherapeutics), Emapalumab, Fadraciclib (CYC065) and seliciclib (roscovitine) (Cyclin-dependent kinase (CDK) inhibitors), Farxiga (dapagliflozin), Favilavir/Favipiravir/T-705/Avigan, Galidesivir, Ganovo (danoprevir), Gil enya (fingolimod) (sphingosine 1-phosphate receptor modulator), Gimsilumab, IFX-1, Ilaris (canakinumab), intravenous immunoglobulin, Ivermectin (importin cc/J3 inhibitor), Kaletra/Aluvia (lopinavir/ritonavir), Kevzara (sarilumab), Kineret (anakinra), LAU-7b (fenretinide), Lenzilumab, Leronlimab (PRO 140), (an anti-Ang2 antibody), Leukine (sargramostim, a granulocyte macrophage colony stimulating factor), Losartan, Valsartan, and Telmisartan (Angiotensin II receptor antagonists), Meplazumab, Metablok (LSALT peptide, a DPEP1 inhibitor), Methylprednisolone and other corticosteroids, 1VIN-166 (ibudilast, Macrophage migration inhibitory factor (MIF) inhibitor), MRx-4DP0004 (a strain of bifidobacterium breve, 4D Pharma), Nafamostat (a serine protease inhibitor), Neuraminidase inhibitors like Tamiflu (oseltamivir), Nitazoxanide (nucleocapsid (N) protein inhibitor), Nivolumab, OT-101 (Mateon), Novaferon (man-made Interferon), Opaganib (yeliva) (Sphingosine kinase-2 inhibitor), Otilimab, PD-1 blocking antibody, peginterferons, such as peginterferon lambda, Pepcid (famotidine), Piclidenoson (A3 adenosine receptor agonist), Prezcobix (darunavir), PUL-042 (Pulmotect, Inc., toll-like receptor (TLR) binder), Rebif (interferon beta-la), RHB-107 (upamostat) (serine protease inhibitor, RedHill Biopharma Ltd.), Selinexor (selective inhibitor of nuclear export (SINE)), SNG001 (Synairgen, inhaled interferon beta-la), Solnatide, stem cells, including mesenchymal stem cells, Multi Stem (Athersys), and PLX (Pluristem Therapeutics), Sylvant (siltuximab), Thymosin, (TJ003234), Tradipitant (neurokinin-1 receptor antagonist), Truvada (emtricitabine and tenofovir), Ultomiris (ravulizumab-cwvz), Vazegepant (CGRP receptor antagonist or blocker), and Xofluza (baloxavir marboxil) Repurposed Antiviral Agents A number of pharmaceutical agents, including agents active against other viruses, have been evaluated against Covid-19, and found to have activity. Any of these compounds can be combined with the compounds described herein. Representative compounds include lopinavir, ritonavir, niclosamide, promazine, PNU, UC2, cinanserin (SQ 10,643), Calmidazolium (C3930), tannic acid, 3-isotheaflavin-3-gallate, theaflavin-3,3' -digallate, glycyrrhizin, S-nitroso-N-acetylpenicillamine, nelfinavir, niclosamide, chloroquine, hydroxychloroquine, 5-benzyloxygramine, ribavirin, Interferons, such as Interferon (IFN)-a, IFN-13, and pegylated versions thereof, as well as combinations of these compounds with ribavirin, chlorpromazine hydrochloride, triflupromazine hydrochloride, gemcitabine, imatinib mesyl ate, dasatinib, and imatinib.
VIII. Pharmaceutical Compositions Hosts, including but not limited to humans, infected with a Coronviridae virus, or the other viruses described, herein can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
A preferred dose of the compound for will be in the range of between about 0.01 and about 10 mg/kg, more generally, between about 0.1 and 5 mg/kg, and, preferably, between about 0.5 and about 2 mg/kg, of body weight of the recipient per day, until the patient has recovered. In some cases, a compound may be administered at a dosage of up to 10 nM, which might be considered a relatively high dose if administered for an extended period of time, but which can be acceptable when administered for the duration of an infection with one or more of the viruses described herein, which is typically on the order of several days to several weeks.
The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent compound to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 600 mg, preferably 70 to 600 mg of active ingredient per unit dosage form. An oral dosage of 5-400 mg is usually convenient.
The concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
The active ingredient can be administered at once, or can be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup can contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories or other antiviral compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
Transdermal Formulations In some embodiments, the compositions are present in the form of transdermal formulations, such as that used in the FDA-approved agonist rotigitine transdetmal (Neupro patch). Another suitable formulation is that described in U.S. Publication No.
20080050424, entitled "Transdermal Therapeutic System for Treating Parkinsonism." This formulation includes a silicone or acrylate-based adhesive, and can include an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.
The transdermal formulations can be single-phase matrices that include a backing layer, an active substance-containing self-adhesive matrix, and a protective film to be removed prior to use. More complicated embodiments contain multiple-layer matrices that may also contain non-adhesive layers and control membranes. If a polyacrylate adhesive is used, it can be crosslinked with multivalent metal ions such as zinc, calcium, aluminum, or titanium ions, such as aluminum acetylacetonate and titanium acetylacetonate.
When silicone adhesives are used, they are typically polydimethylsiloxanes.
However, other organic residues such as, for example, ethyl groups or phenyl groups may in principle be present instead of the methyl groups. Because the active compounds are amines, it may be advantageous to use amine-resistant adhesives. Representative amine- resistant adhesives are described, for example, in EP 0 180 377.
Representative acrylate-based polymer adhesives include acrylic acid, acrylamide, hexyl acryl at e, 2-ethyl hexyl acryl at e, hydroxyethyl acryl ate, o ctyl acryl ate, butyl ac ryl ate, methylacrylate, glycidylacrylate, methacrylic acid, methacryl amide, hexylmethacrylate, 2-ethyl hexylm ethacryl ate, octylm ethacryl ate, methyl m ethacrylate, gl yci dylm ethacryl ate, vinylacetate, vinylpyrrolidone, and combinations thereof.
The adhesive must have a suitable dissolving capacity for the active substance, and the active substance most be able to move within the matrix, and be able to cross through the contact surface to the skin. Those of skill in the art can readily formulate a transdermal formulation with appropriate transdermal transport of the active substance.
Certain pharmaceutically acceptable salts tend to be more preferred for use in transdermal formulations, because they can help the active substance pass the barrier of the stratum corneum. Examples include fatty acid salts, such as stearic acid and oleic acid salts.
Oleate and stearate salts are relatively lipophilic, and can even act as a permeation enhancer in the skin.
Permeation enhancers can also be used. Representative permeation enhancers include fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, glycerol or its fatty acid esters, N-methylpyrrolidone, terpenes such as limonene, alpha-pinene, alpha-terpineol, carvone, carveol, limonene oxide, pinene oxide, and 1,8-eucalyptol.
The patches can generally be prepared by dissolving or suspending the active agent in ethanol or in another suitable organic solvent, then adding the adhesive solution with stirring.
Additional auxiliary substances can be added either to the adhesive solution, the active substance solution or to the active substance-containing adhesive solution.
The solution can then be coated onto a suitable sheet, the solvents removed, a backing layer laminated onto the matrix layer, and patches punched out of the total laminate.
Nanoparticulate Compositions The compounds described herein can also be administered in the form of nanoparticulate compositions. In one embodiment, controlled release nanoparticulate formulations comprise a nanoparticulate active agent to be administered and a rate-controlling polymer which prolongs the release of the agent following administration. In this embodiment, the compositions can release the active agent, following administration, for a time period ranging from about 2 to about 24 hours or up to 30 days or longer. Representative controlled release formulations including a nanoparticulate form of the active agent are described, for example, in U.S. Patent No. 8,293,277.
Nanoparticulate compositions can comprise particles of the active agents described herein, having a non-crosslinked surface stabilizer adsorbed onto, or associated with, their surface.
The average particle size of the nanoparticulates is typically less than about 800 nm, more typically less than about 600 nm, still more typically less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, or less than about 50 nm. In one aspect of this embodiment, at least 50% of the particles of active agent have an average particle size of less than about 800, 600, 400, 300, 250, 100, or 50 nm, respectively, when measured by light scattering techniques.
A variety of surface stabilizers are typically used with nanoparticulate compositions to prevent the particles from clumping or aggregating. Representative surface stabilizers are selected from the group consisting of gelatin, lecithin, dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrroli done, tyloxapol, poloxamers, poloxamines, poloxamine 908, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, an alkyl aryl polyether sulfonate, a mixture of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), SA9OHCO, decanoyl-N-methylglucamide, n-decyl -D-glucopyranoside, n-decyl-D-m altopyranosi de, n-dodecyl -D-glucopyran osi de, n-dodecyl -D-m altosi de, heptanoyl -N-methylglucamide, n-heptyl-D-glucopyranoside, n-heptyl-D-thioglucoside, n-hexyl-D-glucopyranoside, nonanoyl-N-methylglucamide, n-nonyl-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl-D-glucopyranoside, and octyl-D-thioglucopyranoside.
Lysozymes can also be used as surface stabilizers for nanoparticulate compositions.
Certain nanoparticles such as poly(lactic-co-glycolic acid) (PLGA)-nanoparticles are known to target the liver when given by intravenous (IV) or subcutaneously (SQ).
Representative rate controlling polymers into which the nanoparticles can be formulated include chitosan, polyethylene oxide (PEO), polyvinyl acetate phthalate, gum arabic, agar, guar gum, cereal gums, dextran, casein, gelatin, pectin, carrageenan, waxes, shellac, hydrogenated vegetable oils, polyvinyl pyrroli done, hydroxypropyl cellulose (HF'C), hydroxyethyl cellulose (HEC), hydroxypropyl methylcelluose (HPMC), sodium carboxymethylcellulose (CMC), poly(ethylene) oxide, alkyl cellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydrophilic cellulose derivatives, polyethylene glycol, polyvinylpyrrolidone, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinyl acetaldiethylamino acetate, poly(alkylmethacrylate), poly(vinyl acetate), polymers derived from acrylic or methacrylic acid and their respective esters, and copolymers derived from acrylic or methacrylic acid and their respective esters.
Methods of making nanoparticulate compositions are described, for example, in U.S.
Pat. Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances;"
U.S. Pat. No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;" and U.S. Pat. No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles."
Nanoparticulate compositions are also described, for example, in U.S. Pat. No.
5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" U.S. Pat. No. 5,302,401 for "Method to Reduce Particle Size Growth During Lyophilization;" U.S. Pat. No. 5,318,767 for "X-Ray Contrast Compositions Useful in Medical Imaging;" U.S. Pat. No. 5,326,552 for "Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" U.S.
Pat. No.
5,328,404 for "Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;" U.S. Pat.
No. 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;" U.S.
Pat. No. 5,340,564 for Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;" U.S. Pat. No. 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;" U.S. Pat. No.
5,349,957 for "Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;" U.S. Pat.
No. 5,352,459 for "Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;" U.S. Pat. Nos. 5,399,363 and 5,494,683, both for "Surface Modified Anticancer Nanoparticles;" U.S. Pat. No. 5,401,492 for "Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;" U.S. Pat. No. 5,429,824 for "Use of Tyloxapol as a Nanoparticulate Stabilizer;" U.S. Pat. No. 5,447,710 for "Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" U.S. Pat. No. 5,451,393 for "X-Ray Contrast Compositions Useful in Medical Imaging;" U.S. Pat. No. 5,466,440 for "Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays;"
U.S. Pat. No.
5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation;" U.S. Pat. No. 5,472,683 for "Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,500,204 for "Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S.
Pat. No.
5,518,738 for "Nanoparticulate NSAID Formulations;" U.S. Pat. No. 5,521,218 for "Nanoparticulate Iododipamide Derivatives for Use as X-Ray Contrast Agents;"
U.S. Pat. No.
5,525,328 for "Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,543,133 for "Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;" U.S. Pat. No. 5,552,160 for "Surface Modified NSAID Nanoparticles;" U.S. Pat. No. 5,560,931 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" U.S. Pat. No.
5,565,188 for "Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles;" U.S.
Pat. No.
5,569,448 for "Sulfated Non-ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions;" U.S. Pat. No. 5,571,536 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" U.S. Pat. No.
5,573,749 for "Nanoparticulate Diagnostic Mixed Carboxylic Anydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,573,750 for "Diagnostic Imaging X-Ray Contrast Agents;" U.S. Pat. No. 5,573,783 for "Redispersible Nanoparticulate Film Matrices With Protective Overcoats;" U.S. Pat. No. 5,580,579 for "Site-specific Adhesion Within the GI
Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers;" U.S. Pat. No. 5,585,108 for "Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays;" U.S. Pat. No.
5,587,143 for "Butylene Oxide-Ethylene Oxide Block Copolymers Surfactants as Stabilizer Coatings for Nanoparticulate Compositions: U.S. Pat. No. 5,591,456 for "Milled Naproxen with Hydroxypropyl Cellulose as Dispersion Stabilizer: U.S. Pat. No. 5,593,657 for "Novel Barium Salt Formulations Stabilized by Non-ionic and Anionic Stabilizers;" U.S. Pat.
No. 5,622,938 for "Sugar Based Surfactant for Nanocrystals;" U.S. Pat. No. 5,628,981 for "Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents;" U.S. Pat. No. 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging," U.S. Pat. No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances: U.S. Pat. No. 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen;" U.S. Pat. No. 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle Dispersions: U.S. Pat. No. 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions;" U.S.
Pat. No.
Additional representative NOX inhibitors include:
ri..,.,,../-=,õzz.., ,,..2-...,,_(z)n<---- ci 1 _g)n .,/1 ..,,.,...sõ,.,...,1 (Z)n ' \
Pn H H (Z)n Me0 \ Pn ...e,...V i .... ....... -'\',,,..õ,,.., /
e s- ...,.....=0 , .. /;?.õ = 4,,:;<=,-,...¨ .
.................................. I 4,41 0 FL'Il.
'' H!
.,,,,w wherein Z is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl, heterocyclic, alkylaryl, arylalkyl, hydroxyl, nitro, cyano, cyanoalkyl, azido, azidoalkyl, formyl, hydrazino, halo (F, Cl, Br, or 1), OR', MTh, SR', S (0)R' , S (0)2R' , S(0)2NEER' , S(0)2N(R' )R' , SF5, C 0 OR' , C OR', OC OR', NHCOR', N(COR')COR', SCOR', OCOOR', and NHCOOR', wherein each R' is independently H, a C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, heteroaryl , al kyl aryl , or aryl al kyl , wherein the groups can be substituted with one or more substituents as defined above, and n is an integer from 0-4, or a pharmaceutically acceptable salt or prodrug thereof Specific examples of these compounds include H
Ail N
I
:1 .....
.,, Ou H H
,.... N N
õC----\ 14µ''' . -.'''' .14."-' Nsk,:, ===. , _.,,,,, N. , i. ,,,,,L, )_._ il 11 Pi a meo-' ..-*
a toi2, ., -F, F
P 0,s A ir-,=< -1 F ..õ,,,,. fi sN,,,,-- '"\\,N.----\
11 1 =N'-- ?"¨*:) its,,,,, 1 N'ss".% is deuterated analogs thereof, or a pharmaceutically acceptable salt or prodrug thereof.
In one embodiment, the NOX inhibitor is Ebselen, Neopterin, APBA, Diapocynin, or a deuterated analog thereof, or a pharmaceutically-acceptable salt or prodrug thereof.
In another embodiment, the NOX compounds are those disclosed in PCT WO
In still another embodiment, the compounds are NOX inhibitors disclosed in PCT
WO
2013/068972, which are selected from the group consisting of:
4-(2-fluoro-4-methoxypheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyri dine-3,6(2H,5H)-di one;
4-(4-chloropheny1)-2-(2-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoro-4-methoxypheny1)-5-[(1-methyl-1H-pyrazol-3 -y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-[(2-methoxypyridin-4-yl)methyl] -4-methyl-1H-pyrazo lo [4,3 -c]
pyridine-3,6(2H,5H)-dione, 2-(2-methoxypheny1)-4-methyl-5 -(pyridin-3-ylmethyl)-1H-pyrazo lo [4,3 -c]pyridine-3,6(2H,5H)-dione;
4-(4-chloro-2-fluoropheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c] pyridine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3 -ylmethyl)- 1 H-pyrazo lo [4,3 -c]pyri dine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-[(6-methoxypyridin-3 -yl)methy1]-4-methyl-1H-pyrazolo[4,3 -c]
pyridine-3,6 (2H,5H)-di one;
4-(4-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3,6(2H,5H)-di one;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-[(1-methyl-lH-pyrazo-1-3 -y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-(5-chloro-2-fluoropheny1)-2-(2-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c] pyridine-3,6(2H,5H)-dione, 2-(2-chloropheny1)-4-methyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6 (2H,5H)-dione;
2-(2-chl oropheny1)-4-(4-chl oropheny1)-5 -(pyrazin-2-y1 methyl)-1H-pyrazol o[4, 3-c]
pyridine-3,6 (2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazol o[4, 3-c]
pyri dine-3 ,6(2H,5H)-di one;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3 ,6(2H,5H)-dione;
4-(4-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazo lo [4,3 -c]pyri dine-3 ,6(2H, 5H)-dione;
2-(2-methoxypheny1)-4-(3 -methoxypheny1)-5 -[(1 -methyl- 1H-pyrazo- 1-3 -yl)methy1]-1 H-pyrazolo[4, 3 -c]pyridine-3 , 6(2H, 5H)-dione;
2-(2-chloropheny1)-4-(2-fluoro-4-methoxypheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-dione, 4-(2-fluoro-4-methoxypheny1)-2-(2-methoxypheny1)-5 -[( 1 -methyl- 1H-pyrazo- 1-3 -y1) methyl]-1H-pyrazolo[4,3 -c]pyridine-3,6(2H,5H)-dione;
2-(2-methoxypheny1)-4-(4-methoxypheny1)-5 -[(1 -methyl- 1H-pyrazo- 1-3 -yl)methy1]-1 H-pyrazolo[4, 3 -cipyridine-3 , 6(2H, 5H)-dione;
2-(2-methoxypheny1)-4-(3 -methoxypheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo[4, 3-c]
pyridine-3 ,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(pyridin-3 -ylmethyl)-1H-pyrazolo[4,3-c]
pyri dine-3 ,6(2H,5H)-di one;
4-(4-chl oro-2-fluoropheny1)-2-(2-chl oropheny1)-5 - [(2-methoxypyri din-4-yl)methyl] -1H-pyrazol o [4, 3 -c]pyri dine-3 , 6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2-tluoro-4-methoxypheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2,6-difluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3 -c]
pyridine-3 ,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazol o[4, 3-c]
pyridine-3 ,6(2H,5H)-dione, 2-(2-chloropheny1)-4-methyl-5-[(1-methyl-1H-pyrazol-3 -yl)methy1]-1H-pyrazolo [4, 3-c]
pyridine-3 ,6(2H,5H)-dione;
4-(3-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-5-methyl-443-(methylamino)pheny1]-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-di one;
2-(2-methoxypheny1)-4-(4-methoxypheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2-fluoropheny1)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(2,5-ditluoropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(4-chloropheny1)-5-(1,3-thiazol-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, 2-(2-chloropheny1)-4-[3-(dimethylamino)pheny1]-5-[(1-methyl-1H-pyrazol-3-y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-4-(3,5-dichloropheny1)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
4-(3-chloro-2-fluoropheny1)-2-(2-chloropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chloropheny1)-443-(dimethylamino)pheny1]-5-(pyridin-3-ylmethyl)-1H-pyrazolo [4,3 -c]pyri dine-3 ,6(2H, 5H)-di one;
2-(2-chloropheny1)-4-(2,6-difluoropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione;
4-(2-fluoro-5-methoxypheny1)-2-(2-methoxypheny1)-5-(pyrazin-2-ylmethyl)-1H-pyrazol o[4,3-c]pyri dine-3,6(2H,5H)-di one;
2-(2-chloropheny1)-4-(2,5-difluoropheny1)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]
pyridine-3,6(2H,5H)-dione; and 2-(2-chloropheny1)-443-(dimethylamino)pheny1]-5-[(1-methyl-1H-pyrazol-3-y1) methyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione.
Representative CYP450 inhibitors include, but are not limited to, amiodarone, amlodipine, apigenin, aprepitant, bergamottin (grapefruit), buprenorphine, bupropion, caffeine, cafestol, cannabidiol, celecoxib, chloramphenicol, chlorphenamine, chlorpromazine, cimetidine, cinacalcet, ciprofloxacin, citalopram, clarithromycin, clemastine, clofibrate, clomipramine, clotrimazole, cobicistat, cocaine, curcumin (turmeric), cyclizine, delavirdine, desipramine, disulfiram, diltiazem, diphenhydramine, dithiocarbamate, domperidone, doxepin, doxorubicin, duloxetine, echinacea, entacapone, erythromycin, escitalopram, felbam ate, fenofibrate, flavonoids (grapefruit), fluoroquinolones (e.g., ciprofloxacin), fluoxetine, fluvoxamine, fluconazole, fluvastatin, gabapentin, gemfibrozil, gestodene, halofantrine, haloperidol, hydroxyzine, imatinib, indomethacin, indinavir, interferon, isoniazid, itraconazole, JWH-018, ketoconazole, letrozole, lovastatin, levomepromazine, memantine, methylphenidate, metoclopramide, methadone, methimazole, methoxsalen, metyrapone, mibefradil, miconazole, midodrine, mifepristone, milk thistle, moclobemide, modafinil, montelukast, moclobemide, naringenin (grapefruit), nefazodone, nelfinavir, niacin, niacinamide, nicotine, nicotinamide,nilutamide, norfloxacin, orphenadrine, paroxetine, perphenazine, pilocarpine, piperine, phenylbutazone, probenecid, promethazine, proton pump inhibitors (e.g., lansoprazole, omeprazole, pantoprazole, rabeprazole), quercetin, quinidine, ranitidine, risperidone, ritonavir, saquinavir, selegiline, sertraline, star fruit, St.
John's wort, sulconazole, sulfamethoxazole, sulfaphenazole, telithromycin, teniposide, terbinafine, thiazolidinediones, thioridazine, ticlopidine, tioconazole, thiotepa, trimethoprim, topiramate, tranylcypromine, tripelennamine, valerian, valproic acid, verapamil, voriconazole, zafirlukast, and zuclopenthixol.
Representative ACE-2 inhibitors include sulfhydryl-containing agents, such as alacepril, captopril (capoten), and zefnopril, dicarboxylate-containing agents, such as enalapril (vasotec), ramipril (altace), quinapril (accupril), perindopril (coversyl), lisinopril (listril), benazepril (lotensin), imidapril (tanatril), trandolapril (mavik), and cilazapril (inhibace), and phosphonate-containing agents, such as fosinopril (fositen/monopril) For example, when used to treat or prevent infection, the active compound or its prodrug or pharmaceutically acceptable salt can be administered in combination or alternation with another antiviral agent including, but not limited to, those of the formulae above. In general, in combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially.
The dosage will depend on absorption, inactivation and excretion rates of the drug, as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
A number of agents for combination with the compounds described herein are disclosed in Ghosh et al., "Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics," ChemMedChem 10.1002/cmdc.202000223.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include those listed below.
Compounds for Inhibiting the Cytokine Storm Throughout its activation, the inflammatory response must be regulated to prevent a damaging systemic inflammation, also known as a "cytokine storm." A number of cytokines with anti-inflammatory properties are responsible for this, such as IL-10 and transforming growth factor 13 (TGF-13). Each cytokine acts on a different part of the inflammatory response.
For example, products of the Th2 immune response suppress the Thl immune response and vice versa.
By resolving inflammation, one can minimize collateral damage to surrounding cells, with little or no long-term damage to the patient. Accordingly, in addition to using the compounds described herein to inhibit the viral infection, one or more compounds which inhibit the cytokine storm can be co-administered.
Compounds which inhibit the cytokine storm include compounds that target fundamental immune pathways, such as the chemokine network and the cholinergic anti-inflammatory pathway.
JAK inhibitors, such as JAK 1 and JAK 2 inhibitors, can inhibit the cytokine storm, and in some cases, are also antiviral. Representative JAK inhibitors include those disclosed in U.S.
Patent No. 10,022,378, such as Jakafi, Tofacitinib, and Baricitinib, as well as LY3009104/INCB28050, Pacritinib/SB1518, VX-509, GLPG0634, INC424, R-348, CYT387, TG 10138, AEG 3482, and pharmaceutically acceptable salts and prodrugs thereof.
Still further examples include CEP-701 (Lestaurtinib), AZD1480, INC424, R-348, CYT387, TG 10138, AEG 3482, 7-iodo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-aminopheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl) acrylamide, aminopheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl) acrylamide, N-(4-m orpholi n oph enyl )thi en o [3 ,2-d]pyri mi di n -2- am i ne, methyl 2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxylate, N-(4-morpholinopheny1)-5H-pyrrolo[3,2-d]pyrimidin-2-amine, 7-(4-amino-3-methoxypheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzene- sulfonamide, N,N-dimethy1-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 1-ethy1-3-(2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyOurea, N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)metha-nesulfonami de, 2-methoxy-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)pheno- 1, 2-cyano-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, N-(cyanomethyl)-2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidine-7-carboxamide, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, 1-ethy1-3-(4-(2-(4-morpholinophenylamino)thieno[3,2-dipyrimidin-7-y1)-2-(trifluoromethoxy)phenyl)urea, N-(3-nitropheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, 7-i odo-N-(3 -nitrophenyl)thieno[3 ,2-d]pyrimi din-2 -amine, N 1 -(7-(2-ethylphenyl)thi eno [3 ,2-d]pyrimidin-2-yl)benzene-1,3-diamine, N-tert-buty1-3-(2-(4-m orphol inophenyl ami no)thi en o [3 ,2-d]pyri mi di n -7-y1 )b enzen e sul fon ami de, N1-(7-i odothi eno [3 ,2-d]pyrimidin-2-yl)benzene- 1,3 -di amine, 7-(4-amino-3-(trifluoromethoxy)pheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(2-ethylpheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)aceta- mi de, N-(cyanom ethyl )-N-(3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, N-(cyanomethyl)-N-(4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, N-(3-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenyl)methanesulfonamide, 4-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)b-enzenesulfonamide, N-(4-(5-methy1-2-(4-morpholinophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-y-l)phenyl)methanesulfonamide, 7-iodo-N-(4-morpholinopheny1)-5H-pyrrolo[3,2-d]pyrimidin-2-amine, 7-(2-isopropylpheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-bromo-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N7-(2-isopropylpheny1)-N2-(4-morpholinophenyl)thieno[3 ,2-d]pyri mi di n e-2, 7-di amine, N7-(4-isopropylpheny1)-N2-(4-morpholinophenyl)thieno[3,2-d]pyrimidine-2,7-diamine, 745 -amino-2-methylpheny1)-N- (4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide, 7-iodo-N-(3-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-amino-3-nitropheny1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(2-methoxypyridin-3-y1)-N-(4-morpholinophenyl)thieno[3,2-d]pyrimidin-2-amine, (3 -(7-i odothi eno [3 ,2-d]pyrimidin-2-ylamino)phenyl)methanol, N-tert-butyl-3 -(2-(3 -morpholinophenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)benzenesulfonamide, N-tert-buty1-3-(2-(3-(hydroxymethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, N-(4-morpholinopheny1)-7-(4-nitrophenylthio)-5H-pyrrolo[3,2-d]pyrimidin-2- -amine, N-tert-butyl-3 -(2-(3 ,4, 5 -tri m ethoxyphenyl ami no)thi en o [3 ,2-d]pyrimi- di n-7 -yl)b enzene sul fonami de, 7-(4-amino-3 -nitropheny1)-N-(3 ,4-dimethoxyphenyl)thi eno [3 ,2-d]pyrimidin-2-amine, N-(3,4-dimethoxypheny1)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine, N-tert-buty1-3-(2-(3,4-dimethoxyphenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 7-(2-aminopyri mi din- 5 -y1)-N-(3 , 4-dimethoxyphenyl)thi eno [ 3 ,2-d]pyrimidin-2-amine, N-(3,4-di methoxypheny1)-7-(2,6-di methoxypyri din-3 -yl )thi en o [3 , 2- d]-pyri mi di n-2-ami n e, N-(3 , 4-dimethoxypheny1)-7-(2,4-dimethoxypyrimidin-5 -yl)thieno[3,2-d]pyrim- idin-2-amine, 7-iodo-N-(4-(morpholinomethyl)phenyl)thieno[3,2-d]pyrimidin-2-amine, N-tert-buty1-3-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, 2-cyano-N-(4-m ethyl -3 -(2-(4-m orpholi nophenyl ami no)thi en o [3 ,2-d]pyri m i di n -7-y1 )ph enyl )acetami de, ethyl 3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzoate, 7-bromo-N-(4-(2-(pyrroli din- 1 -yl)ethoxy)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, N-(3 -(2-(4-(2-(pyrroli din-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, N-(cyanomethyl)-3-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)benzamide, N-tert-butyl-3 morpholinophenyl amino)thi eno [3 ,2- d]pyrimi din-7-yl)b enz amide, N-tert-butyl-3 -(24441 -ethylpiperidin-4-yloxy)phenylamino)thieno- [3 ,2-d]pyrimidin-7-yl)b enzenesulfonami de, tert-buty1-4-(2-(4-(morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimidin- 7- -y1)- 1 H-pyrazol e- 1-carboxylate, 7-bromo-N-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)thieno[3,2-d]pyrimidin- -2-amine, N-tert-butyl-3-(2-(44(4-ethylpiperazin-1-yl)methyl)phenylamino)- thieno[3,2-d]pyrimidin-7-yl)benzenesulfonamide, N-(444-ethylpiperazin-1-yl)methyl)pheny1)-7-(1H-pyrazol-4-y1)thi en o [3 ,2-d]pyrimi di n -2-am i ne, N-(cy an om ethyl )-3 (morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimi- din-7-yl)benzamide, N-tert-butyl-3 -(2-(4-(2-(pyrroli din- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d] -pyrimi din-7-yl)b enzenesulfonami de, tert-butyl pyrroli din- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)benzylcarb- amate, 3 -(2-(4-(2-(pyrrolidin- 1 -yl)ethoxy)phenyl amino)thi eno [3 ,2-d]pyrimi din-yl)benzenesulfonamide, 7-(3 -chl oro-4-fluoropheny1)-N-(4-(2-(py rrol i di n - 1 -yl)ethoxy)phenyl)thi eno- [3,2-d]pyrimidin-2-amine, tert-butyl 4-(2-(4-(1-ethylpiperidin-4-yloxy)phenylamino)thieno[3 ,2-d]pyrimidin-7-y1-)- 1H-pyrazole- 1 -carb oxyl ate, 7(b enzo [d] [ 1 , 3 ]di oxo1-5-y1)-N-(4-(morphol inomethyl)phenyl)thi eno [3 ,2-d]pyrimi din-2-amine, tert-butyl 5 -(2-(4-(morpholinomethy 1)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-y1)- 1H-indol e- 1 -carb oxyl ate, 7-(2-aminopyrimi din-5 -y1)-N-(4-(morpholinomethyl)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, tert-butyl 4-(2-(-4-(morpholinomethyl)phenylamino)thieno[3,2-dipyrimidin-7-y1)-5 , 6-di-hydropyri dine- 1 (2H)-carboxylate, tert-butyl morpholinomethyl)phenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)benzylcarbamate, N-(3 -(2-(4-(morpholinomethyl)phenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)phen- yl)acetami de, N-(4-(2-(4-(morpholinomethyl)phenylamino)thi eno [3 ,2-d]pyrimidin-7-yl)phen- yl)acetami de, N-(3 -(2-(4-(morphol i n om ethyl )ph enyl ami no)thi en o [3 ,2-d]pyrimi di n -7-y1 )ph en - yl)methanesul fon ami de, 7-(4-(4-methylpiperazin- 1 -yl)pheny1)-N-(4-(morpholinomethyl)phenyl)thi eno-[3 ,2-d]pyrimidin-2-amine, N-(2-methoxy-4-(2-(4-(morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)acetamide, 7-bromo-N-(3 ,4, 5 -trim ethoxyphenyl)thi eno [3 ,2-d]pyrimi di n -2-am i ne, (3 -(243 ,4, 5-trim ethoxyphenyl ami no)thi en o [3 ,2-d]pyrimi di n -7-yl)phenyl)met- hanol, (4-(2-(3 ,4, 5 -trimethoxyphenyl amino)thi eno [3 ,2-d]pyrimidin-7-yl)phen-yl)methanol, (3 -(2-(4-morpholinophenyl amino)thi eno [3 ,2-d]pyrimi din-7-yl)phenyl)methano-1, (4-(2-(4-morpholinophenylamino)thieno[3,2-d]pyrimidin-7-yl)phenyl)methanol, N-(pyrrolidin-1-yl)ethoxy)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzyl)methanesulfonamide, tert-butyl morpholinomethyl)phenylamino)thieno[3,2-d]pyrimidin-7-yl)benzylcarbamate, N-(4 -(morpholinomethyl)pheny1)-7-(3 -(piperazin-1 -yl)phenyl)thi eno [3 ,2-d]pyrimidin-2-amine, 7-(6-(2-morpholinoethyl amino)pyri din-3 -y1)-N-(3,4,5 -trimethoxyphenyl)thieno[3 ,2-d]pyrimidin-2 -amine, 7-(2-ethylpheny1)-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-2-amine, 7-(4-(aminomethyl)pheny1)-N-(4-(morpholinomethyl)phenyl)thieno[3 ,2-d]pyrimidin-2-amine, N-(4-(1-ethylpiperidin-4-yl oxy)pheny1)-7-(1H-pyrazol -4 -yl )thi eno[3,2-d]pyri mi di n-2-am in e, N-(2,4-dimethoxypheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, 7-bromo-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine, N-(3 ,4-dimethoxypheny1)-7-phenylthieno[3,2-d]pyrimidin-2-amine, and pharmaceutically acceptable salts and prodrugs thereof.
HMGB1 antibodies and COX-2 inhibitors can be used, which downregulate the cytokine storm. Examples of such compounds include Actemra (Roche). Celebrex (celecoxib), a COX-2 inhibitor, can be used. IL-8 (CXCL8) inhibitors can also be used.
Chemokine receptor CCR2 antagonists, such as PF-04178903 can reduce pulmonary immune pathology.
Selective a7Ach receptor agonists, such as GTS-21 (DMXB-A) and CNI-1495, can be used. These compounds reduce TNF-a. The late mediator of sepsis, HMGB1, downregulates IFN-y pathways, and prevents the LPS-induced suppression of IL-10 and STAT 3 mechanisms.
Compounds for Treating or Preventing Blood Clots Viruses that cause respiratory infections, including Coronaviruses such as Covid-19, can be associated with pulmonary blood clots, and blood clots that can also do damage to the heart.
The compounds described herein can be co-administered with compounds that inhibit blood clot formation, such as blood thinners, or compounds that break up existing blood clots, such as tissue plasminogen activator (TPA), Integrilin (eptifibatide), abciximab (ReoPro) or tirofiban (Aggrastat).
Blood thinners prevent blood clots from forming, and keep existing blood clots from getting larger. There are two main types of blood thinners. Anticoagulants, such as heparin or warfarin (also called Coumadin), slow down biological processes for producing clots, and antiplatelet aggregation drugs, such as Plavix, aspirin, prevent blood cells called platelets from clumping together to form a clot.
By way of example, Integriling is typically administered at a dosage of 180 mcg/kg intravenous bolus administered as soon as possible following diagnosis, with 2 mcg/kg/min continuous infusion (following the initial bolus) for up to 96 hours of therapy.
Representative platelet aggregation inhibitors include glycoprotein IIB/IIIA
inhibitors, phosphodiesterase inhibitors, adenosine reuptake inhibitors, and adenosine diphosphate (ADP) receptor inhibitors. These can optionally be administered in combination with an anticoagulant.
Representative anti-coagulants include coumarins (vitamin K antagonists), heparin and derivatives thereof, including unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra-low-molecular weight heparin (ULMWH), synthetic pentasaccharide inhibitors of factor Xa, including Fondaparinux, Idraparinux, and Idrabiotaparinux, directly acting oral anticoagulants (DA0Cs), such as dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, and antithrombin protein therapeutics/thrombin inhibitors, such as bivalent drugs hirudin, lepirudin, and bivalirudin and monovalent argatroban.
Representative platelet aggregation inhibitors include pravastatin, Plavix (clopidogrel bisulfate), Pletal (cilostazol), Effient (prasugrel), Aggrenox (aspirin and dipyridamole), Brilinta (ticagrelor), caplacizumab, Kengreal (cangrelor), Persantine (dipyridamole), Ticlid (ticlopidine), Yosprala (aspirin and omeprazole).
Small Molecule Covalent CoV 3CLpro Inhibitors Representative small molecule covalent CoV 3CLpro inhibitors include the following compounds:
CI
'CI 0 , and Non-Covalent CoV 3CLpro Inhibitors Representative non-covalent CoV 3CLpro inhibitors include the following:
1. \
,..,I...
t".
'A
M A:
.:
...:
, ...,..:' se : $ ..
:. .......................................
N, .. ".
, r,.. k , ,. NS
1 x -0 (k,. e .4 e :
0\ 0 ,---- 4 ! N: :- . s si g I 4 s ... , -.--,..
:. .......... 1.. . H. ?I Pi N..",' : `. \.,-:==`' ' \
:t.4.''''' .1( N...,,,"'s ::N:....'" \y-. .. . . .. .. . . .. . .. N¨. : i rs' . 1>=741 \---,, 1 .. . . . . . . .
N., ..,i= e >
...WM, .
f OH 0=
HO-tt ¨
.=:: :.= :7 :,:. .z,:f ........ :. 43-0H
.-,,..." b 4,40 ozNi:,:
' and rt' .:: ..... NMe2:
I., .........,,,z.,::::,.
[1,..Ø<1õ,.,,..,,O...... 4 .. ..
. ,...õ:11,.: ...õ1:,...,..õ...:...õ, il -11... ti t F
)-----SARS-CoV PLpro Inhibitors Representative SARS-Cov PLpro inhibitors include the following:
S--... :::='::":.: :: .:::...,:.: R.:= .
.,?= A= :::: . :::: - .A.- .---,,,l, flii: =.'N = 0g:=''''',..
' ,;$ ...= .1 ;L:::4]: .i! .V*:.
s... ......... = 'No..N. ne A
=,,,,:: .: . =,,,' .::..t,'". :--- '=,õ::,õõ
.,:,...p.õ.. ...,,.ri:,.: = ...,:.:..,. ...:1.i:. ).,..
.... i M.õ.fir' tY == õ... ....
Ni:41. .i ....044.-...,). ...1 ,,,,t.
..
tr- --4 ,.. I
It 1 1 0.
.
8J iM
41,-. :.=z.::-.------'.-II ..'1 "I
,,.,:.:,..,..:05:
Ii and I
L4 .1, L.1 Additional compounds include the following:
.JI" I 0 e N KAU' i 11 1 ,and Additional Compounds that can be Used Additional compounds and compound classes that can be used in combination therapy include the following: Antibodies, including monoclonal antibodies (mAb), Arbidol (umifenovir), Actemra (tocilizumab), APNO1 (Aperion Biologics), ARMS-1 (which includes Cetylpyridinium chloride (CPC)), ASCO9 (Ascletis Pharma), AT-001 (Applied Therapeutics Inc.) and other aldose reductase inhibitors (ART), ATYR1923 (aTyr Pharma, Inc.), Aviptadil (Relief Therapeutics), Azvudine, Bemcentinib, BLD-2660 (Blade Therapeutics), Bevacizumab, Brensocatib, Calquence (acalabrutinib), Camostat mesylate (a TMPRSS2 inhibitor), Camrelizumab, CAP-1002 (Capricor Therapeutics), CD24Fcm, Clevudine, (OncoImmune), CM4620-IE (CalciMedica Inc., CRAC channel inhibitor), Colchicine, convalescent plasma, CYNK-001 (Sorrento Therapeutics), DAS181 (Ansun Pharma), Desferal, Dipyridamole (Persantine), Dociparstat sodium (DSTAT), Duvelisib, Eculizumab, EIDD-2801 (Ridgeback Biotherapeutics), Emapalumab, Fadraciclib (CYC065) and seliciclib (roscovitine) (Cyclin-dependent kinase (CDK) inhibitors), Farxiga (dapagliflozin), Favilavir/Favipiravir/T-705/Avigan, Galidesivir, Ganovo (danoprevir), Gil enya (fingolimod) (sphingosine 1-phosphate receptor modulator), Gimsilumab, IFX-1, Ilaris (canakinumab), intravenous immunoglobulin, Ivermectin (importin cc/J3 inhibitor), Kaletra/Aluvia (lopinavir/ritonavir), Kevzara (sarilumab), Kineret (anakinra), LAU-7b (fenretinide), Lenzilumab, Leronlimab (PRO 140), (an anti-Ang2 antibody), Leukine (sargramostim, a granulocyte macrophage colony stimulating factor), Losartan, Valsartan, and Telmisartan (Angiotensin II receptor antagonists), Meplazumab, Metablok (LSALT peptide, a DPEP1 inhibitor), Methylprednisolone and other corticosteroids, 1VIN-166 (ibudilast, Macrophage migration inhibitory factor (MIF) inhibitor), MRx-4DP0004 (a strain of bifidobacterium breve, 4D Pharma), Nafamostat (a serine protease inhibitor), Neuraminidase inhibitors like Tamiflu (oseltamivir), Nitazoxanide (nucleocapsid (N) protein inhibitor), Nivolumab, OT-101 (Mateon), Novaferon (man-made Interferon), Opaganib (yeliva) (Sphingosine kinase-2 inhibitor), Otilimab, PD-1 blocking antibody, peginterferons, such as peginterferon lambda, Pepcid (famotidine), Piclidenoson (A3 adenosine receptor agonist), Prezcobix (darunavir), PUL-042 (Pulmotect, Inc., toll-like receptor (TLR) binder), Rebif (interferon beta-la), RHB-107 (upamostat) (serine protease inhibitor, RedHill Biopharma Ltd.), Selinexor (selective inhibitor of nuclear export (SINE)), SNG001 (Synairgen, inhaled interferon beta-la), Solnatide, stem cells, including mesenchymal stem cells, Multi Stem (Athersys), and PLX (Pluristem Therapeutics), Sylvant (siltuximab), Thymosin, (TJ003234), Tradipitant (neurokinin-1 receptor antagonist), Truvada (emtricitabine and tenofovir), Ultomiris (ravulizumab-cwvz), Vazegepant (CGRP receptor antagonist or blocker), and Xofluza (baloxavir marboxil) Repurposed Antiviral Agents A number of pharmaceutical agents, including agents active against other viruses, have been evaluated against Covid-19, and found to have activity. Any of these compounds can be combined with the compounds described herein. Representative compounds include lopinavir, ritonavir, niclosamide, promazine, PNU, UC2, cinanserin (SQ 10,643), Calmidazolium (C3930), tannic acid, 3-isotheaflavin-3-gallate, theaflavin-3,3' -digallate, glycyrrhizin, S-nitroso-N-acetylpenicillamine, nelfinavir, niclosamide, chloroquine, hydroxychloroquine, 5-benzyloxygramine, ribavirin, Interferons, such as Interferon (IFN)-a, IFN-13, and pegylated versions thereof, as well as combinations of these compounds with ribavirin, chlorpromazine hydrochloride, triflupromazine hydrochloride, gemcitabine, imatinib mesyl ate, dasatinib, and imatinib.
VIII. Pharmaceutical Compositions Hosts, including but not limited to humans, infected with a Coronviridae virus, or the other viruses described, herein can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
A preferred dose of the compound for will be in the range of between about 0.01 and about 10 mg/kg, more generally, between about 0.1 and 5 mg/kg, and, preferably, between about 0.5 and about 2 mg/kg, of body weight of the recipient per day, until the patient has recovered. In some cases, a compound may be administered at a dosage of up to 10 nM, which might be considered a relatively high dose if administered for an extended period of time, but which can be acceptable when administered for the duration of an infection with one or more of the viruses described herein, which is typically on the order of several days to several weeks.
The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent compound to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 600 mg, preferably 70 to 600 mg of active ingredient per unit dosage form. An oral dosage of 5-400 mg is usually convenient.
The concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
The active ingredient can be administered at once, or can be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup can contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories or other antiviral compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
Transdermal Formulations In some embodiments, the compositions are present in the form of transdermal formulations, such as that used in the FDA-approved agonist rotigitine transdetmal (Neupro patch). Another suitable formulation is that described in U.S. Publication No.
20080050424, entitled "Transdermal Therapeutic System for Treating Parkinsonism." This formulation includes a silicone or acrylate-based adhesive, and can include an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.
The transdermal formulations can be single-phase matrices that include a backing layer, an active substance-containing self-adhesive matrix, and a protective film to be removed prior to use. More complicated embodiments contain multiple-layer matrices that may also contain non-adhesive layers and control membranes. If a polyacrylate adhesive is used, it can be crosslinked with multivalent metal ions such as zinc, calcium, aluminum, or titanium ions, such as aluminum acetylacetonate and titanium acetylacetonate.
When silicone adhesives are used, they are typically polydimethylsiloxanes.
However, other organic residues such as, for example, ethyl groups or phenyl groups may in principle be present instead of the methyl groups. Because the active compounds are amines, it may be advantageous to use amine-resistant adhesives. Representative amine- resistant adhesives are described, for example, in EP 0 180 377.
Representative acrylate-based polymer adhesives include acrylic acid, acrylamide, hexyl acryl at e, 2-ethyl hexyl acryl at e, hydroxyethyl acryl ate, o ctyl acryl ate, butyl ac ryl ate, methylacrylate, glycidylacrylate, methacrylic acid, methacryl amide, hexylmethacrylate, 2-ethyl hexylm ethacryl ate, octylm ethacryl ate, methyl m ethacrylate, gl yci dylm ethacryl ate, vinylacetate, vinylpyrrolidone, and combinations thereof.
The adhesive must have a suitable dissolving capacity for the active substance, and the active substance most be able to move within the matrix, and be able to cross through the contact surface to the skin. Those of skill in the art can readily formulate a transdermal formulation with appropriate transdermal transport of the active substance.
Certain pharmaceutically acceptable salts tend to be more preferred for use in transdermal formulations, because they can help the active substance pass the barrier of the stratum corneum. Examples include fatty acid salts, such as stearic acid and oleic acid salts.
Oleate and stearate salts are relatively lipophilic, and can even act as a permeation enhancer in the skin.
Permeation enhancers can also be used. Representative permeation enhancers include fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, glycerol or its fatty acid esters, N-methylpyrrolidone, terpenes such as limonene, alpha-pinene, alpha-terpineol, carvone, carveol, limonene oxide, pinene oxide, and 1,8-eucalyptol.
The patches can generally be prepared by dissolving or suspending the active agent in ethanol or in another suitable organic solvent, then adding the adhesive solution with stirring.
Additional auxiliary substances can be added either to the adhesive solution, the active substance solution or to the active substance-containing adhesive solution.
The solution can then be coated onto a suitable sheet, the solvents removed, a backing layer laminated onto the matrix layer, and patches punched out of the total laminate.
Nanoparticulate Compositions The compounds described herein can also be administered in the form of nanoparticulate compositions. In one embodiment, controlled release nanoparticulate formulations comprise a nanoparticulate active agent to be administered and a rate-controlling polymer which prolongs the release of the agent following administration. In this embodiment, the compositions can release the active agent, following administration, for a time period ranging from about 2 to about 24 hours or up to 30 days or longer. Representative controlled release formulations including a nanoparticulate form of the active agent are described, for example, in U.S. Patent No. 8,293,277.
Nanoparticulate compositions can comprise particles of the active agents described herein, having a non-crosslinked surface stabilizer adsorbed onto, or associated with, their surface.
The average particle size of the nanoparticulates is typically less than about 800 nm, more typically less than about 600 nm, still more typically less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, or less than about 50 nm. In one aspect of this embodiment, at least 50% of the particles of active agent have an average particle size of less than about 800, 600, 400, 300, 250, 100, or 50 nm, respectively, when measured by light scattering techniques.
A variety of surface stabilizers are typically used with nanoparticulate compositions to prevent the particles from clumping or aggregating. Representative surface stabilizers are selected from the group consisting of gelatin, lecithin, dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrroli done, tyloxapol, poloxamers, poloxamines, poloxamine 908, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, an alkyl aryl polyether sulfonate, a mixture of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), SA9OHCO, decanoyl-N-methylglucamide, n-decyl -D-glucopyranoside, n-decyl-D-m altopyranosi de, n-dodecyl -D-glucopyran osi de, n-dodecyl -D-m altosi de, heptanoyl -N-methylglucamide, n-heptyl-D-glucopyranoside, n-heptyl-D-thioglucoside, n-hexyl-D-glucopyranoside, nonanoyl-N-methylglucamide, n-nonyl-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl-D-glucopyranoside, and octyl-D-thioglucopyranoside.
Lysozymes can also be used as surface stabilizers for nanoparticulate compositions.
Certain nanoparticles such as poly(lactic-co-glycolic acid) (PLGA)-nanoparticles are known to target the liver when given by intravenous (IV) or subcutaneously (SQ).
Representative rate controlling polymers into which the nanoparticles can be formulated include chitosan, polyethylene oxide (PEO), polyvinyl acetate phthalate, gum arabic, agar, guar gum, cereal gums, dextran, casein, gelatin, pectin, carrageenan, waxes, shellac, hydrogenated vegetable oils, polyvinyl pyrroli done, hydroxypropyl cellulose (HF'C), hydroxyethyl cellulose (HEC), hydroxypropyl methylcelluose (HPMC), sodium carboxymethylcellulose (CMC), poly(ethylene) oxide, alkyl cellulose, ethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydrophilic cellulose derivatives, polyethylene glycol, polyvinylpyrrolidone, cellulose acetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, polyvinyl acetaldiethylamino acetate, poly(alkylmethacrylate), poly(vinyl acetate), polymers derived from acrylic or methacrylic acid and their respective esters, and copolymers derived from acrylic or methacrylic acid and their respective esters.
Methods of making nanoparticulate compositions are described, for example, in U.S.
Pat. Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances;"
U.S. Pat. No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;" and U.S. Pat. No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles."
Nanoparticulate compositions are also described, for example, in U.S. Pat. No.
5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" U.S. Pat. No. 5,302,401 for "Method to Reduce Particle Size Growth During Lyophilization;" U.S. Pat. No. 5,318,767 for "X-Ray Contrast Compositions Useful in Medical Imaging;" U.S. Pat. No. 5,326,552 for "Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" U.S.
Pat. No.
5,328,404 for "Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;" U.S. Pat.
No. 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;" U.S.
Pat. No. 5,340,564 for Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;" U.S. Pat. No. 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;" U.S. Pat. No.
5,349,957 for "Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;" U.S. Pat.
No. 5,352,459 for "Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;" U.S. Pat. Nos. 5,399,363 and 5,494,683, both for "Surface Modified Anticancer Nanoparticles;" U.S. Pat. No. 5,401,492 for "Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;" U.S. Pat. No. 5,429,824 for "Use of Tyloxapol as a Nanoparticulate Stabilizer;" U.S. Pat. No. 5,447,710 for "Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" U.S. Pat. No. 5,451,393 for "X-Ray Contrast Compositions Useful in Medical Imaging;" U.S. Pat. No. 5,466,440 for "Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays;"
U.S. Pat. No.
5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation;" U.S. Pat. No. 5,472,683 for "Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,500,204 for "Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S.
Pat. No.
5,518,738 for "Nanoparticulate NSAID Formulations;" U.S. Pat. No. 5,521,218 for "Nanoparticulate Iododipamide Derivatives for Use as X-Ray Contrast Agents;"
U.S. Pat. No.
5,525,328 for "Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,543,133 for "Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;" U.S. Pat. No. 5,552,160 for "Surface Modified NSAID Nanoparticles;" U.S. Pat. No. 5,560,931 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" U.S. Pat. No.
5,565,188 for "Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles;" U.S.
Pat. No.
5,569,448 for "Sulfated Non-ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions;" U.S. Pat. No. 5,571,536 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" U.S. Pat. No.
5,573,749 for "Nanoparticulate Diagnostic Mixed Carboxylic Anydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" U.S. Pat. No. 5,573,750 for "Diagnostic Imaging X-Ray Contrast Agents;" U.S. Pat. No. 5,573,783 for "Redispersible Nanoparticulate Film Matrices With Protective Overcoats;" U.S. Pat. No. 5,580,579 for "Site-specific Adhesion Within the GI
Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers;" U.S. Pat. No. 5,585,108 for "Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays;" U.S. Pat. No.
5,587,143 for "Butylene Oxide-Ethylene Oxide Block Copolymers Surfactants as Stabilizer Coatings for Nanoparticulate Compositions: U.S. Pat. No. 5,591,456 for "Milled Naproxen with Hydroxypropyl Cellulose as Dispersion Stabilizer: U.S. Pat. No. 5,593,657 for "Novel Barium Salt Formulations Stabilized by Non-ionic and Anionic Stabilizers;" U.S. Pat.
No. 5,622,938 for "Sugar Based Surfactant for Nanocrystals;" U.S. Pat. No. 5,628,981 for "Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents;" U.S. Pat. No. 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging," U.S. Pat. No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances: U.S. Pat. No. 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen;" U.S. Pat. No. 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle Dispersions: U.S. Pat. No. 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions;" U.S.
Pat. No.
6,045,829 "Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;" U.S. Pat. No. 6,068,858 for "Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;" U.S. Pat. No. 6,153,225 for "Injectable Formulations of Nanoparticulate Naproxen: U.S. Pat. No. 6,165,506 for "New Solid Dose Form of Nanoparticulate Naproxen;" U.S. Pat. No. 6,221,400 for "Methods of Treating Mammals Using Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors;" U.S. Pat. No. 6,264,922 for "Nebulized Aerosols Containing Nanoparticle Dispersions;" U.S. Pat. No. 6,267,989 for "Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions," U.S. Pat. No. 6,270,806 for "Use of PEG-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions;"
U.S. Pat. No.
6,316,029 for "Rapidly Disintegrating Solid Oral Dosage Form," U.S. Pat. No 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate: U.S. Pat. No.
6,428,814 for "Bioadhesive nanoparticulate compositions having cationic surface stabilizers;" U.S. Pat. No.
6,431,478 for "Small Scale Mill;" and U.S. Pat. No. 6,432,381 for "Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract," all of which are specifically incorporated by reference. In addition, U.S. Patent Application No.
20020012675 Al, published on Jan. 31, 2002, for "Controlled Release Nanoparticulate Compositions,"
describes nanoparticulate compositions, and is specifically incorporated by reference.
Amorphous small particle compositions are described, for example, in U.S. Pat.
No.
4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent;" U.S. Pat.
No. 4,826,689 for "Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;" U.S. Pat. No. 4,997,454 for "Method for Making Uniformly-Sized Particles From Insoluble Compounds;" U.S. Pat. No. 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;"
and U.S. Pat. No. 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter."
Certain nanoformulations can enhance the absorption of drugs by releasing drug into the lumen in a controlled manner, thus reducing solubility issues. The intestinal wall is designed to absorb nutrients and to act as a barrier to pathogens and macromolecules.
Small amphipathic and lipophilic molecules can be absorbed by partitioning into the lipid bilayers and crossing the intestinal epithelial cells by passive diffusion, while nanoformulation absorption may be more complicated because of the intrinsic nature of the intestinal wall. The first physical obstacle to nanoparticle oral absorption is the mucus barrier which covers the luminal surface of the intestine and colon. The mucus barrier contains distinct layers and is composed mainly of heavily glycosylated proteins called mucins, which have the potential to block the absorption of certain nanoformulations. Modifications can be made to produce nanoformulations with increased mucus-penetrating properties (Ensign et al., "Mucus penetrating nanoparticles:
biophysical tool and method of drug and gene delivery," Adv Mater 24: 3887-3894 (2012)).
Once the mucus coating has been traversed, the transport of nanoformulations across intestinal epithelial cells can be regulated by several steps, including cell surface binding, endocytosis, intracellular trafficking and exocytosis, resulting in transcytosis (transport across the interior of a cell) with the potential involvement of multiple subcellular structures.
Moreover, nanoformulations can also travel between cells through opened tight junctions, defined as paracytosis. Non-phagocytic pathways, which involve clathrin-mediated and caveolae-mediated endocytosis and macropinocytosis, are the most common mechanisms of nanoformulation absorption by the oral route.
Non-oral administration can provide various benefits, such as direct targeting to the desired site of action and an extended period of drug action. Transdermal administration has been optimized for nanoformulations, such as solid lipid nanoparticles (SLNs) and NEs, which are characterized by good biocompatibility, lower cytotoxicity and desirable drug release modulation (Cappel and Kreuter, "Effect of nanoparticles on transdermal drug delivery. J
Microencapsul 8: 369-374 (1991)). Nasal administration of nanoformulations allows them to penetrate the nasal mucosal membrane, via a transmucosal route by endocytosis or via a carrier-or receptor-mediated transport process (Illum, -Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?" J. Pharm. Sci 96: 473-483 (2007)), an example of which is the nasal administration of chitosan nanoparticles of tizanidine to increase brain penetration and drug efficacy in mice (Patel et al., "Improved transnasal transport and brain uptake of tizanidine HC1-loaded thiolated chitosan nanoparticles for alleviation of pain,"
J. Pharm. Sci 10 L 690-706 (2012)). Pulmonary administration provides a large surface area and relative ease of access. The mucus barrier, metabolic enzymes in the tracheobronchial region and macrophages in the alveoli are typically the main barriers for drug penetration.
Particle size is a major factor determining the diffusion of nanoformulation in the bronchial tree, with particles in the nano-sized region more likely to reach the alveolar region and particles with diameters between 1 and 5 jtm expected to deposit in the bronchioles (Musante et al., "Factors affecting the deposition of inhaled porous drug particles," J Pharm Sci 91: 1590-1600 (2002)). A limit to absorption has been shown for larger particles, presumably because of an inability to cross the air-blood barrier. Particles can gradually release the drug, which can consequently penetrate into the blood stream or, alternatively, particles can be phagocytosed by alveolar macrophages (Bailey and Berkland, "Nanoparticle formulations in pulmonary drug delivery," Med. Res. Rev., 29: 196-212 (2009)).
Certain nanoformulations have a minimal penetration through biological membranes in sites of absorption and for these, iv. administration can be the preferred route to obtain an efficient distribution in the body (Wacker, "Nanocarriers for intravenous injection¨The long hard road to the market," Int. J. Pharm., 457: 50-62., 2013).
The distribution of nanoformulations can vary widely depending on the delivery system used, the characteristics of the nanoformulation, the variability between individuals, and the rate of drug loss from the nanoformulations. Certain nanoparticles, such as solid drug nanoparticles (SDNs), improve drug absorption, which does not require them to arrive intact in the systemic circulation. Other nanoparticles survive the absorption process, thus altering the distribution and clearance of the contained drug.
Nanoformulations of a certain size and composition can diffuse in tissues through well-characterized processes, such as the enhanced permeability and retention effect, whereas others accumulate in specific cell populations, which allows one to target specific organs. Complex biological barriers can protect organs from exogenous compounds, and the blood¨brain barrier (BBB) represents an obstacle for many therapeutic agents. Many different types of cells including endothelial cells, microglia, pericytes and astrocytes are present in the BBB, which exhibits extremely restrictive tight junctions, along with highly active efflux mechanisms, limiting the permeation of most drugs. Transport through the BBB is typically restricted to small lipophilic molecules and nutrients that are carried by specific transporters. One of the most important mechanisms regulating diffusion of nanoformulations into the brain is endocytosis by brain capillary endothelial cells.
Recent studies have correlated particle properties with nanoformulation entry pathways and processing in the human BBB endothelial barrier, indicating that uncoated nanoparticles have limited penetration through the BBB and that surface modification can influence the efficiency and mechanisms of endocytosis (Lee et al., "Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse," J.
Pharmacol. Exp.
Ther. 292: 1048-1052 (2000)). Accordingly, surface-modified nanoparticles which cross the BBB, and deliver one or more of the compounds described herein, are within the scope of the disclosure.
Macrophages in the liver are a major pool of the total number of macrophages in the body. Kupffer cells in the liver possess numerous receptors for selective phagocytosis of opsonized particles (receptors for complement proteins and for the fragment crystallizable part of IgG). Phagocytosis can provide a mechanism for targeting the macrophages, and providing local delivery (i.e., delivery inside the macrophages) of the compounds described herein (TRUE?).
Nanoparticles linked to polyethylene glycol (PEG) have minimal interactions with receptors, which inhibits phagocytosis by the mononuclear phagocytic system (Bazile et al., "Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system," J.
Pharm. Sci. 84: 493-498 (1995)).
Representative nanoformulations include inorganic nanoparticles, SDNs, SLNs, NEs, liposomes, polymeric nanoparticles and dendrimers. The compounds described herein can be contained inside a nanoformulation, or, as is sometimes the case with inorganic nanoparticles and dendrimers, attached to the surface. Hybrid nanoformulations, which contain elements of more than one nanoformulation class, can also be used.
SDNs are lipid-free nanoparticles, which can improve the oral bioavailability and exposure of poorly water-soluble drugs (Chan, "Nanodrug particles and nanoformulations for drug delivery," Adv. Drug. Deliv. Rev. 63: 405 (2011)). SDNs include a drug and a stabilizer, and are produced using 'top-down' (high pressure homogenization and wet milling) or bottom-up (solvent evaporation and precipitation) approaches.
SLNs consist of a lipid (or lipids) which is solid at room temperature, an emulsifier and water. Lipids utilized include, but are not limited to, triglycerides, partial glycerides, fatty acids, steroids and waxes. SLNs are most suited for delivering highly lipophilic drugs.
Liquid droplets of less than a 1000 nm dispersed in an immiscible liquid are classified as NEs. NEs are used as carriers for both hydrophobic and hydrophilic agents, and can be administered orally, transdermally, intravenously, intranasally, and ocularly.
Oral administration can be preferred for chronic therapy, and NEs can effectively enhance oral bioavailability of small molecules, peptides and proteins.
Polymeric nanoparticles are solid particles typically around 200-800 nm in size, which can include synthetic and/or natural polymers, and can optionally be pegylated to minimize phagocytosis. Polymeric nanoparticles can increase the bioavailability of drugs and other substances, compared with traditional formulations. Their clearance depends on several factors, including the choice of polymers (including polymer size, polymer charge and targeting ligands), with positively charged nanoparticles larger than 100 nm being eliminated predominantly via the liver (Alexis et al., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515 (2008)).
Dendrimers are tree-like, nanostructured polymers which are commonly 10-20 nm in diameter.
Liposomes are spherical vesicles which include a phospholipid bilayer. A
variety of lipids can be utilized, allowing for a degree of control in degradation level.
In addition to oral dosing, liposomes can be administered in many ways, including intravenously (McCaskill et al., 2013), transdermally (Pierre and Dos Santos Miranda Costa, 2011), intravitreally (Honda et al., 2013) and through the lung (Chattopadhyay, 2013). Liposomes can be combined with synthetic polymers to form lipid-polymer hybrid nanoparticles, extending their ability to target specific sites in the body. The clearance rate of liposome-encased drugs is determined by both drug release and destruction of liposomes (uptake of liposomes by phagocyte immune cells, aggregation, pH-sensitive breakdown, etc.) (Ishida et al., "Liposome clearance," Biosci Rep 22:
197-224 (2002)).
One of more of these nanoparticulate formulations can be used to deliver the active agents described herein to the macrophages, across the blood brain barrier, and other locations as appropriate.
Controlled Release Formulations In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. For example, enterically coated compounds can be used to protect cleavage by stomach acid.
Methods for preparation of such formulations will be apparent to those skilled in the art.
Suitable materials can also be obtained commercially.
Liposomal suspensions (including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in US Pat. No. 4,522,811 (incorporated by reference).
For example, liposome formulations can be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations have the indicated meanings:
DMS0 dimethylsulfoxide DCM dichloromethane DMAP 4-dimethylaminopyridine Et0Ac (AcOEt) ethyl acetate HOAc Acetic acid hour hex hexane DIPEA Diisopropylethylamine Liq. Liquid LCMS Liquid chromatography mass spectrometry TLC thin layer chromatography molar Me0H Methanol Et0H Ethanol iPrOH Isopropyl alcohol nBuOH n-Butyl alcohol pTs0H p-Toluene sulfonic acid TMSCN Trim ethyl si 1 yl cyanide TMSC1 Trimethylsilylchloride TMSOTf Trimethylsilyltriflate Et3N Triethylamine nBuLi n-Butyl lithium min minute II or RT room temperature TBAF Tetrabutyl aturn oniurn fluoride THF tetrahydrofuran IX. General Methods for Preparing Active Compounds Methods for the facile preparation of active compounds are known in the art and result from the selective combination known methods. The compounds disclosed herein can be prepared as described in detail below, or by other methods known to those skilled in the art.
It will be understood by one of ordinary skill in the art that variations of detail can be made without departing from the spirit and in no way limiting the scope of the present invention.
Some compounds within certain of the general formulas described herein are commercially available. For some compounds, the syntheses described herein are exemplary and can be used as a starting point to prepare additional compounds of the formulas described herein. These compounds can be prepared in various ways, including those synthetic schemes shown and described herein. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise routes based on the disclosures herein;
all such modifications and alternate routes are within the scope of the claims.
The various reaction schemes are summarized below.
Scheme 1 is a synthetic approach to nucleosides 3. (Base and other variables listed in the Scheme are as defined in active compound section) Scheme 2 is an alternate synthetic approach to nucleosides 3. (Base and other variables Ii st ed in the Scheme are as defined in active compound section) Compounds of Formula A can be prepared by first preparing nucleosides 1, which in turn can be accomplished by one of ordinary skill in the art, using methods outlined in: (a) Raj agopalan, P.; Boudinot, F. D; Chu, C. K.; Tennant, B. C.; Baldwin, B. H.;
Antiviral Nucleosides: Chiral Synthesis and Chemotheraphy: Chu, C. K.; Eds. Elsevier:
2003. b) Recent Advances in Nucleosides: Chemistry and Chemotherapy: Chu, C. K.; Eds.
Elsevier:
2002. c) Frontiers in Nucleosides & Nucleic Acids, 2004, Eds. R. F. Schinazi &
D. C. Liotta, IHL Press, Tucker, GA, USA, pp: 319-37 d) Handbook of Nucleoside Synthesis:
Vorbruggen H. & Ruh-Pohlenz C. John Wiley & sons 2001), and by general Schemes 1-2.
Specifically, nucleosides 3 can be prepared by coupling sugar 1 with a protected, silylated or free nucleoside base in the presence of Lewis acid such as TMSOTf. Deprotection of the 3'- and 5'-hydroxyls gives nucleoside 3.
Analogous compounds of Formula B can be prepared using compounds like Compound 1, but with a fluorine rather than OPr at the 2'-position. Representative synthetic methods are described, for example, in U.S. Patent No. 8,716,262.
R1 R1 ip, PrO R113 Y HO R.-)(Base -,./
0, ) R2 ,C0.._\
LG 1) Lewis Acid protected, silylated R or free nucleoside base i--13 + 2) deprotectionw R2 R3 OPr OPr OH OH
1 nucleoside base may contain suitable protection; 3 Pr = protection;
LG = OCOalkyl, OCOaryl, OCOalkylaryl;
R-1, R1B, 2, I-(- R3, and Y are as defined in active compound section Similarly, compounds like Compound 1, but with a Y substituent at the 2'-position and/or an R substituent at the 3'-position, can be used to prepare nucleosides similar to Compound 3, but with Y or R substitution at the 2'- and/or 3'-positions, respectively.
Also, analogous compounds where the oxygen in the sugar ring is replaced with one of the other variables defined by R5 can also be prepared.
Scheme 1 A synthetic approach to nucleosides 3. (Base are as defined in active compound section) In the schemes described herein, if a nucleoside base includes functional groups that might interfere with, or be decomposed or otherwise converted during the coupling steps, such functional groups can be protected using suitable protecting groups. After the coupling step, protected functional groups, if any, can be deprotected.
Alternatively, nucleosides 3 can be prepared from 1 ' -halo, F-sulfonate or 1 ' - hydroxy compounds 2. For the case of l'-halo or l'-sulfonate a protected or free nucleoside base in the presence of a base such as triethyl amine or sodium hydride followed by deprotection would give nucleosides 3. For the case of l'-hydroxy a protected or free nucleoside base in the presence of a Mitsunobu coupling agent such as diisopropyl azodicarboxylate followed by deprotection would give nucleosides 3.
Analogous compounds of Formula B can be prepared using compounds like Compound 1, but with a fluorine rather than OPr at the 2'-position. Representative synthetic methods are described, for example, in U.S. Patent No. 8,716,262.
HO y Base PrO R1 B y 1 ) Base or protected or free Mitsunobu R3 R2 1 + nucleoside base 2) deprotection R2 OPr OPr OH OH
2 nucleoside base may contain suitable protection; 3 Pr = protection;
X = halogen, sulfonate or OH;
R1, R1B, R3, and Y are as defined in active compound section Scheme 2 An alternate synthetic approach to nucleosides 3. (Base, It', RIB, ¨2, K and R3 are as defined in active compound section) Similarly, compounds like Compound 2, but with a Y substituent at the 2'-position and/or an R substituent at the 3'-position, can be used to prepare nucleosides similar to Compound 3_ but with Y or R substitution at the 2'- and/or 3'-positions, respectively.
Also, analogous compounds where the oxygen in the sugar ring is replaced with one of the other variables defined by It5 can also be prepared.
In the schemes described herein, if a nucleoside base includes functional groups that might interfere with, or be decomposed or otherwise converted during the reaction steps, such functional groups can be protected using suitable protecting groups that can be removed.
Protected functional groups, if any, can be deprotected later on Nft xi, N õ
N
In the case of C-nucleosides prepared from bases: 1) and 2) -T NH
methods outlined in W009132123, W009132135, W02011150288 and W02011035250 can be used.
In the case of C-nucleosides prepared from other bases, methods outlined in Temburnikar K, Seley-Radtke KL. Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides. Beilstein J Org Chem. 2018;14:772-785 can be used.
In the case of carbocyclic nucleosides, methods outlined in the following references can be used:
- Advances in the enantioselective synthesis of carbocyclic nucleosides, Chem. Soc. Rev., 2013, 42, 5056 - The latest progress in the synthesis of carbocyclic nucleosides".
Nucleosides, Nucleotides & Nucleic Acids. 2000, 19 (3): 651-690 - New progresses in the enantioselective synthesis and biological properties of carbocyclic nucleosides". Mini Reviews in Medicinal Chemistry 2003 3(2): 95-114.
- Chemical synthesis of carbocyclic analogues of nucleosides". Chemical Synthesis of Nucleoside Analogues. Hoboken: John Wiley & Sons. 2003 pp. 535-604 Dioxolane nucleoside analags can be prepared by adapting the chemistry outlined in J.
Org. Chem. 1995, 60, 6, 1546-1553.
Incorporation of Deuterium:
It is expected that single or multiple replacement of hydrogen with deuterium (carbon-hydrogen bonds to carbon-deuterium bond) at site(s) of metabolism in the sugar portion of a nucleoside antiviral agent will slow down the rate of metabolism. This can provide a relatively longer half-life, and slower clearance from the body. The slow metabolism of a therapeutic nucleoside is expected to add extra advantage to a therapeutic candidate, while other physical or biochemical properties are not affected. Intracellular hydrolysis or deuterium exchanges my result in liberation of deuterium oxide (D20).
Methods for incorporating deuterium into amino acids, phenol, sugars, and bases, are well known to those of skill in the art. Representative methods are disclosed in U.S. Patent No.
9,045,521.
A large variety of enzymatic and chemical methods have been developed for deuterium incorporation at both the sugar and nucleoside stages to provide high levels of deuterium incorporation (D/H ratio). The enzymatic method of deuterium exchange generally has low levels of incorporation. Enzymatic incorporation has further complications due to cumbersome isolation techniques which are required for isolation of deuterated mononucleotide blocks.
Schmidt et al., Ann. Chem. 1974, 1856; Schmidt et al., Chem. Ber., 1968, 101, 590, describes synthesis of 5',5'-2H2-adenosine which was prepared from 2',3'-0-isopropylideneadenosine-5'-carboxylic acid or from methyl-2,3-isopropylidene-beta-D-ribofuranosiduronic acid, Dupre, M.
and Gaudemer, A., Tetrahedron Lett. 1978, 2783. Kintanar, et al., Am. Chem.
Soc. 1998, 110, 6367 reported that diastereoisomeric mixtures of 5'-deuterioadenosine and 5'(R/S)-deuteratedthymidine can be obtained with reduction of the appropriate 5'-aldehydes using sodium borodeuteride or lithium aluminum deuteride (98 atom % 2H
incorporation). Berger et al., Nucleoside & Nucleotides 1987, 6, 395 described the conversion of the 5'-aldehyde derivative of 2'deoxyguanosine to 5' or 4'-deuterio-2'-deoxyguanosine by heating the aldehyde in 2H20/pyridine mixture (1:1) followed by reduction of the aldehyde with NaBat.
Ajmera et al., Labelled Compd. 1986, 23, 963 described procedures to obtain 4'-deuterium labeled uridine and thymidine (98 atom % 2H). Sinhababu, et al., J.
Am. Chem. Soc.
1985, 107, 7628) demonstrated deuterium incorporation at the C3' (97 atom %
2H) of adenosine during sugar synthesis upon stereoselective reduction of 1,2:5,6-di-O-isopropylidene-13-D-hexofuranos-3-ulose to 1,2:5,6-di-0-isopropylidene-3-deuterio-P-D-ribohexofuranose using sodium borodeuteride and subsequently proceeding further to the nucleoside synthesis. Robins, et al., Org. Chem. 1990, 55, 410 reported synthesis of more than 95% atom 2H
incorporation at C3' of adenosine with virtually complete stereoselectivity upon reduction of the 2'-0-tert-butyldimethylsilyl(TBDMS) 3-ketonucleoside by sodium borodeuteride in acetic acid. David, S. and Eustache, J., Carbohyd. Res. 1971, 16,46 and David, S. and Eustache, J., Carbohyd. Res.
1971, 20, 319 described syntheses of 2'-deoxy-2'(S)-deuterio-uridine and cytidine. The synthesis was carried out by the use of 1-methyl-2-deoxy-2'-(S)-deuterio ribofuranoside.
Radatus, et al., J Am Chem. Soc. 1971, 93, 3086 described chemical procedures for synthesizing 2'-monodeuterated (R or S)-2'-deoxycytidines. These structures were synthesized from selective 2-monodeuterated-2-deoxy-D-riboses, which were obtained upon stereospecific reduction of a 2,3-dehydro-hexopyranose with lithium aluminum deuteride and oxidation of the resulting glycal. Wong et al. J. Am. Chem. Soc. 1978, 100, 3548 reported obtaining deoxy-1 -deuterio-D-erythro-pentose, 2-deoxy-2(S)-deuterio-D-erythro-pentose and 2-deoxy-1,2(S)-dideuterio-D-erythro-pentose from D-arabinose by a reaction sequence involving the formation and LiAlD4 reduction of ketene dithioacetal derivatives.
Pathak et al. J., Tetrahedron 1986, 42, 5427) reported stereospecific synthesis of all eight 2' or 2'-deuterio-2'-deoxynucleosides by reductive opening of appropriate methyl 2,3-anhydro-beta-D-ribo or beta-D-lyxofuranosides with LiAlD4. Wu et al. J. Tetrahedron 1987, 43, 2355 described the synthesis of all 2',2"-dideuterio-2'-deoxynucleosides, for both deoxy and ribonucleosides, starting with oxidation of C2' of sugar and subsequent reduction with NaBD4 or LiAlD4 followed by deoxygenation by tributyltin deuteride. Roy et al. J.
Am. Chem. Soc.
1986, 108, 1675, reported 2',2'-dideuterio-2'-deoxyguanosine and thymidine can be prepared from 2-deoxyribose 5-phosphate using 2-deoxyribose 5-phosphate aldolase enzyme in 2H20 achieving some 90 atom % deuteration. Similarly, the synthesis of 4',5',5'-2H3-guanosine can be carried out.
Therefore, it is clear that each position of the sugar residue can be selectively labeled.
A useful alternative method of stereospecific deuteration was developed to synthesize polydeuterated sugars. This method employed exchange of hydrogen with deuterium at the hydroxyl bearing carbon (i.e. methylene and methine protons of hydroxyl bearing carbon) using deuterated Raney nickel catalyst in 2H20.
Various techniques are available to synthesize fully deuterated deoxy and ribonucleosides. Thus, in one method, exchange reaction of deuterated Raney nickel-4120 with sugars, a number of deuterated nucleosides specifically labeled at 2', 3' and 4' positions were prepared. The procedure consisted of deuteration at 2', 3' and 4' positions of methyl beta-D-arabinopyranoside by Raney nickel-2H20 exchange reaction followed by reductive elimination of '2-hydroxyl group by tributyltin deuteride to give methyl beta-D-2' ,2',3' ,4' -2H4-2-deoxyribopyranoside, which was converted to methyl beta-D-2' ,2',3 ',4' -21-14-2'-deoxyribofuranoside and glycosylated to give various 2',2',3',4'-21-14-nucleosides (>97 atom %
2H incorporation for H3' & H4'.
The synthesis of deuterated phenols is described, for example, in Hoyer, H.
(1950), Synthese des pan-Deutero-o-nitro-phenols. Chem. Ber., 83: 131-136. This chemistry can be adapted to prepare substituted phenols with deuterium labels. Deuterated phenols, and substituted analogs thereof, can be used, for example, to prepare phenoxy groups in phosphoramidate prodrugs.
The synthesis of deuterated amino acids is described, for example, in Matthews et al., Biochimica et Biophysica Acta (BBA) - General Subjects, Volume 497, Issue 1, 29 March 1977, Pages 1-13. These and similar techniques can be used to prepare deuterated amino acids, which can be used to prepare phosphoramidate prodrugs of the nucleosides described herein.
One method for synthesizing a deuterated analog of the compounds described herein involves synthesizing a deuterated ribofuranoside with a 4' -alkynyl substitution; and attaching a nucleobase to the deuterated ribofuranoside to form a deuterated nucleoside.
A prodrug, such as a phosphoramidate prodrug, can be formed by modifying the 5' -OH group on the nucleoside. Where a deuterated phenol and/or deuterated amino acid is used, one can prepare a deuterated phosphoramidate prodrug.
Another method involves synthesizing a ribofuranoside with 4'-alkynyl substitution, and attaching a deuterated nucleobase to form a deuterated nucleoside. This method can optionally be performed using a deuterated furanoside to provide additional deuteration. As with the method described above, the nucleoside can be converted into a prodrug form, which prodrug form can optionally include additional deuteration.
A third method involves synthesizing a ribofuranoside with 4' -alkynyl substitution, attaching a nucleobase to form a nucleoside, and converting the nucleoside to a phosphoramidate prodrug using one or both of a deuterated amino acid or phenol analog in the phosphoramidate synthesis.
Accordingly, using the techniques described above, one can provide one or more deuterium atoms in the sugar, base, and/or prodrug portion of the nucleoside compounds described herein.
Specific Examples Specific representative compounds were prepared as per the following examples and reaction sequences; the examples and the diagrams depicting the reaction sequences are offered by way of illustration, to aid in the understanding of the invention and should not be construed to limit in any way the invention set forth in the claims which follow thereafter. The present compounds can also be used as intermediates in subsequent examples to produce additional compounds as described herein. No attempt has necessarily been made to optimize the yields obtained in any of the reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc.
(Milwaukee, WI) and EMD Chemicals Inc. (Gibbstown, NJ). Reagents were purchased from commercial sources. Unless noted otherwise, the materials used in the examples were obtained from readily available commercial suppliers or synthesized by standard methods known to one skilled in the art of chemical synthesis Melting points (mp) were determined on an El ectrothermal digit melting point apparatus and are uncorrected. 1I-1 and "C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiplet). All J- values are in Hz. Mass spectra were determined on a Micromass Platform LC spectrometer using electrospray techniques.
Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA).
Analytic TLC
was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F
silica gel plates. Column chromatography was carried out on Silica Gel or via reverse-phase high performance liquid chromatography.
Example 1 The techniques shown below can be used to prepare other compounds described herein Experimental (IL NH HMDS, rNH (NH
1\1,NN
N, Bz0 N 0 TMSCI
'WOAc H Bz0 0 NH3/Me0H HO
SnCI4 3 d Bz0 OBz J. Org. Chem r.t., ays 1974, 3654-3660 Bz0 OBz HO OH
N\
"N
1)-N
t N
1. TMSCI, Et3N, CH3CN HO HOAc/Me0H HO 'N 0 2. POCI3 3. 1,2,4-Triazole rT HO
OH
TMSO OTMS
Scheme 3. Synthesis of Compound 25 2-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-y1)-1,2,4-triazine-3,5(211,411)-dione (23):
A mixture of compound 22 (10.5 g, prepared by following the chemistry described in J.
Org. Chem. 1974, 3654-3660) in saturated NH3/Me0H (250 mL) was stirred at room temperature for 3 days. After removal of the volatiles under reduced pressure, the residue was purified by flash chromatography (0 - 20% Me0H in dichloromethane) to give 23 (3.5 g, 76%).
1H NMR (CD30D): 7.44 (s, 1H), 6.08 (d, J= 3.2Hz, 1H), 4.42 (dd, J= 5.2Hz, J=
3.2Hz, 1H), 4.24 (t, J= 5.6Hz, 1H), 3.96 (m, 1H), 3.73 (dd, J=12.0 Hz, J= 3.6Hz, 1H), 3.60 (dd, J= 12.0Hz, J= 5.6Hz, 1H); 13C NMR (CD30D): 158.27, 149.97, 137.36, 91.71, 85.87, 74.42, 71.91, 63.43;
LCMS: 246 (M + 1)+.
2-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-y1)-5-methoxy-1,2,4-triazin-3(2H)-one (25):
To a stirred suspension of 23 (123 mg, 0.5 mmol, 1 eq) in acetonitrile (5 mL), triethylamine (1.05 mL, 7.5 mmol, 15eq) and chlorotrimethylsilane (0.32 mL, 2.5 mmol, 5eq) were added dropwi se at 0 C. The cooling bath was removed and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then cooled down to 0 C and POC13 (145uL) was added dropwise. The reaction mixture was stirred for 15 min and 1,2,4-triazole (345 mg, 5 mmol, 10 eq) was added. The reaction mixture was stirred at room temperature overnight, and then poured into a pH 7.4 buffer solution (20 mL). The mixture was extracted with DCM (3 x 30 mL). The combined organic phases were dried over sodium sulfate. After the volatiles were removed under reduced pressure, the residue was dissolved in Me0H/HOAc (4:1, 5 mL) and stirred overnight. After removal of the voaltils, the residue was purified by column using 0 ¨ 10% methanol in DCM to give product 3 (70.6 mg, 54%). LCMS:
282 (M +
Na+). NM_R (CD30D): 7.80 (s, 1H), 6.20 (d, J = 3.2 Hz, 1H), 4.43 (dd, J = 5.2 Hz, J = 3.2 Hz, 1H), 4.28 (t, J = 5.6 Hz, 1H), 4.03 -4.00 (m, 1H), 4.01 (s, 3H), 3.75 (dd, J = 8.0 Hz, J = 3.6 Hz, 1H), 3.62 (dd, J = 12.4 Hz, J = 5.6 Hz, 1H); 1-3C NMR (CD30D): 166.70, 155.93, 130.25, 93.29, 86.11, 74.83, 71.93, 63.43, 55.68.
J. Am. Chem. Soc. 2005, 27, 8846.
oriFi 3 steps NH2 d >, HOza.....Crs NH2 a,b,c 35a 35b e, f e, f N N
NH2 37a-b CI
36a-b /=N h N /=N
N
I
N1\1-11L0/-06 N
N
CI
CI
38a 38a 39b 39b Scheme 4. Synthesis of compound 38a-b and 39a-b: a) Boc20, DMAP, Et3N, 4 A MS, THF, rt, 4 h. b) NaBH4, Me0H, 0 C, 4 h. c) H20, reflux, 24 h. d) H2, Pd-C, Me0H, rt, 5 h. e) N-(2-Amino-4,6-dichloro-5-pyrimidinyl)formamide, DIPEA, n-BuOH, 160 C, 24 h. f) Ac20, DMAP, Et3N, 4 A MS, DCM, rt, 24 h. g) Amyl nitrite, TMSC1, 4 A MS, DCM, 0-5 C, 1 h. h) Bu2SnO, toluen, reflux, 16 h. i) t-BuMgC1, L-Alanine, N-RS)-(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphiny1]-,1-methylethyl ester, 4 A MS, THF, 0 C to rt, overnight.
((lS,4R)-4-Aminocyclopent-2-en-1-yl)methanol (35a) was prepared according to the procedures reported in J. Am. Chem. Soc. 2005, 127, 24, 8846-8855.
A mixture of Vince lactam 33 (1 eq.), di-t-butyl dicarbonate (1.2 eq.), DMAP
(0.1 eq.) and Et3N
(1.2 eq.) in T1-if (0.5 M) was stirred at room temperature for 4 hours and then evaporated. The residue was dissolved in AcOEt, washed with 1M HC1, then with a solution of 5%
NaHCO3 and brine, dried over MgSO4 filtered and concentrated under vacuo. Crude product was purified flash chromatography on silica gel (Hexanes/AcOEt - 1:0 to 85:25) to afford pure NBoc intermediate as a white solid (92%). This compound was dissolved in methanol (0.3 M) and cool down to 0 C. NaBH4 (4 eq.) was added in 6 portions over 1 hour and the reaction was stirred at 0 C for 30 min and then 4 hours at room temperature. Volatiles were evaporated and the residue was partitioned between water and AcOEt (2:3). The aqueous phase was extracted with AcOEt. Combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The resulting white solid was refluxed in water (0.25 M) for 24 hours. Water was removed under vacuo to afford the desired compound (4) as a brown oil.
((1R,3S)-3-Aminocyclopentyl)methanol (35b) was prepared according to the procedures reported in J. Am. Chem. Soc. 2005, 127, 24, 8846-8855.
A mixture of 35a (1 eq.) and 10% Pd-C (0.04 eq.) in Me0H (0.115 M) was stirred under atmospheric pressure of H2 at room temperature for 4 hours. The Pd-C was filtered off on a Celite pad, washed with Me0H, and the combined filtrate were evaporated to afford 35b as a slightly brown oil (quantitative yield).
((lS,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl acetate (36a) and ((1R,3S)-3-(2-amino-6-chloro-9H-purin-9-yl)cyclopentyl)methyl acetate (36b).
In a sealed vessel, to a solution of compound 35a or 35b (1 eq.) in n-BuOH
(0.3 M), was added DIPEA (4 eq.) and N-(2-Amino-4,6-dichloro-5-pyrimidinyl)formamide (1.5eq.).
The mixture was heated at 130 C for 24 hours. Volatiles were evaporated and the crude product was purified silica gel flash chromatography (DCM/Me0H - 1:0 to 95:5). The resulting compound was suspended in DCM (0.1 M) and DMAP (0.2 eq.), Et3N (2 eq.) and Ac20 (1.1 eq.) were added at room temperature. The clear solution was stirred for 24 hours at room temperature, then the volatiles were removed under vacuum. The residue was dissolved in a saturated solution of NaHCO3, extracted thrice with AcOEt. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The residue was purified using silica gel flash chromatography (DCM/Me0H - 1:0 to 95:5) to afford compounds (6a,b).
(36a). (48%, over 2 steps). NMIR (400 MHz, Acetone-d6) 6 8.00 (d, J = 1.3 Hz, 1H, H8), 6.26 ¨ 6.19 (m, 3H, NH2, H2'), 6.06 (dq, J = 5.6, 1.9 Hz, 1H, H3'), 5.64 (dddd, J = 9.0, 5.9, 3.5, 1.8 Hz, 1H, H1'), 4.21 (dd, J = 6.1, 1.2 Hz, 2H, H5'), 3.24 (ddt, J = 8.1, 5.9, 3.4 Hz, 1H, H4'), 2.93 -2.77 (m, 1H, H6'a), 2.05 (s, 3H, C-CH3), 1.83 (dtd, J = 13.7, 6.0, 1.2 Hz, 1H, H6'b). 13C
NMR (101 MHz, Acetone-d6) 6 171.0 (C=0), 160.6 (Cquat), 154.8 (Cquat), 151.0 (Cquat), 141.6 (C8), 138.1 (C2'), 131.0 (C3'), 125.7 (Cquat), 67.0 (C5'), 60.4 (Cl'), 45.3 (C4'), 35.0 (C6'), 20.7 (CO-CH3). HRMS-EST (m/z) [M+H]+ calcd for C13H14C1N502 : 307.0836, found:
307.0902.
(36b). (50%, over 2 steps). 1-1-1NMR (400 MHz, Acetone-d6) 6 8.13 (s, 1H, H8), 6.20 (bs, 2H, NH2), 4.88 (dq, J = 9.8, 8.1 Hz, 1H, H1'), 4.22 - 4.03 (m, 2H, H5'), 2.58 -2.40 (m, 2H, H4', H2' a), 2.36 - 2.10 (m, 2H, H3'), 2.05 (s, 3H, C-CH), 2.08 - 1.89 (m, 2H, H2'b, H6'a), 1.88 -1.75 (m, 1H, H6'b). 1-3C NMR (101 MHz, Acetone-d6) 6 171.1 (C=0), 160.5 (Cquat), 155.0 (Cquat), 151.0 (Cquat), 142.2 (C8), 125.9 (Cquat), 68.1 (C5'), 56.4 (C1'), 37.9 (C4'), 36.0 (C2'), 31.5 (C3'), 27.6 (C6'), 20.7 (CO-CH3). HRMS-ESI (m/z) [M+E-1]+ calcd for C13H16C1N502 : 309.0993, found: 309.1063.
01S,4R)-4-(2,6-dichloro-9H-purin-9-yl)cyclopent-2-en-l-y1)methyl acetate (37a) and ((1R,3S)-3-(2,6-dichloro-911-purin-9-y1)cyclopentyl)methyl acetate (37b).
A mixture of amyl nitrite (6 eq.) in DCM (0.47 M) was cool down to 0 C. TMSC1 (3 eq.) was added dropwise followed by a solution of (36a,b) (1 eq.) in DCM (0.47 M). The mixture was stirred between 0 and 5 C for 1 hour and then quenched with a saturated solution of Na2S03.
The aqueous layer was extracted thrice with DCM. Combined organic layers were washed with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated under vacuo. The residue purified by flash chromatography (Hex/AcOEt - 2:8 to 8:2) to afford compounds (7a,b).
(37a). (74%). 1-E1 NMR (400 MHz, Acetone-d6) 6 8.51 (s, 1H, H8), 6.27 (dt, J =
5.7, 2.1 Hz, 1H, H2'), 6.10 (dt, J = 5.6, 2.2 Hz, 1H, H3'), 5.82 (ddq, J = 9.9, 6.0, 2.1 Hz, 1H, H1'), 4.16 (dq, J = 11.0, 5.8, 5.4 Hz, 2H, H5'), 3.26 (tddd, J = 8.1, 5.9, 4.1, 2.2 Hz, 1H, H4'), 2.94 (dt, J = 14.0, 8.7 Hz, 1H, H6'a), 2.00 (s, 3H, C-CH3), 1.90 (dt, J = 14.1, 5.9 Hz, 1H, H6'b).13C NIVIR (101 MHz, Acetone-d6) 6 171.0 (C=0), 154.3 (Cquat), 152.4 (Cquat), 151.1 (Cquat), 140.6 (C8), 139.1 (C2'), 132.2 (Cquat), 130.2 (C3'), 66.9 (C5'), 61.6 (Cl'), 45.5 (C4'), 35.1 (C6'), 20.7 (CO-CH3). HRMS-ESI (m/z) [M+E-1]+ calcd for C13H1202N402 : 326.0337, found:
326.0408.
(37b). (76%). 1H NMR (400 MHz, Acetone-d6) 68.70 (s, 1H, H8), 5.22 - 5.00 (m, 1H, H1'), 4.23 -4.07 (m, 2H, H5'), 2.65 -2.47 (m, 2H, H4', H2'a), 2.40 (dddd, J = 14.0,
U.S. Pat. No.
6,316,029 for "Rapidly Disintegrating Solid Oral Dosage Form," U.S. Pat. No 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate: U.S. Pat. No.
6,428,814 for "Bioadhesive nanoparticulate compositions having cationic surface stabilizers;" U.S. Pat. No.
6,431,478 for "Small Scale Mill;" and U.S. Pat. No. 6,432,381 for "Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract," all of which are specifically incorporated by reference. In addition, U.S. Patent Application No.
20020012675 Al, published on Jan. 31, 2002, for "Controlled Release Nanoparticulate Compositions,"
describes nanoparticulate compositions, and is specifically incorporated by reference.
Amorphous small particle compositions are described, for example, in U.S. Pat.
No.
4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent;" U.S. Pat.
No. 4,826,689 for "Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;" U.S. Pat. No. 4,997,454 for "Method for Making Uniformly-Sized Particles From Insoluble Compounds;" U.S. Pat. No. 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;"
and U.S. Pat. No. 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter."
Certain nanoformulations can enhance the absorption of drugs by releasing drug into the lumen in a controlled manner, thus reducing solubility issues. The intestinal wall is designed to absorb nutrients and to act as a barrier to pathogens and macromolecules.
Small amphipathic and lipophilic molecules can be absorbed by partitioning into the lipid bilayers and crossing the intestinal epithelial cells by passive diffusion, while nanoformulation absorption may be more complicated because of the intrinsic nature of the intestinal wall. The first physical obstacle to nanoparticle oral absorption is the mucus barrier which covers the luminal surface of the intestine and colon. The mucus barrier contains distinct layers and is composed mainly of heavily glycosylated proteins called mucins, which have the potential to block the absorption of certain nanoformulations. Modifications can be made to produce nanoformulations with increased mucus-penetrating properties (Ensign et al., "Mucus penetrating nanoparticles:
biophysical tool and method of drug and gene delivery," Adv Mater 24: 3887-3894 (2012)).
Once the mucus coating has been traversed, the transport of nanoformulations across intestinal epithelial cells can be regulated by several steps, including cell surface binding, endocytosis, intracellular trafficking and exocytosis, resulting in transcytosis (transport across the interior of a cell) with the potential involvement of multiple subcellular structures.
Moreover, nanoformulations can also travel between cells through opened tight junctions, defined as paracytosis. Non-phagocytic pathways, which involve clathrin-mediated and caveolae-mediated endocytosis and macropinocytosis, are the most common mechanisms of nanoformulation absorption by the oral route.
Non-oral administration can provide various benefits, such as direct targeting to the desired site of action and an extended period of drug action. Transdermal administration has been optimized for nanoformulations, such as solid lipid nanoparticles (SLNs) and NEs, which are characterized by good biocompatibility, lower cytotoxicity and desirable drug release modulation (Cappel and Kreuter, "Effect of nanoparticles on transdermal drug delivery. J
Microencapsul 8: 369-374 (1991)). Nasal administration of nanoformulations allows them to penetrate the nasal mucosal membrane, via a transmucosal route by endocytosis or via a carrier-or receptor-mediated transport process (Illum, -Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?" J. Pharm. Sci 96: 473-483 (2007)), an example of which is the nasal administration of chitosan nanoparticles of tizanidine to increase brain penetration and drug efficacy in mice (Patel et al., "Improved transnasal transport and brain uptake of tizanidine HC1-loaded thiolated chitosan nanoparticles for alleviation of pain,"
J. Pharm. Sci 10 L 690-706 (2012)). Pulmonary administration provides a large surface area and relative ease of access. The mucus barrier, metabolic enzymes in the tracheobronchial region and macrophages in the alveoli are typically the main barriers for drug penetration.
Particle size is a major factor determining the diffusion of nanoformulation in the bronchial tree, with particles in the nano-sized region more likely to reach the alveolar region and particles with diameters between 1 and 5 jtm expected to deposit in the bronchioles (Musante et al., "Factors affecting the deposition of inhaled porous drug particles," J Pharm Sci 91: 1590-1600 (2002)). A limit to absorption has been shown for larger particles, presumably because of an inability to cross the air-blood barrier. Particles can gradually release the drug, which can consequently penetrate into the blood stream or, alternatively, particles can be phagocytosed by alveolar macrophages (Bailey and Berkland, "Nanoparticle formulations in pulmonary drug delivery," Med. Res. Rev., 29: 196-212 (2009)).
Certain nanoformulations have a minimal penetration through biological membranes in sites of absorption and for these, iv. administration can be the preferred route to obtain an efficient distribution in the body (Wacker, "Nanocarriers for intravenous injection¨The long hard road to the market," Int. J. Pharm., 457: 50-62., 2013).
The distribution of nanoformulations can vary widely depending on the delivery system used, the characteristics of the nanoformulation, the variability between individuals, and the rate of drug loss from the nanoformulations. Certain nanoparticles, such as solid drug nanoparticles (SDNs), improve drug absorption, which does not require them to arrive intact in the systemic circulation. Other nanoparticles survive the absorption process, thus altering the distribution and clearance of the contained drug.
Nanoformulations of a certain size and composition can diffuse in tissues through well-characterized processes, such as the enhanced permeability and retention effect, whereas others accumulate in specific cell populations, which allows one to target specific organs. Complex biological barriers can protect organs from exogenous compounds, and the blood¨brain barrier (BBB) represents an obstacle for many therapeutic agents. Many different types of cells including endothelial cells, microglia, pericytes and astrocytes are present in the BBB, which exhibits extremely restrictive tight junctions, along with highly active efflux mechanisms, limiting the permeation of most drugs. Transport through the BBB is typically restricted to small lipophilic molecules and nutrients that are carried by specific transporters. One of the most important mechanisms regulating diffusion of nanoformulations into the brain is endocytosis by brain capillary endothelial cells.
Recent studies have correlated particle properties with nanoformulation entry pathways and processing in the human BBB endothelial barrier, indicating that uncoated nanoparticles have limited penetration through the BBB and that surface modification can influence the efficiency and mechanisms of endocytosis (Lee et al., "Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse," J.
Pharmacol. Exp.
Ther. 292: 1048-1052 (2000)). Accordingly, surface-modified nanoparticles which cross the BBB, and deliver one or more of the compounds described herein, are within the scope of the disclosure.
Macrophages in the liver are a major pool of the total number of macrophages in the body. Kupffer cells in the liver possess numerous receptors for selective phagocytosis of opsonized particles (receptors for complement proteins and for the fragment crystallizable part of IgG). Phagocytosis can provide a mechanism for targeting the macrophages, and providing local delivery (i.e., delivery inside the macrophages) of the compounds described herein (TRUE?).
Nanoparticles linked to polyethylene glycol (PEG) have minimal interactions with receptors, which inhibits phagocytosis by the mononuclear phagocytic system (Bazile et al., "Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system," J.
Pharm. Sci. 84: 493-498 (1995)).
Representative nanoformulations include inorganic nanoparticles, SDNs, SLNs, NEs, liposomes, polymeric nanoparticles and dendrimers. The compounds described herein can be contained inside a nanoformulation, or, as is sometimes the case with inorganic nanoparticles and dendrimers, attached to the surface. Hybrid nanoformulations, which contain elements of more than one nanoformulation class, can also be used.
SDNs are lipid-free nanoparticles, which can improve the oral bioavailability and exposure of poorly water-soluble drugs (Chan, "Nanodrug particles and nanoformulations for drug delivery," Adv. Drug. Deliv. Rev. 63: 405 (2011)). SDNs include a drug and a stabilizer, and are produced using 'top-down' (high pressure homogenization and wet milling) or bottom-up (solvent evaporation and precipitation) approaches.
SLNs consist of a lipid (or lipids) which is solid at room temperature, an emulsifier and water. Lipids utilized include, but are not limited to, triglycerides, partial glycerides, fatty acids, steroids and waxes. SLNs are most suited for delivering highly lipophilic drugs.
Liquid droplets of less than a 1000 nm dispersed in an immiscible liquid are classified as NEs. NEs are used as carriers for both hydrophobic and hydrophilic agents, and can be administered orally, transdermally, intravenously, intranasally, and ocularly.
Oral administration can be preferred for chronic therapy, and NEs can effectively enhance oral bioavailability of small molecules, peptides and proteins.
Polymeric nanoparticles are solid particles typically around 200-800 nm in size, which can include synthetic and/or natural polymers, and can optionally be pegylated to minimize phagocytosis. Polymeric nanoparticles can increase the bioavailability of drugs and other substances, compared with traditional formulations. Their clearance depends on several factors, including the choice of polymers (including polymer size, polymer charge and targeting ligands), with positively charged nanoparticles larger than 100 nm being eliminated predominantly via the liver (Alexis et al., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515 (2008)).
Dendrimers are tree-like, nanostructured polymers which are commonly 10-20 nm in diameter.
Liposomes are spherical vesicles which include a phospholipid bilayer. A
variety of lipids can be utilized, allowing for a degree of control in degradation level.
In addition to oral dosing, liposomes can be administered in many ways, including intravenously (McCaskill et al., 2013), transdermally (Pierre and Dos Santos Miranda Costa, 2011), intravitreally (Honda et al., 2013) and through the lung (Chattopadhyay, 2013). Liposomes can be combined with synthetic polymers to form lipid-polymer hybrid nanoparticles, extending their ability to target specific sites in the body. The clearance rate of liposome-encased drugs is determined by both drug release and destruction of liposomes (uptake of liposomes by phagocyte immune cells, aggregation, pH-sensitive breakdown, etc.) (Ishida et al., "Liposome clearance," Biosci Rep 22:
197-224 (2002)).
One of more of these nanoparticulate formulations can be used to deliver the active agents described herein to the macrophages, across the blood brain barrier, and other locations as appropriate.
Controlled Release Formulations In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. For example, enterically coated compounds can be used to protect cleavage by stomach acid.
Methods for preparation of such formulations will be apparent to those skilled in the art.
Suitable materials can also be obtained commercially.
Liposomal suspensions (including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in US Pat. No. 4,522,811 (incorporated by reference).
For example, liposome formulations can be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations have the indicated meanings:
DMS0 dimethylsulfoxide DCM dichloromethane DMAP 4-dimethylaminopyridine Et0Ac (AcOEt) ethyl acetate HOAc Acetic acid hour hex hexane DIPEA Diisopropylethylamine Liq. Liquid LCMS Liquid chromatography mass spectrometry TLC thin layer chromatography molar Me0H Methanol Et0H Ethanol iPrOH Isopropyl alcohol nBuOH n-Butyl alcohol pTs0H p-Toluene sulfonic acid TMSCN Trim ethyl si 1 yl cyanide TMSC1 Trimethylsilylchloride TMSOTf Trimethylsilyltriflate Et3N Triethylamine nBuLi n-Butyl lithium min minute II or RT room temperature TBAF Tetrabutyl aturn oniurn fluoride THF tetrahydrofuran IX. General Methods for Preparing Active Compounds Methods for the facile preparation of active compounds are known in the art and result from the selective combination known methods. The compounds disclosed herein can be prepared as described in detail below, or by other methods known to those skilled in the art.
It will be understood by one of ordinary skill in the art that variations of detail can be made without departing from the spirit and in no way limiting the scope of the present invention.
Some compounds within certain of the general formulas described herein are commercially available. For some compounds, the syntheses described herein are exemplary and can be used as a starting point to prepare additional compounds of the formulas described herein. These compounds can be prepared in various ways, including those synthetic schemes shown and described herein. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise routes based on the disclosures herein;
all such modifications and alternate routes are within the scope of the claims.
The various reaction schemes are summarized below.
Scheme 1 is a synthetic approach to nucleosides 3. (Base and other variables listed in the Scheme are as defined in active compound section) Scheme 2 is an alternate synthetic approach to nucleosides 3. (Base and other variables Ii st ed in the Scheme are as defined in active compound section) Compounds of Formula A can be prepared by first preparing nucleosides 1, which in turn can be accomplished by one of ordinary skill in the art, using methods outlined in: (a) Raj agopalan, P.; Boudinot, F. D; Chu, C. K.; Tennant, B. C.; Baldwin, B. H.;
Antiviral Nucleosides: Chiral Synthesis and Chemotheraphy: Chu, C. K.; Eds. Elsevier:
2003. b) Recent Advances in Nucleosides: Chemistry and Chemotherapy: Chu, C. K.; Eds.
Elsevier:
2002. c) Frontiers in Nucleosides & Nucleic Acids, 2004, Eds. R. F. Schinazi &
D. C. Liotta, IHL Press, Tucker, GA, USA, pp: 319-37 d) Handbook of Nucleoside Synthesis:
Vorbruggen H. & Ruh-Pohlenz C. John Wiley & sons 2001), and by general Schemes 1-2.
Specifically, nucleosides 3 can be prepared by coupling sugar 1 with a protected, silylated or free nucleoside base in the presence of Lewis acid such as TMSOTf. Deprotection of the 3'- and 5'-hydroxyls gives nucleoside 3.
Analogous compounds of Formula B can be prepared using compounds like Compound 1, but with a fluorine rather than OPr at the 2'-position. Representative synthetic methods are described, for example, in U.S. Patent No. 8,716,262.
R1 R1 ip, PrO R113 Y HO R.-)(Base -,./
0, ) R2 ,C0.._\
LG 1) Lewis Acid protected, silylated R or free nucleoside base i--13 + 2) deprotectionw R2 R3 OPr OPr OH OH
1 nucleoside base may contain suitable protection; 3 Pr = protection;
LG = OCOalkyl, OCOaryl, OCOalkylaryl;
R-1, R1B, 2, I-(- R3, and Y are as defined in active compound section Similarly, compounds like Compound 1, but with a Y substituent at the 2'-position and/or an R substituent at the 3'-position, can be used to prepare nucleosides similar to Compound 3, but with Y or R substitution at the 2'- and/or 3'-positions, respectively.
Also, analogous compounds where the oxygen in the sugar ring is replaced with one of the other variables defined by R5 can also be prepared.
Scheme 1 A synthetic approach to nucleosides 3. (Base are as defined in active compound section) In the schemes described herein, if a nucleoside base includes functional groups that might interfere with, or be decomposed or otherwise converted during the coupling steps, such functional groups can be protected using suitable protecting groups. After the coupling step, protected functional groups, if any, can be deprotected.
Alternatively, nucleosides 3 can be prepared from 1 ' -halo, F-sulfonate or 1 ' - hydroxy compounds 2. For the case of l'-halo or l'-sulfonate a protected or free nucleoside base in the presence of a base such as triethyl amine or sodium hydride followed by deprotection would give nucleosides 3. For the case of l'-hydroxy a protected or free nucleoside base in the presence of a Mitsunobu coupling agent such as diisopropyl azodicarboxylate followed by deprotection would give nucleosides 3.
Analogous compounds of Formula B can be prepared using compounds like Compound 1, but with a fluorine rather than OPr at the 2'-position. Representative synthetic methods are described, for example, in U.S. Patent No. 8,716,262.
HO y Base PrO R1 B y 1 ) Base or protected or free Mitsunobu R3 R2 1 + nucleoside base 2) deprotection R2 OPr OPr OH OH
2 nucleoside base may contain suitable protection; 3 Pr = protection;
X = halogen, sulfonate or OH;
R1, R1B, R3, and Y are as defined in active compound section Scheme 2 An alternate synthetic approach to nucleosides 3. (Base, It', RIB, ¨2, K and R3 are as defined in active compound section) Similarly, compounds like Compound 2, but with a Y substituent at the 2'-position and/or an R substituent at the 3'-position, can be used to prepare nucleosides similar to Compound 3_ but with Y or R substitution at the 2'- and/or 3'-positions, respectively.
Also, analogous compounds where the oxygen in the sugar ring is replaced with one of the other variables defined by It5 can also be prepared.
In the schemes described herein, if a nucleoside base includes functional groups that might interfere with, or be decomposed or otherwise converted during the reaction steps, such functional groups can be protected using suitable protecting groups that can be removed.
Protected functional groups, if any, can be deprotected later on Nft xi, N õ
N
In the case of C-nucleosides prepared from bases: 1) and 2) -T NH
methods outlined in W009132123, W009132135, W02011150288 and W02011035250 can be used.
In the case of C-nucleosides prepared from other bases, methods outlined in Temburnikar K, Seley-Radtke KL. Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides. Beilstein J Org Chem. 2018;14:772-785 can be used.
In the case of carbocyclic nucleosides, methods outlined in the following references can be used:
- Advances in the enantioselective synthesis of carbocyclic nucleosides, Chem. Soc. Rev., 2013, 42, 5056 - The latest progress in the synthesis of carbocyclic nucleosides".
Nucleosides, Nucleotides & Nucleic Acids. 2000, 19 (3): 651-690 - New progresses in the enantioselective synthesis and biological properties of carbocyclic nucleosides". Mini Reviews in Medicinal Chemistry 2003 3(2): 95-114.
- Chemical synthesis of carbocyclic analogues of nucleosides". Chemical Synthesis of Nucleoside Analogues. Hoboken: John Wiley & Sons. 2003 pp. 535-604 Dioxolane nucleoside analags can be prepared by adapting the chemistry outlined in J.
Org. Chem. 1995, 60, 6, 1546-1553.
Incorporation of Deuterium:
It is expected that single or multiple replacement of hydrogen with deuterium (carbon-hydrogen bonds to carbon-deuterium bond) at site(s) of metabolism in the sugar portion of a nucleoside antiviral agent will slow down the rate of metabolism. This can provide a relatively longer half-life, and slower clearance from the body. The slow metabolism of a therapeutic nucleoside is expected to add extra advantage to a therapeutic candidate, while other physical or biochemical properties are not affected. Intracellular hydrolysis or deuterium exchanges my result in liberation of deuterium oxide (D20).
Methods for incorporating deuterium into amino acids, phenol, sugars, and bases, are well known to those of skill in the art. Representative methods are disclosed in U.S. Patent No.
9,045,521.
A large variety of enzymatic and chemical methods have been developed for deuterium incorporation at both the sugar and nucleoside stages to provide high levels of deuterium incorporation (D/H ratio). The enzymatic method of deuterium exchange generally has low levels of incorporation. Enzymatic incorporation has further complications due to cumbersome isolation techniques which are required for isolation of deuterated mononucleotide blocks.
Schmidt et al., Ann. Chem. 1974, 1856; Schmidt et al., Chem. Ber., 1968, 101, 590, describes synthesis of 5',5'-2H2-adenosine which was prepared from 2',3'-0-isopropylideneadenosine-5'-carboxylic acid or from methyl-2,3-isopropylidene-beta-D-ribofuranosiduronic acid, Dupre, M.
and Gaudemer, A., Tetrahedron Lett. 1978, 2783. Kintanar, et al., Am. Chem.
Soc. 1998, 110, 6367 reported that diastereoisomeric mixtures of 5'-deuterioadenosine and 5'(R/S)-deuteratedthymidine can be obtained with reduction of the appropriate 5'-aldehydes using sodium borodeuteride or lithium aluminum deuteride (98 atom % 2H
incorporation). Berger et al., Nucleoside & Nucleotides 1987, 6, 395 described the conversion of the 5'-aldehyde derivative of 2'deoxyguanosine to 5' or 4'-deuterio-2'-deoxyguanosine by heating the aldehyde in 2H20/pyridine mixture (1:1) followed by reduction of the aldehyde with NaBat.
Ajmera et al., Labelled Compd. 1986, 23, 963 described procedures to obtain 4'-deuterium labeled uridine and thymidine (98 atom % 2H). Sinhababu, et al., J.
Am. Chem. Soc.
1985, 107, 7628) demonstrated deuterium incorporation at the C3' (97 atom %
2H) of adenosine during sugar synthesis upon stereoselective reduction of 1,2:5,6-di-O-isopropylidene-13-D-hexofuranos-3-ulose to 1,2:5,6-di-0-isopropylidene-3-deuterio-P-D-ribohexofuranose using sodium borodeuteride and subsequently proceeding further to the nucleoside synthesis. Robins, et al., Org. Chem. 1990, 55, 410 reported synthesis of more than 95% atom 2H
incorporation at C3' of adenosine with virtually complete stereoselectivity upon reduction of the 2'-0-tert-butyldimethylsilyl(TBDMS) 3-ketonucleoside by sodium borodeuteride in acetic acid. David, S. and Eustache, J., Carbohyd. Res. 1971, 16,46 and David, S. and Eustache, J., Carbohyd. Res.
1971, 20, 319 described syntheses of 2'-deoxy-2'(S)-deuterio-uridine and cytidine. The synthesis was carried out by the use of 1-methyl-2-deoxy-2'-(S)-deuterio ribofuranoside.
Radatus, et al., J Am Chem. Soc. 1971, 93, 3086 described chemical procedures for synthesizing 2'-monodeuterated (R or S)-2'-deoxycytidines. These structures were synthesized from selective 2-monodeuterated-2-deoxy-D-riboses, which were obtained upon stereospecific reduction of a 2,3-dehydro-hexopyranose with lithium aluminum deuteride and oxidation of the resulting glycal. Wong et al. J. Am. Chem. Soc. 1978, 100, 3548 reported obtaining deoxy-1 -deuterio-D-erythro-pentose, 2-deoxy-2(S)-deuterio-D-erythro-pentose and 2-deoxy-1,2(S)-dideuterio-D-erythro-pentose from D-arabinose by a reaction sequence involving the formation and LiAlD4 reduction of ketene dithioacetal derivatives.
Pathak et al. J., Tetrahedron 1986, 42, 5427) reported stereospecific synthesis of all eight 2' or 2'-deuterio-2'-deoxynucleosides by reductive opening of appropriate methyl 2,3-anhydro-beta-D-ribo or beta-D-lyxofuranosides with LiAlD4. Wu et al. J. Tetrahedron 1987, 43, 2355 described the synthesis of all 2',2"-dideuterio-2'-deoxynucleosides, for both deoxy and ribonucleosides, starting with oxidation of C2' of sugar and subsequent reduction with NaBD4 or LiAlD4 followed by deoxygenation by tributyltin deuteride. Roy et al. J.
Am. Chem. Soc.
1986, 108, 1675, reported 2',2'-dideuterio-2'-deoxyguanosine and thymidine can be prepared from 2-deoxyribose 5-phosphate using 2-deoxyribose 5-phosphate aldolase enzyme in 2H20 achieving some 90 atom % deuteration. Similarly, the synthesis of 4',5',5'-2H3-guanosine can be carried out.
Therefore, it is clear that each position of the sugar residue can be selectively labeled.
A useful alternative method of stereospecific deuteration was developed to synthesize polydeuterated sugars. This method employed exchange of hydrogen with deuterium at the hydroxyl bearing carbon (i.e. methylene and methine protons of hydroxyl bearing carbon) using deuterated Raney nickel catalyst in 2H20.
Various techniques are available to synthesize fully deuterated deoxy and ribonucleosides. Thus, in one method, exchange reaction of deuterated Raney nickel-4120 with sugars, a number of deuterated nucleosides specifically labeled at 2', 3' and 4' positions were prepared. The procedure consisted of deuteration at 2', 3' and 4' positions of methyl beta-D-arabinopyranoside by Raney nickel-2H20 exchange reaction followed by reductive elimination of '2-hydroxyl group by tributyltin deuteride to give methyl beta-D-2' ,2',3' ,4' -2H4-2-deoxyribopyranoside, which was converted to methyl beta-D-2' ,2',3 ',4' -21-14-2'-deoxyribofuranoside and glycosylated to give various 2',2',3',4'-21-14-nucleosides (>97 atom %
2H incorporation for H3' & H4'.
The synthesis of deuterated phenols is described, for example, in Hoyer, H.
(1950), Synthese des pan-Deutero-o-nitro-phenols. Chem. Ber., 83: 131-136. This chemistry can be adapted to prepare substituted phenols with deuterium labels. Deuterated phenols, and substituted analogs thereof, can be used, for example, to prepare phenoxy groups in phosphoramidate prodrugs.
The synthesis of deuterated amino acids is described, for example, in Matthews et al., Biochimica et Biophysica Acta (BBA) - General Subjects, Volume 497, Issue 1, 29 March 1977, Pages 1-13. These and similar techniques can be used to prepare deuterated amino acids, which can be used to prepare phosphoramidate prodrugs of the nucleosides described herein.
One method for synthesizing a deuterated analog of the compounds described herein involves synthesizing a deuterated ribofuranoside with a 4' -alkynyl substitution; and attaching a nucleobase to the deuterated ribofuranoside to form a deuterated nucleoside.
A prodrug, such as a phosphoramidate prodrug, can be formed by modifying the 5' -OH group on the nucleoside. Where a deuterated phenol and/or deuterated amino acid is used, one can prepare a deuterated phosphoramidate prodrug.
Another method involves synthesizing a ribofuranoside with 4'-alkynyl substitution, and attaching a deuterated nucleobase to form a deuterated nucleoside. This method can optionally be performed using a deuterated furanoside to provide additional deuteration. As with the method described above, the nucleoside can be converted into a prodrug form, which prodrug form can optionally include additional deuteration.
A third method involves synthesizing a ribofuranoside with 4' -alkynyl substitution, attaching a nucleobase to form a nucleoside, and converting the nucleoside to a phosphoramidate prodrug using one or both of a deuterated amino acid or phenol analog in the phosphoramidate synthesis.
Accordingly, using the techniques described above, one can provide one or more deuterium atoms in the sugar, base, and/or prodrug portion of the nucleoside compounds described herein.
Specific Examples Specific representative compounds were prepared as per the following examples and reaction sequences; the examples and the diagrams depicting the reaction sequences are offered by way of illustration, to aid in the understanding of the invention and should not be construed to limit in any way the invention set forth in the claims which follow thereafter. The present compounds can also be used as intermediates in subsequent examples to produce additional compounds as described herein. No attempt has necessarily been made to optimize the yields obtained in any of the reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc.
(Milwaukee, WI) and EMD Chemicals Inc. (Gibbstown, NJ). Reagents were purchased from commercial sources. Unless noted otherwise, the materials used in the examples were obtained from readily available commercial suppliers or synthesized by standard methods known to one skilled in the art of chemical synthesis Melting points (mp) were determined on an El ectrothermal digit melting point apparatus and are uncorrected. 1I-1 and "C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiplet). All J- values are in Hz. Mass spectra were determined on a Micromass Platform LC spectrometer using electrospray techniques.
Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA).
Analytic TLC
was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F
silica gel plates. Column chromatography was carried out on Silica Gel or via reverse-phase high performance liquid chromatography.
Example 1 The techniques shown below can be used to prepare other compounds described herein Experimental (IL NH HMDS, rNH (NH
1\1,NN
N, Bz0 N 0 TMSCI
'WOAc H Bz0 0 NH3/Me0H HO
SnCI4 3 d Bz0 OBz J. Org. Chem r.t., ays 1974, 3654-3660 Bz0 OBz HO OH
N\
"N
1)-N
t N
1. TMSCI, Et3N, CH3CN HO HOAc/Me0H HO 'N 0 2. POCI3 3. 1,2,4-Triazole rT HO
OH
TMSO OTMS
Scheme 3. Synthesis of Compound 25 2-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-y1)-1,2,4-triazine-3,5(211,411)-dione (23):
A mixture of compound 22 (10.5 g, prepared by following the chemistry described in J.
Org. Chem. 1974, 3654-3660) in saturated NH3/Me0H (250 mL) was stirred at room temperature for 3 days. After removal of the volatiles under reduced pressure, the residue was purified by flash chromatography (0 - 20% Me0H in dichloromethane) to give 23 (3.5 g, 76%).
1H NMR (CD30D): 7.44 (s, 1H), 6.08 (d, J= 3.2Hz, 1H), 4.42 (dd, J= 5.2Hz, J=
3.2Hz, 1H), 4.24 (t, J= 5.6Hz, 1H), 3.96 (m, 1H), 3.73 (dd, J=12.0 Hz, J= 3.6Hz, 1H), 3.60 (dd, J= 12.0Hz, J= 5.6Hz, 1H); 13C NMR (CD30D): 158.27, 149.97, 137.36, 91.71, 85.87, 74.42, 71.91, 63.43;
LCMS: 246 (M + 1)+.
2-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-y1)-5-methoxy-1,2,4-triazin-3(2H)-one (25):
To a stirred suspension of 23 (123 mg, 0.5 mmol, 1 eq) in acetonitrile (5 mL), triethylamine (1.05 mL, 7.5 mmol, 15eq) and chlorotrimethylsilane (0.32 mL, 2.5 mmol, 5eq) were added dropwi se at 0 C. The cooling bath was removed and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then cooled down to 0 C and POC13 (145uL) was added dropwise. The reaction mixture was stirred for 15 min and 1,2,4-triazole (345 mg, 5 mmol, 10 eq) was added. The reaction mixture was stirred at room temperature overnight, and then poured into a pH 7.4 buffer solution (20 mL). The mixture was extracted with DCM (3 x 30 mL). The combined organic phases were dried over sodium sulfate. After the volatiles were removed under reduced pressure, the residue was dissolved in Me0H/HOAc (4:1, 5 mL) and stirred overnight. After removal of the voaltils, the residue was purified by column using 0 ¨ 10% methanol in DCM to give product 3 (70.6 mg, 54%). LCMS:
282 (M +
Na+). NM_R (CD30D): 7.80 (s, 1H), 6.20 (d, J = 3.2 Hz, 1H), 4.43 (dd, J = 5.2 Hz, J = 3.2 Hz, 1H), 4.28 (t, J = 5.6 Hz, 1H), 4.03 -4.00 (m, 1H), 4.01 (s, 3H), 3.75 (dd, J = 8.0 Hz, J = 3.6 Hz, 1H), 3.62 (dd, J = 12.4 Hz, J = 5.6 Hz, 1H); 1-3C NMR (CD30D): 166.70, 155.93, 130.25, 93.29, 86.11, 74.83, 71.93, 63.43, 55.68.
J. Am. Chem. Soc. 2005, 27, 8846.
oriFi 3 steps NH2 d >, HOza.....Crs NH2 a,b,c 35a 35b e, f e, f N N
NH2 37a-b CI
36a-b /=N h N /=N
N
I
N1\1-11L0/-06 N
N
CI
CI
38a 38a 39b 39b Scheme 4. Synthesis of compound 38a-b and 39a-b: a) Boc20, DMAP, Et3N, 4 A MS, THF, rt, 4 h. b) NaBH4, Me0H, 0 C, 4 h. c) H20, reflux, 24 h. d) H2, Pd-C, Me0H, rt, 5 h. e) N-(2-Amino-4,6-dichloro-5-pyrimidinyl)formamide, DIPEA, n-BuOH, 160 C, 24 h. f) Ac20, DMAP, Et3N, 4 A MS, DCM, rt, 24 h. g) Amyl nitrite, TMSC1, 4 A MS, DCM, 0-5 C, 1 h. h) Bu2SnO, toluen, reflux, 16 h. i) t-BuMgC1, L-Alanine, N-RS)-(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphiny1]-,1-methylethyl ester, 4 A MS, THF, 0 C to rt, overnight.
((lS,4R)-4-Aminocyclopent-2-en-1-yl)methanol (35a) was prepared according to the procedures reported in J. Am. Chem. Soc. 2005, 127, 24, 8846-8855.
A mixture of Vince lactam 33 (1 eq.), di-t-butyl dicarbonate (1.2 eq.), DMAP
(0.1 eq.) and Et3N
(1.2 eq.) in T1-if (0.5 M) was stirred at room temperature for 4 hours and then evaporated. The residue was dissolved in AcOEt, washed with 1M HC1, then with a solution of 5%
NaHCO3 and brine, dried over MgSO4 filtered and concentrated under vacuo. Crude product was purified flash chromatography on silica gel (Hexanes/AcOEt - 1:0 to 85:25) to afford pure NBoc intermediate as a white solid (92%). This compound was dissolved in methanol (0.3 M) and cool down to 0 C. NaBH4 (4 eq.) was added in 6 portions over 1 hour and the reaction was stirred at 0 C for 30 min and then 4 hours at room temperature. Volatiles were evaporated and the residue was partitioned between water and AcOEt (2:3). The aqueous phase was extracted with AcOEt. Combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The resulting white solid was refluxed in water (0.25 M) for 24 hours. Water was removed under vacuo to afford the desired compound (4) as a brown oil.
((1R,3S)-3-Aminocyclopentyl)methanol (35b) was prepared according to the procedures reported in J. Am. Chem. Soc. 2005, 127, 24, 8846-8855.
A mixture of 35a (1 eq.) and 10% Pd-C (0.04 eq.) in Me0H (0.115 M) was stirred under atmospheric pressure of H2 at room temperature for 4 hours. The Pd-C was filtered off on a Celite pad, washed with Me0H, and the combined filtrate were evaporated to afford 35b as a slightly brown oil (quantitative yield).
((lS,4R)-4-(2-Amino-6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl acetate (36a) and ((1R,3S)-3-(2-amino-6-chloro-9H-purin-9-yl)cyclopentyl)methyl acetate (36b).
In a sealed vessel, to a solution of compound 35a or 35b (1 eq.) in n-BuOH
(0.3 M), was added DIPEA (4 eq.) and N-(2-Amino-4,6-dichloro-5-pyrimidinyl)formamide (1.5eq.).
The mixture was heated at 130 C for 24 hours. Volatiles were evaporated and the crude product was purified silica gel flash chromatography (DCM/Me0H - 1:0 to 95:5). The resulting compound was suspended in DCM (0.1 M) and DMAP (0.2 eq.), Et3N (2 eq.) and Ac20 (1.1 eq.) were added at room temperature. The clear solution was stirred for 24 hours at room temperature, then the volatiles were removed under vacuum. The residue was dissolved in a saturated solution of NaHCO3, extracted thrice with AcOEt. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The residue was purified using silica gel flash chromatography (DCM/Me0H - 1:0 to 95:5) to afford compounds (6a,b).
(36a). (48%, over 2 steps). NMIR (400 MHz, Acetone-d6) 6 8.00 (d, J = 1.3 Hz, 1H, H8), 6.26 ¨ 6.19 (m, 3H, NH2, H2'), 6.06 (dq, J = 5.6, 1.9 Hz, 1H, H3'), 5.64 (dddd, J = 9.0, 5.9, 3.5, 1.8 Hz, 1H, H1'), 4.21 (dd, J = 6.1, 1.2 Hz, 2H, H5'), 3.24 (ddt, J = 8.1, 5.9, 3.4 Hz, 1H, H4'), 2.93 -2.77 (m, 1H, H6'a), 2.05 (s, 3H, C-CH3), 1.83 (dtd, J = 13.7, 6.0, 1.2 Hz, 1H, H6'b). 13C
NMR (101 MHz, Acetone-d6) 6 171.0 (C=0), 160.6 (Cquat), 154.8 (Cquat), 151.0 (Cquat), 141.6 (C8), 138.1 (C2'), 131.0 (C3'), 125.7 (Cquat), 67.0 (C5'), 60.4 (Cl'), 45.3 (C4'), 35.0 (C6'), 20.7 (CO-CH3). HRMS-EST (m/z) [M+H]+ calcd for C13H14C1N502 : 307.0836, found:
307.0902.
(36b). (50%, over 2 steps). 1-1-1NMR (400 MHz, Acetone-d6) 6 8.13 (s, 1H, H8), 6.20 (bs, 2H, NH2), 4.88 (dq, J = 9.8, 8.1 Hz, 1H, H1'), 4.22 - 4.03 (m, 2H, H5'), 2.58 -2.40 (m, 2H, H4', H2' a), 2.36 - 2.10 (m, 2H, H3'), 2.05 (s, 3H, C-CH), 2.08 - 1.89 (m, 2H, H2'b, H6'a), 1.88 -1.75 (m, 1H, H6'b). 1-3C NMR (101 MHz, Acetone-d6) 6 171.1 (C=0), 160.5 (Cquat), 155.0 (Cquat), 151.0 (Cquat), 142.2 (C8), 125.9 (Cquat), 68.1 (C5'), 56.4 (C1'), 37.9 (C4'), 36.0 (C2'), 31.5 (C3'), 27.6 (C6'), 20.7 (CO-CH3). HRMS-ESI (m/z) [M+E-1]+ calcd for C13H16C1N502 : 309.0993, found: 309.1063.
01S,4R)-4-(2,6-dichloro-9H-purin-9-yl)cyclopent-2-en-l-y1)methyl acetate (37a) and ((1R,3S)-3-(2,6-dichloro-911-purin-9-y1)cyclopentyl)methyl acetate (37b).
A mixture of amyl nitrite (6 eq.) in DCM (0.47 M) was cool down to 0 C. TMSC1 (3 eq.) was added dropwise followed by a solution of (36a,b) (1 eq.) in DCM (0.47 M). The mixture was stirred between 0 and 5 C for 1 hour and then quenched with a saturated solution of Na2S03.
The aqueous layer was extracted thrice with DCM. Combined organic layers were washed with saturated NaHCO3 and brine, dried over MgSO4, filtered and concentrated under vacuo. The residue purified by flash chromatography (Hex/AcOEt - 2:8 to 8:2) to afford compounds (7a,b).
(37a). (74%). 1-E1 NMR (400 MHz, Acetone-d6) 6 8.51 (s, 1H, H8), 6.27 (dt, J =
5.7, 2.1 Hz, 1H, H2'), 6.10 (dt, J = 5.6, 2.2 Hz, 1H, H3'), 5.82 (ddq, J = 9.9, 6.0, 2.1 Hz, 1H, H1'), 4.16 (dq, J = 11.0, 5.8, 5.4 Hz, 2H, H5'), 3.26 (tddd, J = 8.1, 5.9, 4.1, 2.2 Hz, 1H, H4'), 2.94 (dt, J = 14.0, 8.7 Hz, 1H, H6'a), 2.00 (s, 3H, C-CH3), 1.90 (dt, J = 14.1, 5.9 Hz, 1H, H6'b).13C NIVIR (101 MHz, Acetone-d6) 6 171.0 (C=0), 154.3 (Cquat), 152.4 (Cquat), 151.1 (Cquat), 140.6 (C8), 139.1 (C2'), 132.2 (Cquat), 130.2 (C3'), 66.9 (C5'), 61.6 (Cl'), 45.5 (C4'), 35.1 (C6'), 20.7 (CO-CH3). HRMS-ESI (m/z) [M+E-1]+ calcd for C13H1202N402 : 326.0337, found:
326.0408.
(37b). (76%). 1H NMR (400 MHz, Acetone-d6) 68.70 (s, 1H, H8), 5.22 - 5.00 (m, 1H, H1'), 4.23 -4.07 (m, 2H, H5'), 2.65 -2.47 (m, 2H, H4', H2'a), 2.40 (dddd, J = 14.0,
7.9, 6.2, 1.4 Hz, 1H, H3'a), 2.35 ¨ 2.23 (m, 1H, H3'b), 2.05 (s, 3H, C-CH3), 2.09 ¨ 1.94 (m, 2H, H2'b, H6'a), 1.93 ¨ 1.78 (m, 1H, H6'b). 1-3C NMR (101 MHz, Acetone-d6) 6 171.0 (C=0), 154.5 (Cquat), 152.3 (Cquat), 151.2 (Cquat), 147.0 (C8), 132.2 (Cquat), 67.9 (C5'), 57.3 (Cl'), 37.9 (C4'), 36.3 (C2'), 31.7 (C3'), 27.5 (C6'), 20.7 (CO-CH3). HRMS-ESI (m/z) [M+f1]+
calcd for C13H14C12N402 : 328.0494, found: 328.0565.. Rf : 0.4 (DCM/Me0H 95:5).
((lS,4R)-4-(2,6-dichloro-911-purin-9-y1)cyclopent-2-en-1-yHmethanol (38a) and ((1R,3S)-3-(2,6-dichloro-911-purin-9-yl)cyclopentyl)methanol (38b).
A mixture of 37a,b (1 eq.) and Bu2SnO (3 eq.) in toluene (0.0075 M) was refluxed for 16 -18 hours and then the solvent was removed in vacuo. The residue was purified by flash chromatography (Hex/AcOEt -1:9 to 0:1. to afford product 8a,b.
(38a). (70%). 1-1-1NMR (400 MHz, Methanol-d4) 6 8.57 (s, 1H, H8), 6.26 (dt, J
= 5.7, 2.1 Hz, 1H, H2'), 5.97 (dt, J = 5.6, 2.2 Hz, 1H, H3'), 5.77 (ddq, J = 9.2, 5.6, 2.0 Hz, 1H, H1'), 3.69 ¨
3.55 (m, 2H, H5'), 3.11 ¨2.99 (m, 1H, H4'), 2.85 (dt, J= 14.1, 8.9 Hz, 1H, H6'a), 1.81 (dt, J=
14.1, 5.4 Hz, 1H, H6'b). '3C NMR (101 MHz, Methanol-d4) 6 154.34 (Cquat), 153.55 (Cquat), 151.66 (Cquat), 147.55 (C8), 140.99 (C2'), 131.89 (Cquat), 129.71 (C3'), 65.06 (C5'), 62.33 (Cl'), 49.28 (C4'), 35.10 (C6'). HRMS-ESI (m/z) [M+H]+ calcd for CiillioC12N40 :284.0232, found: 284.0304.
(38b). (42%). 1-1-1NMR (400 MHz, Methanol-d4) 69.11 (s, 1H, H8), 5.44 (dq, J =
9.6, 7.9 Hz, 1H, H1'), 4.07 (dd, J = 6.3, 4.4 Hz, 2H, H5'), 2.97 ¨ 2.87 (d, J= 12.6 Hz, 1H, H2'a), 2.83 ¨
2.71 (m, 2H, H4', H3'a), 2.68 ¨ 2.53 (m, 1H, H3'b), 2.47 ¨ 2.12 (m, 3H, H2'b, H6'a, H6'b).
1-3C NIVIK (101 MHz, Methanol-d4) 6 154.6 (Cquat), 153.4 (Cquat), 151.7 (Cquat), 147.7 (C8), 132.0 (Cquat), 66.4 (C5'), 58.3 (Cl'), 41.5 (C4'), 36.4 (C2'), 32.2 (C3'), 27.6 (C6'). FIRMS-EST (m/z) [M+f1]+ calcd for CiiHi2C12N40 : 286.0388, found: 286.0460.
Isopropyl ((((1S,4R)-4-(2,6-dichloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (39a) and isopropyl (0(1R,3S)-3-(2,6-dichloro-911-purin-9-yl)cyclopentyl)methoxy)(phenoxy)phosphory1)-L-alaninate (39b).
Under inert atmosphere, compound 38a,b (1 eq.) was dissolved into anhydrous THF (0.26 M), with 4 A MS. The reaction mixture was cooled down to 0 C and t-BuMgC1 (1.7 M
in THF, 3.1 eq.) was added dropwise. The reaction was stirred for 30 min at 0 C and then stirred for 30 min at room temperature. (S)-2-1-(S)-(2,3,4,5,6-Pentafluoro-phenoxy)-phenoxy-phos-phorylamino] propionic acid isopropyl ester (2.5 eq.) dissolved in THF (0.5 M) was added dropwise to the previous solution at 0 C . After 30 min at that temperature, the reaction was warmed up to room temperature stirred overnight. Volatiles were then removed under vaccum and the residue was diluted in a solution of saturated NaHCO3. The aqueous layer was extracted 3 times with AcOEt. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The residue was purified by flash chromatography (Hex/AcOEt - 1:1 to 0:1) to afford compound 39a,b.
(39a). (31%). 1H NWIR (400 MHz, Acetone-d6) 6 (8.50 (s, 1H, H8), 7.33 (dd, J =
calcd for C13H14C12N402 : 328.0494, found: 328.0565.. Rf : 0.4 (DCM/Me0H 95:5).
((lS,4R)-4-(2,6-dichloro-911-purin-9-y1)cyclopent-2-en-1-yHmethanol (38a) and ((1R,3S)-3-(2,6-dichloro-911-purin-9-yl)cyclopentyl)methanol (38b).
A mixture of 37a,b (1 eq.) and Bu2SnO (3 eq.) in toluene (0.0075 M) was refluxed for 16 -18 hours and then the solvent was removed in vacuo. The residue was purified by flash chromatography (Hex/AcOEt -1:9 to 0:1. to afford product 8a,b.
(38a). (70%). 1-1-1NMR (400 MHz, Methanol-d4) 6 8.57 (s, 1H, H8), 6.26 (dt, J
= 5.7, 2.1 Hz, 1H, H2'), 5.97 (dt, J = 5.6, 2.2 Hz, 1H, H3'), 5.77 (ddq, J = 9.2, 5.6, 2.0 Hz, 1H, H1'), 3.69 ¨
3.55 (m, 2H, H5'), 3.11 ¨2.99 (m, 1H, H4'), 2.85 (dt, J= 14.1, 8.9 Hz, 1H, H6'a), 1.81 (dt, J=
14.1, 5.4 Hz, 1H, H6'b). '3C NMR (101 MHz, Methanol-d4) 6 154.34 (Cquat), 153.55 (Cquat), 151.66 (Cquat), 147.55 (C8), 140.99 (C2'), 131.89 (Cquat), 129.71 (C3'), 65.06 (C5'), 62.33 (Cl'), 49.28 (C4'), 35.10 (C6'). HRMS-ESI (m/z) [M+H]+ calcd for CiillioC12N40 :284.0232, found: 284.0304.
(38b). (42%). 1-1-1NMR (400 MHz, Methanol-d4) 69.11 (s, 1H, H8), 5.44 (dq, J =
9.6, 7.9 Hz, 1H, H1'), 4.07 (dd, J = 6.3, 4.4 Hz, 2H, H5'), 2.97 ¨ 2.87 (d, J= 12.6 Hz, 1H, H2'a), 2.83 ¨
2.71 (m, 2H, H4', H3'a), 2.68 ¨ 2.53 (m, 1H, H3'b), 2.47 ¨ 2.12 (m, 3H, H2'b, H6'a, H6'b).
1-3C NIVIK (101 MHz, Methanol-d4) 6 154.6 (Cquat), 153.4 (Cquat), 151.7 (Cquat), 147.7 (C8), 132.0 (Cquat), 66.4 (C5'), 58.3 (Cl'), 41.5 (C4'), 36.4 (C2'), 32.2 (C3'), 27.6 (C6'). FIRMS-EST (m/z) [M+f1]+ calcd for CiiHi2C12N40 : 286.0388, found: 286.0460.
Isopropyl ((((1S,4R)-4-(2,6-dichloro-9H-purin-9-yl)cyclopent-2-en-1-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (39a) and isopropyl (0(1R,3S)-3-(2,6-dichloro-911-purin-9-yl)cyclopentyl)methoxy)(phenoxy)phosphory1)-L-alaninate (39b).
Under inert atmosphere, compound 38a,b (1 eq.) was dissolved into anhydrous THF (0.26 M), with 4 A MS. The reaction mixture was cooled down to 0 C and t-BuMgC1 (1.7 M
in THF, 3.1 eq.) was added dropwise. The reaction was stirred for 30 min at 0 C and then stirred for 30 min at room temperature. (S)-2-1-(S)-(2,3,4,5,6-Pentafluoro-phenoxy)-phenoxy-phos-phorylamino] propionic acid isopropyl ester (2.5 eq.) dissolved in THF (0.5 M) was added dropwise to the previous solution at 0 C . After 30 min at that temperature, the reaction was warmed up to room temperature stirred overnight. Volatiles were then removed under vaccum and the residue was diluted in a solution of saturated NaHCO3. The aqueous layer was extracted 3 times with AcOEt. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuo. The residue was purified by flash chromatography (Hex/AcOEt - 1:1 to 0:1) to afford compound 39a,b.
(39a). (31%). 1H NWIR (400 MHz, Acetone-d6) 6 (8.50 (s, 1H, H8), 7.33 (dd, J =
8.7, 7.1 Hz, 2H, Harom), 7.29 ¨ 7.20 (m, 2H, Harom), 7.14 (tq, J = 7.7, 1.1 Hz, 1H, Harom), 6.29 ¨ 6.18 (m, 1H, H2'), 6.09 (dt, J = 5.7, 2.2 Hz, 1H, H3'), 5.81 (ddq, J = 9.9, 6.0, 2.1 Hz, 1H, H1'), 4.92 (p, J = 6.2 Hz, 1H, 0-CH), 4.84 ¨ 4.74 (m, 1H, NH), 4.23 ¨4.11 (m, 2H, H5'), 4.01 ¨3.85 (m, 1H, N-CH), 3.34 ¨ 3.24 (m, 1H, H4'), 2.91 (dt, J = 14.1, 8.8 Hz, 1H, H6' a), 2.80 (t, J = 1.1 Hz, 1H, NH), 1.99¨ 1.80 (m, 1H, H6'b), 1.32 (dd, J = 7.1, 0.9 Hz, 3H, CH-CH3), 1.19 (dd, J = 6.2, 1.7 Hz, 6H, 2 x CH-CH3).13C NMR (101 MHz, Acetone-d6) 6 173.5 (C=0), 154.3 (Cquat), 152.4 (Cquat), 152.2 Cquat), 151.1 (Cquat), 146.7 (C8), 138.8 (C2'), 132.1 (Cquat), 130.5 (C3'), 130.3 (2 x Carom), 125.2 (Carom), 121.1 (2 x Carom), 69.5 ¨68.3 (m, C5', 0-CH), 61.5 (C1'), 51.2 (NH-CH), 46.8 (C4'), 34.71 (C6'), 21.9 (2 x C-CH3), 21,8 (C-CH3).
31P NMR (162 MHz, Acetone-d6) 6 2.78. HRMS-ESI (m/z) [M+H]+ calcd for C23H26C12N505P:
553.1049, found: 553.1124.
(39b). (48%). 1H NMR (400 MHz, Acetone-d6) 6 8.63 (s, 1H, H8), 7.34 (dd, J =
8.7, 7.0 Hz, 2H, Harom), 7.33 ¨7.23 (m, 2H, Harom), 7.20 ¨ 7.10 (m, 1H, Harom), 5.05 (d, J
= 8.1 Hz, 1H, H1'), 4.98 ¨ 4.90 (m, 1H, 0-CH), 4.92 ¨ 4.77 (m, 1H, NH), 4.14 (qt, J= 10.2, 6.4 Hz, 2H, H5'), 4.01 ¨3.87 (m, 1H, NTI-CH), 2.64 ¨ 2.42 (m, 2H, H4', H2'a), 2.36 (dtd, J =
13.4, 7.8, 5.5 Hz, 1H, H3' a), 2.20 (dtd, J = 12.9, 9.0, 7.4 Hz, 1H, H3'b), 2.00 ¨ 1.93 (m, 2H, H2'b, H6'a), 1.92 ¨
1.79 (m, 1H, H6' a), 1.39¨ 1.26 (m, 3H, CH-CH3), 1.26¨ 1.14 (m, 6H, 2 x CH-CH3).13C NMR_ (101 MHz, Acetone-d6) 6 173.6 (C=0), 154.5 (Cquat), 152.3 (Cquat), 152.3 (Cquat), 151.1 (Cquat), 146.9 (C8), 132.1 (Cquat), 130.3 (2 x Carom), 125.2 (Carom), 121.2 (2 x Carom), 70.0 (C5'), 69.0 (0-CH), 57.2 (C1'), 51.2 (NH-CH), 39.0 (C4'), 35.9 (C2'), 31.8 (C3'), 27.0 (C6'), 21.9 (2 x C-CH3), 21.8 (C-CH3). 31P NMR (162 MHz, Acetone-d6) 6 2.66. HRMS-ESI
(m/z) [M+H]+ calcd for C23H28C12N505P : 555.1205, found: 555.1281.
ri)L'N1-1 'N 0 0 H
Bz0 1. BSA/MeCN (NH
1i)1\1H
N
0_,...(0Bz MW 120 C/30 min ______________________________________ Bz0 N'N 0 Me0H .. HO--__iN 0 ).- 0 2. TMSOTf _______________________________________________________ ).-OBz0Bz MW 120 C/30 min '.1.---(1--- NH4OH
90% OH OH
48 OBz0Bz 79% 50 rILNH
Acetone/p-Ts0H HO..__ N.NO THF/t-BuMgC1 2,2-Dimethoxypropane 0-y phosphorylating agent .-90%
Ox0 48%
Y 7 o ii)LNH Y 0 ?L'NH
O. .{..NI
,r( NI HCO2H/H20 or._ n NP.P.-ON'NO
0 H oPh N 0 ___________ 0 RT/ 6 h 0 H OPh 0 32%
Ox0 OH OH
Scheme 5. Synthesis of Compounds 50 and 53.
(2R,3R,4R,5R)-5-((benzoyloxy)methyl)-2-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(311)-y1)-3-methyltetrahydrofuran-3,4-diy1 dibenzoate (49):
6-Azauracil (565 mg, 5 mmol) was suspended in acetonitrile (5 mL) in a microwave vial, and BSA (4.5 mL) was added. The suspension was heated under microwave irradiation at 120 C
for 30 min. The solution was cooled down to rt, and compound 48 (580 mg, 1 mmol) was added, followed by TMSOTf (1 mL). The vial was heated under microwave irradiation at 120 C for 30 min. The reaction mixture was slowly added to a saturated aq NaHCO3 solution (50 mL) and stirred for 15 min. The mixture was then diluted with ethyl acetate (60 mL), filtered through a pad of celite and the organic layer separated. The aqueous layer was extracted with ethyl acetate (2x40 mL). The combined organic layers were washed with brine (50 mL), and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane-Et0Ac (4:1 to 1:1) to give 514 mg of product (90 %) as a yellow foam. 1H-NIVIR (CDC13): 0 8.68 (s, 1H), 8.14-8.11 (m, 4H), 8.02-8.00 (m, 2H), 7.64-7.34 (m, 10H), 7.11 (s, 1H), 6.03-6.01 (d, 1H), 4.78-4.73 (m, 2H), 4.55-4.51 (m, 1H), 1.77 (s, 3H).
2-02R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-y1)-1,2,4-triazine-3,5(2H,4H)-dione (50):
To a mixture of 49 (240 mg, 0.42 mmol) in Me0H (4 mL) was added conc. NH4OH (5 mL).
The mixture was stirred at RT overnight. The volatiles were evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1 to 4:1) to give 86 mg (79%) of product as a white foam. '1-1-NWIR (DMSO-d6): H 7.54 (s, 1H), 5.96 (s, 1H), 5.04 (s, br, 2H), 4.57 (s, br, 1H), 3.84-3.48 (m, 4H), 1.04 (s, 3H).
24(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2,3a-trimethyltetrahydrofuro [3,4-d][1,31dioxo1-4-yl)-1,2,4-triazine-3,5(2H,4H)-dione (51):
To a mixture of 50 (140 mg, 0.54 mmol) in dry acetone (5 mL) were added 2,2-dimethoxypropane (0.66 mL, 5.4 mmol) and p-Ts0H-H20 (124 mg, 0.65 mmol). The mixture was stirred at RT for 24 hrs. The reaction was quenched by Et3N (2 mL), and the solvent was evaporated. The residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1) to give 145 mg (90%) of product as a white powder. 1-1-1-NMR
(CD30D):
0 7.49 (s, 1H), 6.36 (s, 1H), 4.42-4.41 (d, 1H), 4.25-4.21 (m, 1H), 3.76-3.66 (m, 2H), 1.53, 1.45, 1.35 (3s, 9H).
Isopropyl ((S)-(((3aR,4R,6R,6aR)-6-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yI)-2,2,6a-trimethyltetrahydrofuro [3,4-d] [1,3] dioxo1-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (52):
To a stirred mixture of 51 (132 mg, 0.44 mmol) in THF (2 mL) at 0 C was added t-BuMgC1 (1.0 M solution in THF, 0.92 mL, 0.92 mmol) dropwise, and the mixture was stirred at 0 C for 30 min. The mixture was allowed to warmed up to RT, and was stirred at RT for another 30 min. The mixture was then cooled down to 0 C, and a solution of {(S)-2-1-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino] propionic acid isopropyl ester}
(240 mg, 0.53 mmol) in THE (1 mL) was added dropwise. After addition, the reaction mixture was allowed to warmed up to RT, and stirred at RT overnight. The reaction was quenched by Me0H
(0.5 mL). The solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (95:5 to 9:1) to give 120 mg (48%) of product. 111-NMR (CD30D): 0 7.49 (s, 1H), 7.37-7.33 (m, 2H), 7.24-7.16 (m, 3H), 6.35 (d, 1H), 4.98-4.93 (m, 1H), 4.38-4.20 (m, 3H), 3.89-3.76 (m, 2H), 1.51 (s, 3H), 1.45 (s, 3H), 1.34-1.31 (m, 6H), 1.22 (t, 6H).
Isopropyl ((S)-(((2R,3R,4R,5R)-5-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-y1)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (53):
A suspension of 52 (100 mg, 0.18 mmol) in formic acid (2 mL) and water (0.5 mL) was stirred at RT for 6 hrs. The solvent was evaporated and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1) to give 30 mg (32%) of product as a white foam, and 22 mg (22%) of starting material. 41-NMR (CD30D): 0 7.45 (s, 1H), 7.38-7.34 (m, 2H), 7.25-7.17 (m, 3H), 6.18 (s, 1H), 4.98-4.93 (m, 1H), 4.33-4.29 (m, 2H), 4.18-4.14 (m, 1H), 4.03-4.01 (d, 1H), 3.93-3.87 (m, 1H), 1.33 (d, 3H), 1.23 (t, 6H), 1.19 (s, 3H).
HRMS calc for C21H3oN4010P (M+H+): 529.1700, found 529.1685.
NrcN
N _TO N
Nk-N
r;1"-NH Nx = 0 I
H 6ph Scheme 6 Synthesis of Compounds 57 and 58: Reagents and conditions: a) Me0H, Pd2(dba)3, Xantphos, Cs2CO3, toluene, 60 C, 3 hr, 93%; b) Pd2(dba)3, Xantphos, isobutyramide, Cs2CO3, toluene, 110 C, overnight, 74%; c) Sodium methoxide, methanol, rt-50 'V, 5 hrs, 60% yield for two steps for 4; d) t-ButylMgC1, THF, rt, overnight, 25-82%.
Compound 54 was prepared according to the chemistry described in:
(1) Sznaidmart, N/1,, Painter, G. R.; Almond, M. R.; Cleary, D, G.; Pesyan, A., Methods to manufacture 1,3-dioxolane nucleosides and their chiral enzymic resolution. PCT
Int.
Appl. 2005, W02005074654, 98 pp.
(2) ) Sznaidman, M. L.; Du, J.; Pesyan, A.; Cleary, D. G.; Hurley, P. K.;
Waligora, F.;
Almond, M. R. Synthesis of (¨)-DAPD. Nucleosides, Nucleotides Nucleic Acids 2004, 23, 1875-1887 02R,4R)-4-(2,6-dichloro-911-purin-9-y1)-1,3-dioxolan-2-y1)methyl isobutyrate (54):
1-E1 NMR (CDC13, 400 MHz): 8.53 (s, 1 H), 6.56 (d, J = 4.4 Hz, 1 H), 5.35 (t, J = 2.8 Hz, 1 H), 4.59-4.33 (m, 4 H), 2.64-2.57 (m, 1 H), 1.19 (d, J= 6.8 Hz, 3 H), 1.14 (d, J= 6.8 Hz, 3 H). LRMS (ESI): m/z calcd for C13H14C12N404 (M-FNa)+: 383.03, observed 382.9.
((2R,4R)-4-(2-chloro-6-nicthoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methyl isobutyratc (55):
To a suspension of 54 (0.9 g, 2.49 mmol), Xantphos (112 mg, 0.19 mmol), tris(dibenzylideneacetone)dipalladium (0) (65 mg, 0.07 mmol), cesium carbonate (1.15 g, 3.52 mmol) in toluene (12 mL) under nitrogen was added methanol (0.11 mL, 2.7 mmol). The reaction mixture was heated at 60 C for 3 hr, filtered, washed with ethyl acetate, concentrated, and purified by flash chromatography using ethyl acetate: hexane = 2: 1 to obtain 55 (820 mg, 93% yield). 1H NMR (CDC13, 400 MHz): 8.26 (s, 1 H), 6.48-6.49 (q, J = 0.8 Hz, J = 4.8 Hz, 1 H), 5.27-5.28 (t, J = 2.8 Hz, 1 H), 4.46-4.49 (dd, J = 0.8 Hz, J = 10.0 Hz, 1 H), 4.37-4.41 (dd, J
= 2.8 Hz, J = 12.8 Hz, 1 H), 4.29-4.33 (dd, J = 3.2 Hz, J = 12.8 Hz, 1 H), 4.24-4.28 (dd, J = 5.2 Hz, J = 10.0 Hz, 1 H), 4.17 (s, 3 H), 2.54-2.61 (m, 1 H), 1.13-1.15 (d, J =
6.8 Hz, 3 H), 1.09-1.10 (d, J = 6.8 Hz, 3 H). LRMS (ESI): m/z calcd for C14H18C1N405 (M-PH):
357.09 observed 356.88.
((2R,4R)-4-(2-isobutyramido-6-methoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methyl isobutyrate (56):
A suspension of 55 (112mg, 0.31 mmol), tris(dibenzylideneacetone)dipalladium(0) (6.5 mg, 0.007 mmol), xantphos (11.2 mg, 0.019 mmol), cesium carbonate (115 mg, 0.35 mmol) and isobutyramide (33.5 mg, 0.38 mmol) in toluene (2 mL) was heated at 110 C for 12 h, then filtered through celite, concentrated under vaccum and purified by flash chromatography to give 56 (94 mg, 74% yield). 1-H NN4R (CDC13, 400 MHz): 8.11 (s, 1 H), 8.10 (brs, 1 H), 6.42-6.43 (d, J = 4.0 Hz,1H), 5.24-5.25 (t, J = 2.8 Hz, 1 H), 4.47-4.50 (dd, J = 1.2 Hz, J = 10.0 Hz, 1 H), 4.312-4.319 (d, J = 2.8 Hz, 2 H), 4.21-4.25 (dd, J = 5.6 Hz, J = 10.0 Hz, 1 H), 4.07 (s, 3 H), 3.10(brs, 1 H), 2.50-2.57 (m, 1 H), 1.22-1.24 (2d, J = 0.8 Hz, 6 H), 1.05-1.12 (2d, J = 7.2 Hz, 6 H). LRMS (ESI): m/z calcd for C18H26N506 (M-FH) : 408.18 observed 407.98.
((2R,4R)-4-(2-amino-6-methoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methanol (57):
To a solution of 56 (4.98 mmol) in with methanol (10 mL) was added sodium methoxide (25%, 3 mL). The solution was stirred for 5 h at room temperature and then heated to 50 C for 30 min. After evaporation under vaccum, the residue was purified by column chromtrography (Dichloromethane: methanol = 60: 3) to afford 57 (800 mg, 60%). 1-H NMR
(CDC13, 400 MHz):
8.12 (s, 1 H), 6.30 (dd, J = 1.6 Hz, J = 5.6 Hz, 1 H), 5.08 (t, J = 2.8 Hz, 1 H), 4.46 (dd, J = 1.6 Hz, J = 10.0 Hz, 1 H), 4.21 (dd, J = 5.2 Hz, J = 9.6 Hz, 1 H), 3.75 (t, J =
2.0 Hz, 2 H). LRMS
(ESI): m/z calcd for C10H14N504 (M+H)+: 268.10, observed 268.04.
Ethyl (0(2R,4R)-4-(2-amino-6-methoxy-911-purin-9-y1)-1,3-dioxolan-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (58):
A solution of 57 (50 mg, 0.18 mmol) in THF (3 mL) was added t-butylmagnesium chloride (0.54 mL, 1 M in THE, 0.54 mmol). The reaction mixture was stirred at rt for 30 min, before addition of the corresponding phosphoramide chloride (0.54 mL, 1 Mmn THF, 0.54 mmol). The reaction mixture was stirred overnight, quenched with saturated ammonium chloride (1 mL) and directly purified by column chromatography (dichloromethane: methanol =
100: 1 to 100:
5) to afford the desired compound.
CI CI
NN NN
HONCI
Scheme 7 Synthesis of Compound 59: Reagents and conditions: a) n-Bu2SnO, toluene, 130 C, overnight, 65 %.
((2R,4R)-4-(2,6-dichloro-911-purin-9-y1)-1,3-dioxolan-2-yHmethanol (59):
A suspension of dichloropurine 54 (3g, 8.30 mmol) and dibutyltin (IV) oxide (6 g, 24.1 mmol) in toluene (50 mL) was heated to 130 C overnight. After evaporation of the volatiles under vacuum, the residue was directly purified by coumn chromatography (Dichloromethane:
methanol = 100: Ito 100: 10) to afford 59 (65%).
NMR (CD30D, 400 MHz): 8.90 (s, 1 H), 6.57(d, J = 5.0 Hz, 1 H), 5.17 (t, J = 2.0 Hz, 1 H), 4.65 (d, J = 10.1 Hz, 1 H), 4.35-4.31 (dd, J
= 5.0 Hz, J= 10.1 Hz, 1 H), 3.86-3.77 (m, 2 H). LRMS (ESI): m/z calcd for (M-FNa)+: 312.99, observed 312.9.
N Ni-LN
4-0 N CI a H0,1µ....j1 N" CI
HO N N
CI
Scheme 8: Synthesis of compound 60 and 61: Reagents and conditions: a) NH3/CH3OH, CH3OH, rt, 2 days, 25 % for 2 and 63% for 3.
02R,4R)-4-(2-chloro-6-methoxy-911-purin-9-y1)-1,3-dioxolan-2-y1)methanol (60) and 02R,4R)-4-(6-amino-2-chloro-9H-purin-9-y1)-1,3-dioxolan-2-yl)methanol (61):
A solution of 54 (1g, 2.76 mmol) in NH3/CH3OH (10 mL) was stirred for 2 days at room temperature. After evaporation of the volatiles, the residue was purified flash chromatography (Dichloromethane: methanol = 100: 1 to 100: 10) to afford 60 (35%) and 61 (63%).
(60): 1H NMR (CD30D, 400 MHz): 8.61 (s, 1 H), 6.51-6.49 (dd, J = 0.8 Hz, J =
4.8 Hz, 1 H), 5.15 (t, J = 2.4 Hz, 1 H), 4.59-4.56 (dd, J = 0.8 Hz, J = 10.0 Hz, 1 H), 4.33-4.29 (dd, J= 5.2 Hz, J = 10.0 Hz, 1 H), 4.16 (s, 3 H), 3.84-3.80 (m, 2 H). LRMS (ESI): m/z calcd for CioHliC1N404 (M-FNa)+: 309.04, observed 309Ø
(61): 1H NMR (CD30D, 400 MHz): 8.42 (s, 1 H), 6.41-6.40 (dd, J = 4.4 Hz, 1 H), 5.13 (d, J =
2.4 Hz, 1 H), 4.52-4.49 (d, J= 10.0 Hz, 1 H), 4.30-4.26 (dd, J= 5.2 Hz, J=
10.0 Hz, 1 H), 3.83-3.75 (m, 2 H). LRMS (ESI): m/z calcd for C9H1oC1N503 (M-FNa)+: 294.03, observed 294Ø
Ha.,..
c.-0- BzCI
Pyridine, BzO'Ic2_ PDC, Ac20 BzOo 0 DCM, rt,'' --f0 OH 0-4\ 0 C to rt OH 0-4\ on 0 2h 92% 0-4\
60 84% 61 62 Bz0 MeMgBr Bz0f2_ Ac20, H2SO4 Vit:31,..,.0Ac THF, 0 AcOH, 0 C, 0.5 h OH 0--.\\ 0 C to rt, OAc OAc 74% on 63 52% 64 Cli''NIIH (1X
( 1) Uracil, BSA N ".-..0 N 0 4 A MS, ACN, HO
55 C, 1 h... Bz0 NH3 2) TMSOTf, Me0H, rt, on C to rt, 5 h OAc OAc 66% OH OH
33%
Scheme 9: Synthesis of Compound 66.
3'Me sugar 64 was synthetized following. W02019090111 Al and Tetrahedron, 2002, 58, 9593. 3'Me-Uridine 66 was synthetized following Bioorg. Med. Chem. 2008, 16, 6319 and Biochemistry 1992, 31, 45, 11210-11215.
1-O2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-4-methy-ltetrahydrofuran-2-yOpyrimidine-2,4(1H,31/)-dione 66 as a white foam (66%). IHNMR (400 MHz, Methanol-d4)6 8.19 (d, 1H, J= 8.1 Hz), 6.05 (d, 1H, J = 7.8 Hz), 5.73 (d, 1H, J= 8.0 Hz), 4.05 (d, 1H, J
= 7.8 Hz), 3.95 (t, 1H, J= 2.2 Hz), 3.80-3.68 (m, 2H), 1.38 (s, 3H). 13C NMR
(101 MHz, Methanol-d4) 6 164.7, 151.5, 141.9, 101.5, 87.8 87.2, 77.5 76.6, 60.8, 18.7.
HRMS-ESI (m/z) [M-FH] calcd. 259.0852. for C1oH15N206 :, found 259.0930.
NHBz NH2 1 N4-BzCytosine C-L'N
,BSA I I
N 0 Bz0 4 A
MS, ACN, N 0 HO
rt, 1 h NH3 Me0H, 0 C to rt OAc OAc 2) TMSOTf, OAc OAc 24 h OH OH
0 C to rt 6 h 10%' 85% 68 Scheme 10: Synthesis of Compound 68.
(2R,3S,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-y1)-2-((benzoyloxy)methyl)-3-methyltetrahydrofuran-3,4-diy1 diacetate 67: 4-N-benzoyl-cytosine (1.49 g, 4,8 mmol, 1.2 eq.) and /V,0-bistrimethylsilylacetamide (1.9 mL, 8.00 mmol, 2 eq.) were heated at 55 C in acetonitrile (12 mL) until a clear solution was observed. Then (31?,4,S,51-?)-((benzoyloxy)methyl)-4-methyltetrahydrofuran-2,3,4-triy1 triacetate 64 (1.58 g, 4 mmol, 1 eq.) was added and the mixture was cooled to 0 C. Trimethylsilyl triflate (2.2 mL, 12 mmol, 3 eq.) was added dropwise, and the mixture was stirred at room temperature for 6 h.
The reaction mixture was then poured into sat NH4C1 (100 mL), extracted with di chl oromethane (3 > 50 mL).
The organic layers were combined, washed with brine (50 ml), dried over MgSO4, filtered, and concentrated in vacuo to dryness. The crude product was purified by flash chromatography (Hexane/Ethyl acetate 100/0 to 0/100) to give the title compound (210 mg, 10%) as a white foam. 1-HN1VIR (400 MHz, Acetone-d6) 6 8.20 - 8.11 (m, 3H), 8.11 -8.06 (m, 2H), 7.72 - 7.60 (m, 2H), 7.55 (q, 4 H, J = 7.5 Hz), 7.29 (s, 1H), 6.26 (d, 1H, J = 6.9 Hz), 5.57 (d, 1H, J = 7.0 Hz), 4.94 (dd, 1H, J = 5.3, 3.9 Hz), 4.82 -4.64 (m, 2H), 2.14 (s, 3H), 2.09 (s, 3H), 1.77 (s, 3H).
NIVIR (101 MHz, Acetone-d6) 6 170.5, 170.4, 166.4, 163.7, 145.2, 134.3, 133.7, 130.6, 130.33, 129.6, 12.4, 129.1, 87.7, 84.5, 82.2, 78.9, 64.3, 21.8, 20.5, 17.9.
4-amino-14(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-4-methyltetrahydrofuran-2-yl)pyrimidin-2(1//)-one 68. To a solution of compound 67 (0.21 g, mmol, eq.) in methanol (8 ml) was bubbled NH3(0. The reaction was stirred at room temperature for 24 hours, then evaporated and purified by flash chromatography (Dichloromethane /Methanol 100/0 to 85/15) to give the title compound (88.8 mg, 85%) as a white foam. I-H NMR (400 MHz, Methanol-d4) 6 8.03 (d, 1H, J= 7.5 Hz), 5.95 (d, 1H, J= 7.5 Hz), 5.89 (d, 1H, J= 7.5 Hz), 4.07 (d, 1H, J=
7.5 Hz), 3.93 (t, 1H, J = 2.9 Hz), 3.77 ¨ 3.60 (m, 2H), 1.34 (s, 3H). 13C NMR
(101 MHz, Methanol-d4) 6 166.1, 157.6, 142.7, 94.9, 89.4, 87.8, 78.0, 76.7, 60.9, 47.3, 47.1, 46.9, 18.8.
HRMS-ESI (m/z) [M-FE] calcd.258.1012. for C1oH16N305 :, found 258.1089.
/) t-BuMgCI, L-JyH NH phosphoramidate H2SO4 N--k-0 reagent 70, HO MeO2Prop HO THF, 0 C to rt, OH OH Aetone, rt, 0 0 2) HCI, Me0H
66 3 h rt, 7 h 80% 69 30% over 2 steps H LNO
õT
H (5( OH OH
Scheme 11: Synthesis of Compound 71.
.`NH
/ 11 HN-P-0,, 1) POCI3, Et3N
t-BuMgCI, 0 0 triazole, phosphoramidate ACN, 69 reagent 70 IVP (Sr) 0 0 0 C to it, on THF, 0 C 2) NH4OH
to it, on, 1,4-dioxane, it, on 77% 72 22% over 2 steps CL'N
I
_NO HCI (12 M) 11 HN-P-0, NO
(SP) 0 0 Me0H, OH OH
0 C to rt, 5 h 73 (Sp) 45% 74 Scheme 12: Synthesis of Compound 74.
(1-03aR,4R,6R,6aS)-6-(hydroxymethyl)-2,2,6a-trimethyltetrahydrofuro13,4-d][1,31clioxol-4-y1)pyrimidine-2,4(1H,31/)-dione 69. To a solution of 66 (55 mg, 0.21 mmol, 1 eq.) in acetone (4.2 ml) was added dimethoxy propane (0.11 ml, 0.84 mmol, 4 eq.) and conc.
sulfuric acid (0.002 ml, 0.042 mmol, 0.2 eq.) at room temperature. The resulting reaction mixture was stirred 3 hours. Then, sodium carbonate was added and the resulting mixture was filtered and volatiles were removed under vacuum. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (50.1mg, 80 %) as a white foam. 'H NMR (400 MHz, Methanol-d4) 6 7.79 (d, 1H, J
= 8.0 Hz), 5.86 (d, 1H, J= 2.1 Hz), 5.73 (d, 1H, J= 8.0 Hz), 4.53 (d, 1H, J =
2.1 Hz), 4.12 -3.10 (m, 1H), 3.82 - 3.70 (m, 2H), 1.55 (s, 3H), 1.48 (s, 3H), 1.41 (s, 3H).
13C NMR (101 MHz, Methanol-d4) 6 164.7, 150.5, 141.3, 114.0, 99.6, 90.2, 89.9, 87.7, 87.3, 58.3, 27.1, 26.2, 17.3.
HRMS-ESI (m/z) [M+E1] calcd. 299.1195. for C13H19N206 :, found 299.1244.
isopropyl ((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-y1)-3,4-dihydroxy-3-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 71.
Under inert atmosphere, compound 31 (0.21 g, 0.7 mmol, 1 eq.) was dissolved into anhydrous THF
(2.7 ml, 0.26M), with 4 A molecular thieves. The mixture was cooled down to 0 C and t-BuMgC1 (1M in THE, 2.18 ml, 2.18 mmol, 3.1 eq.) was added dropwise. The reaction was left 30 min at 0 C and then 30 min at room temperature. The reaction was cooled down to 0 C and a solution of }(S)-2-[-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]
propionic acid isopropyl ester} 70 (0.48 g, 1.05 mmol, 1.5 eq.) in dry THF
(2.1 ml, 0.5M) was added. The reaction was stirred overnight at room temperature and after completion of the reaction, HCl (12 M, 20 eq.) was added dropwise at 0 C. The mixture was stirred at room temperature for 7 h. After addition of a solution of ammonia in methanol (10 ml), volatiles were removed under vacuum. The resulting residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (111 mg, 30% over 2 steps) as a white foam. 11-INMR (400 MHz, DMSO-d6) 11.37 (s, 1H), 7.69 (d, 1H, J= 8.1 Hz), 7.38 (t, 2H, J = 7.8 Hz), 7.26- 7.15 (m, 3H), 6.09 (dd, 1H, J= 12.9, 10.0 Hz), 5.86 (d,1 H, J=
8.0 Hz), 5.56 (d, 1H, J= 8.1 Hz), 5.50 (d, 1H, J= 6.3 Hz), 5.00 (s, 1H), 4.86 (p, 1H, J= 6.3 Hz), 4.14 (dt, 1H, J= 10.2, 4.8 Hz), 4.05 (dt, 1H, J= 10.9, 4.7 Hz), 3.96 (d, 1H, J = 4.4 Hz), 3.86 -3.74 (m, 2H), 1.22 (d,J= 7.0 Hz, 3H), 1.19- 1.12(m, 9H).13C NMR (101 MHz, DMSO-d6) 6 172.5, 162.9, 151.0, 150.6, 140.7, 129.6, 124.6, 120.1, 102.1, 85.6, 84.5, 75.7, 75.6, 68.0, 65.5, 49.7, 21.4, 21.3, 19.8 . 31P NMR (162 MHz, DMSO-d6) 6 3.68.
Isopropyl (0(3aS,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(211)-y1)-2,2,3a-trimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 72. Under inert atmosphere, isopropylidene derivative 69 (0.21 g, 0.7 mmol, 1 eq.) was dissolved into anhydrous THF (2.7 ml, 0.26M), with 4 A molecular thieves.
The mixture was cooled down to 0 C and t-BuMgC1 (1M in THF, 2.18 ml, 2.18 mmol, 3.1 eq.) was added dropwise. The reaction was left 30 min at 0 C and then 30 min at room temperature. A solution of {(S)-2-[-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]
propionic acid isopropyl ester} 70 (0.48 g, 1.05 mmol, 1.5 eq.) in dry THF (2.1 ml, 0.5M).was added dropwise to the reaction. After being stirred overnight at room temperature, the reaction was diluted with a saturated solution ofNaHCO3(25 ml) and extracted with ethyl acetate (3 x 20 m1). The organic layers were combined, washed with brine (20 ml), dried over MgSO4, filtered, and concentrated in vacuo to dryness. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (300 mg, 77%) as a white foam. 1EINIVIR
(400 MHz, Acetone-d6) 6 10.15 (s, 1H), 7.68 (d, 1H, J = 8.1 Hz), 7.41 - 7.33 (m, 2H), 7.29 (dt, 2H, J= 7.6, 1.3 Hz), 7.18 (ddq, 1H, J= 8.6, 7.6, 1.1 Hz), 5.87 (d, 1H, J= 2.2 Hz), 5.63 (dq, 1H, J= 8.1, 1.0 Hz), 4.95 (hept, 1HõI = 6.3 Hz,), 4.85 (s, 1H), 4.65 (d, 1H, J=
2.2 Hz), 4.38 - 4.23 (m, 1H), 4.27 4.18 (m, 2H), 3.94 (tq, 1H, J= 9.8, 7.1 Hz), 1.52 (d, 6H, J= 3.8 Hz), 1.38 (s, 3H), 1.34 (dd, 3H, J= 7.1, 0.9 Hz), 1.20 (dd, 6H, J= 6.2, 1.8 Hz).13C NMR (101 MHz, Acetone-d6) 183.2, 173.1, 161.8, 160.7, 151.5, 140.0, 135.1, 130.9, 124.7, 112.6, 100.9, 100.0, 97.8, 96.0, 78.8, 74.97, 60.8, 37.9, 37.0, 31.5, 30.4, 29.3. 31P NMR (162 MHz, Acetone-d6) 6 2.95. HRMS-ESI (m/z) [M+Hr calcd.568.1982. for C25H35N3010P :, found 568.2072.
isopropyl (0(3aS,4R,6R,6aR)-6-(4-amino-2-oxopyrimidin-1(2H)-y1)-2,2,3a-trimethyltetrahydrofuro [3,441[1,31dioxo1-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 73 To a solution of 1,2,4-triazole (750 mg, 10.85 mmol, 31 eq.) in acetonitrile (20 ml, 0.088M) was added. Et3N (1.65 mL, 11.69 mmol, 33.4 eq.) and phosphoryl chloride (0.17 mL, 1.82 mmol, 5.2 eq.) at 0 C. The mixture was stirred at 0 C for 3 hours before addition of a solution of 72 (200 mg, 0.8 mmol, 1 eq.) in ACN (4.5 ml, 0.35M). The reaction mixture was stirred overnight at room temperature. The reaction was then diluted with ethyl acetate (100 ml), filtered off, washed with sat NaHCO3 (20 ml) and brine (20 m1). The organic layer was concentrated under vacuum and the residue purified by flash column chromatography (Hexane/Ethyl acetate, 100/0 to 20/80) to afford the desired triazole intermediate. To a solution of this intermediate in 1,4-doxane (3 mL) was added aqueous ammonia (0.5 mL) at room temperature. The resulting reaction mixture was stirred for 2.5 hours before evaporation of the volatiles under vacuum. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (42.1 mg, 22 % over 2 steps) as a white foam. 1H NMR (400 MHz, Methanol- d4) 6 7.70 (d, 1H, J= 7.5 Hz), 7.35 (t, 2H, J= 7.8 Hz), 7.28 -7.22 (m, 2H), 7.19 (t, 1H, J= 7.4 Hz), 5.89 (d, 1H, J= 7.5 Hz), 5.82 (d, 1H, J= 1.8 Hz), 4.96 (h, 1H, J = 6.2 Hz), 4.47 (d, 1H, J = 1.9 H), 4.28 (dddd, 3H, J= 24.9, 12.1, 6.6, 3.5 Hz), 3.89 (dq, 1H, J = 9.6, 7.1 Hz), 1.52 (s, 3H), 1.43 (s, 3H), 1.37 (s, 3H), 1.33 (d, 3H, J= 7.1 Hz), 1.21 (d, 6H, J= 6.3 Hz).13C NIVIR (101 MHz, Methanol- d4) 6 173.0, 166.4, 156.4, 150.7,141.6, 129.3, 124.8, 120.1, 120.0, 114.1, 94.8, 91.2, 90.0, 86.9, 85.5, 85.4, 68.7, 64.8, 50.2, 26.9, 25.8, 20.5, 19.0, 18.2. 31P NMR (162 MHz, Methanol- d4) 6 3.71.
isopropyl ((((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(211)-y1)-3,4-dihydroxy-3-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 74.
Compound 73 (43 mg, 0.076 mmol, 1 eq.) was dissolved in methanol (2 ml) and HCI (12 M, 0.3 ml) was added dropwise at 0 C. The mixture was stirred at room temperature for 5 h.
before addition of a saturated solution of ammonia in methanol (10 m1). Volatiles were removed under vacuum and the residue purified by flash chromatography (Dichloromethane/Methanol, 100/0 to 85/15) to give the title compound (17.4 mg, 45%) as a white foam. 1-H NMR (400 MHz, Methanol- d4) 6 7.68 (d, 1H, 7.6 Hz), 7.27 (dd, 2H, 8.8, 7.2 Hz), 7.19 ¨ 7.07 (m, 3H), 5.92 (d, 1H, 7.3 Hz), 5.82¨ 5.70 (m, 1H), 4.86 (p, 1H, 1= 6.3 Hz,), 4.28 ¨ 4.08 (m, 2H), 4.04 -4.00 (m, /H), 3.82-373 (m, 2H), 1.26¨ 1.17 (m, 6H), 1.12 (dd, J= 6.2, 2.2 Hz, 6H).).13C NMR
(101 MHz, Methanol- d4) 6 172.8, 166.0, 157.7, 150.6, 150.5, 141.3, 129.6, 129.5, 124.9, 120.0, 95.4, 88.3, 85.1, 78.2, 76.3, 68.8, 65.8, 50.3, 20.5, 20.4, 19.2, 18.9.3'P NMR (162 MHz, Methanol- d4) 6 3.59.
Example 2 Cellular Toxicity Assays The toxicity of the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (see Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xi e M.-Y., Hart G.C., Smith G.A.
& Hahn E.F.
Antimicrob. Agents Chemother. 1990, 34, 1061-67). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC50 was obtained from the concentration-response curve using the median effective method described previously (see Chou T.-C. & Talalay P.
Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F. Antiviral Res. 1994, 25, 1-11).
Example 3 Mitochondrial Toxicity Assays in HepG2 Cells:
i) Effect of Compounds on Cell Growth and Lactic Acid Production: The effect on the growth of HepG2 cells can be determined by incubating cells in the presence of 0 uM, 0.1 uM, 1 uM, 10 uM and 100 uM drug. Cells (5 x 104 per well) can be plated into 12-well cell culture clusters in minimum essential medium with nonessential amino acids supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and 1%
penicillin/streptomycin and incubated for 4 days at 37 C. At the end of the incubation period the cell number can be determined using a hemocytometer. Also taught by Pan-Zhou X-R, Cui L, Zhou X-J, Sommadossi J-P, Darley-Usmer VM. "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," Antimicrob. Agents Chemother. 2000; 44:
496-503.
To measure the effects of the compounds on lactic acid production, HepG2 cells from a stock culture can be diluted and plated in 12-well culture plates at 2.5 x 104 cells per well.
Various concentrations (0 M, 0.1 M, 1 M, 10 1.1.M and 100 M) of compound can be added, and the cultures can be incubated at 37 C in a humidified 5% CO2 atmosphere for 4 days. At day 4, the number of cells in each well can be determined and the culture medium collected. The culture medium can then be filtered, and the lactic acid content in the medium determined using a colorimetric lactic acid assay (Sigma-Aldrich). Since lactic acid product can be considered a marker for impaired mitochondrial function, elevated levels of lactic acid production detected in cells grown in the presence of test compounds indicates a drug-induced cytotoxic effect.
Effect on Compounds on Mitochondricd DNA Synthesis: a real-time PCR assay to accurately quantify mitochondrial DNA content has been developed (see Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Grier J, Thamish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ, Schinazi RF. Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogs. Antimicrob. Agents Chemother. 2002;
46: 3854-60).
This assay can be used in all studies described in this application that determine the effect of compounds on mitochondrial DNA content. In this assay, low-passage- number HepG2 cells are seeded at 5,000 cells/well in collagen-coated 96-well plates. Test compounds are added to the medium to obtain final concentrations of 0 M, 0.1 M, 10 M and 100 M. On culture day 7, cellular nucleic acids can be prepared by using commercially available columns (RNeasy 96 kit; Qiagen). These kits co-purify RNA and DNA, and hence, total nucleic acids are eluted from the columns. The mitochondria] cytochrome c oxidase subunit TI
(COXII) gene and the 13-actin or rRNA gene can be amplified from 5 1 of the eluted nucleic acids using a multiplex Q-PCR protocol with suitable primers and probes for both target and reference amplifications. For COXII the following sense, probe and antisense primers can be used, respectively: 5'- TGCCCGCCATCATCC TA-3', 5 '-tetrachl oro-6-carb oxyfluorescein-TCC TCATCGCCCTCCCATCCC-TAMRA-3' and 5'-CGTCTGTTATGTAAAGGATGCGT-3'. For exon 3 of the 13-actin gene (GenBank accession number E01094) the sense, probe, and antisense primers are 5'-GCGCGGCTACAGCTTCA-3', 5 ' -6-F AMC AC CAC GGCC GAGCGGGATAMRA-3' and 5'-TCTCCTTAATGTCACGCACGAT-3', respectively. The primers and probes for the rRNA
gene are commercially available from Applied Biosystems. Since equal amplification efficiencies are obtained for all genes, the comparative CT method can be used to investigate potential inhibition of mitochondrial DNA synthesis. The comparative CT method uses arithmetic formulas in which the amount of target (COXII gene) is normalized to the amount of an endogenous reference (the B-actin or rRNA gene) and is relative to a calibrator (a control with no drug at day 7). The arithmetic formula for this approach is given by 2-AACT, where AACT is (CT for average target test sample - CT for target control) - (CT for average reference test -CT for reference control) (see Johnson MR, K Wang, JB Smith, MJ Heslin, RB Diasio.
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 2000; 278:175-184). A
decrease in mitochondrial DNA content in cells grown in the presence of drug indicates mitochondrial toxicity.
Example 4 Mitochondria' Toxicity- Glu/Gal Protocol Summary HepG2 cells are plated on 96 or 384 well tissue culture polystyrene plates.
After 24 hr the cells are dosed with test compound at a range of concentrations and incubated for 72 hr in medium supplemented with either galactose or glucose. Test compounds are said to cause mitochondrial toxicity if the cells grown in galactose-containing medium are more sensitive to the test compound than the cells grown in glucose-containing medium.
Objective: To measure the sensitivity of HepG2 cells grown in medium containing either galactose or glucose to the test compound.
Experimental Procedure HepG2 human hepatocellular carcinoma cells are plated on 96 or 384-well tissue culture polystyrene plates containing either galactose or glucose containing medium supplemented with % fetal bovine serum and antibiotics and incubated overnight. The cells are dosed with increasing concentrations of the test compound (final DMSO concentration 0.5 %; typical final test compound concentrations of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03 [1M for an eight point dose response curve; n = 3 replicates per concentration) and the cells are incubated for 72 hr.
Appropriate controls are simultaneously used as quality controls. Cell viability is measured using Hoechst staining and cell counting by a HCS reader.
Example 5 Mitochonclrial Toxicity Assays in Neuro2A Cells To estimate the potential of the compounds described herein to cause neuronal toxicity, mouse Neuro2A cells (American Type Culture Collection 131) can be used as a model system (see Ray AS, Hernandez-Santiago BI, Mathew JS, Murakami E, Bozeman C, Xie MY, Dutschman GE, Gullen E, Yang Z, Hurwitz S, Cheng YC, Chu CK, McClure H, Schinazi RF, Anderson KS. Mechanism of anti-human immunodeficiency virus activity of beta-D-cyclopropylamino-2' ,3' -didehydro-2' ,3 ' -dideoxyguanosine. Antimicrob.
Agents Chemother.
2005, 49, 1994-2001). The concentrations necessary to inhibit cell growth by 50% (CC50) can be measured using the 3-(4,5-dimethyl-thiazol-2-y1)-2,5- diphenyltetrazolium bromide dye-based assay, as described. Perturbations in cellular lactic acid and mitochondria] DNA levels at defined concentrations of drug can be carried out as described above. ddC and AZT can be used as control nucleoside analogs.
Example 6 Assay fOr Bone Marrow Cytotoxicity Primary human bone marrow mononuclear cells can be obtained commercially from Cambrex Bioscience (Walkersville, MD). CFU-GM assays is carried out using a bilayer soft agar in the presence of 50 units/mL human recombinant granulocyte/macrophage colony-stimulating factor, while BFU-E assays used a ethylcellulose matrix containing 1 unit/mL
erythropoietin (see Sommadossi JP, Carlisle R. Toxicity of 3' -azido-3'-deoxythymidine and
31P NMR (162 MHz, Acetone-d6) 6 2.78. HRMS-ESI (m/z) [M+H]+ calcd for C23H26C12N505P:
553.1049, found: 553.1124.
(39b). (48%). 1H NMR (400 MHz, Acetone-d6) 6 8.63 (s, 1H, H8), 7.34 (dd, J =
8.7, 7.0 Hz, 2H, Harom), 7.33 ¨7.23 (m, 2H, Harom), 7.20 ¨ 7.10 (m, 1H, Harom), 5.05 (d, J
= 8.1 Hz, 1H, H1'), 4.98 ¨ 4.90 (m, 1H, 0-CH), 4.92 ¨ 4.77 (m, 1H, NH), 4.14 (qt, J= 10.2, 6.4 Hz, 2H, H5'), 4.01 ¨3.87 (m, 1H, NTI-CH), 2.64 ¨ 2.42 (m, 2H, H4', H2'a), 2.36 (dtd, J =
13.4, 7.8, 5.5 Hz, 1H, H3' a), 2.20 (dtd, J = 12.9, 9.0, 7.4 Hz, 1H, H3'b), 2.00 ¨ 1.93 (m, 2H, H2'b, H6'a), 1.92 ¨
1.79 (m, 1H, H6' a), 1.39¨ 1.26 (m, 3H, CH-CH3), 1.26¨ 1.14 (m, 6H, 2 x CH-CH3).13C NMR_ (101 MHz, Acetone-d6) 6 173.6 (C=0), 154.5 (Cquat), 152.3 (Cquat), 152.3 (Cquat), 151.1 (Cquat), 146.9 (C8), 132.1 (Cquat), 130.3 (2 x Carom), 125.2 (Carom), 121.2 (2 x Carom), 70.0 (C5'), 69.0 (0-CH), 57.2 (C1'), 51.2 (NH-CH), 39.0 (C4'), 35.9 (C2'), 31.8 (C3'), 27.0 (C6'), 21.9 (2 x C-CH3), 21.8 (C-CH3). 31P NMR (162 MHz, Acetone-d6) 6 2.66. HRMS-ESI
(m/z) [M+H]+ calcd for C23H28C12N505P : 555.1205, found: 555.1281.
ri)L'N1-1 'N 0 0 H
Bz0 1. BSA/MeCN (NH
1i)1\1H
N
0_,...(0Bz MW 120 C/30 min ______________________________________ Bz0 N'N 0 Me0H .. HO--__iN 0 ).- 0 2. TMSOTf _______________________________________________________ ).-OBz0Bz MW 120 C/30 min '.1.---(1--- NH4OH
90% OH OH
48 OBz0Bz 79% 50 rILNH
Acetone/p-Ts0H HO..__ N.NO THF/t-BuMgC1 2,2-Dimethoxypropane 0-y phosphorylating agent .-90%
Ox0 48%
Y 7 o ii)LNH Y 0 ?L'NH
O. .{..NI
,r( NI HCO2H/H20 or._ n NP.P.-ON'NO
0 H oPh N 0 ___________ 0 RT/ 6 h 0 H OPh 0 32%
Ox0 OH OH
Scheme 5. Synthesis of Compounds 50 and 53.
(2R,3R,4R,5R)-5-((benzoyloxy)methyl)-2-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(311)-y1)-3-methyltetrahydrofuran-3,4-diy1 dibenzoate (49):
6-Azauracil (565 mg, 5 mmol) was suspended in acetonitrile (5 mL) in a microwave vial, and BSA (4.5 mL) was added. The suspension was heated under microwave irradiation at 120 C
for 30 min. The solution was cooled down to rt, and compound 48 (580 mg, 1 mmol) was added, followed by TMSOTf (1 mL). The vial was heated under microwave irradiation at 120 C for 30 min. The reaction mixture was slowly added to a saturated aq NaHCO3 solution (50 mL) and stirred for 15 min. The mixture was then diluted with ethyl acetate (60 mL), filtered through a pad of celite and the organic layer separated. The aqueous layer was extracted with ethyl acetate (2x40 mL). The combined organic layers were washed with brine (50 mL), and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane-Et0Ac (4:1 to 1:1) to give 514 mg of product (90 %) as a yellow foam. 1H-NIVIR (CDC13): 0 8.68 (s, 1H), 8.14-8.11 (m, 4H), 8.02-8.00 (m, 2H), 7.64-7.34 (m, 10H), 7.11 (s, 1H), 6.03-6.01 (d, 1H), 4.78-4.73 (m, 2H), 4.55-4.51 (m, 1H), 1.77 (s, 3H).
2-02R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-y1)-1,2,4-triazine-3,5(2H,4H)-dione (50):
To a mixture of 49 (240 mg, 0.42 mmol) in Me0H (4 mL) was added conc. NH4OH (5 mL).
The mixture was stirred at RT overnight. The volatiles were evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1 to 4:1) to give 86 mg (79%) of product as a white foam. '1-1-NWIR (DMSO-d6): H 7.54 (s, 1H), 5.96 (s, 1H), 5.04 (s, br, 2H), 4.57 (s, br, 1H), 3.84-3.48 (m, 4H), 1.04 (s, 3H).
24(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2,3a-trimethyltetrahydrofuro [3,4-d][1,31dioxo1-4-yl)-1,2,4-triazine-3,5(2H,4H)-dione (51):
To a mixture of 50 (140 mg, 0.54 mmol) in dry acetone (5 mL) were added 2,2-dimethoxypropane (0.66 mL, 5.4 mmol) and p-Ts0H-H20 (124 mg, 0.65 mmol). The mixture was stirred at RT for 24 hrs. The reaction was quenched by Et3N (2 mL), and the solvent was evaporated. The residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1) to give 145 mg (90%) of product as a white powder. 1-1-1-NMR
(CD30D):
0 7.49 (s, 1H), 6.36 (s, 1H), 4.42-4.41 (d, 1H), 4.25-4.21 (m, 1H), 3.76-3.66 (m, 2H), 1.53, 1.45, 1.35 (3s, 9H).
Isopropyl ((S)-(((3aR,4R,6R,6aR)-6-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yI)-2,2,6a-trimethyltetrahydrofuro [3,4-d] [1,3] dioxo1-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (52):
To a stirred mixture of 51 (132 mg, 0.44 mmol) in THF (2 mL) at 0 C was added t-BuMgC1 (1.0 M solution in THF, 0.92 mL, 0.92 mmol) dropwise, and the mixture was stirred at 0 C for 30 min. The mixture was allowed to warmed up to RT, and was stirred at RT for another 30 min. The mixture was then cooled down to 0 C, and a solution of {(S)-2-1-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino] propionic acid isopropyl ester}
(240 mg, 0.53 mmol) in THE (1 mL) was added dropwise. After addition, the reaction mixture was allowed to warmed up to RT, and stirred at RT overnight. The reaction was quenched by Me0H
(0.5 mL). The solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (95:5 to 9:1) to give 120 mg (48%) of product. 111-NMR (CD30D): 0 7.49 (s, 1H), 7.37-7.33 (m, 2H), 7.24-7.16 (m, 3H), 6.35 (d, 1H), 4.98-4.93 (m, 1H), 4.38-4.20 (m, 3H), 3.89-3.76 (m, 2H), 1.51 (s, 3H), 1.45 (s, 3H), 1.34-1.31 (m, 6H), 1.22 (t, 6H).
Isopropyl ((S)-(((2R,3R,4R,5R)-5-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-y1)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (53):
A suspension of 52 (100 mg, 0.18 mmol) in formic acid (2 mL) and water (0.5 mL) was stirred at RT for 6 hrs. The solvent was evaporated and the residue was purified by flash chromatography on silica gel eluting with CH2C12-Me0H (9:1) to give 30 mg (32%) of product as a white foam, and 22 mg (22%) of starting material. 41-NMR (CD30D): 0 7.45 (s, 1H), 7.38-7.34 (m, 2H), 7.25-7.17 (m, 3H), 6.18 (s, 1H), 4.98-4.93 (m, 1H), 4.33-4.29 (m, 2H), 4.18-4.14 (m, 1H), 4.03-4.01 (d, 1H), 3.93-3.87 (m, 1H), 1.33 (d, 3H), 1.23 (t, 6H), 1.19 (s, 3H).
HRMS calc for C21H3oN4010P (M+H+): 529.1700, found 529.1685.
NrcN
N _TO N
Nk-N
r;1"-NH Nx = 0 I
H 6ph Scheme 6 Synthesis of Compounds 57 and 58: Reagents and conditions: a) Me0H, Pd2(dba)3, Xantphos, Cs2CO3, toluene, 60 C, 3 hr, 93%; b) Pd2(dba)3, Xantphos, isobutyramide, Cs2CO3, toluene, 110 C, overnight, 74%; c) Sodium methoxide, methanol, rt-50 'V, 5 hrs, 60% yield for two steps for 4; d) t-ButylMgC1, THF, rt, overnight, 25-82%.
Compound 54 was prepared according to the chemistry described in:
(1) Sznaidmart, N/1,, Painter, G. R.; Almond, M. R.; Cleary, D, G.; Pesyan, A., Methods to manufacture 1,3-dioxolane nucleosides and their chiral enzymic resolution. PCT
Int.
Appl. 2005, W02005074654, 98 pp.
(2) ) Sznaidman, M. L.; Du, J.; Pesyan, A.; Cleary, D. G.; Hurley, P. K.;
Waligora, F.;
Almond, M. R. Synthesis of (¨)-DAPD. Nucleosides, Nucleotides Nucleic Acids 2004, 23, 1875-1887 02R,4R)-4-(2,6-dichloro-911-purin-9-y1)-1,3-dioxolan-2-y1)methyl isobutyrate (54):
1-E1 NMR (CDC13, 400 MHz): 8.53 (s, 1 H), 6.56 (d, J = 4.4 Hz, 1 H), 5.35 (t, J = 2.8 Hz, 1 H), 4.59-4.33 (m, 4 H), 2.64-2.57 (m, 1 H), 1.19 (d, J= 6.8 Hz, 3 H), 1.14 (d, J= 6.8 Hz, 3 H). LRMS (ESI): m/z calcd for C13H14C12N404 (M-FNa)+: 383.03, observed 382.9.
((2R,4R)-4-(2-chloro-6-nicthoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methyl isobutyratc (55):
To a suspension of 54 (0.9 g, 2.49 mmol), Xantphos (112 mg, 0.19 mmol), tris(dibenzylideneacetone)dipalladium (0) (65 mg, 0.07 mmol), cesium carbonate (1.15 g, 3.52 mmol) in toluene (12 mL) under nitrogen was added methanol (0.11 mL, 2.7 mmol). The reaction mixture was heated at 60 C for 3 hr, filtered, washed with ethyl acetate, concentrated, and purified by flash chromatography using ethyl acetate: hexane = 2: 1 to obtain 55 (820 mg, 93% yield). 1H NMR (CDC13, 400 MHz): 8.26 (s, 1 H), 6.48-6.49 (q, J = 0.8 Hz, J = 4.8 Hz, 1 H), 5.27-5.28 (t, J = 2.8 Hz, 1 H), 4.46-4.49 (dd, J = 0.8 Hz, J = 10.0 Hz, 1 H), 4.37-4.41 (dd, J
= 2.8 Hz, J = 12.8 Hz, 1 H), 4.29-4.33 (dd, J = 3.2 Hz, J = 12.8 Hz, 1 H), 4.24-4.28 (dd, J = 5.2 Hz, J = 10.0 Hz, 1 H), 4.17 (s, 3 H), 2.54-2.61 (m, 1 H), 1.13-1.15 (d, J =
6.8 Hz, 3 H), 1.09-1.10 (d, J = 6.8 Hz, 3 H). LRMS (ESI): m/z calcd for C14H18C1N405 (M-PH):
357.09 observed 356.88.
((2R,4R)-4-(2-isobutyramido-6-methoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methyl isobutyrate (56):
A suspension of 55 (112mg, 0.31 mmol), tris(dibenzylideneacetone)dipalladium(0) (6.5 mg, 0.007 mmol), xantphos (11.2 mg, 0.019 mmol), cesium carbonate (115 mg, 0.35 mmol) and isobutyramide (33.5 mg, 0.38 mmol) in toluene (2 mL) was heated at 110 C for 12 h, then filtered through celite, concentrated under vaccum and purified by flash chromatography to give 56 (94 mg, 74% yield). 1-H NN4R (CDC13, 400 MHz): 8.11 (s, 1 H), 8.10 (brs, 1 H), 6.42-6.43 (d, J = 4.0 Hz,1H), 5.24-5.25 (t, J = 2.8 Hz, 1 H), 4.47-4.50 (dd, J = 1.2 Hz, J = 10.0 Hz, 1 H), 4.312-4.319 (d, J = 2.8 Hz, 2 H), 4.21-4.25 (dd, J = 5.6 Hz, J = 10.0 Hz, 1 H), 4.07 (s, 3 H), 3.10(brs, 1 H), 2.50-2.57 (m, 1 H), 1.22-1.24 (2d, J = 0.8 Hz, 6 H), 1.05-1.12 (2d, J = 7.2 Hz, 6 H). LRMS (ESI): m/z calcd for C18H26N506 (M-FH) : 408.18 observed 407.98.
((2R,4R)-4-(2-amino-6-methoxy-9H-purin-9-y1)-1,3-dioxolan-2-yl)methanol (57):
To a solution of 56 (4.98 mmol) in with methanol (10 mL) was added sodium methoxide (25%, 3 mL). The solution was stirred for 5 h at room temperature and then heated to 50 C for 30 min. After evaporation under vaccum, the residue was purified by column chromtrography (Dichloromethane: methanol = 60: 3) to afford 57 (800 mg, 60%). 1-H NMR
(CDC13, 400 MHz):
8.12 (s, 1 H), 6.30 (dd, J = 1.6 Hz, J = 5.6 Hz, 1 H), 5.08 (t, J = 2.8 Hz, 1 H), 4.46 (dd, J = 1.6 Hz, J = 10.0 Hz, 1 H), 4.21 (dd, J = 5.2 Hz, J = 9.6 Hz, 1 H), 3.75 (t, J =
2.0 Hz, 2 H). LRMS
(ESI): m/z calcd for C10H14N504 (M+H)+: 268.10, observed 268.04.
Ethyl (0(2R,4R)-4-(2-amino-6-methoxy-911-purin-9-y1)-1,3-dioxolan-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate (58):
A solution of 57 (50 mg, 0.18 mmol) in THF (3 mL) was added t-butylmagnesium chloride (0.54 mL, 1 M in THE, 0.54 mmol). The reaction mixture was stirred at rt for 30 min, before addition of the corresponding phosphoramide chloride (0.54 mL, 1 Mmn THF, 0.54 mmol). The reaction mixture was stirred overnight, quenched with saturated ammonium chloride (1 mL) and directly purified by column chromatography (dichloromethane: methanol =
100: 1 to 100:
5) to afford the desired compound.
CI CI
NN NN
HONCI
Scheme 7 Synthesis of Compound 59: Reagents and conditions: a) n-Bu2SnO, toluene, 130 C, overnight, 65 %.
((2R,4R)-4-(2,6-dichloro-911-purin-9-y1)-1,3-dioxolan-2-yHmethanol (59):
A suspension of dichloropurine 54 (3g, 8.30 mmol) and dibutyltin (IV) oxide (6 g, 24.1 mmol) in toluene (50 mL) was heated to 130 C overnight. After evaporation of the volatiles under vacuum, the residue was directly purified by coumn chromatography (Dichloromethane:
methanol = 100: Ito 100: 10) to afford 59 (65%).
NMR (CD30D, 400 MHz): 8.90 (s, 1 H), 6.57(d, J = 5.0 Hz, 1 H), 5.17 (t, J = 2.0 Hz, 1 H), 4.65 (d, J = 10.1 Hz, 1 H), 4.35-4.31 (dd, J
= 5.0 Hz, J= 10.1 Hz, 1 H), 3.86-3.77 (m, 2 H). LRMS (ESI): m/z calcd for (M-FNa)+: 312.99, observed 312.9.
N Ni-LN
4-0 N CI a H0,1µ....j1 N" CI
HO N N
CI
Scheme 8: Synthesis of compound 60 and 61: Reagents and conditions: a) NH3/CH3OH, CH3OH, rt, 2 days, 25 % for 2 and 63% for 3.
02R,4R)-4-(2-chloro-6-methoxy-911-purin-9-y1)-1,3-dioxolan-2-y1)methanol (60) and 02R,4R)-4-(6-amino-2-chloro-9H-purin-9-y1)-1,3-dioxolan-2-yl)methanol (61):
A solution of 54 (1g, 2.76 mmol) in NH3/CH3OH (10 mL) was stirred for 2 days at room temperature. After evaporation of the volatiles, the residue was purified flash chromatography (Dichloromethane: methanol = 100: 1 to 100: 10) to afford 60 (35%) and 61 (63%).
(60): 1H NMR (CD30D, 400 MHz): 8.61 (s, 1 H), 6.51-6.49 (dd, J = 0.8 Hz, J =
4.8 Hz, 1 H), 5.15 (t, J = 2.4 Hz, 1 H), 4.59-4.56 (dd, J = 0.8 Hz, J = 10.0 Hz, 1 H), 4.33-4.29 (dd, J= 5.2 Hz, J = 10.0 Hz, 1 H), 4.16 (s, 3 H), 3.84-3.80 (m, 2 H). LRMS (ESI): m/z calcd for CioHliC1N404 (M-FNa)+: 309.04, observed 309Ø
(61): 1H NMR (CD30D, 400 MHz): 8.42 (s, 1 H), 6.41-6.40 (dd, J = 4.4 Hz, 1 H), 5.13 (d, J =
2.4 Hz, 1 H), 4.52-4.49 (d, J= 10.0 Hz, 1 H), 4.30-4.26 (dd, J= 5.2 Hz, J=
10.0 Hz, 1 H), 3.83-3.75 (m, 2 H). LRMS (ESI): m/z calcd for C9H1oC1N503 (M-FNa)+: 294.03, observed 294Ø
Ha.,..
c.-0- BzCI
Pyridine, BzO'Ic2_ PDC, Ac20 BzOo 0 DCM, rt,'' --f0 OH 0-4\ 0 C to rt OH 0-4\ on 0 2h 92% 0-4\
60 84% 61 62 Bz0 MeMgBr Bz0f2_ Ac20, H2SO4 Vit:31,..,.0Ac THF, 0 AcOH, 0 C, 0.5 h OH 0--.\\ 0 C to rt, OAc OAc 74% on 63 52% 64 Cli''NIIH (1X
( 1) Uracil, BSA N ".-..0 N 0 4 A MS, ACN, HO
55 C, 1 h... Bz0 NH3 2) TMSOTf, Me0H, rt, on C to rt, 5 h OAc OAc 66% OH OH
33%
Scheme 9: Synthesis of Compound 66.
3'Me sugar 64 was synthetized following. W02019090111 Al and Tetrahedron, 2002, 58, 9593. 3'Me-Uridine 66 was synthetized following Bioorg. Med. Chem. 2008, 16, 6319 and Biochemistry 1992, 31, 45, 11210-11215.
1-O2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-4-methy-ltetrahydrofuran-2-yOpyrimidine-2,4(1H,31/)-dione 66 as a white foam (66%). IHNMR (400 MHz, Methanol-d4)6 8.19 (d, 1H, J= 8.1 Hz), 6.05 (d, 1H, J = 7.8 Hz), 5.73 (d, 1H, J= 8.0 Hz), 4.05 (d, 1H, J
= 7.8 Hz), 3.95 (t, 1H, J= 2.2 Hz), 3.80-3.68 (m, 2H), 1.38 (s, 3H). 13C NMR
(101 MHz, Methanol-d4) 6 164.7, 151.5, 141.9, 101.5, 87.8 87.2, 77.5 76.6, 60.8, 18.7.
HRMS-ESI (m/z) [M-FH] calcd. 259.0852. for C1oH15N206 :, found 259.0930.
NHBz NH2 1 N4-BzCytosine C-L'N
,BSA I I
N 0 Bz0 4 A
MS, ACN, N 0 HO
rt, 1 h NH3 Me0H, 0 C to rt OAc OAc 2) TMSOTf, OAc OAc 24 h OH OH
0 C to rt 6 h 10%' 85% 68 Scheme 10: Synthesis of Compound 68.
(2R,3S,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-y1)-2-((benzoyloxy)methyl)-3-methyltetrahydrofuran-3,4-diy1 diacetate 67: 4-N-benzoyl-cytosine (1.49 g, 4,8 mmol, 1.2 eq.) and /V,0-bistrimethylsilylacetamide (1.9 mL, 8.00 mmol, 2 eq.) were heated at 55 C in acetonitrile (12 mL) until a clear solution was observed. Then (31?,4,S,51-?)-((benzoyloxy)methyl)-4-methyltetrahydrofuran-2,3,4-triy1 triacetate 64 (1.58 g, 4 mmol, 1 eq.) was added and the mixture was cooled to 0 C. Trimethylsilyl triflate (2.2 mL, 12 mmol, 3 eq.) was added dropwise, and the mixture was stirred at room temperature for 6 h.
The reaction mixture was then poured into sat NH4C1 (100 mL), extracted with di chl oromethane (3 > 50 mL).
The organic layers were combined, washed with brine (50 ml), dried over MgSO4, filtered, and concentrated in vacuo to dryness. The crude product was purified by flash chromatography (Hexane/Ethyl acetate 100/0 to 0/100) to give the title compound (210 mg, 10%) as a white foam. 1-HN1VIR (400 MHz, Acetone-d6) 6 8.20 - 8.11 (m, 3H), 8.11 -8.06 (m, 2H), 7.72 - 7.60 (m, 2H), 7.55 (q, 4 H, J = 7.5 Hz), 7.29 (s, 1H), 6.26 (d, 1H, J = 6.9 Hz), 5.57 (d, 1H, J = 7.0 Hz), 4.94 (dd, 1H, J = 5.3, 3.9 Hz), 4.82 -4.64 (m, 2H), 2.14 (s, 3H), 2.09 (s, 3H), 1.77 (s, 3H).
NIVIR (101 MHz, Acetone-d6) 6 170.5, 170.4, 166.4, 163.7, 145.2, 134.3, 133.7, 130.6, 130.33, 129.6, 12.4, 129.1, 87.7, 84.5, 82.2, 78.9, 64.3, 21.8, 20.5, 17.9.
4-amino-14(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-4-methyltetrahydrofuran-2-yl)pyrimidin-2(1//)-one 68. To a solution of compound 67 (0.21 g, mmol, eq.) in methanol (8 ml) was bubbled NH3(0. The reaction was stirred at room temperature for 24 hours, then evaporated and purified by flash chromatography (Dichloromethane /Methanol 100/0 to 85/15) to give the title compound (88.8 mg, 85%) as a white foam. I-H NMR (400 MHz, Methanol-d4) 6 8.03 (d, 1H, J= 7.5 Hz), 5.95 (d, 1H, J= 7.5 Hz), 5.89 (d, 1H, J= 7.5 Hz), 4.07 (d, 1H, J=
7.5 Hz), 3.93 (t, 1H, J = 2.9 Hz), 3.77 ¨ 3.60 (m, 2H), 1.34 (s, 3H). 13C NMR
(101 MHz, Methanol-d4) 6 166.1, 157.6, 142.7, 94.9, 89.4, 87.8, 78.0, 76.7, 60.9, 47.3, 47.1, 46.9, 18.8.
HRMS-ESI (m/z) [M-FE] calcd.258.1012. for C1oH16N305 :, found 258.1089.
/) t-BuMgCI, L-JyH NH phosphoramidate H2SO4 N--k-0 reagent 70, HO MeO2Prop HO THF, 0 C to rt, OH OH Aetone, rt, 0 0 2) HCI, Me0H
66 3 h rt, 7 h 80% 69 30% over 2 steps H LNO
õT
H (5( OH OH
Scheme 11: Synthesis of Compound 71.
.`NH
/ 11 HN-P-0,, 1) POCI3, Et3N
t-BuMgCI, 0 0 triazole, phosphoramidate ACN, 69 reagent 70 IVP (Sr) 0 0 0 C to it, on THF, 0 C 2) NH4OH
to it, on, 1,4-dioxane, it, on 77% 72 22% over 2 steps CL'N
I
_NO HCI (12 M) 11 HN-P-0, NO
(SP) 0 0 Me0H, OH OH
0 C to rt, 5 h 73 (Sp) 45% 74 Scheme 12: Synthesis of Compound 74.
(1-03aR,4R,6R,6aS)-6-(hydroxymethyl)-2,2,6a-trimethyltetrahydrofuro13,4-d][1,31clioxol-4-y1)pyrimidine-2,4(1H,31/)-dione 69. To a solution of 66 (55 mg, 0.21 mmol, 1 eq.) in acetone (4.2 ml) was added dimethoxy propane (0.11 ml, 0.84 mmol, 4 eq.) and conc.
sulfuric acid (0.002 ml, 0.042 mmol, 0.2 eq.) at room temperature. The resulting reaction mixture was stirred 3 hours. Then, sodium carbonate was added and the resulting mixture was filtered and volatiles were removed under vacuum. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (50.1mg, 80 %) as a white foam. 'H NMR (400 MHz, Methanol-d4) 6 7.79 (d, 1H, J
= 8.0 Hz), 5.86 (d, 1H, J= 2.1 Hz), 5.73 (d, 1H, J= 8.0 Hz), 4.53 (d, 1H, J =
2.1 Hz), 4.12 -3.10 (m, 1H), 3.82 - 3.70 (m, 2H), 1.55 (s, 3H), 1.48 (s, 3H), 1.41 (s, 3H).
13C NMR (101 MHz, Methanol-d4) 6 164.7, 150.5, 141.3, 114.0, 99.6, 90.2, 89.9, 87.7, 87.3, 58.3, 27.1, 26.2, 17.3.
HRMS-ESI (m/z) [M+E1] calcd. 299.1195. for C13H19N206 :, found 299.1244.
isopropyl ((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-y1)-3,4-dihydroxy-3-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 71.
Under inert atmosphere, compound 31 (0.21 g, 0.7 mmol, 1 eq.) was dissolved into anhydrous THF
(2.7 ml, 0.26M), with 4 A molecular thieves. The mixture was cooled down to 0 C and t-BuMgC1 (1M in THE, 2.18 ml, 2.18 mmol, 3.1 eq.) was added dropwise. The reaction was left 30 min at 0 C and then 30 min at room temperature. The reaction was cooled down to 0 C and a solution of }(S)-2-[-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]
propionic acid isopropyl ester} 70 (0.48 g, 1.05 mmol, 1.5 eq.) in dry THF
(2.1 ml, 0.5M) was added. The reaction was stirred overnight at room temperature and after completion of the reaction, HCl (12 M, 20 eq.) was added dropwise at 0 C. The mixture was stirred at room temperature for 7 h. After addition of a solution of ammonia in methanol (10 ml), volatiles were removed under vacuum. The resulting residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (111 mg, 30% over 2 steps) as a white foam. 11-INMR (400 MHz, DMSO-d6) 11.37 (s, 1H), 7.69 (d, 1H, J= 8.1 Hz), 7.38 (t, 2H, J = 7.8 Hz), 7.26- 7.15 (m, 3H), 6.09 (dd, 1H, J= 12.9, 10.0 Hz), 5.86 (d,1 H, J=
8.0 Hz), 5.56 (d, 1H, J= 8.1 Hz), 5.50 (d, 1H, J= 6.3 Hz), 5.00 (s, 1H), 4.86 (p, 1H, J= 6.3 Hz), 4.14 (dt, 1H, J= 10.2, 4.8 Hz), 4.05 (dt, 1H, J= 10.9, 4.7 Hz), 3.96 (d, 1H, J = 4.4 Hz), 3.86 -3.74 (m, 2H), 1.22 (d,J= 7.0 Hz, 3H), 1.19- 1.12(m, 9H).13C NMR (101 MHz, DMSO-d6) 6 172.5, 162.9, 151.0, 150.6, 140.7, 129.6, 124.6, 120.1, 102.1, 85.6, 84.5, 75.7, 75.6, 68.0, 65.5, 49.7, 21.4, 21.3, 19.8 . 31P NMR (162 MHz, DMSO-d6) 6 3.68.
Isopropyl (0(3aS,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(211)-y1)-2,2,3a-trimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 72. Under inert atmosphere, isopropylidene derivative 69 (0.21 g, 0.7 mmol, 1 eq.) was dissolved into anhydrous THF (2.7 ml, 0.26M), with 4 A molecular thieves.
The mixture was cooled down to 0 C and t-BuMgC1 (1M in THF, 2.18 ml, 2.18 mmol, 3.1 eq.) was added dropwise. The reaction was left 30 min at 0 C and then 30 min at room temperature. A solution of {(S)-2-[-(S)-(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphorylamino]
propionic acid isopropyl ester} 70 (0.48 g, 1.05 mmol, 1.5 eq.) in dry THF (2.1 ml, 0.5M).was added dropwise to the reaction. After being stirred overnight at room temperature, the reaction was diluted with a saturated solution ofNaHCO3(25 ml) and extracted with ethyl acetate (3 x 20 m1). The organic layers were combined, washed with brine (20 ml), dried over MgSO4, filtered, and concentrated in vacuo to dryness. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (300 mg, 77%) as a white foam. 1EINIVIR
(400 MHz, Acetone-d6) 6 10.15 (s, 1H), 7.68 (d, 1H, J = 8.1 Hz), 7.41 - 7.33 (m, 2H), 7.29 (dt, 2H, J= 7.6, 1.3 Hz), 7.18 (ddq, 1H, J= 8.6, 7.6, 1.1 Hz), 5.87 (d, 1H, J= 2.2 Hz), 5.63 (dq, 1H, J= 8.1, 1.0 Hz), 4.95 (hept, 1HõI = 6.3 Hz,), 4.85 (s, 1H), 4.65 (d, 1H, J=
2.2 Hz), 4.38 - 4.23 (m, 1H), 4.27 4.18 (m, 2H), 3.94 (tq, 1H, J= 9.8, 7.1 Hz), 1.52 (d, 6H, J= 3.8 Hz), 1.38 (s, 3H), 1.34 (dd, 3H, J= 7.1, 0.9 Hz), 1.20 (dd, 6H, J= 6.2, 1.8 Hz).13C NMR (101 MHz, Acetone-d6) 183.2, 173.1, 161.8, 160.7, 151.5, 140.0, 135.1, 130.9, 124.7, 112.6, 100.9, 100.0, 97.8, 96.0, 78.8, 74.97, 60.8, 37.9, 37.0, 31.5, 30.4, 29.3. 31P NMR (162 MHz, Acetone-d6) 6 2.95. HRMS-ESI (m/z) [M+Hr calcd.568.1982. for C25H35N3010P :, found 568.2072.
isopropyl (0(3aS,4R,6R,6aR)-6-(4-amino-2-oxopyrimidin-1(2H)-y1)-2,2,3a-trimethyltetrahydrofuro [3,441[1,31dioxo1-4-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 73 To a solution of 1,2,4-triazole (750 mg, 10.85 mmol, 31 eq.) in acetonitrile (20 ml, 0.088M) was added. Et3N (1.65 mL, 11.69 mmol, 33.4 eq.) and phosphoryl chloride (0.17 mL, 1.82 mmol, 5.2 eq.) at 0 C. The mixture was stirred at 0 C for 3 hours before addition of a solution of 72 (200 mg, 0.8 mmol, 1 eq.) in ACN (4.5 ml, 0.35M). The reaction mixture was stirred overnight at room temperature. The reaction was then diluted with ethyl acetate (100 ml), filtered off, washed with sat NaHCO3 (20 ml) and brine (20 m1). The organic layer was concentrated under vacuum and the residue purified by flash column chromatography (Hexane/Ethyl acetate, 100/0 to 20/80) to afford the desired triazole intermediate. To a solution of this intermediate in 1,4-doxane (3 mL) was added aqueous ammonia (0.5 mL) at room temperature. The resulting reaction mixture was stirred for 2.5 hours before evaporation of the volatiles under vacuum. The residue was purified by flash chromatography (Dichloromethane /Methanol, 100/0 to 90/10) to give the title compound (42.1 mg, 22 % over 2 steps) as a white foam. 1H NMR (400 MHz, Methanol- d4) 6 7.70 (d, 1H, J= 7.5 Hz), 7.35 (t, 2H, J= 7.8 Hz), 7.28 -7.22 (m, 2H), 7.19 (t, 1H, J= 7.4 Hz), 5.89 (d, 1H, J= 7.5 Hz), 5.82 (d, 1H, J= 1.8 Hz), 4.96 (h, 1H, J = 6.2 Hz), 4.47 (d, 1H, J = 1.9 H), 4.28 (dddd, 3H, J= 24.9, 12.1, 6.6, 3.5 Hz), 3.89 (dq, 1H, J = 9.6, 7.1 Hz), 1.52 (s, 3H), 1.43 (s, 3H), 1.37 (s, 3H), 1.33 (d, 3H, J= 7.1 Hz), 1.21 (d, 6H, J= 6.3 Hz).13C NIVIR (101 MHz, Methanol- d4) 6 173.0, 166.4, 156.4, 150.7,141.6, 129.3, 124.8, 120.1, 120.0, 114.1, 94.8, 91.2, 90.0, 86.9, 85.5, 85.4, 68.7, 64.8, 50.2, 26.9, 25.8, 20.5, 19.0, 18.2. 31P NMR (162 MHz, Methanol- d4) 6 3.71.
isopropyl ((((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(211)-y1)-3,4-dihydroxy-3-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphory1)-L-alaninate 74.
Compound 73 (43 mg, 0.076 mmol, 1 eq.) was dissolved in methanol (2 ml) and HCI (12 M, 0.3 ml) was added dropwise at 0 C. The mixture was stirred at room temperature for 5 h.
before addition of a saturated solution of ammonia in methanol (10 m1). Volatiles were removed under vacuum and the residue purified by flash chromatography (Dichloromethane/Methanol, 100/0 to 85/15) to give the title compound (17.4 mg, 45%) as a white foam. 1-H NMR (400 MHz, Methanol- d4) 6 7.68 (d, 1H, 7.6 Hz), 7.27 (dd, 2H, 8.8, 7.2 Hz), 7.19 ¨ 7.07 (m, 3H), 5.92 (d, 1H, 7.3 Hz), 5.82¨ 5.70 (m, 1H), 4.86 (p, 1H, 1= 6.3 Hz,), 4.28 ¨ 4.08 (m, 2H), 4.04 -4.00 (m, /H), 3.82-373 (m, 2H), 1.26¨ 1.17 (m, 6H), 1.12 (dd, J= 6.2, 2.2 Hz, 6H).).13C NMR
(101 MHz, Methanol- d4) 6 172.8, 166.0, 157.7, 150.6, 150.5, 141.3, 129.6, 129.5, 124.9, 120.0, 95.4, 88.3, 85.1, 78.2, 76.3, 68.8, 65.8, 50.3, 20.5, 20.4, 19.2, 18.9.3'P NMR (162 MHz, Methanol- d4) 6 3.59.
Example 2 Cellular Toxicity Assays The toxicity of the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (see Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xi e M.-Y., Hart G.C., Smith G.A.
& Hahn E.F.
Antimicrob. Agents Chemother. 1990, 34, 1061-67). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC50 was obtained from the concentration-response curve using the median effective method described previously (see Chou T.-C. & Talalay P.
Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F. Antiviral Res. 1994, 25, 1-11).
Example 3 Mitochondrial Toxicity Assays in HepG2 Cells:
i) Effect of Compounds on Cell Growth and Lactic Acid Production: The effect on the growth of HepG2 cells can be determined by incubating cells in the presence of 0 uM, 0.1 uM, 1 uM, 10 uM and 100 uM drug. Cells (5 x 104 per well) can be plated into 12-well cell culture clusters in minimum essential medium with nonessential amino acids supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and 1%
penicillin/streptomycin and incubated for 4 days at 37 C. At the end of the incubation period the cell number can be determined using a hemocytometer. Also taught by Pan-Zhou X-R, Cui L, Zhou X-J, Sommadossi J-P, Darley-Usmer VM. "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," Antimicrob. Agents Chemother. 2000; 44:
496-503.
To measure the effects of the compounds on lactic acid production, HepG2 cells from a stock culture can be diluted and plated in 12-well culture plates at 2.5 x 104 cells per well.
Various concentrations (0 M, 0.1 M, 1 M, 10 1.1.M and 100 M) of compound can be added, and the cultures can be incubated at 37 C in a humidified 5% CO2 atmosphere for 4 days. At day 4, the number of cells in each well can be determined and the culture medium collected. The culture medium can then be filtered, and the lactic acid content in the medium determined using a colorimetric lactic acid assay (Sigma-Aldrich). Since lactic acid product can be considered a marker for impaired mitochondrial function, elevated levels of lactic acid production detected in cells grown in the presence of test compounds indicates a drug-induced cytotoxic effect.
Effect on Compounds on Mitochondricd DNA Synthesis: a real-time PCR assay to accurately quantify mitochondrial DNA content has been developed (see Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Grier J, Thamish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ, Schinazi RF. Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogs. Antimicrob. Agents Chemother. 2002;
46: 3854-60).
This assay can be used in all studies described in this application that determine the effect of compounds on mitochondrial DNA content. In this assay, low-passage- number HepG2 cells are seeded at 5,000 cells/well in collagen-coated 96-well plates. Test compounds are added to the medium to obtain final concentrations of 0 M, 0.1 M, 10 M and 100 M. On culture day 7, cellular nucleic acids can be prepared by using commercially available columns (RNeasy 96 kit; Qiagen). These kits co-purify RNA and DNA, and hence, total nucleic acids are eluted from the columns. The mitochondria] cytochrome c oxidase subunit TI
(COXII) gene and the 13-actin or rRNA gene can be amplified from 5 1 of the eluted nucleic acids using a multiplex Q-PCR protocol with suitable primers and probes for both target and reference amplifications. For COXII the following sense, probe and antisense primers can be used, respectively: 5'- TGCCCGCCATCATCC TA-3', 5 '-tetrachl oro-6-carb oxyfluorescein-TCC TCATCGCCCTCCCATCCC-TAMRA-3' and 5'-CGTCTGTTATGTAAAGGATGCGT-3'. For exon 3 of the 13-actin gene (GenBank accession number E01094) the sense, probe, and antisense primers are 5'-GCGCGGCTACAGCTTCA-3', 5 ' -6-F AMC AC CAC GGCC GAGCGGGATAMRA-3' and 5'-TCTCCTTAATGTCACGCACGAT-3', respectively. The primers and probes for the rRNA
gene are commercially available from Applied Biosystems. Since equal amplification efficiencies are obtained for all genes, the comparative CT method can be used to investigate potential inhibition of mitochondrial DNA synthesis. The comparative CT method uses arithmetic formulas in which the amount of target (COXII gene) is normalized to the amount of an endogenous reference (the B-actin or rRNA gene) and is relative to a calibrator (a control with no drug at day 7). The arithmetic formula for this approach is given by 2-AACT, where AACT is (CT for average target test sample - CT for target control) - (CT for average reference test -CT for reference control) (see Johnson MR, K Wang, JB Smith, MJ Heslin, RB Diasio.
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 2000; 278:175-184). A
decrease in mitochondrial DNA content in cells grown in the presence of drug indicates mitochondrial toxicity.
Example 4 Mitochondria' Toxicity- Glu/Gal Protocol Summary HepG2 cells are plated on 96 or 384 well tissue culture polystyrene plates.
After 24 hr the cells are dosed with test compound at a range of concentrations and incubated for 72 hr in medium supplemented with either galactose or glucose. Test compounds are said to cause mitochondrial toxicity if the cells grown in galactose-containing medium are more sensitive to the test compound than the cells grown in glucose-containing medium.
Objective: To measure the sensitivity of HepG2 cells grown in medium containing either galactose or glucose to the test compound.
Experimental Procedure HepG2 human hepatocellular carcinoma cells are plated on 96 or 384-well tissue culture polystyrene plates containing either galactose or glucose containing medium supplemented with % fetal bovine serum and antibiotics and incubated overnight. The cells are dosed with increasing concentrations of the test compound (final DMSO concentration 0.5 %; typical final test compound concentrations of 100, 30, 10, 3, 1, 0.3, 0.1, 0.03 [1M for an eight point dose response curve; n = 3 replicates per concentration) and the cells are incubated for 72 hr.
Appropriate controls are simultaneously used as quality controls. Cell viability is measured using Hoechst staining and cell counting by a HCS reader.
Example 5 Mitochonclrial Toxicity Assays in Neuro2A Cells To estimate the potential of the compounds described herein to cause neuronal toxicity, mouse Neuro2A cells (American Type Culture Collection 131) can be used as a model system (see Ray AS, Hernandez-Santiago BI, Mathew JS, Murakami E, Bozeman C, Xie MY, Dutschman GE, Gullen E, Yang Z, Hurwitz S, Cheng YC, Chu CK, McClure H, Schinazi RF, Anderson KS. Mechanism of anti-human immunodeficiency virus activity of beta-D-cyclopropylamino-2' ,3' -didehydro-2' ,3 ' -dideoxyguanosine. Antimicrob.
Agents Chemother.
2005, 49, 1994-2001). The concentrations necessary to inhibit cell growth by 50% (CC50) can be measured using the 3-(4,5-dimethyl-thiazol-2-y1)-2,5- diphenyltetrazolium bromide dye-based assay, as described. Perturbations in cellular lactic acid and mitochondria] DNA levels at defined concentrations of drug can be carried out as described above. ddC and AZT can be used as control nucleoside analogs.
Example 6 Assay fOr Bone Marrow Cytotoxicity Primary human bone marrow mononuclear cells can be obtained commercially from Cambrex Bioscience (Walkersville, MD). CFU-GM assays is carried out using a bilayer soft agar in the presence of 50 units/mL human recombinant granulocyte/macrophage colony-stimulating factor, while BFU-E assays used a ethylcellulose matrix containing 1 unit/mL
erythropoietin (see Sommadossi JP, Carlisle R. Toxicity of 3' -azido-3'-deoxythymidine and
9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hepatopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 1987; 31: 452-454; Sommadossi, JP, Schinazi, RF, Chu, CK, and Xie, MY. Comparison of cytotoxicity of the (-) and (+) enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. Biochem.
Pharmacol. 1992; 44:1921- 1925). Each experiment can be performed in duplicate in cells from three different donors. AZT is used as a positive control. Cells can be incubated in the presence of the compound for 14-18 days at 37 C with 5% CO2, and colonies of greater than 50 cells can be counted using an inverted microscope to determine the IC50.
The 50%
inhibitory concentration (IC50) can be obtained by least-squares linear regression analysis of the logarithm of drug concentration versus BFU-E survival fractions.
Statistical analysis can be performed with Student's t test for independent non-paired samples.
Example 7 In vitro human mitochondria' RATA polymerase (POLRAJT) assay In vitro RNA nucleotide incorporation assays with POLRMT (INDIGO Biosciences) can be performed as previously described (Arnold et al. 2012). Briefly, 32P-radiolabeled RNA
primer (5'-UUUUGCCGCGCC) can be hybridized to 3 molar excess of the appropriate DNA
template (5'-GGGAATGCANGGCGCGGC where position N can be replaced by A, T, or C).
125 nM of POLRMT can be incubated with 500 nM of 5'-radiolabled RNA/DNA
hybrid, 10 mM MgC12 and 100 pM of the corresponding nucleoside triphosphate. For non-nucleoside analogs, 100 pIVI of inhibitor can be added at the same time as 100 [iM UTP.
Incorporation can be allowed to proceed for 2 h at 30 C and reactions are stopped by the addition of 10 mM EDTA
and formamide. Samples are visualized on 20% denaturing polyacrylamide gel.
Data can be analyzed by normalizing the product fraction for each nucleoside triphosphate analog to that of the corresponding natural nucleoside triphosphate.
Example 8 Effect of Nucleotide Analogs on the DNA Polymerase and Exonuclease Activities of Mitochondria' DNA Polymerase y i) Purification of Human Polymerase y: The recombinant large and small subunits of polymerase 7 can be purified as described previously (see Graves SW, Johnson AA, Johnson KA. Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase. Biochemistry. 1998, 37, 6050-8;
Johnson AA, Tsai Y, Graves SW, Johnson KA. Human mitochondrial DNA polymerase holoenzyme:
reconstitution and characterization. Biochemistry 2000; 39: 1702-8). The protein concentration can be determined spectrophotometrically at 280 nm, with extinction coefficients of 234,420, and 71,894 M-1 cm-1 for the large and the small subunits of polymerase 7, respectively.
ii) Kinetic Analyses of Nucleotide Incorporation: Pre-steady-state kinetic analyses can be performed to determine the catalytic efficiency of incorporation (k/K) for DNA
polymerase 7 for nucleoside-TP and natural dNTP substrates. This allowed determination of the relative ability of this enzyme to incorporate modified analogs and predict toxicity. Pre-steady-state kinetic analyses of incorporation of nucleotide analogs by DNA
polymerase 7 would be carried out essentially as described previously (see Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004, 62, 57-64; Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother.
2004, 48, 1300-6). Briefly, a pre-incubated mixture of large (250 nM) and small (1.25 mM) subunits of polymerase 7 and 60nM DNA template/primer in 50mM Tris-HC1, 100 mM
NaCl, pH 7.8, can be added to a solution containing MgCl2 (2.5 mM) and various concentrations of nucleotide analogs. Reactions can be quenched and analyzed as described previously. Data can be fit to the same equations as described above.
iii) Assay for Human Polymerase y 3 ' 5' Exonuclease Activity: The human polymerase exonuclease activity can be studied by measuring the rate of formation of the cleavage products in the absence of dNTP. The reaction can be initiated by adding MgCl2 (2.5mM) to a pre-incubated mixture of polymerase 7 large subunit (40nM), small subunit (270nM), and 1,500nM chain-terminated template/primer in 50mM Tris-HCl, 100mM NaCl, pH 7.8, and quenched with 0.3M EDTA at the designated time points. All reaction mixtures would be analyzed on 20% denaturing polyacrylamide sequencing gels (8M urea), imaged on a Bio-Rad GS-525 molecular image system, and quantified with Molecular Analyst (Bio-Rad). Products formed from the early time points would be plotted as a function of time. Data would be fitted by linear regression with Sigma Plot (Jandel Scientific). The slope of the line can be divided by the active enzyme concentration in the reaction to calculate the kexo for exonuclease activity (see Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5- fluorocytidine analogs by mitochondria]
DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004; 62:
57-64;
Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS. Relationship between antiviral activity and host toxicity:
comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA
polymerase. Antimicrob Agents Chemother. 2004; 48: 1300-6).
Example 9 Inhibition of Human DNA Polymerases by NTP 's Study Objectives To determine whether a nucleoside-triphosphate analog inhibits human DNA
polymerases Alpha, Beta and Gamma and to calculate IC50 values.
Materials and Methods Human DNA Polymerase Alpha ¨ Enzyme can be purchased from Chimerx (cat#1075) and assayed based on their recommendations with some modifications. The 2'-Me-UTP was treated with Inorganic Pyrophosphatase (Sigma) to remove any pyrophosphate contamination.
A final concentration of 500 uM 2'-Me-UTP can be incubated with 1 mM DTT, 50 mM Tris, 50 mM NaCl, 6 mM MgCl2, and 1 unit of pyrophosphatase for 1 hour at 37 C
followed by inactivation at 95 C for 10 minutes. A mixture of 0.05 units of Human DNA
Polymerase Alpha and a 5' end radi label ed 24nt DNA primer (5' -TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 48nt DNA template (5'-CAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 uM in 60 mM
Tris-HC1 (pH
8.0), 5 mM magnesium acetate, 0.3 mg/ml bovine serum albumin, 1 mM
dithiothreitol, 0.1 mM
spermine, 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ul for min at 37 C (all concentrations represent final concentrations after mixing).
The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products are separated on a 20%
polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX. Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)t'slope) to determine ICso values using Graphpad Prism or Synergy Software K al ei dagraph . Data can be normalized to controls.
Human DNA Polymerase Beta Enzyme can be purchased from Chimerx (cat#1077) and assayed based on their recommendations with some modifications. A mixture of 0.1 units of Human DNA Polymerase Beta and a 5'end radiolabeled 24nt DNA primer (5'-TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 48nt DNA template (5' -CAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 0M in 50 mM
Tris-HC1 (pH
8.7), 10 mM KC1, 10 mM MgCl2, 0.4 mg/ml bovine serum albumin, 1 mM
dithiothreitol, 15%
(v/v) glycerol, and 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ttl for 5 min at 37 C (all concentrations represent final concentrations after mixing). The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products can be separated on a 20% polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX.
Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)t'slope) to determine ICso values using Graphpad Prism or SynergySoftware Kaleidagraph. Data can be normalized to controls..
Human DNA Polymerase Gamma ¨ Enzyme can be purchased from Chimerx (cat#1076) and assayed based on their recommendations with some modifications.
A mixture of 0.625 units of Human DNA Polymerase Gamma and a 5' end radiolabeled 24nt DNA primer (5'-TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 36nt DNA template (5'-TCTCTAGAAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 tiM in 50 mM Tri s-HC1 (pH 7.8), 100 mM NaCl, 5 mM MgCl2, and 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ttl for 200 min at 37 C (all concentrations represent final concentrations after mixing). The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products can be separated on a 20% polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX.
Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)"slope) to determine ICso values using Graphpad Prism or SynergySoftware Kaleidograph. Data can be normalized to controls.
Example 10 Cellular Pharmacology in HepG2 cells HepG2 cells are obtained from the American Type Culture Collection (Rockville, MD), and are grown in 225 cm2 tissue culture flasks in minimal essential medium supplemented with non-essential amino acids, 1% penicillin-streptomycin. The medium is renewed every three days, and the cells are subcultured once a week. After detachment of the adherent monolayer with a 10 minute exposure to 30 mL of trypsin-EDTA and three consecutive washes with medium, confluent HepG2 cells are seeded at a density of 2.5 x 106 cells per well in a 6-well plate and exposed to 10 1.1.M of [3fl] labeled active compound (500 dpm/pmol) for the specified time periods.
The cells are maintained at 37 C under a 5% CO2 atmosphere. At the selected time points, the cells are washed three times with ice-cold phosphate-buffered saline (PBS).
Intracellular active compound and its respective metabolites are extracted by incubating the cell pellet overnight at -20 C with 60% methanol followed by extraction with an additional 20 pal of cold methanol for one hour in an ice bath. The extracts are then combined, dried under gentle filtered airflow and stored at -20 C until HPLC analysis.
Example 11 Cellular Pharmacology in PBM cells Test compounds are incubated in PBM cells at 50 1.1.M for 4 h at 37 C. Then the drug containing media is removed and the PBM cells are washed twice with PBS to remove extracellular drugs. The intracellular drugs are extracted from 10 x 106 PBM
cells using 1 mL
70% ice-cold methanol (containing 10 nM of the internal standard ddATP).
Following precipitation, the samples are maintained at room temperature for 15 min followed by vortexing for 30 sec, and then stored 12 h at -20 C. The supernatant is then evaporated to dryness. Dry samples would be stored at -20 C until LC-MS/MS analysis. Prior to analysis, each sample is reconstituted in 100 uL mobile phase A, and centrifuged at 20,000 g to remove insoluble particulates.
Gradient separation is performed on a Hypersil GOLD column (100 x 1.0 mm, 3 tim particle size; Thermo Scientific, Waltham, MA, USA). Mobile phase A consists of 2 mM
ammonium phosphate and 3 mM hexylamine. Acetonitrile is increased from 10 to 80% in 15 min, and kept at 80% for 3 min. Equilibration at 10% acetonitrile lasts 15 min.
The total run time is 33 min. The flow rate is maintained at 50 iL/min and a
Pharmacol. 1992; 44:1921- 1925). Each experiment can be performed in duplicate in cells from three different donors. AZT is used as a positive control. Cells can be incubated in the presence of the compound for 14-18 days at 37 C with 5% CO2, and colonies of greater than 50 cells can be counted using an inverted microscope to determine the IC50.
The 50%
inhibitory concentration (IC50) can be obtained by least-squares linear regression analysis of the logarithm of drug concentration versus BFU-E survival fractions.
Statistical analysis can be performed with Student's t test for independent non-paired samples.
Example 7 In vitro human mitochondria' RATA polymerase (POLRAJT) assay In vitro RNA nucleotide incorporation assays with POLRMT (INDIGO Biosciences) can be performed as previously described (Arnold et al. 2012). Briefly, 32P-radiolabeled RNA
primer (5'-UUUUGCCGCGCC) can be hybridized to 3 molar excess of the appropriate DNA
template (5'-GGGAATGCANGGCGCGGC where position N can be replaced by A, T, or C).
125 nM of POLRMT can be incubated with 500 nM of 5'-radiolabled RNA/DNA
hybrid, 10 mM MgC12 and 100 pM of the corresponding nucleoside triphosphate. For non-nucleoside analogs, 100 pIVI of inhibitor can be added at the same time as 100 [iM UTP.
Incorporation can be allowed to proceed for 2 h at 30 C and reactions are stopped by the addition of 10 mM EDTA
and formamide. Samples are visualized on 20% denaturing polyacrylamide gel.
Data can be analyzed by normalizing the product fraction for each nucleoside triphosphate analog to that of the corresponding natural nucleoside triphosphate.
Example 8 Effect of Nucleotide Analogs on the DNA Polymerase and Exonuclease Activities of Mitochondria' DNA Polymerase y i) Purification of Human Polymerase y: The recombinant large and small subunits of polymerase 7 can be purified as described previously (see Graves SW, Johnson AA, Johnson KA. Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase. Biochemistry. 1998, 37, 6050-8;
Johnson AA, Tsai Y, Graves SW, Johnson KA. Human mitochondrial DNA polymerase holoenzyme:
reconstitution and characterization. Biochemistry 2000; 39: 1702-8). The protein concentration can be determined spectrophotometrically at 280 nm, with extinction coefficients of 234,420, and 71,894 M-1 cm-1 for the large and the small subunits of polymerase 7, respectively.
ii) Kinetic Analyses of Nucleotide Incorporation: Pre-steady-state kinetic analyses can be performed to determine the catalytic efficiency of incorporation (k/K) for DNA
polymerase 7 for nucleoside-TP and natural dNTP substrates. This allowed determination of the relative ability of this enzyme to incorporate modified analogs and predict toxicity. Pre-steady-state kinetic analyses of incorporation of nucleotide analogs by DNA
polymerase 7 would be carried out essentially as described previously (see Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004, 62, 57-64; Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother.
2004, 48, 1300-6). Briefly, a pre-incubated mixture of large (250 nM) and small (1.25 mM) subunits of polymerase 7 and 60nM DNA template/primer in 50mM Tris-HC1, 100 mM
NaCl, pH 7.8, can be added to a solution containing MgCl2 (2.5 mM) and various concentrations of nucleotide analogs. Reactions can be quenched and analyzed as described previously. Data can be fit to the same equations as described above.
iii) Assay for Human Polymerase y 3 ' 5' Exonuclease Activity: The human polymerase exonuclease activity can be studied by measuring the rate of formation of the cleavage products in the absence of dNTP. The reaction can be initiated by adding MgCl2 (2.5mM) to a pre-incubated mixture of polymerase 7 large subunit (40nM), small subunit (270nM), and 1,500nM chain-terminated template/primer in 50mM Tris-HCl, 100mM NaCl, pH 7.8, and quenched with 0.3M EDTA at the designated time points. All reaction mixtures would be analyzed on 20% denaturing polyacrylamide sequencing gels (8M urea), imaged on a Bio-Rad GS-525 molecular image system, and quantified with Molecular Analyst (Bio-Rad). Products formed from the early time points would be plotted as a function of time. Data would be fitted by linear regression with Sigma Plot (Jandel Scientific). The slope of the line can be divided by the active enzyme concentration in the reaction to calculate the kexo for exonuclease activity (see Murakami E, Ray AS, Schinazi RF, Anderson KS. Investigating the effects of stereochemistry on incorporation and removal of 5- fluorocytidine analogs by mitochondria]
DNA polymerase gamma: comparison of D- and L-D4FC-TP. Antiviral Res. 2004; 62:
57-64;
Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS. Relationship between antiviral activity and host toxicity:
comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA
polymerase. Antimicrob Agents Chemother. 2004; 48: 1300-6).
Example 9 Inhibition of Human DNA Polymerases by NTP 's Study Objectives To determine whether a nucleoside-triphosphate analog inhibits human DNA
polymerases Alpha, Beta and Gamma and to calculate IC50 values.
Materials and Methods Human DNA Polymerase Alpha ¨ Enzyme can be purchased from Chimerx (cat#1075) and assayed based on their recommendations with some modifications. The 2'-Me-UTP was treated with Inorganic Pyrophosphatase (Sigma) to remove any pyrophosphate contamination.
A final concentration of 500 uM 2'-Me-UTP can be incubated with 1 mM DTT, 50 mM Tris, 50 mM NaCl, 6 mM MgCl2, and 1 unit of pyrophosphatase for 1 hour at 37 C
followed by inactivation at 95 C for 10 minutes. A mixture of 0.05 units of Human DNA
Polymerase Alpha and a 5' end radi label ed 24nt DNA primer (5' -TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 48nt DNA template (5'-CAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 uM in 60 mM
Tris-HC1 (pH
8.0), 5 mM magnesium acetate, 0.3 mg/ml bovine serum albumin, 1 mM
dithiothreitol, 0.1 mM
spermine, 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ul for min at 37 C (all concentrations represent final concentrations after mixing).
The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products are separated on a 20%
polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX. Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)t'slope) to determine ICso values using Graphpad Prism or Synergy Software K al ei dagraph . Data can be normalized to controls.
Human DNA Polymerase Beta Enzyme can be purchased from Chimerx (cat#1077) and assayed based on their recommendations with some modifications. A mixture of 0.1 units of Human DNA Polymerase Beta and a 5'end radiolabeled 24nt DNA primer (5'-TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 48nt DNA template (5' -CAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 0M in 50 mM
Tris-HC1 (pH
8.7), 10 mM KC1, 10 mM MgCl2, 0.4 mg/ml bovine serum albumin, 1 mM
dithiothreitol, 15%
(v/v) glycerol, and 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ttl for 5 min at 37 C (all concentrations represent final concentrations after mixing). The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products can be separated on a 20% polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX.
Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)t'slope) to determine ICso values using Graphpad Prism or SynergySoftware Kaleidagraph. Data can be normalized to controls..
Human DNA Polymerase Gamma ¨ Enzyme can be purchased from Chimerx (cat#1076) and assayed based on their recommendations with some modifications.
A mixture of 0.625 units of Human DNA Polymerase Gamma and a 5' end radiolabeled 24nt DNA primer (5'-TCAGGTCCCTGTTCGGGCGCCACT) anneal to a 36nt DNA template (5'-TCTCTAGAAGTGGCGCCCGAACAGGGACCTGAAAGC) can be mixed with increasing concentrations of compound from 0 to 100 tiM in 50 mM Tri s-HC1 (pH 7.8), 100 mM NaCl, 5 mM MgCl2, and 0.05 mM of each dCTP, dGTP, dTTP, dATP in a final reaction volume of 20 ttl for 200 min at 37 C (all concentrations represent final concentrations after mixing). The reactions can be stopped by mixing with 0.3 M (final) EDTA. Products can be separated on a 20% polyacrylamide gel and quantitated on a Bio-Rad Molecular Imager FX.
Results from the experiments can be fit to a dose response equation, (y min +((y max)-(y min)))/(1+(compound concentration)/ICso)"slope) to determine ICso values using Graphpad Prism or SynergySoftware Kaleidograph. Data can be normalized to controls.
Example 10 Cellular Pharmacology in HepG2 cells HepG2 cells are obtained from the American Type Culture Collection (Rockville, MD), and are grown in 225 cm2 tissue culture flasks in minimal essential medium supplemented with non-essential amino acids, 1% penicillin-streptomycin. The medium is renewed every three days, and the cells are subcultured once a week. After detachment of the adherent monolayer with a 10 minute exposure to 30 mL of trypsin-EDTA and three consecutive washes with medium, confluent HepG2 cells are seeded at a density of 2.5 x 106 cells per well in a 6-well plate and exposed to 10 1.1.M of [3fl] labeled active compound (500 dpm/pmol) for the specified time periods.
The cells are maintained at 37 C under a 5% CO2 atmosphere. At the selected time points, the cells are washed three times with ice-cold phosphate-buffered saline (PBS).
Intracellular active compound and its respective metabolites are extracted by incubating the cell pellet overnight at -20 C with 60% methanol followed by extraction with an additional 20 pal of cold methanol for one hour in an ice bath. The extracts are then combined, dried under gentle filtered airflow and stored at -20 C until HPLC analysis.
Example 11 Cellular Pharmacology in PBM cells Test compounds are incubated in PBM cells at 50 1.1.M for 4 h at 37 C. Then the drug containing media is removed and the PBM cells are washed twice with PBS to remove extracellular drugs. The intracellular drugs are extracted from 10 x 106 PBM
cells using 1 mL
70% ice-cold methanol (containing 10 nM of the internal standard ddATP).
Following precipitation, the samples are maintained at room temperature for 15 min followed by vortexing for 30 sec, and then stored 12 h at -20 C. The supernatant is then evaporated to dryness. Dry samples would be stored at -20 C until LC-MS/MS analysis. Prior to analysis, each sample is reconstituted in 100 uL mobile phase A, and centrifuged at 20,000 g to remove insoluble particulates.
Gradient separation is performed on a Hypersil GOLD column (100 x 1.0 mm, 3 tim particle size; Thermo Scientific, Waltham, MA, USA). Mobile phase A consists of 2 mM
ammonium phosphate and 3 mM hexylamine. Acetonitrile is increased from 10 to 80% in 15 min, and kept at 80% for 3 min. Equilibration at 10% acetonitrile lasts 15 min.
The total run time is 33 min. The flow rate is maintained at 50 iL/min and a
10 iL injection is used. The autosampler and the column compartment are typically maintained at 4.5 and 30 C, respectively.
The first 3.5 min of the analysis is diverted to waste. The mass spectrometer is operated in positive ionization mode with a spray voltage of 3.2 kV.
Example 12 Chikungynya Virus Antiviral Activity Assay Methods for evaluating the efficacy of the compounds described herein against Chikungunya virus, a representative Togaviridae virus, is shown, for example, in Ehteshami, M., Tao, S., Zandi, K., Hsiao, H.M., Jiang, Y., Hammond, E., Amblard, F., Russell, 0Ø, Mertis, A., and Schinazi, R.F.: Characterization of13-D-N4-hydroxycytidine as a novel inhibitor of chikungunya virus. Antimirob Agents Chemother, 2017 Apr; 61(4): e02395-16.
Anti-Chikungunya Activity can also be evaluated as outlined in "Anti-Chikungunya Viral Activities of Aplysiatoxin-Related Compounds from the Marine Cyanobacterium Trichodesmium erythraeum" Gupta, D. K.; Kaur, P.; Leong, S. T.; Tan, L. T.
Prinsep, M. R.;
Chu, J J. H. Mar Drugs. Jan 2014; 12(1): 115-127; 10.3390/md12010115 and references cited therein.
Example 13 Assaying Compounds for Efficacy Against Mayaro Virus Infection:
A representative assay for determining the efficacy of the compounds described herein against the Mayaro virus, another representative Togaviridae virus, is disclosed in Cavalheiro et al., "Macrophages as target cells for Mayaro virus infection: involvement of reactive oxygen species in the inflammatory response during virus replication," Anais da Academia Brasileira de Ciencias (2016) 88(3): 1485-1499, (Annals of the Brazilian Academy of Sciences). The procedures are summarized below.
Cell Culture and Virus Propagation RAW 264.7, a mouse leukaemic macrophage cell line, and J774, a mouse reticulum sarcoma cell line, can be maintained in RPMI-1640 medium (LGC) supplemented with 10%
fetal bovine serum (FBS; Invitrogen Life Technologies) in a humidified incubator at 37 C with 5% CO2. Mouse peritoneal macrophages can be obtained from C57B1/6 animals by the intraperitoneal injection of 1 mL of sterile 3% thioglycollate. After 96 h, the peritoneal macrophages can be harvested, washed with RPMI and centrifuged at 1,500 rpm for five minutes. Then, the macrophages can be plated at a density of 2 x 106 cells/well in a 6-well plate with RPMI-1640 supplemented with 10% FBS and incubated at 37 C with 5% CO2.
After 24 h, the plates can be washed with RPMI to remove non-adherent cells before the assays.
MAYV (ATCC VR 66, strain TR 4675) and SINV (AR339) can be propagated in BHK-21 cells grown in a-Minimum Essential Medium (a-MEM; Invitrogen Life Technologies) supplemented with 10% FBS. The cells can be infected with a multiplicity of infection (MOI) of 0.1. After 16 h for SINV and 30 h for MAYV, the culture media can be harvested and cell debris can be removed by centrifugation at 2,000 x g for 10 min and the supernatant can be stored at -80 C. Virus stocks titers can be determined by plaque assay in BHK-21 cells.
Macrophage Infection Assays Cells can be incubated with MAYV or SINV at a MOI of 1 (for RAW 264.7 and J774) or 5 (for primary peritoneal macrophages), for 1 h at 37 C in 5% CO2. Then, the medium containing the non-adsorbed virus can be removed, the cells can be washed with serum-free medium and cultured in RPMI supplemented with 5% FBS, at 37 C in 5% CO2 After the desired periods of infection, conditioned media can be collected for virus titration, LDH assay and cytokine quantification. Cellular extracts can be used for MTT and flow cytometry assays.
Virus inactivated by heating at 65 C for 30 min can be used as control. In some experiments, cells can be treated with 10 mM N-acetyl-L-cysteine (NAC; Sigma- Aldrich) or 50 1.M
apocynin (Sigma-Aldrich) for 15h after infection with MAYV.
Virus Titration by Plaque Assay BHK-21 cells can be seeded, for example, at a density of 1.25 x 105 cells per well in 12-wells plates and incubated at 37 C overnight. Ten-fold serial dilutions of the virus samples can be prepared in a-MEM and incubated with the cells for 1 h at 37 C (0.2 mL per well). After 1 h adsorption, 2 mL of 1% carboxymethylcellulose (w/v) (Sigma- Aldrich) in a-MEM
supplemented with 2% FBS can be layered onto the infected monolayers and the cells can be incubated at 37 C for 30 h or 48 h, for SINV or MAYV, respectively. Plaques can be visualized by staining the monolayer with 1 mL 1% crystal violet in 20% ethanol.
Cell Viability Assays Determination of macrophage viability during infection can be assessed by 3-(4,5-dimethylthiazol- 2-y1)-2,5-diphenyltetrazolium bromide (MTT) or lactate dehydrogenase (LDH) release assays. For the MTT assay, cells can be incubated with 0.5 mL
0.5 mg/mL MTT
(USB Corporation) in PBS solution for 90 min at 37 C. Then, unreacted dye can be discarded and formazan crystals can be An Acad Bras Cienc (2016) 88 (3) 1488 Mariana G.
Cavalheiro et al. solubilized in 0.04 M HCI solution in isopropanol (1 mL per well). The absorbance of samples can be measured at 570 nm and 650 nm for background correction.
Lactate dehydrogenase (LDH) release from infected macrophages can be determined by using an LDH
detection kit (Promega CytoTox 96 assay kit). The procedures can be performed according to manufacturer' s instructions.
Quantitation of Infected Cells by Flow Cytometry Flow cytometry analysis can be performed to assess the frequency of MAYV- or SINV-infected cells by detecting intracellular viral antigens. After the desired periods of infection, cells can be washed with PBS, detached by scraping, harvested and fixed in 4%
formaldehyde in PBS at room temperature for 15 min. After washing, cells can be permeabilized with 0.1%
saponin in PBS and incubated with blocking solution (PBS supplemented with 2%
FBS and 0.1% bovine serum albumin) for 20 min, at room temperature. Then, cells can be incubated for 1 h with mouse anti-Eastern Equine Encephalitis virus monoclonal antibody (Chemicon International, Millipore), which reacts with an El epitope shared by all alphaviruses. Then, cells can be washed and stained with anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen) for 30 min. The percentage of infected cells can be analyzed by FACScan Flow Cytometer and CellQuest software (Becton Dickinson).
Characterization of Cell Death Apoptosis/necrosis after infection can be quantified by a double staining method using The Vybrant Apoptosis Assay Kit#2 (Molecular Probes). After the infection period, RAW
264.7 cells can be washed with PBS, detached by scraping, harvested and stained with Annexin V Alexa Fluor 488 (0.5 jAg/ mL) and propidium iodide (PI, 0.25 lAg/mL). To further characterize MAYV-induced cell death, the activity of caspases 3 and 7 can be measured using the MuseTM
Caspase-3/7 Kit (Millipore) adapted to flow cytometry. Cells can be washed with PBS, detached by scraping, harvested and incubated with MuseTM Caspase-3/7 Reagent 1:8 and MuseTM
Caspase 7-AAD, according to the manufacturer's protocol. For both assays, the percentage of apoptotic and necrotic cells can be analyzed by FACScan Flow Cytometer using the CellQuest software (Bectan Dickinson). UV radiated cells and cells subjected to a freeze-thaw procedure can be used as controls.
Quantitation of Reactive Oxygen Species (ROS) The amount of intracellular reactive oxygen species (ROS) can be measured by the formation of the oxidized derivative of 5-(and 6-)-chloromethy1-2',T-dichlorodihydrofluorescein diacetate (DCF, Molecular Probes). After 15 h of infection with MAYV, adherent cells can be washed with PBS and incubated with DCF 0.5 [IM for 45 minutes.
Then, the cells can be washed again, detached by scraping and harvested and analyzed by FACScan Flow Cytometer using the CellQuest software (Bectan Dickinson).
Quantitation of Cytokines The concentrations of cytokines in the conditioned medium of macrophage cultures can be determined by ELISA. 'TNF concentration can be quantified using the Standard ELISA Development kit (PeproTech), according to the manufacturer's protocol Example 14 Yellow Fever Virus (YFV) Antiviral Activity Assay: Primary assay for antiviral activity A monolayer of Human Rhabdomyosarcoma (RD) cells will be grown in 96-well plate in MEM containing 2% inactivated FBS. The tested compounds will be added to the wells in triplicate together with YFV at an MOT= 1. The plate will then be incubated at 37 C with 5%
CO2 for 72 hours. The assay will be conducted in triplicate for each concentration of each compound. After three days, the plate will be viewed under the microscope and the degree of cytopathic effect (CPE) as measure of virus replication inhibition will be expressed as the percent yield of virus control. The results will be evaluated by performing the MTS assay (Promega, WI, USA) according to the manufacturer's protocols. All experiments will be repeated three times independently.
Focus forming unit reduction assay (FFURA) Antiviral activity of each compound will be determined by measuring the reduction in the number of YFV infectious foci in RD cells following treatment with increasing concentrations of each compound. Briefly, infected RD cells which will be treated with different concentrations of each compound will be incubated for 2 days post infection using conditioned-growth medium supplemented with 2% FBS and 1.5% carboxymethyl cellulose (CMC).
Antiviral activity of each compound will be determined after visualizing and counting viral foci.
The number of YFV foci will be counted using Elispot machine and the virus titer will be expressed as Foci Forming-Unit (FFU). Antiviral activities of the compounds will be determined by calculating the percentage of foci reduction (%RF) against the controls maintained in parallel using the following formula; RF (%) = (C-T) 100/C, where, C is the mean of the number of foci from triplicates treatment without compound added (vehicle control) and T is the mean of the number of foci from triplicates of each treatment measures with the respective compound. Results will represent as the means standard error of the mean (SEM) from triplicate assay from three independent experiments. Results were confirmed by virus yield reduction assay using quantitative RT-PCR.
Virus yield reduction assay Monolayers of RD cells will be prepared in 96-well cell culture microplate and overlaid with YFV (moi = 0.1) for 1 hour. After virus adsorption, cells will be washed 3 times with cold sterile PBS to remove unattached viruses and then the cells will be treated for 2 days with increasing concentrations of the tested compounds. After 2 days, the YFV RNA
will be extracted from the infected/treated cells and supernatant separately and the yield of YFV will quantified using a one-step specific quantitative RT-PCR for YFV.
Nevertheless, the antiviral activity of each nucleoside analogues will be investigated using focus forming unit reduction assay (FFURA) as described previously Time-of-drug-addition assay Confluent monolayers of RD cells will be prepared in 96-well cell culture plate and will be pre-treated with EC90 of each effective drug for 2 h before infection with YFV at MOI =1, concurrently with infection as well as 1, 2, 4 and 6 h post-infection. The cells will then be incubated in the presence of compound for 48 h. At the end of the incubation period, viral load for each time point of treatment will be determined using qRT-PCR as mentioned above.
Statistical analysis Graph Pad Prism for Windows, Version 5 (Graph Pad Software Inc., San Diego, CA, 2005) will be used to determine the half maximal effective concentration EC50 values and also EC90 of each effective compound. All ECso and EC90 values will be calculated as the means standard error of the mean (SEM) from triplicate assay from three independent experiments.
Example 15 HCV Rep/icon Assay]
Huh 7 Clone B cells containing HCV Replicon RNA can be seeded in a 96-well plate at 5000 cells/well, and the compounds tested at 10 iitM in triplicate immediately after seeding.
Following five days incubation (37 C, 5% CO2), total cellular RNA can be isolated by using versaGene RNA purification kit from Gentra. Replicon RNA and an internal control (TaqMan rRNA control reagents, Applied Biosystems) can be amplified in a single step multiplex Real Time RT-PCR Assay. The antiviral effectiveness of the compounds can be calculated by subtracting the threshold RT-PCR cycle of the test compound from the threshold RT-PCR cycle of the no-drug control (ACt HCV). A ACt of 3.3 equals a 1-log reduction (equal to 90% less starting material) in Replicon RNA levels. The cytotoxicity of the compounds can also be calculated by using the ACt rRNA values. 2'-C-Me-C can be used as the positive control. To determine EC90 and IC50 values, ACt: values can first be first converted into fraction of starting material and then can be used to calculate the % inhibition.
Example 16 Efficacy of the Compounds' Described Herein Against Dengue The essential role of a particular viral protein (Dengue virus envelope protein (E)) in viral propogation. Mondotte et al., J. Virol. July 2007, vol. 81 no. 13 7136-7148 discloses an assay useful for identifying compounds for treating infections caused by the Dengue virus, and this assay can be used to identify those compounds described herein which are active against Dengue.
Another assay is described in Levin, 14th International Symposium on Hepatitis C Virus & Related Viruses, Glasgow, UK, 9-13 September 2007. The assay relates to human and Dengue virus polymerase, where putative compounds can be tested against the enzymes, preferably in duplicate, over a range of concentrations, such as from U.S mM
to 100 mM. The compounds can also be run alongside a control (no inhibitor), a solvent dilution (0.016% to 2%
DMSO) and a reference inhibitor.
A suitable high throughput assay for Dengue is described in Lim et al., Antiviral Research, Volume 80, Issue 3, December 2008, Pages 360-369. Dengue virus (DENV) NS5 possesses methyltransferase (MTase) activity at its N-terminal amino acid sequence and is responsible for formation of a type 1 cap structure, m7GpppAm2'-0 in the viral genomic RNA.
Optimal in vitro conditions for DENV2 2'-0-MTase activity can be characterized using purified recombinant protein and a short biotinylated GTP-capped RNA template. Steady-state kinetics parameters derived from initial velocities can be used to establish a robust scintillation proximity assay for compound testing. Pre-incubation studies by Lim et al., Antiviral Research, Volume 80, Issue 3, December 2008, Pages 360-369, showed that MTase¨AdoMet and MTase¨
RNA complexes can be equally catalytically competent and the enzyme supports a random bi kinetic mechanism. Lim validated the assay with competitive inhibitory agents, S-adenosyl-homocysteine and two homologues, sinefungin and dehydrosinefungin. A GTP-binding pocket present at the N-terminal of DENV2 MTase can be previously postulated to be the cap-binding site. This assay allows rapid and highly sensitive detection of 2'-0-MTase activity, and can be readily adapted for high-throughput screening for inhibitory compounds.
Example 17 Atiti-Norovirus Activity Compounds can exhibit anti-norovirus activity by inhibiting norovirus polymerase and/or helicase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
There is currently no approved pharmaceutical treatment for Norovirus infection (http://www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus-qa.htm), and this has probably at least in part been due to the lack of availability of a cell culture system.
Recently, a replicon system has been developed for the original Norwalk G-I strain (Chang, K. 0., et al.
(2006) Virology 353:463-473).
Both Norovirus replicons and Hepatitis C replicons require viral helicase, protease, and polymerase to be functional in order for replication of the replicon to occur.
Most recently, an in vitro cell culture infectivity assay has been reported utilizing Norovirus genogroup I and II
inoculums (Straub, T. M. et al. (2007) Emerg. Infect. Dis. 13(3):396-403).
This assay is performed in a rotating-wall bioreactor utilizing small intestinal epithelial cells on microcarrier beads. The infectivity assay may be useful for screening entry inhibitors.
Diagnosis of Norovirus Infection One can diagnose a norovirus infection by detecting viral RNA in the stools of affected persons, using reverse transcription-polymerase chain reaction (RT-PCR) assays. The virus can be identified from stool specimens taken within 48 to 72 hours after onset of symptoms, although one can obtain satisfactory results using RT-PCR on samples taken as long as 7 days after the onset of symptoms. Other diagnostic methods include electron microscopy and serologic assays for a rise in titer in paired sera collected at least three weeks apart. There are also commercial enzyme-linked immunoassays available, but these tend to have relatively low sensitivity, limiting their use to diagnosis of the etiology of outbreaks.
Clinical diagnosis of norovirus infection is often used, particularly when other causative agents of gastroenteritis have been ruled out.
Example 18 Determining the Efficacy of the Compounds against ZIKV and DENT/Infection Material and methods for ZIKV and DENV (serotypes 1-4) infections assays:
Viruses: ZIKV PRVABC59 strain (NCBI accession KU501215) was obtained from the Centers for Diseases Control and Prevention. Virus stocks were generated on C6/36 or Vero cells and viral titers are determined by endpoint titration in Vero (African Green monkey kidney) or human cells, including neuroblastoma (U251), and hepatoblastoma (Huh7). DENV
stocks (kindly provided by Dr. Guey Chuen Perng (Emory University & National Cheng Kung University, Taiwan) were generated in Vero or Baby Hamster Kidney cells (BHK) (Clark et al., 2016).
Cytopathic-reduction assay for ZIKV or DENV: For the cytopathic-reduction assay, cells (Vero, U251 or Huh7) are seeded in 96-well plates at lx iO4 cells/well and incubated overnight. The next day, culture medium containing 50% cell culture infectious doses of ZIKV
or DENV (tested in Vero or BI-IK cells) are added after which 2-fold serial dilutions of the compounds are added. Cell cytopathic effect (CPE) is measured by MTS readout system (CellTiter 96 AQueous One Solution Proliferation kit, Promega) four (Vero) or five (U251 or Huh7) days after compound addition to determine the levels of ZIKV replication inhibition (Zmurko et al., 2016; Gavegnano et al., 2017). For DENV serotypes 1-4, CPE is measured four to five days after compound addition in Vero or BHK cells.
Focus formation assay: For the focus formation assay (FFA), Vero cells are routinely seeded in 96-well plates at 1.5x104 cells/well and incubated overnight. Next, culture medium containing 70-100 focus forming units of ZIKV or DENV (serotypes 1-4) plus 2-fold serial dilutions of the compounds are added to the cells and incubated for 2 h followed by the addition of overlay methylcellulose medium. Following 2-3 days of incubation, foci are stained using anti-Flavivirus group antigen (4G2, Millipore), followed by HRP-anti-mouse IgG
and TrueBlue substrate, and imaged using CTL-Immunospot S6 Micro Analyzer (Priyamvada et al., 2016).
Real-time RT-PCR assay: For the RT-PCR assays, Vero, U251, or Huh7 cells (15,000/well) are seeded in 96-well microplates, and cultured overnight prior to use for infections with ZIKV (MOI= 0.001 for Vero or M01-0.5 for U251 or Huh7) or DENV
(with MOI varying from 0.001 to 0.1 for different stocks of serotypes 1-4 for Vero cells). Compounds are added at a dose-dependent manner 1-2 h after ZIKV or DENV. After four days incubation, purified RNA are reverse transcribed into cDNA and amplified in a one-step RT-PCR multiplex reaction with LightCycler 480 RNA Master Hydrolysis Probe (Roche, Indianapolis, IN) using highly conserved sequences complementary to a 76 bp fragment from the ZIKV
envelope gene as previously described by Lanciotti (Lanciotti et al., 2008), and an endogenous control (TaqMan Ribosomal RNA Control or beta globin reagents; Applied Biosystems) by using the LightCycler 480 Instrument II (Roche). For detection of dengue viruses, we utilized oligonucleotides primers and probes serotype-specific that rapidly detects all four serotypes in a fourplex RT-PCR assay (Johnoson et al., 2005). For all virological tests, percent inhibition and EC50 value (compound concentration that inhibits viral antigen expression or viral replication by 50%) are determined using CalcuSyn software (Biosoft).
Combination studies for ZIKV or DENV.
One goal is to focus on compounds with sub-04 concentrations for hit to lead development, with cell selectivity index (SI) >100. Hit compounds that demonstrate antiviral potency with no apparent cytotoxicity can be selected for drug-drug combinations with compounds that exhibit different mechanism of action, including viral entry and host inhibitors, among others; These combinations can result in synergistic effects and optimal low doses to rapidly eliminate ZIKV or DENV from infected individuals.
One can use the Chou and Talalay method (Chou & Talalay 1984) for determining synergy, antagonism or additivity (Bassit et al., 2008; Schinazi et al., 2012), particularly with respect to combinations.
Material and methods for DENV2 (serotype 2) replicon assay:
Baby hamster kidney (BHK-21) stable cell lines expressing dengue virus serotype 2 [DENV2, New Guinea C strain, Qing et al., 2010)] was kindly provided by Mehul S. Suthar (Emory University).
DENV2 replicon-harboring baby hamster kidney (BHK) cells are exposed to test compounds at concentrations varying from 0.2 to 20 litM to assessment of antiviral activity.
Rendla luciferase levels (Promega) are quantified 48 hours after test compounds addition to determine the levels of replication inhibition (EC5o, [tM).
References 1. Clark, K.B., Hsiao, H.M., Bassit L., Crowe J.E. Jr., Schinazi R.F., Pemg G.C., Villinger F. Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells. Virology. 493, 162-72 (2016).
2. Zmurko, J., Marques, R. E., Schols, D., Verbeken, E., Kaptein, S. J. F.
& Neyts, J. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Neglected Tropical Diseases 10, e0004695, doi:10.1371/
journal.pntd.0004695 (2016).
3. Gavegnano C, Bassit LC, Cox BD, Hsiao H-M, Johnson EL, Suthar M, Chakraborty R, Schinazi RF. Jak inhibitors modulate production of replication-competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells. Pathogens &
immunity. 2, 199-218 (2017).
4. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan M J, Wilson PC, Ahmed R, Suthar MS, Wrammert J. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. PNAS 113, 7852-7857, (2016).
5. Lanciotti R, Kosoy 0, Laven J, Velez J, Lambert A, Johnson A, Stanfield S, Duffy M. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 14, 1232-1239 (2008).
6. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 43(10), 4977-4983 (2005).
7. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships:
the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22, 27-55 (1984).
8. Bassit L, Grier J, Bennett M, Schinazi RF. Combinations of 2'-C-methylcytidine analogues with interferon-a1pha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother. 19(1), 25-31 (2008).
9. Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother. 56(12), 6186-91 (2012).
10. Qing M, Liu W, Yuan Z et al., A high-throughput assay using dengue-1 virus like particles for drug discovery. Antiviral Res. 86(2), 163-71 (2010).
Example 19 MERS Assay Cells and Virus:
Human lung carcinoma cells (A-549) can be used for the primary antiviral assays and can be obtained from American Type Culture Collection (ATCC, Rockville, Md., USA). The cells can be passed in minimal essential medium (MEM with 0.15% NaCH03, Hyclone Laboratories, Logan, Utah, USA) supplemented with 10% fetal bovine serum. When evaluating compounds for efficacy, the serum can be reduced to a final concentration of 2%
and the medium can contain gentamicin (Sigma-Aldrich, St. Louis, Mo.) at 50 ittg/mL. Since the MERS-Co virus did not produce detectable virus cytopathic effects, virus replication in A549 cells can be detected by titering virus supernatant fluids from infected, compound-treated A549 cells in Vero 76 cells.
Vero 76 cells can be obtained from ATCC and can be routinely passed in MEM
with 0.15% NaCH03 supplemented with 5% fetal bovine serum. When evaluating compounds, the serum can be reduced to a final concentration of 2% and supplemented with 50 [tg/mL of gentamicin.
The Middle Eastern coronavirus strain EMC (MERS-CoV) was an original isolate from humans that was amplified in cell culture by Ron Fouchier (Erasmus Medical Center, Rotterdam, the Netherlands) and was obtained from the Centers for Disease Control (Atlanta, Ga.).
Controls:
Infergeng (interferon alfacon-1, a recombinant non-naturally occurring type-I
interferon (Blatt, L., et al., J. Interferon Cytokine Res. (1996) 16(7):489-499 and Alberti, A., BioDrugs (1999) 12(5):343-357) can be used as the positive control drug in all antiviral assays. Infergen=0.03 ng/mL.
Antiviral Assay:
Virus can be diluted in MEM to a multiplicity of infection=0.001 and each compound can be diluted in MEM+2% FBS using a half-log 8 dilution series. Compound can be added first to 96 well plates of confluent A549 cells followed within 5 mins by virus. Each test compound dilution can be evaluated for inhibition in triplicate. After plating, the plates can be incubated at 37 C. for 4 d. The plates can then be frozen at -80 C.
Virus Yield Reduction Assay:
Infectious virus yields from each well from the antiviral assay can be determined. Each plate from an antiviral assays can be thawed. Samples wells at each compound concentration tested can be pooled and titered for infectious virus by CPE assay in Vero 76 cells. The wells can be scored for CPE and virus titers calculated. A 90% reduction in virus yield can then be calculated by regression analysis. This represented a one log10 inhibition in titer when compared to untreated virus controls.
Example 20 VEEV Assay 96-well plates of HeLa-Ohio cells can be prepared and incubated overnight The plates can be seeded at 4 X 104 cells per well, which yields 90-100% confluent monolayers in each well after overnight incubation. The test compounds in DMSO can be started at a concentration of 100 jtM. 8-fold serial dilutions in MEM medium with 0.1% DMSO, 0% FBS, and 501.tg/mL
gentamicin with the test compound concentrations being prepared. To 5 test wells on the 96-well plate can be added 100 1.1L of each concentration and the plate can be incubated at 37 C
+5% CO2 for 2 h or 18 h. 3 wells of each dilution with the TC-83 strain Venezuelan equine encephalitis virus (ATCC, stock titer: 106.8 CCID50/mL) prepared in the medium as described above can be added. 2 wells (uninfected toxicity controls) can be added MEM
with no virus. 6 wells can be infected with untreated virus controls. To 6 wells can be added media only as cell controls. A blind, known active compound can be tested in parallel as a positive control. The plate can be incubated at 37 C +5% CO2 for 3 d. The plate can be read microscopically for visual CPE and a Neutral red dye plate can also be read using BIO-TEK
Instruments INC.
EL800. For virus yield reduction assays, the supernatant fluid can be collected from each concentration. The temperature can be held at -80 and each compound can be tested in triplicate. The CC50 can be determined by regression analysis using the CPE of toxicity control wells compared with cell controls. The virus titers can be tested in triplicate using a standard endpoint dilution CCID50 assay and titer calculations can be determined using the Reed-Muench (1948) equation. The concentration of compound required to reduce virus yield by 1 logto (90%) using regression analysis can be calculated (EC90 value). The concentration of compound required to reduce virus yield by 50% using regression analysis can be calculated (EC50 value).
Example 21 Rift Valley Fever Assay The compounds described herein can be tested for activity against Rift Valley Fever virus using methods known to those skilled in the art (e.g., described in Panchal et al., Antiviral Res. (2012) 93(1):23-29).
Example 22 Determining the Efficacy of the Compounds against HCoV-0C43 and SARS-CoV-2 Infections Viruses HCoV-0C43 was obtained from ATCC (Manasas, VA) and SARS-CoV-2 was provided by BET Resources (NR-52281: USA-WA/2020). HCoV-0C43 and SARS-CoV-2 were propagated in Huh-7 and Vero cells, respectively and titrated by TCID5o method followed by storage of aliquots at -80 C until further use.
Antiviral Activity Assay using Virus Yield Assay Method To determine the best time point for the virus yield assay, a kinetic replication of SARS-CoV-2 and HCoV-0C43 in Vero, Caco2, Calu3 and Huh-7 cells was performed, respectively, and the yield of progeny virus was assessed from the supernatant of viral infected cells at different interval time points using specific q-RT PCR for each virus as mentioned earlier. We determined that 48 and 72 h post-infection were the optimum time point for SARS-CoV-2 and HCoV-0C43, respectively, as there was no observed cell death and cytopathic effect (CPE) on infected cells and more importantly, significant increase in the virus RNA copy number which harvested from the supernatant of the infected cells were observed at that time for SARS-CoV-2 and also HCoV-0C43.
In the next step towards defining the antiviral activity of each compound, we have assessed the antiviral activity of each compound in a dose-dependent manner against SARS-CoV-2 and HCoV-0C43 using a virus yield inhibition assay by determining the viral RNA copy number in collected supernatants, compared to the results from infected but untreated cells, and non-infected and untreated cells as necessary controls. All experiments were performed in triplicate and each experiment repeated three times independently to achieve reliable and statistically meaningful results.
The median effective concentration (EC5o) and the concentration with 90% of inhibitory effect (EC90) were calculated using GraphPad PRISM for Mac, version (GraphPad Software Inc., San Diego, CA, 2005) and reported as the mean standard deviation (SD).
Table 1 Structures Anti-SARS-CoV-2 activity in Vero cells (1uM) EC5o ECoo NH
NL0 035 2.5 OH OH
rj(NH
, 0 N 0 <i OPh OH OH
N
HO NN N 0 <10 OH OH
rjk'IN
HO NN N 0 <10 HO OH
rijNH
'N 0 10 HO
OH OH
NH
'N 0 I 0 s,=k H OPh OH OH
NN
HO 6.0 15.2 OH OH
SH
NN
NN
HO 11.1 23.5 HO OH
/L-I
HO N 0 9.2 29.6 Me HO OH
I T.ji\i HO 7.6 28.8 1cL04.Me HO OH
O. 9 N - - - P - - <10 o H
<
( OH OH
F3C OMe HO NN' <10 OH OH
r-i-L NH
0 HO N <10 OH OH
)NH
N HO <10 NH
I
N, N0 <10 0 H oPh OH F
<10 r.**1.
, Bz0 NH
HONO
<10 eX
HO N 0 <10 slc- 0 ci Ci ,I14N
HO
) ¨
N
=
HOõ N N't; <10 0 jc--0 OH
NH2 <10 HO o OH OH
<10 'NH
'N
\ .1 0 <10 o o N o ), OPh HO OH
SP
0 <10 tk,0 HO, OH OH
o <10 .' -ANH
tsg I A, -- -Nilo OH OH
<-1 HOõ
) OH oH
NH2 <10 N
NN
,j HO
OH OH
NH2 <10 N
z N N
169,) OH OH
CI:
N
, N
2.3 6.5 N
pc.113 =
HO <10 >10 <li=-= 1 "NH
õ.õ1õ.
;1 0 HO, t >10 0 =
H oPh 1 NH2 > 1 0 HO N CI
CI
N N
I <10 HO NN CI
(;!
NN
u N CI >10
The first 3.5 min of the analysis is diverted to waste. The mass spectrometer is operated in positive ionization mode with a spray voltage of 3.2 kV.
Example 12 Chikungynya Virus Antiviral Activity Assay Methods for evaluating the efficacy of the compounds described herein against Chikungunya virus, a representative Togaviridae virus, is shown, for example, in Ehteshami, M., Tao, S., Zandi, K., Hsiao, H.M., Jiang, Y., Hammond, E., Amblard, F., Russell, 0Ø, Mertis, A., and Schinazi, R.F.: Characterization of13-D-N4-hydroxycytidine as a novel inhibitor of chikungunya virus. Antimirob Agents Chemother, 2017 Apr; 61(4): e02395-16.
Anti-Chikungunya Activity can also be evaluated as outlined in "Anti-Chikungunya Viral Activities of Aplysiatoxin-Related Compounds from the Marine Cyanobacterium Trichodesmium erythraeum" Gupta, D. K.; Kaur, P.; Leong, S. T.; Tan, L. T.
Prinsep, M. R.;
Chu, J J. H. Mar Drugs. Jan 2014; 12(1): 115-127; 10.3390/md12010115 and references cited therein.
Example 13 Assaying Compounds for Efficacy Against Mayaro Virus Infection:
A representative assay for determining the efficacy of the compounds described herein against the Mayaro virus, another representative Togaviridae virus, is disclosed in Cavalheiro et al., "Macrophages as target cells for Mayaro virus infection: involvement of reactive oxygen species in the inflammatory response during virus replication," Anais da Academia Brasileira de Ciencias (2016) 88(3): 1485-1499, (Annals of the Brazilian Academy of Sciences). The procedures are summarized below.
Cell Culture and Virus Propagation RAW 264.7, a mouse leukaemic macrophage cell line, and J774, a mouse reticulum sarcoma cell line, can be maintained in RPMI-1640 medium (LGC) supplemented with 10%
fetal bovine serum (FBS; Invitrogen Life Technologies) in a humidified incubator at 37 C with 5% CO2. Mouse peritoneal macrophages can be obtained from C57B1/6 animals by the intraperitoneal injection of 1 mL of sterile 3% thioglycollate. After 96 h, the peritoneal macrophages can be harvested, washed with RPMI and centrifuged at 1,500 rpm for five minutes. Then, the macrophages can be plated at a density of 2 x 106 cells/well in a 6-well plate with RPMI-1640 supplemented with 10% FBS and incubated at 37 C with 5% CO2.
After 24 h, the plates can be washed with RPMI to remove non-adherent cells before the assays.
MAYV (ATCC VR 66, strain TR 4675) and SINV (AR339) can be propagated in BHK-21 cells grown in a-Minimum Essential Medium (a-MEM; Invitrogen Life Technologies) supplemented with 10% FBS. The cells can be infected with a multiplicity of infection (MOI) of 0.1. After 16 h for SINV and 30 h for MAYV, the culture media can be harvested and cell debris can be removed by centrifugation at 2,000 x g for 10 min and the supernatant can be stored at -80 C. Virus stocks titers can be determined by plaque assay in BHK-21 cells.
Macrophage Infection Assays Cells can be incubated with MAYV or SINV at a MOI of 1 (for RAW 264.7 and J774) or 5 (for primary peritoneal macrophages), for 1 h at 37 C in 5% CO2. Then, the medium containing the non-adsorbed virus can be removed, the cells can be washed with serum-free medium and cultured in RPMI supplemented with 5% FBS, at 37 C in 5% CO2 After the desired periods of infection, conditioned media can be collected for virus titration, LDH assay and cytokine quantification. Cellular extracts can be used for MTT and flow cytometry assays.
Virus inactivated by heating at 65 C for 30 min can be used as control. In some experiments, cells can be treated with 10 mM N-acetyl-L-cysteine (NAC; Sigma- Aldrich) or 50 1.M
apocynin (Sigma-Aldrich) for 15h after infection with MAYV.
Virus Titration by Plaque Assay BHK-21 cells can be seeded, for example, at a density of 1.25 x 105 cells per well in 12-wells plates and incubated at 37 C overnight. Ten-fold serial dilutions of the virus samples can be prepared in a-MEM and incubated with the cells for 1 h at 37 C (0.2 mL per well). After 1 h adsorption, 2 mL of 1% carboxymethylcellulose (w/v) (Sigma- Aldrich) in a-MEM
supplemented with 2% FBS can be layered onto the infected monolayers and the cells can be incubated at 37 C for 30 h or 48 h, for SINV or MAYV, respectively. Plaques can be visualized by staining the monolayer with 1 mL 1% crystal violet in 20% ethanol.
Cell Viability Assays Determination of macrophage viability during infection can be assessed by 3-(4,5-dimethylthiazol- 2-y1)-2,5-diphenyltetrazolium bromide (MTT) or lactate dehydrogenase (LDH) release assays. For the MTT assay, cells can be incubated with 0.5 mL
0.5 mg/mL MTT
(USB Corporation) in PBS solution for 90 min at 37 C. Then, unreacted dye can be discarded and formazan crystals can be An Acad Bras Cienc (2016) 88 (3) 1488 Mariana G.
Cavalheiro et al. solubilized in 0.04 M HCI solution in isopropanol (1 mL per well). The absorbance of samples can be measured at 570 nm and 650 nm for background correction.
Lactate dehydrogenase (LDH) release from infected macrophages can be determined by using an LDH
detection kit (Promega CytoTox 96 assay kit). The procedures can be performed according to manufacturer' s instructions.
Quantitation of Infected Cells by Flow Cytometry Flow cytometry analysis can be performed to assess the frequency of MAYV- or SINV-infected cells by detecting intracellular viral antigens. After the desired periods of infection, cells can be washed with PBS, detached by scraping, harvested and fixed in 4%
formaldehyde in PBS at room temperature for 15 min. After washing, cells can be permeabilized with 0.1%
saponin in PBS and incubated with blocking solution (PBS supplemented with 2%
FBS and 0.1% bovine serum albumin) for 20 min, at room temperature. Then, cells can be incubated for 1 h with mouse anti-Eastern Equine Encephalitis virus monoclonal antibody (Chemicon International, Millipore), which reacts with an El epitope shared by all alphaviruses. Then, cells can be washed and stained with anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen) for 30 min. The percentage of infected cells can be analyzed by FACScan Flow Cytometer and CellQuest software (Becton Dickinson).
Characterization of Cell Death Apoptosis/necrosis after infection can be quantified by a double staining method using The Vybrant Apoptosis Assay Kit#2 (Molecular Probes). After the infection period, RAW
264.7 cells can be washed with PBS, detached by scraping, harvested and stained with Annexin V Alexa Fluor 488 (0.5 jAg/ mL) and propidium iodide (PI, 0.25 lAg/mL). To further characterize MAYV-induced cell death, the activity of caspases 3 and 7 can be measured using the MuseTM
Caspase-3/7 Kit (Millipore) adapted to flow cytometry. Cells can be washed with PBS, detached by scraping, harvested and incubated with MuseTM Caspase-3/7 Reagent 1:8 and MuseTM
Caspase 7-AAD, according to the manufacturer's protocol. For both assays, the percentage of apoptotic and necrotic cells can be analyzed by FACScan Flow Cytometer using the CellQuest software (Bectan Dickinson). UV radiated cells and cells subjected to a freeze-thaw procedure can be used as controls.
Quantitation of Reactive Oxygen Species (ROS) The amount of intracellular reactive oxygen species (ROS) can be measured by the formation of the oxidized derivative of 5-(and 6-)-chloromethy1-2',T-dichlorodihydrofluorescein diacetate (DCF, Molecular Probes). After 15 h of infection with MAYV, adherent cells can be washed with PBS and incubated with DCF 0.5 [IM for 45 minutes.
Then, the cells can be washed again, detached by scraping and harvested and analyzed by FACScan Flow Cytometer using the CellQuest software (Bectan Dickinson).
Quantitation of Cytokines The concentrations of cytokines in the conditioned medium of macrophage cultures can be determined by ELISA. 'TNF concentration can be quantified using the Standard ELISA Development kit (PeproTech), according to the manufacturer's protocol Example 14 Yellow Fever Virus (YFV) Antiviral Activity Assay: Primary assay for antiviral activity A monolayer of Human Rhabdomyosarcoma (RD) cells will be grown in 96-well plate in MEM containing 2% inactivated FBS. The tested compounds will be added to the wells in triplicate together with YFV at an MOT= 1. The plate will then be incubated at 37 C with 5%
CO2 for 72 hours. The assay will be conducted in triplicate for each concentration of each compound. After three days, the plate will be viewed under the microscope and the degree of cytopathic effect (CPE) as measure of virus replication inhibition will be expressed as the percent yield of virus control. The results will be evaluated by performing the MTS assay (Promega, WI, USA) according to the manufacturer's protocols. All experiments will be repeated three times independently.
Focus forming unit reduction assay (FFURA) Antiviral activity of each compound will be determined by measuring the reduction in the number of YFV infectious foci in RD cells following treatment with increasing concentrations of each compound. Briefly, infected RD cells which will be treated with different concentrations of each compound will be incubated for 2 days post infection using conditioned-growth medium supplemented with 2% FBS and 1.5% carboxymethyl cellulose (CMC).
Antiviral activity of each compound will be determined after visualizing and counting viral foci.
The number of YFV foci will be counted using Elispot machine and the virus titer will be expressed as Foci Forming-Unit (FFU). Antiviral activities of the compounds will be determined by calculating the percentage of foci reduction (%RF) against the controls maintained in parallel using the following formula; RF (%) = (C-T) 100/C, where, C is the mean of the number of foci from triplicates treatment without compound added (vehicle control) and T is the mean of the number of foci from triplicates of each treatment measures with the respective compound. Results will represent as the means standard error of the mean (SEM) from triplicate assay from three independent experiments. Results were confirmed by virus yield reduction assay using quantitative RT-PCR.
Virus yield reduction assay Monolayers of RD cells will be prepared in 96-well cell culture microplate and overlaid with YFV (moi = 0.1) for 1 hour. After virus adsorption, cells will be washed 3 times with cold sterile PBS to remove unattached viruses and then the cells will be treated for 2 days with increasing concentrations of the tested compounds. After 2 days, the YFV RNA
will be extracted from the infected/treated cells and supernatant separately and the yield of YFV will quantified using a one-step specific quantitative RT-PCR for YFV.
Nevertheless, the antiviral activity of each nucleoside analogues will be investigated using focus forming unit reduction assay (FFURA) as described previously Time-of-drug-addition assay Confluent monolayers of RD cells will be prepared in 96-well cell culture plate and will be pre-treated with EC90 of each effective drug for 2 h before infection with YFV at MOI =1, concurrently with infection as well as 1, 2, 4 and 6 h post-infection. The cells will then be incubated in the presence of compound for 48 h. At the end of the incubation period, viral load for each time point of treatment will be determined using qRT-PCR as mentioned above.
Statistical analysis Graph Pad Prism for Windows, Version 5 (Graph Pad Software Inc., San Diego, CA, 2005) will be used to determine the half maximal effective concentration EC50 values and also EC90 of each effective compound. All ECso and EC90 values will be calculated as the means standard error of the mean (SEM) from triplicate assay from three independent experiments.
Example 15 HCV Rep/icon Assay]
Huh 7 Clone B cells containing HCV Replicon RNA can be seeded in a 96-well plate at 5000 cells/well, and the compounds tested at 10 iitM in triplicate immediately after seeding.
Following five days incubation (37 C, 5% CO2), total cellular RNA can be isolated by using versaGene RNA purification kit from Gentra. Replicon RNA and an internal control (TaqMan rRNA control reagents, Applied Biosystems) can be amplified in a single step multiplex Real Time RT-PCR Assay. The antiviral effectiveness of the compounds can be calculated by subtracting the threshold RT-PCR cycle of the test compound from the threshold RT-PCR cycle of the no-drug control (ACt HCV). A ACt of 3.3 equals a 1-log reduction (equal to 90% less starting material) in Replicon RNA levels. The cytotoxicity of the compounds can also be calculated by using the ACt rRNA values. 2'-C-Me-C can be used as the positive control. To determine EC90 and IC50 values, ACt: values can first be first converted into fraction of starting material and then can be used to calculate the % inhibition.
Example 16 Efficacy of the Compounds' Described Herein Against Dengue The essential role of a particular viral protein (Dengue virus envelope protein (E)) in viral propogation. Mondotte et al., J. Virol. July 2007, vol. 81 no. 13 7136-7148 discloses an assay useful for identifying compounds for treating infections caused by the Dengue virus, and this assay can be used to identify those compounds described herein which are active against Dengue.
Another assay is described in Levin, 14th International Symposium on Hepatitis C Virus & Related Viruses, Glasgow, UK, 9-13 September 2007. The assay relates to human and Dengue virus polymerase, where putative compounds can be tested against the enzymes, preferably in duplicate, over a range of concentrations, such as from U.S mM
to 100 mM. The compounds can also be run alongside a control (no inhibitor), a solvent dilution (0.016% to 2%
DMSO) and a reference inhibitor.
A suitable high throughput assay for Dengue is described in Lim et al., Antiviral Research, Volume 80, Issue 3, December 2008, Pages 360-369. Dengue virus (DENV) NS5 possesses methyltransferase (MTase) activity at its N-terminal amino acid sequence and is responsible for formation of a type 1 cap structure, m7GpppAm2'-0 in the viral genomic RNA.
Optimal in vitro conditions for DENV2 2'-0-MTase activity can be characterized using purified recombinant protein and a short biotinylated GTP-capped RNA template. Steady-state kinetics parameters derived from initial velocities can be used to establish a robust scintillation proximity assay for compound testing. Pre-incubation studies by Lim et al., Antiviral Research, Volume 80, Issue 3, December 2008, Pages 360-369, showed that MTase¨AdoMet and MTase¨
RNA complexes can be equally catalytically competent and the enzyme supports a random bi kinetic mechanism. Lim validated the assay with competitive inhibitory agents, S-adenosyl-homocysteine and two homologues, sinefungin and dehydrosinefungin. A GTP-binding pocket present at the N-terminal of DENV2 MTase can be previously postulated to be the cap-binding site. This assay allows rapid and highly sensitive detection of 2'-0-MTase activity, and can be readily adapted for high-throughput screening for inhibitory compounds.
Example 17 Atiti-Norovirus Activity Compounds can exhibit anti-norovirus activity by inhibiting norovirus polymerase and/or helicase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
There is currently no approved pharmaceutical treatment for Norovirus infection (http://www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus-qa.htm), and this has probably at least in part been due to the lack of availability of a cell culture system.
Recently, a replicon system has been developed for the original Norwalk G-I strain (Chang, K. 0., et al.
(2006) Virology 353:463-473).
Both Norovirus replicons and Hepatitis C replicons require viral helicase, protease, and polymerase to be functional in order for replication of the replicon to occur.
Most recently, an in vitro cell culture infectivity assay has been reported utilizing Norovirus genogroup I and II
inoculums (Straub, T. M. et al. (2007) Emerg. Infect. Dis. 13(3):396-403).
This assay is performed in a rotating-wall bioreactor utilizing small intestinal epithelial cells on microcarrier beads. The infectivity assay may be useful for screening entry inhibitors.
Diagnosis of Norovirus Infection One can diagnose a norovirus infection by detecting viral RNA in the stools of affected persons, using reverse transcription-polymerase chain reaction (RT-PCR) assays. The virus can be identified from stool specimens taken within 48 to 72 hours after onset of symptoms, although one can obtain satisfactory results using RT-PCR on samples taken as long as 7 days after the onset of symptoms. Other diagnostic methods include electron microscopy and serologic assays for a rise in titer in paired sera collected at least three weeks apart. There are also commercial enzyme-linked immunoassays available, but these tend to have relatively low sensitivity, limiting their use to diagnosis of the etiology of outbreaks.
Clinical diagnosis of norovirus infection is often used, particularly when other causative agents of gastroenteritis have been ruled out.
Example 18 Determining the Efficacy of the Compounds against ZIKV and DENT/Infection Material and methods for ZIKV and DENV (serotypes 1-4) infections assays:
Viruses: ZIKV PRVABC59 strain (NCBI accession KU501215) was obtained from the Centers for Diseases Control and Prevention. Virus stocks were generated on C6/36 or Vero cells and viral titers are determined by endpoint titration in Vero (African Green monkey kidney) or human cells, including neuroblastoma (U251), and hepatoblastoma (Huh7). DENV
stocks (kindly provided by Dr. Guey Chuen Perng (Emory University & National Cheng Kung University, Taiwan) were generated in Vero or Baby Hamster Kidney cells (BHK) (Clark et al., 2016).
Cytopathic-reduction assay for ZIKV or DENV: For the cytopathic-reduction assay, cells (Vero, U251 or Huh7) are seeded in 96-well plates at lx iO4 cells/well and incubated overnight. The next day, culture medium containing 50% cell culture infectious doses of ZIKV
or DENV (tested in Vero or BI-IK cells) are added after which 2-fold serial dilutions of the compounds are added. Cell cytopathic effect (CPE) is measured by MTS readout system (CellTiter 96 AQueous One Solution Proliferation kit, Promega) four (Vero) or five (U251 or Huh7) days after compound addition to determine the levels of ZIKV replication inhibition (Zmurko et al., 2016; Gavegnano et al., 2017). For DENV serotypes 1-4, CPE is measured four to five days after compound addition in Vero or BHK cells.
Focus formation assay: For the focus formation assay (FFA), Vero cells are routinely seeded in 96-well plates at 1.5x104 cells/well and incubated overnight. Next, culture medium containing 70-100 focus forming units of ZIKV or DENV (serotypes 1-4) plus 2-fold serial dilutions of the compounds are added to the cells and incubated for 2 h followed by the addition of overlay methylcellulose medium. Following 2-3 days of incubation, foci are stained using anti-Flavivirus group antigen (4G2, Millipore), followed by HRP-anti-mouse IgG
and TrueBlue substrate, and imaged using CTL-Immunospot S6 Micro Analyzer (Priyamvada et al., 2016).
Real-time RT-PCR assay: For the RT-PCR assays, Vero, U251, or Huh7 cells (15,000/well) are seeded in 96-well microplates, and cultured overnight prior to use for infections with ZIKV (MOI= 0.001 for Vero or M01-0.5 for U251 or Huh7) or DENV
(with MOI varying from 0.001 to 0.1 for different stocks of serotypes 1-4 for Vero cells). Compounds are added at a dose-dependent manner 1-2 h after ZIKV or DENV. After four days incubation, purified RNA are reverse transcribed into cDNA and amplified in a one-step RT-PCR multiplex reaction with LightCycler 480 RNA Master Hydrolysis Probe (Roche, Indianapolis, IN) using highly conserved sequences complementary to a 76 bp fragment from the ZIKV
envelope gene as previously described by Lanciotti (Lanciotti et al., 2008), and an endogenous control (TaqMan Ribosomal RNA Control or beta globin reagents; Applied Biosystems) by using the LightCycler 480 Instrument II (Roche). For detection of dengue viruses, we utilized oligonucleotides primers and probes serotype-specific that rapidly detects all four serotypes in a fourplex RT-PCR assay (Johnoson et al., 2005). For all virological tests, percent inhibition and EC50 value (compound concentration that inhibits viral antigen expression or viral replication by 50%) are determined using CalcuSyn software (Biosoft).
Combination studies for ZIKV or DENV.
One goal is to focus on compounds with sub-04 concentrations for hit to lead development, with cell selectivity index (SI) >100. Hit compounds that demonstrate antiviral potency with no apparent cytotoxicity can be selected for drug-drug combinations with compounds that exhibit different mechanism of action, including viral entry and host inhibitors, among others; These combinations can result in synergistic effects and optimal low doses to rapidly eliminate ZIKV or DENV from infected individuals.
One can use the Chou and Talalay method (Chou & Talalay 1984) for determining synergy, antagonism or additivity (Bassit et al., 2008; Schinazi et al., 2012), particularly with respect to combinations.
Material and methods for DENV2 (serotype 2) replicon assay:
Baby hamster kidney (BHK-21) stable cell lines expressing dengue virus serotype 2 [DENV2, New Guinea C strain, Qing et al., 2010)] was kindly provided by Mehul S. Suthar (Emory University).
DENV2 replicon-harboring baby hamster kidney (BHK) cells are exposed to test compounds at concentrations varying from 0.2 to 20 litM to assessment of antiviral activity.
Rendla luciferase levels (Promega) are quantified 48 hours after test compounds addition to determine the levels of replication inhibition (EC5o, [tM).
References 1. Clark, K.B., Hsiao, H.M., Bassit L., Crowe J.E. Jr., Schinazi R.F., Pemg G.C., Villinger F. Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells. Virology. 493, 162-72 (2016).
2. Zmurko, J., Marques, R. E., Schols, D., Verbeken, E., Kaptein, S. J. F.
& Neyts, J. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Neglected Tropical Diseases 10, e0004695, doi:10.1371/
journal.pntd.0004695 (2016).
3. Gavegnano C, Bassit LC, Cox BD, Hsiao H-M, Johnson EL, Suthar M, Chakraborty R, Schinazi RF. Jak inhibitors modulate production of replication-competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells. Pathogens &
immunity. 2, 199-218 (2017).
4. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan M J, Wilson PC, Ahmed R, Suthar MS, Wrammert J. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. PNAS 113, 7852-7857, (2016).
5. Lanciotti R, Kosoy 0, Laven J, Velez J, Lambert A, Johnson A, Stanfield S, Duffy M. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 14, 1232-1239 (2008).
6. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 43(10), 4977-4983 (2005).
7. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships:
the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22, 27-55 (1984).
8. Bassit L, Grier J, Bennett M, Schinazi RF. Combinations of 2'-C-methylcytidine analogues with interferon-a1pha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother. 19(1), 25-31 (2008).
9. Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother. 56(12), 6186-91 (2012).
10. Qing M, Liu W, Yuan Z et al., A high-throughput assay using dengue-1 virus like particles for drug discovery. Antiviral Res. 86(2), 163-71 (2010).
Example 19 MERS Assay Cells and Virus:
Human lung carcinoma cells (A-549) can be used for the primary antiviral assays and can be obtained from American Type Culture Collection (ATCC, Rockville, Md., USA). The cells can be passed in minimal essential medium (MEM with 0.15% NaCH03, Hyclone Laboratories, Logan, Utah, USA) supplemented with 10% fetal bovine serum. When evaluating compounds for efficacy, the serum can be reduced to a final concentration of 2%
and the medium can contain gentamicin (Sigma-Aldrich, St. Louis, Mo.) at 50 ittg/mL. Since the MERS-Co virus did not produce detectable virus cytopathic effects, virus replication in A549 cells can be detected by titering virus supernatant fluids from infected, compound-treated A549 cells in Vero 76 cells.
Vero 76 cells can be obtained from ATCC and can be routinely passed in MEM
with 0.15% NaCH03 supplemented with 5% fetal bovine serum. When evaluating compounds, the serum can be reduced to a final concentration of 2% and supplemented with 50 [tg/mL of gentamicin.
The Middle Eastern coronavirus strain EMC (MERS-CoV) was an original isolate from humans that was amplified in cell culture by Ron Fouchier (Erasmus Medical Center, Rotterdam, the Netherlands) and was obtained from the Centers for Disease Control (Atlanta, Ga.).
Controls:
Infergeng (interferon alfacon-1, a recombinant non-naturally occurring type-I
interferon (Blatt, L., et al., J. Interferon Cytokine Res. (1996) 16(7):489-499 and Alberti, A., BioDrugs (1999) 12(5):343-357) can be used as the positive control drug in all antiviral assays. Infergen=0.03 ng/mL.
Antiviral Assay:
Virus can be diluted in MEM to a multiplicity of infection=0.001 and each compound can be diluted in MEM+2% FBS using a half-log 8 dilution series. Compound can be added first to 96 well plates of confluent A549 cells followed within 5 mins by virus. Each test compound dilution can be evaluated for inhibition in triplicate. After plating, the plates can be incubated at 37 C. for 4 d. The plates can then be frozen at -80 C.
Virus Yield Reduction Assay:
Infectious virus yields from each well from the antiviral assay can be determined. Each plate from an antiviral assays can be thawed. Samples wells at each compound concentration tested can be pooled and titered for infectious virus by CPE assay in Vero 76 cells. The wells can be scored for CPE and virus titers calculated. A 90% reduction in virus yield can then be calculated by regression analysis. This represented a one log10 inhibition in titer when compared to untreated virus controls.
Example 20 VEEV Assay 96-well plates of HeLa-Ohio cells can be prepared and incubated overnight The plates can be seeded at 4 X 104 cells per well, which yields 90-100% confluent monolayers in each well after overnight incubation. The test compounds in DMSO can be started at a concentration of 100 jtM. 8-fold serial dilutions in MEM medium with 0.1% DMSO, 0% FBS, and 501.tg/mL
gentamicin with the test compound concentrations being prepared. To 5 test wells on the 96-well plate can be added 100 1.1L of each concentration and the plate can be incubated at 37 C
+5% CO2 for 2 h or 18 h. 3 wells of each dilution with the TC-83 strain Venezuelan equine encephalitis virus (ATCC, stock titer: 106.8 CCID50/mL) prepared in the medium as described above can be added. 2 wells (uninfected toxicity controls) can be added MEM
with no virus. 6 wells can be infected with untreated virus controls. To 6 wells can be added media only as cell controls. A blind, known active compound can be tested in parallel as a positive control. The plate can be incubated at 37 C +5% CO2 for 3 d. The plate can be read microscopically for visual CPE and a Neutral red dye plate can also be read using BIO-TEK
Instruments INC.
EL800. For virus yield reduction assays, the supernatant fluid can be collected from each concentration. The temperature can be held at -80 and each compound can be tested in triplicate. The CC50 can be determined by regression analysis using the CPE of toxicity control wells compared with cell controls. The virus titers can be tested in triplicate using a standard endpoint dilution CCID50 assay and titer calculations can be determined using the Reed-Muench (1948) equation. The concentration of compound required to reduce virus yield by 1 logto (90%) using regression analysis can be calculated (EC90 value). The concentration of compound required to reduce virus yield by 50% using regression analysis can be calculated (EC50 value).
Example 21 Rift Valley Fever Assay The compounds described herein can be tested for activity against Rift Valley Fever virus using methods known to those skilled in the art (e.g., described in Panchal et al., Antiviral Res. (2012) 93(1):23-29).
Example 22 Determining the Efficacy of the Compounds against HCoV-0C43 and SARS-CoV-2 Infections Viruses HCoV-0C43 was obtained from ATCC (Manasas, VA) and SARS-CoV-2 was provided by BET Resources (NR-52281: USA-WA/2020). HCoV-0C43 and SARS-CoV-2 were propagated in Huh-7 and Vero cells, respectively and titrated by TCID5o method followed by storage of aliquots at -80 C until further use.
Antiviral Activity Assay using Virus Yield Assay Method To determine the best time point for the virus yield assay, a kinetic replication of SARS-CoV-2 and HCoV-0C43 in Vero, Caco2, Calu3 and Huh-7 cells was performed, respectively, and the yield of progeny virus was assessed from the supernatant of viral infected cells at different interval time points using specific q-RT PCR for each virus as mentioned earlier. We determined that 48 and 72 h post-infection were the optimum time point for SARS-CoV-2 and HCoV-0C43, respectively, as there was no observed cell death and cytopathic effect (CPE) on infected cells and more importantly, significant increase in the virus RNA copy number which harvested from the supernatant of the infected cells were observed at that time for SARS-CoV-2 and also HCoV-0C43.
In the next step towards defining the antiviral activity of each compound, we have assessed the antiviral activity of each compound in a dose-dependent manner against SARS-CoV-2 and HCoV-0C43 using a virus yield inhibition assay by determining the viral RNA copy number in collected supernatants, compared to the results from infected but untreated cells, and non-infected and untreated cells as necessary controls. All experiments were performed in triplicate and each experiment repeated three times independently to achieve reliable and statistically meaningful results.
The median effective concentration (EC5o) and the concentration with 90% of inhibitory effect (EC90) were calculated using GraphPad PRISM for Mac, version (GraphPad Software Inc., San Diego, CA, 2005) and reported as the mean standard deviation (SD).
Table 1 Structures Anti-SARS-CoV-2 activity in Vero cells (1uM) EC5o ECoo NH
NL0 035 2.5 OH OH
rj(NH
, 0 N 0 <i OPh OH OH
N
HO NN N 0 <10 OH OH
rjk'IN
HO NN N 0 <10 HO OH
rijNH
'N 0 10 HO
OH OH
NH
'N 0 I 0 s,=k H OPh OH OH
NN
HO 6.0 15.2 OH OH
SH
NN
NN
HO 11.1 23.5 HO OH
/L-I
HO N 0 9.2 29.6 Me HO OH
I T.ji\i HO 7.6 28.8 1cL04.Me HO OH
O. 9 N - - - P - - <10 o H
<
( OH OH
F3C OMe HO NN' <10 OH OH
r-i-L NH
0 HO N <10 OH OH
)NH
N HO <10 NH
I
N, N0 <10 0 H oPh OH F
<10 r.**1.
, Bz0 NH
HONO
<10 eX
HO N 0 <10 slc- 0 ci Ci ,I14N
HO
) ¨
N
=
HOõ N N't; <10 0 jc--0 OH
NH2 <10 HO o OH OH
<10 'NH
'N
\ .1 0 <10 o o N o ), OPh HO OH
SP
0 <10 tk,0 HO, OH OH
o <10 .' -ANH
tsg I A, -- -Nilo OH OH
<-1 HOõ
) OH oH
NH2 <10 N
NN
,j HO
OH OH
NH2 <10 N
z N N
169,) OH OH
CI:
N
, N
2.3 6.5 N
pc.113 =
HO <10 >10 <li=-= 1 "NH
õ.õ1õ.
;1 0 HO, t >10 0 =
H oPh 1 NH2 > 1 0 HO N CI
CI
N N
I <10 HO NN CI
(;!
NN
u N CI >10
11 N-11L; N
<10 I
<10 zi z <10 0: 0 ^1.c.
Li CI <10 N
0 .3 0 N----NNr CI
NN
OH
<10 OH OH
HN
HO N <10 HO OH
HO
-HN N\
HO N <10 HO OH
HN)c,,F
O
0 H <10 OH OH
HO
HN
HO N <10 HO OH
HO
N
OH
<10 N
OH OH
H2N <10 N N
OH
N
OH OH
HS <10 OH
N
OH OH
0 <10 HO NO
F
NHOH
I N
N 1.2 8.7 HO
OH OH
o T 9.3 >10 HNPO
si 0 OH OH
I
N 0 0.4 3.6 HO
OH OH
NH
NO 2.5 <10 CI
OH OH
NH
HO
2.5 83.4 HO
)1'.1 1\111-1 10 HO
HO I N
NO
<1 0 (95%) co Remdesivir 1.2 3.6 Example 23 Enzymatic Evaluation of SARS-CoV-2 RNAdependent RNA Polymerase Inhibitors The severe acute respiratory syndrome¨coronavirus 2 (SARS-CoV-2) outbreak has caused a global coronavirus (COVID-19) pandemic. The RNA-dependent RNA
polymerase (RdRp), also known as n5p12, is a core component of the virus replication and transcription complex and handles the replication and transcription of viral RNA (Yi Jiang, et al., "RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19,"
Biochemical and Biophysical Research Communications, Volume 538, 2021, Pages 47-53).
RdRp also appears to be a primary target for the antiviral drug remdesivir.
COVID-19 virus nsp12 forms a complex with cofactors nsp7 and nsp8. Fig. 1 shows the structure of the COVID-19 virus nsp12-nsp7-nsp8 complex, including the domain organization of COVID-19 virus nsp12. The interdomain borders are labeled with residue numbers. The N-terminal portion with no cryo-EM map density and the C-terminal residues that cannot be observed in the map are not included in the assignment. The polymerase motifs are colored as follows: motif A, yellow; motif B, red; motif C, green; motif D, violet; motif E, cyan; motif F, blue; and motif G, light brown. This complex is disclosed in Gao et al., "Structure of the RNA-dependent RNA polymerase from COVID-19 virus," Science 368 (6492), (2020).
Fig. 2 is a schematic illustration of the structure of the N-tertninal NiRAN
domain and 13 hairpin of RdRp. The interacting residues in the palm and fingers subdomain of the Relltp domain and the NiRAN domain are identified by the labels.
Fig. 3 is a schematic illustration showing one embodiment of how an inhibitor triphosphate can interfere with RNA synthesis. An RNA polymerase is an enzyme that synthesizes RNA from a DNA template. As shown in Fig. 3, when a growing RNA
chain comes into contact with an RNA polymerase and a naturally-occurring nucleoside triphosphate, the RNA chain is extended. However, when an unnatural inhibitor triphosphate is present, there is an error when the RNA polymerase seeks to add the inhibitor triphosphate to the growing RNA
chain.
To measure the ability of modified nucleoside triphosphate inhibitors to disrupt RNA
synthesis, a 0.1 iirM RdRP complex (reconstituted from three individual nsp proteins) was prepared by mixing the three proteins, then incubating them on ice for 30 minutes.
The complex was buffered using 25mM Tris-HC1 (pH 8). To this buffered solution of the RdRP complex was added 50 pM of a 17-mer RNA primer and 1 !AM of a 43-mer RNA
template, and the solution was incubated on ice for around 15 minutes.
Once the complex was formed, 0.1 04 hot GTP was added, followed by addition of NTP mixtures (50 mM ATP, CTP and TTP; 25 mM GTP) to provide the nucleoside triphosphates needed for RNA synthesis. Then, either control (water) or an inhibitor triphosphate was added. Two inhibitor triphosphates were evaluated, namely, Remdesivir and frisNH
HO N, OH OH
The total reaction mixture, with a volume of around 10 pL, was maintained for 10 mins at 30 C, followed by addition of 5mM MnC12, then the mixture was maintained for 30 more mins at 30 C. The results of polymerase inhibition and/or inhibition of RNA
synthesis are shown in Figure 4.
rIANH
HO N,N,-L0 iCcL
As shown in Fig. 4, when either OH OH
or Remdesivir was added, RNA
synthesis was inhibited in a dosage dependent manner. At concentrations of 1, 10 and 100 pM, RNA synthesis was not significantly inhibited. However, significant inhibition was observed at concentrations of 250 and 500 RM. Because the virus does not typically persist for long periods of time, this level of drug concentration can be safely tolerated for the limited periods of time in which it is to be administered.
The present disclosure is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.
<10 I
<10 zi z <10 0: 0 ^1.c.
Li CI <10 N
0 .3 0 N----NNr CI
NN
OH
<10 OH OH
HN
HO N <10 HO OH
HO
-HN N\
HO N <10 HO OH
HN)c,,F
O
0 H <10 OH OH
HO
HN
HO N <10 HO OH
HO
N
OH
<10 N
OH OH
H2N <10 N N
OH
N
OH OH
HS <10 OH
N
OH OH
0 <10 HO NO
F
NHOH
I N
N 1.2 8.7 HO
OH OH
o T 9.3 >10 HNPO
si 0 OH OH
I
N 0 0.4 3.6 HO
OH OH
NH
NO 2.5 <10 CI
OH OH
NH
HO
2.5 83.4 HO
)1'.1 1\111-1 10 HO
HO I N
NO
<1 0 (95%) co Remdesivir 1.2 3.6 Example 23 Enzymatic Evaluation of SARS-CoV-2 RNAdependent RNA Polymerase Inhibitors The severe acute respiratory syndrome¨coronavirus 2 (SARS-CoV-2) outbreak has caused a global coronavirus (COVID-19) pandemic. The RNA-dependent RNA
polymerase (RdRp), also known as n5p12, is a core component of the virus replication and transcription complex and handles the replication and transcription of viral RNA (Yi Jiang, et al., "RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19,"
Biochemical and Biophysical Research Communications, Volume 538, 2021, Pages 47-53).
RdRp also appears to be a primary target for the antiviral drug remdesivir.
COVID-19 virus nsp12 forms a complex with cofactors nsp7 and nsp8. Fig. 1 shows the structure of the COVID-19 virus nsp12-nsp7-nsp8 complex, including the domain organization of COVID-19 virus nsp12. The interdomain borders are labeled with residue numbers. The N-terminal portion with no cryo-EM map density and the C-terminal residues that cannot be observed in the map are not included in the assignment. The polymerase motifs are colored as follows: motif A, yellow; motif B, red; motif C, green; motif D, violet; motif E, cyan; motif F, blue; and motif G, light brown. This complex is disclosed in Gao et al., "Structure of the RNA-dependent RNA polymerase from COVID-19 virus," Science 368 (6492), (2020).
Fig. 2 is a schematic illustration of the structure of the N-tertninal NiRAN
domain and 13 hairpin of RdRp. The interacting residues in the palm and fingers subdomain of the Relltp domain and the NiRAN domain are identified by the labels.
Fig. 3 is a schematic illustration showing one embodiment of how an inhibitor triphosphate can interfere with RNA synthesis. An RNA polymerase is an enzyme that synthesizes RNA from a DNA template. As shown in Fig. 3, when a growing RNA
chain comes into contact with an RNA polymerase and a naturally-occurring nucleoside triphosphate, the RNA chain is extended. However, when an unnatural inhibitor triphosphate is present, there is an error when the RNA polymerase seeks to add the inhibitor triphosphate to the growing RNA
chain.
To measure the ability of modified nucleoside triphosphate inhibitors to disrupt RNA
synthesis, a 0.1 iirM RdRP complex (reconstituted from three individual nsp proteins) was prepared by mixing the three proteins, then incubating them on ice for 30 minutes.
The complex was buffered using 25mM Tris-HC1 (pH 8). To this buffered solution of the RdRP complex was added 50 pM of a 17-mer RNA primer and 1 !AM of a 43-mer RNA
template, and the solution was incubated on ice for around 15 minutes.
Once the complex was formed, 0.1 04 hot GTP was added, followed by addition of NTP mixtures (50 mM ATP, CTP and TTP; 25 mM GTP) to provide the nucleoside triphosphates needed for RNA synthesis. Then, either control (water) or an inhibitor triphosphate was added. Two inhibitor triphosphates were evaluated, namely, Remdesivir and frisNH
HO N, OH OH
The total reaction mixture, with a volume of around 10 pL, was maintained for 10 mins at 30 C, followed by addition of 5mM MnC12, then the mixture was maintained for 30 more mins at 30 C. The results of polymerase inhibition and/or inhibition of RNA
synthesis are shown in Figure 4.
rIANH
HO N,N,-L0 iCcL
As shown in Fig. 4, when either OH OH
or Remdesivir was added, RNA
synthesis was inhibited in a dosage dependent manner. At concentrations of 1, 10 and 100 pM, RNA synthesis was not significantly inhibited. However, significant inhibition was observed at concentrations of 250 and 500 RM. Because the virus does not typically persist for long periods of time, this level of drug concentration can be safely tolerated for the limited periods of time in which it is to be administered.
The present disclosure is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.
Claims (117)
1. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (A) or Formula (A1) to a patient in need of treatment or prevention thereof:
4R1 iAL
p R Base R2 R5 y R3 R8 R8' Formula A
iA
Base R R4 R3 ___________________________________ R5' R8 Formul a A 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI is and R1A are, independently, H, CH3, CH3F, CHF2, or CF3, wherein, when RI
is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or R1 and R1A can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl;
R3 is H, substituted or unsubstituted Cl-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H , F , N 3 , substituted or unsubstituted (C1-8)alkyl, substituted or unsubstituted (C2-8)alkenyl, substituted or unsubstituted (C2-8)alkynyl, 0-(C1-8) alkyl and N3 when R5 is CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, R5 and le' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C242 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, R4 is OH, an optionally substituted 0-linked amino acid, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C142 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, 0-CH2-P-(OH)3, 0-CH2-P-(OH)3, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of R4, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
(a) ORI-' where R1' selected from the group consisting of H, OH
OH
-I=P.õ
OH
, Li, Na, K, substituted or unsubstituted C1-2oalkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C1-6 hal oalkyl, C2-3(alkyl)0C1_20a1kyl, aryl, and heteroaryl, such as phenyl and pyridinyl, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2R16 and (CH2)0.6 CON(R16)2;
where R16 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3.10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1_5 alkyl, or C1.5 alkyl substituted with a C1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
, 0 (h) the ester of a D- or L-amino acid R17 and R18 are independently H, C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1_20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C 1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1_5 alkyl, or C1_5 alkyl substituted with a C1-6alkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
Base is selected from the group consisting of:
Rg Rg Rg N
N
Xl X2 X kl'11.1,, , o N
R
N, N11,_ X2 , and jvivvs XI is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cycloalkyl, C-(C I-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-0R22, C-N(R22)2, C-halo, C-CN or N, X1' is CH, C-(CI-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH-,, hal o (i .e., F, Cl, Br, or I), SH, NHOH, 0(C1_10)alkyl, 0(C240)alkene, 0(C2_10)alkyne, 0(C34cycloalkyl, -0-C(0)-alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3,6 cycloalkyl, S(C1-0alkyl, S(C240)alkene, S(C240)alkyne, S(C3_7)cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((C1_10)alkyl)2, NH(C3_7)cycloalkyl, an optionally unsaturated NH(C0)(Ci_20)alkyl, an optionally unsaturated NH(C0)0(Ci_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(C1_20)alkyl, or an optionally unsaturated NHO(CO)NH(Ci_ 20)alkyl, (C1-3)alkyl, R9' is OH, NH2, SH, NHOH, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2_12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, oi -0-C(0)0-C3-6 cycloalkyl, Rth is H or F, X2' is N or CH, and W is 0 or S.
4R1 iAL
p R Base R2 R5 y R3 R8 R8' Formula A
iA
Base R R4 R3 ___________________________________ R5' R8 Formul a A 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI is and R1A are, independently, H, CH3, CH3F, CHF2, or CF3, wherein, when RI
is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or R1 and R1A can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl;
R3 is H, substituted or unsubstituted Cl-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H , F , N 3 , substituted or unsubstituted (C1-8)alkyl, substituted or unsubstituted (C2-8)alkenyl, substituted or unsubstituted (C2-8)alkynyl, 0-(C1-8) alkyl and N3 when R5 is CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, R5 and le' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C242 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, R4 is OH, an optionally substituted 0-linked amino acid, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C142 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, 0-CH2-P-(OH)3, 0-CH2-P-(OH)3, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of R4, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
(a) ORI-' where R1' selected from the group consisting of H, OH
OH
-I=P.õ
OH
, Li, Na, K, substituted or unsubstituted C1-2oalkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C1-6 hal oalkyl, C2-3(alkyl)0C1_20a1kyl, aryl, and heteroaryl, such as phenyl and pyridinyl, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2R16 and (CH2)0.6 CON(R16)2;
where R16 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3.10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1_5 alkyl, or C1.5 alkyl substituted with a C1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
, 0 (h) the ester of a D- or L-amino acid R17 and R18 are independently H, C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1_20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C 1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1_5 alkyl, or C1_5 alkyl substituted with a C1-6alkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
Base is selected from the group consisting of:
Rg Rg Rg N
N
Xl X2 X kl'11.1,, , o N
R
N, N11,_ X2 , and jvivvs XI is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cycloalkyl, C-(C I-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-0R22, C-N(R22)2, C-halo, C-CN or N, X1' is CH, C-(CI-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH-,, hal o (i .e., F, Cl, Br, or I), SH, NHOH, 0(C1_10)alkyl, 0(C240)alkene, 0(C2_10)alkyne, 0(C34cycloalkyl, -0-C(0)-alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3,6 cycloalkyl, S(C1-0alkyl, S(C240)alkene, S(C240)alkyne, S(C3_7)cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((C1_10)alkyl)2, NH(C3_7)cycloalkyl, an optionally unsaturated NH(C0)(Ci_20)alkyl, an optionally unsaturated NH(C0)0(Ci_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(C1_20)alkyl, or an optionally unsaturated NHO(CO)NH(Ci_ 20)alkyl, (C1-3)alkyl, R9' is OH, NH2, SH, NHOH, -0-C(0)-Ci-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2_12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, oi -0-C(0)0-C3-6 cycloalkyl, Rth is H or F, X2' is N or CH, and W is 0 or S.
2. The method of Claim 1, wherein R5 is O.
3. The method of Claim 2, wherein R2 is H or substituted or unsubstituted C2-8alkynyl.
4. The method of Claim 1, wherein R3 is H.
5. The method of Claim 1, wherein Rl is and R1A are H.
6. The method of Claim 1, wherein R8 and R8' are OH.
7. The method of Claim 1, wherein R4 is OH or 0-P(0)R6R7.
R9' Rloy XNW
R9' Rloy XNW
8. The method of Claim 1, wherein Base is avini
9. The method of Claim 8, wherein R9' is OH, NH2, or NHOH
Xi,D
N
I
Xi,D
N
I
10. The method of Claim 1, wherein Base is sAfr's
11. The method of Claim 10, wherein X2 is NH2, OH or SH.
12. A method for treating or preventing a Coronayiridae, Flayiyiridae, Picornayiridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (B) or (B1) to a patient in need of treatment or prevention thereof:
Ri 1 0 R._A Base R
D'P'O R8' Formula B
RiA 0 Base R3 ___________________________ RN2 \NNNN A
R /
R8' Formula BI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RI-, RiA, R2, R3, lc ¨55 and R'are as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR' where R1-5 is selected from the group consisting of H, substituted or unsubstituted Cl.20alkyl, substituted or unsubstituted C3.6cycloalkyl, C1.4(alkyl)aryl, benzyl, Cl-6 haloalkyl, C2-3(alkyl)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyridinyl, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0_6CO2R1-6 and (CH2)0.6 CON(R1-6)2;
,0 (b) the ester of a D- or L-amino acid , R17 and Ri8 are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(Ci-óalkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a Cl-óalkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3.10 cycloalkyl, or cycloalkyl; and =
(c) where R3 is selected from the group consisting of substituted or unsubstituted Cl-2oalkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2.1o)alkene, substituted or unsubstituted (C2.10)alkyne, C1-4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
Ri 1 0 R._A Base R
D'P'O R8' Formula B
RiA 0 Base R3 ___________________________ RN2 \NNNN A
R /
R8' Formula BI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RI-, RiA, R2, R3, lc ¨55 and R'are as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR' where R1-5 is selected from the group consisting of H, substituted or unsubstituted Cl.20alkyl, substituted or unsubstituted C3.6cycloalkyl, C1.4(alkyl)aryl, benzyl, Cl-6 haloalkyl, C2-3(alkyl)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyridinyl, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0_6CO2R1-6 and (CH2)0.6 CON(R1-6)2;
,0 (b) the ester of a D- or L-amino acid , R17 and Ri8 are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(Ci-óalkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a Cl-óalkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3.10 cycloalkyl, or cycloalkyl; and =
(c) where R3 is selected from the group consisting of substituted or unsubstituted Cl-2oalkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2.1o)alkene, substituted or unsubstituted (C2.10)alkyne, C1-4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
13. The method of Claim 12, wherein R5 is O.
14. The method of Claim 12, wherein R2 is H or substituted or unsubstituted C2-8 alkynyl.
15. The method of Claim 12, wherein R3 is H.
16. The method of Claim 12, wherein R8' is OH.
17. The method of Claim 12, wherein Y is H.
18. The method of Claim 12, wherein RI and RIA are H.
19. The method of Claim 12, wherein A is O.
20. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (C) or (C1) to a patient in need of treatment or prevention thereof:
X
R1 1A N, R5 v v -'17( R3 Formula C
X
N
Rit R1 /LW
_________________________________________________________ R2 R8' R8 Formula C1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, RI-, RiA., R2, ¨3, R5, Rg, Rg' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-Cl-12 alkyl, -0-C(0)-C2-12alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
X
R1 1A N, R5 v v -'17( R3 Formula C
X
N
Rit R1 /LW
_________________________________________________________ R2 R8' R8 Formula C1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, RI-, RiA., R2, ¨3, R5, Rg, Rg' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-Cl-12 alkyl, -0-C(0)-C2-12alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
21. The method of Claim 20, wherein R5 is O.
22. The method of Claim 20, wherein R2 is H or substituted or unsubstituted C2-alkynyl.
23. The method of Claim 20, wherein R3 is H.
24. The method of Claim 20, wherein Rg and Rg' are OH.
25. The method of Claim 20, wherein Y is H.
26. The method of Claim 20, wherein R is H.
27. The method of Claim 20, wherein Z is H.
28. The method of Claim 20, wherein X is OH, NH2 or NHOH.
29. The method of Claim 20, wherein W is O.
30. The method of Claim 20, wherein RI- and RIA are H.
31. The method of Claim 20, wherein R4 is OH or 0-P(0)R6R7.
32. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (3) or (131) to a patient in need of treatment or prevention thereof:
X
ZR
A
-17(.R3 Formula D
X
Z
vv R3 \
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, Rl, RiA, R2, R3, R5, Rs' and Y are as defined in Formula A, and A and D are as defined in Formula C.
X
ZR
A
-17(.R3 Formula D
X
Z
vv R3 \
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, Rl, RiA, R2, R3, R5, Rs' and Y are as defined in Formula A, and A and D are as defined in Formula C.
33. The method of Claim 32, wherein R5 is O.
34. The method of Claim 32, wherein R2 is H or substituted or unsubstituted C2-alkynyl.
35. The method of Claim 32, wherein R3 is H.
36. The method of Claim 32, wherein -128' is OH
37. The method of Claim 32, wherein Y is H.
38. The method of Claim 32, wherein R is H.
39. The method of Claim 32, wherein Z is H.
40. The method of Claim 32, wherein X is OH, NH2 or NHOH.
41. The method of Claim 32, wherein W is O.
42. The method of Claim 32, wherein RI- and RIA are H.
43. The method of Claim 32, wherein R4 is OH or 0-P(0)R6R7.
44. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (E) or (El) to a patient in need of treatment or prevention thereof:
At R1 R R1A Base ico 47R3R23 Formula E
Base R
Formula E1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, R1, R1A, R2, R3,and R4 are as defined in Formula A, R30 is O or CH7, R31 is O or S, R31 is O when R30 is S, and R32 and R33 are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
At R1 R R1A Base ico 47R3R23 Formula E
Base R
Formula E1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, R1, R1A, R2, R3,and R4 are as defined in Formula A, R30 is O or CH7, R31 is O or S, R31 is O when R30 is S, and R32 and R33 are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
45. The method of Claim 44, wherein R30 is O.
46. The method of Claim 44, wherein R31 is O.
47. The method of Claim 44, wherein R32 and R33 are, independently, H or F.
48. The method of Claim 44, wherein R3 is H.
49. The method of Claim 44, wherein R2 is N3 or substituted or unsubstituted alkynyl.
50. The method of Claim 44, wherein R1 and R1A are H.
51. The method of Claim 44, wherein R4 is OH or or O-P(O)R6R7.
X
X
52. The method of Claim 44, wherein Base is
53. The method of Claim 52, wherein Xl is N.
54. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (F) or (F1) to a patient in need of treatment or prevention thereof:
R4pR iA
base ¨
R2ç
Formula F
RiA
Base R3 ____________________________________ Formula Fl or a pharmaceutically acceptable salt or prodnig thereof, wherein.
Base, Rl, RiA, R2, 3, _I( ¨and R4 are as defined in Formula A, R34 is 0 or CH2, and R35 and R36 are independently H, F or CH3.
R4pR iA
base ¨
R2ç
Formula F
RiA
Base R3 ____________________________________ Formula Fl or a pharmaceutically acceptable salt or prodnig thereof, wherein.
Base, Rl, RiA, R2, 3, _I( ¨and R4 are as defined in Formula A, R34 is 0 or CH2, and R35 and R36 are independently H, F or CH3.
55. The method of Claim 54, wherein R35 and R36 are H.
56. The method of Claim 54, wherein R34 is CH2.
57. The method of Claim 54, wherein R4 is OH or or 0-P(0)R6R7.
58. The method of Claim 54, wherein wherein R3 is H.
59. The method of Claim 54, wherein R2 is H or substituted or unsubstituted C2-alkynyl.
60. The method of Claim 54, wherein R1 and RIA are H.
61. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound having one of the following formulas to a patient in need of treatment or prevention thereof:
rrA-NH )-0 rrILNH
rLs N
0 HNI-P-0--_ IV, N-N --Lo HO --.3 N 0 (c) A
OPh OH OH OH OH OH OH
, , , ilAsNH N,1 N
HO---30 NN- ..Ls HO-- NNS HO---- NNO
(1 (31 OH OH OH OH OH OH
, , , HN-OH
r\,1 if-A-NH rfANH
HO-- N,N,...S HO, NNO HO, N ,N.-LO
C:c 0 ------- _____________________________________________________________ ----F
OH OH OH F OH F
riLNH 1)(NH (j-LNH
, N, N L O HO, N
0 'N'-0 HO HO-irliN-OH OH OH OH OH
rliNH Y
(111 N,N0 N,N0 HO-14N- HO---- HO-14!
OH OH OH OH OH OH
, (ILNH
HO, N,N,--.0 c--0--) ' N NN
) HO C TN , ) 5C--1:
_.-N,N-J f) --,N.--LNH2 /1 ($
, FICYOH , HCI:T-r0H
, 1-10-FOH
NN C----rj-N
C-1-'---L'N
HO H2c40 \ N-NN
HO N'e N% NH2 /HC177)1-1 HO OH / HO
OH
1 yH 1 Id I 11 HO--- NO Bz0-, N 0 1-10---- N 0 , , N......----,N )..
HO 1 J, N - HO N ---' N HO N 0 C14.Me OH OH HO OH HO OH
, CI
HO N ---"-- N'' t Me ,..,-------,, HO OH
CI CI
N
' N
I ,,L
____. 0z 0 N ---- Nr CI
'===--w :,,...,--- -...., / O
A A, CI
CI
N --,/L. N
l ,<.1\1.. i HO 1\1--- CI õN.., 0--==,. ------,N<:-------,..0 I
0 0 , or , N-----LN
HO-A______ ci___ N C I
0 , or a pharmaceutically acceptable salt or prodrug thereof.
rrA-NH )-0 rrILNH
rLs N
0 HNI-P-0--_ IV, N-N --Lo HO --.3 N 0 (c) A
OPh OH OH OH OH OH OH
, , , ilAsNH N,1 N
HO---30 NN- ..Ls HO-- NNS HO---- NNO
(1 (31 OH OH OH OH OH OH
, , , HN-OH
r\,1 if-A-NH rfANH
HO-- N,N,...S HO, NNO HO, N ,N.-LO
C:c 0 ------- _____________________________________________________________ ----F
OH OH OH F OH F
riLNH 1)(NH (j-LNH
, N, N L O HO, N
0 'N'-0 HO HO-irliN-OH OH OH OH OH
rliNH Y
(111 N,N0 N,N0 HO-14N- HO---- HO-14!
OH OH OH OH OH OH
, (ILNH
HO, N,N,--.0 c--0--) ' N NN
) HO C TN , ) 5C--1:
_.-N,N-J f) --,N.--LNH2 /1 ($
, FICYOH , HCI:T-r0H
, 1-10-FOH
NN C----rj-N
C-1-'---L'N
HO H2c40 \ N-NN
HO N'e N% NH2 /HC177)1-1 HO OH / HO
OH
1 yH 1 Id I 11 HO--- NO Bz0-, N 0 1-10---- N 0 , , N......----,N )..
HO 1 J, N - HO N ---' N HO N 0 C14.Me OH OH HO OH HO OH
, CI
HO N ---"-- N'' t Me ,..,-------,, HO OH
CI CI
N
' N
I ,,L
____. 0z 0 N ---- Nr CI
'===--w :,,...,--- -...., / O
A A, CI
CI
N --,/L. N
l ,<.1\1.. i HO 1\1--- CI õN.., 0--==,. ------,N<:-------,..0 I
0 0 , or , N-----LN
HO-A______ ci___ N C I
0 , or a pharmaceutically acceptable salt or prodrug thereof.
62. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of one of the following formulas to a patient in need of treatment or prevention thereof:
SH
0 NH2 N-.../L, NH /pl.¨A.-, N
I )N
HO--.. N,N.,=.0 _I J
Haw ---..õ..-., HO N----- N--..
-,..
() CL4 OH OH OH OH HO OH
, CI
e__LN
- -,:-0 N----)z--. N
N
HO HO V N''' or CI
N
M e HO OH HO OH , 0 , , or a pharmaceutically-acceptable salt or prodrug thereof.
SH
0 NH2 N-.../L, NH /pl.¨A.-, N
I )N
HO--.. N,N.,=.0 _I J
Haw ---..õ..-., HO N----- N--..
-,..
() CL4 OH OH OH OH HO OH
, CI
e__LN
- -,:-0 N----)z--. N
N
HO HO V N''' or CI
N
M e HO OH HO OH , 0 , , or a pharmaceutically-acceptable salt or prodrug thereof.
63. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of one of the following formulas to a patient in need of treatment or prevention thereof:
(11 z- CI j 'NH
-A-, N 0 -....
H 0,, N-P-0, g 121N-P-0-. N 0 ..,_ 0 0 u ,.....c_ OH OH OH OH OH OH
NHOH
0 HO,NH
.)-k-" I-1 N 0 N ''.-.0 ------"'"---'N
CA. NH
H 0 ( H_O),c) .._... 0 HO, NJ .., ''''' '''''0 HO., N 0 CI \ __________ i OH OH OH OH
, HO, N 0 , or a pharmaceutically-acceptable salt or prodrug thereof.
(11 z- CI j 'NH
-A-, N 0 -....
H 0,, N-P-0, g 121N-P-0-. N 0 ..,_ 0 0 u ,.....c_ OH OH OH OH OH OH
NHOH
0 HO,NH
.)-k-" I-1 N 0 N ''.-.0 ------"'"---'N
CA. NH
H 0 ( H_O),c) .._... 0 HO, NJ .., ''''' '''''0 HO., N 0 CI \ __________ i OH OH OH OH
, HO, N 0 , or a pharmaceutically-acceptable salt or prodrug thereof.
64. The method of any of Claims 1-63, wherein the compounds can be present in the13-D or p-L configuration.
65. The method of any of Claims 1-63, wherein the virus is a Coronavirus.
66. The method of Claim 64, wherein the Coronavirus is SARS-CoV2, MERS, SARS, or OC-43.
67. The method of Claim 66, wherein the Coronavirus is SARS-CoV2.
68. The method of any of Claims 1-63, wherein the compound is co-administered with one or more additi on al active compounds sel ected from the group con si sting of fusi on inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, and agents of distinct or unknown mechanism.
69. The method of Claim 68, wherein the compound is administered with remdesivir, N-hydroxy cytidine, or a pharmaceutically-acceptable salt or prodrug thereof
70. The method of Claim 68, wherein the additional active compound is a JAK
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
71. The method of Claim 68, wherein the one or more additional active agents comprise an anticoagulant or a platelet aggregation inhibitor.
72. The method of Claim 68, wherein the one or more additional active agents comprise an ACE-2 inhibitor, a CYP-450 inhibitor, or NOX inhibitor.
73. The use of a compound of any of Claims 1-63 in the preparation of a medicament for use in treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection.
74. The use of Claim 73, wherein the infection is a Coronaviridae infection.
75. The use of Claim 74, wherein the Coronavirus is SARS-CoV2, MERS, SARS, or OC-43.
76. The use of Claim 74, wherein the Coronavirus is SARS-CoV2.
77. The use of Claim 73, wherein the medicament further comprises one or more additional active compounds selected from the group consisting of fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, and agents of di stinct or unknown m ech an i sm .
78. The use of Claim 73, wherein the medicament further comprises remdesivir, N-hydroxy cytidine, or a pharmaceutically-acceptable salt or prodrug thereof.
79. The use of Claim 73, wherein the medicament further comprises a JAK
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a phatmaceutically-acceptable salt or prodrug thereof
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a phatmaceutically-acceptable salt or prodrug thereof
80. The use of Claim 73, wherein the medicament further comprises an anticoagulant or a platelet aggregation inhibitor.
81. The use of Claim 73, wherein the medicament further comprises an ACE-2 inhibitor, a CYP-450 inhibitor, or a NOX inhibitor.
82. The use of Claim 73, wherein the medicament is is a transdermal composition or a n an oparti cul ate compositi on .
83. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (A) or Formula (A1) to a patient in need of treatment or prevention thereof:
R4 R1 RlA
Base R5 .õ..LR3 R8 R8' Formula A
Base RiA
R3 ____________________________________________________ R2 R8' R8 Formula A1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R' is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI- is and RI-A are, independently, H, CH3, CH7F, CHF2, or CF3, wherein, when RI- is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or RI- and RI-A can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl, R3 is H, substituted or unsubstituted Ci-s alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H , F , N 3 , substituted or unsubstituted (Ci-s)alkyl, substituted or unsubstituted (C2-s)alkenyl, substituted or unsubstituted (C2-s)alkynyl, 0-(C 1-s) alkyl and N3 when R5 is CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C¨CF2 or C¨CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, le and le' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-Ci -12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1_12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2_12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, le is OH, an optionally substituted 0-linked amino acid, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, 0-CH2-P-(OH)3, 0-CH2-P-(OH)3, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of le, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
' OH
(a) OR' where R15 selected from the group consisting of H, OH
1i II: OH
-P
' 1 0 OH
OH
, Li, Na, K, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C1-6 haloalkyl, C2-3(alkyl)0C1.2palkyl, aryl, and heteroaryl, such as ph eny 1 an d py ri di ny 1, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2106 and (CH2)0-6 CON(R1-6)2;
where R16 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.70 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1_5 alkyl substituted with a C1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
Fi17 -N
(b) the ester of a D- or L-amino acid R17 and R18 are independently H, C1.20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C 1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1-6alkyl, al koxy, di (C1-6alkyl )-ami no, fluoro, C3_10 cycl oal kyl , or cycl oal kyl ;
HN
X
Base is is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cycloalkyl, C-(CI-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-0R22, C-N(R22)2, C-halo, C-CN or N, X1' is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH2, hal o (i . e F , Cl, Br, or I), SH, NHOH, 0(C1.10)alkyl, 0(C2.10)alkene, 0(C2.10)alkyne, 0(C3.7)cycloalkyl, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, S(C1-S(C2.10)alkene, S(C2.10)alkyne, S(C34cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((C1_10)alkyl)2, NH(C3.7)cycloalkyl, an optionally unsaturated NH(C0)(Ci_20)alkyl, an optionally unsaturated NH(C0)0(Ci_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(C1.20)alkyl, or an optionally unsaturated NHO(CO)NH(C1_ 20)alkyl, (C1-3)alkyl, R9' is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, is H or F, X2' is N or CH, and W is 0 or S.
R4 R1 RlA
Base R5 .õ..LR3 R8 R8' Formula A
Base RiA
R3 ____________________________________________________ R2 R8' R8 Formula A1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Y and R are, independently, selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R' is independently a -C(0)-C1-12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1-12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2-12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, RI- is and RI-A are, independently, H, CH3, CH7F, CHF2, or CF3, wherein, when RI- is Me, the carbon to which it is attached may be wholly or partially R or S or any mixture thereof, or RI- and RI-A can combine to form a C3-7 cycloalkyl ring;
R2 is H, CN, N3, F, CH2-halogen, CH2-N3, 0-CH2-P-(OH)3, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl or substituted or unsubstituted C2-8 alkynyl, R3 is H, substituted or unsubstituted Ci-s alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, or N3 when R5 is 0, and R3 is selected from the group consisting of H , F , N 3 , substituted or unsubstituted (Ci-s)alkyl, substituted or unsubstituted (C2-s)alkenyl, substituted or unsubstituted (C2-s)alkynyl, 0-(C 1-s) alkyl and N3 when R5 is CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C¨CF2 or C¨CH2, R5 is 0, CH2, Se, CHF, CF2, -C(CH3)-, -C(cyclopropyl)-, C=CF2 or C=CH2, le and le' are independently selected from the group consisting of H, OH, halo, an optionally substituted 0-linked amino acid, substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-alkynyl, substituted or unsubstituted C3-6 cycloalkyl, cyano, cyanoalkyl, azido, azidoalkyl, OR', SR', wherein each R is independently a -C(0)-Ci -12 alkyl, -C(0)-C2-12 alkenyl, -C(0)-C2-12 alkynyl, -C(0)-C3-6 cycloalkyl, -C(0)0-C1_12 alkyl, -C(0)0-C2-12 alkenyl, -C(0)0-C2_12 alkynyl, -C(0)0-C3-6 cycloalkyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of halogen (fluoro, chloro, bromo or iodo), hydroxyl, amino, alkylamino, arylamino, alkoxy, nitro, and cyano, le is OH, an optionally substituted 0-linked amino acid, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, 0C1-6 alkyl, 0C1-6 haloalkyl, 0C1-6 alkoxy, 0C2-6 alkenyl, 0C2-6 alkynyl, 0C3-6 cycloalkyl, 0-P(0)R6R7, 0-CH2-P-(OH)3, 0-CH2-P-(OH)3, or a mono-, di-, or triphosphate, wherein, when chirality exists at the phosphorous center of le, it may be wholly or partially Rp or Sp or any mixture thereof, R6 and R7 are independently selected from the group consisting of:
' OH
(a) OR' where R15 selected from the group consisting of H, OH
1i II: OH
-P
' 1 0 OH
OH
, Li, Na, K, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C1-6 haloalkyl, C2-3(alkyl)0C1.2palkyl, aryl, and heteroaryl, such as ph eny 1 an d py ri di ny 1, wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH2)0.6CO2106 and (CH2)0-6 CON(R1-6)2;
where R16 is independently H, substituted or unsubstituted C1_20 alkyl, the carbon chain derived from a fatty alcohol or C1.70 alkyl substituted with a C1-6 alkyl, C1-6 alkoxy, di(C1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, cycloalkyl- C1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1_5 alkyl substituted with a C1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl;
Fi17 -N
(b) the ester of a D- or L-amino acid R17 and R18 are independently H, C1.20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C 1-6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1-6alkyl, al koxy, di (C1-6alkyl )-ami no, fluoro, C3_10 cycl oal kyl , or cycl oal kyl ;
HN
X
Base is is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-(C3-7)cycloalkyl, C-(CI-6) haloalkyl, C-(C1-6)hydroxyalkyl, C-0R22, C-N(R22)2, C-halo, C-CN or N, X1' is CH, C-(C1-6)alkyl, C-(C2-6)alkenyl, C-(C2-6)alkynyl, C-halo, C-CN or N
R9 and X2 are independently H, OH, NH2, hal o (i . e F , Cl, Br, or I), SH, NHOH, 0(C1.10)alkyl, 0(C2.10)alkene, 0(C2.10)alkyne, 0(C3.7)cycloalkyl, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-12 alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, -0-C(0)0-C3-6 cycloalkyl, S(C1-S(C2.10)alkene, S(C2.10)alkyne, S(C34cycloalkyl, an optionally unsaturated NH(C1-10)alkyl, an optionally unsaturated N((C1_10)alkyl)2, NH(C3.7)cycloalkyl, an optionally unsaturated NH(C0)(Ci_20)alkyl, an optionally unsaturated NH(C0)0(Ci_20)alkyl, NHOH, an optionally unsaturated NHO(C0)(C1.20)alkyl, or an optionally unsaturated NHO(CO)NH(C1_ 20)alkyl, (C1-3)alkyl, R9' is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, is H or F, X2' is N or CH, and W is 0 or S.
84. The method of Claim 83, wherein R5 is 0, R2 is H or substituted or unsubstituted C2-g alkynyl, R5 is H, R1 is and RiA are H, le and R8' are OH, R4 is OH or 0-P(0)R6R7, R9' is OH, NH2, or NHOH, and/or X2 is NH2, OH or SH.
85. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (B) or (B1) to a patient in need of treatment or prevention thereof:
0 RA Base A ZZR2----y R3 p 0 R8' Formula B
Base 0 R3 ____________________________________________________________ A
R
R8' Formul a B1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RiA, R2, R3, ¨5, and R'are as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR' where RI' is selected from the group consisting of H, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C 1-6 haloalkyl, C2-3(alky1)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH7)0_6CO7R16 and (CH40,6 CON(R16)2;
RI?
r OR16' (b) the ester of a D- or L-amino acid , R17 and Rig are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1_6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1-6alkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl; and Sõ R 3 ( c) 0 where R3' is selected from the group consisting of substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2.10)alkene, substituted or unsubstituted (C2_10)alkyne, C1_4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
0 RA Base A ZZR2----y R3 p 0 R8' Formula B
Base 0 R3 ____________________________________________________________ A
R
R8' Formul a B1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, Y, R, RiA, R2, R3, ¨5, and R'are as defined in Formula A, A is 0 or S, and D is selected from the group consisting of:
(a) OR' where RI' is selected from the group consisting of H, substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6cycloalkyl, C1-4(alkyl)aryl, benzyl, C 1-6 haloalkyl, C2-3(alky1)0C1_20 alkyl, aryl, and heteroaryl, such as phenyl and pyri di nyl , wherein aryl and heteroaryl are optionally substituted with zero to three substituents independently selected from the group consisting of (CH7)0_6CO7R16 and (CH40,6 CON(R16)2;
RI?
r OR16' (b) the ester of a D- or L-amino acid , R17 and Rig are independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1.20 alkyl optionally substituted with a C1-6 alkyl, alkoxy, di(C1-6alkyl)- amino, fluoro, C3_10 cycloalkyl, cycloalkyl-C1_6 alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl;
wherein the substituents are C1.5 alkyl, or C1.5 alkyl substituted with a C1-6alkyl, alkoxy, di(C1-6alkyl)-amino, fluoro, C3_10 cycloalkyl, or cycloalkyl; and Sõ R 3 ( c) 0 where R3' is selected from the group consisting of substituted or unsubstituted C1-20alkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted (C2.10)alkene, substituted or unsubstituted (C2_10)alkyne, C1_4(alkyl)aryl, aryl, heteroaryl, and C1-6 haloalkyl.
86. The method of Claim 85, wherein R5 is 0, R2 is H or substituted or unsubstituted C2-8 alkynyl, R3 is H, Rg' is OH, Y is H, RI- and RI-A are H, and/or A is O.
87. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (C) or (C1) to a patient in need of treatment or prevention thereof:
X
R1 1A N, R
YrC3 R2 __________________________________________________ W
R8 R8' Formula C
X
___________________________________________________________ R1A
_________________________________________________________ R2 R8' R8 Formula CI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, R1A, 2, K R3, R5, R8, R8' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
X
R1 1A N, R
YrC3 R2 __________________________________________________ W
R8 R8' Formula C
X
___________________________________________________________ R1A
_________________________________________________________ R2 R8' R8 Formula CI
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R, R1A, 2, K R3, R5, R8, R8' and Y are as defined in Formula A, X is OH, NH2, SH, NHOH, -0-C(0)-C1-12 alkyl, -0-C(0)-C2-12 alkenyl, -0-C(0)-C2-alkynyl, -0-C(0)-C3-6 cycloalkyl, -0-C(0)0-C1-12 alkyl, -0-C(0)0-C2-12 alkenyl, -0-C(0)0-C2-12 alkynyl, or -0-C(0)0-C3-6 cycloalkyl, Z is H or F, and W is 0 or S.
88. The method of Claim 87, wherein R5 is 0, R2 is H or substituted or unsubstituted C244 alkynyl, le is H, R8 and R8. are OH, Y is H, R is H, Z is H, X is OH, NH2 or NHOH, W
is 0, RI- and RI-A are H, and/or R4 is OH or 0-P(0)R6R7.
is 0, RI- and RI-A are H, and/or R4 is OH or 0-P(0)R6R7.
89. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (D) or (D1) to a patient in need of treatment or prevention thereof:
X
A ZR2 __ R _________________________________________________ p 0 R8' 1=3( Formula D
X
N
N N w \ /A
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, R3, RiA, R2, R3, R5, R8' and Y are as defined in Formula A, and A and D are as defined in Formula C.
X
A ZR2 __ R _________________________________________________ p 0 R8' 1=3( Formula D
X
N
N N w \ /A
Formula D1 or a pharmaceutically acceptable salt or prodrug thereof, wherein R, R3, RiA, R2, R3, R5, R8' and Y are as defined in Formula A, and A and D are as defined in Formula C.
90. The method of Claim 89, wherein R5 is 0, R2 is H or substituted or unsubstituted C2-8 alkynyl, R3 is H, R8' is OH, Y is H, R is H, Z is H, X is OH, NH2 or NHOH, W is 0, R3 and R1A are H, and/or R4 is OH or 0-P(0)R6R7.
91. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (E) or (El) to a patient in need of treatment or prevention thereof:
R RlA
base R2 -*-1.---R314. ____________________________________ R3 Formula E
Base R
Formula El or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, It', IVA, R2, R3, and le are as defined in Formula A, R3 is 0 or CH2, R31 is 0 or S, R3" is 0 when R3 is S, and R32 and R" are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
R RlA
base R2 -*-1.---R314. ____________________________________ R3 Formula E
Base R
Formula El or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, It', IVA, R2, R3, and le are as defined in Formula A, R3 is 0 or CH2, R31 is 0 or S, R3" is 0 when R3 is S, and R32 and R" are independently H, F, C1-C3 alkyl, C2-C3 alkene, or C2-C3 alkyne.
92. The method of Claim 91, wherein R3 is 0, R31 is 0, R32 and R33 are, independently, H or F, R3 is H, R2 is N3 or substituted or unsubstituted C2-8 alkynyl, It' and R1A are H, R4 is OH or 0-P(0)R6R7, and/or X1 is N.
93. A method for treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection, comprising administering a treatment or preventative amount of a compound of Formula (F) or (F1) to a patient in need of treatment or prevention thereof:
R
base Formula F
RiA
Base R3 ____________________________________ Formula F 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, RI-, RiA, R2, lc ¨ 3, and R4 are as defined in Formula A, R34 is 0 or CH2, and R35 and R36 are independently H, F or CH3
R
base Formula F
RiA
Base R3 ____________________________________ Formula F 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Base, RI-, RiA, R2, lc ¨ 3, and R4 are as defined in Formula A, R34 is 0 or CH2, and R35 and R36 are independently H, F or CH3
94. The method of Claim 93, wherein R35 and R36 are H, R34 is Cth, R4 is OH or or 0-P(0)R6R7, R3 is H, R2 is H or substituted or unsubstituted C2-8 alkynyl, and/or RI- and R1A are H.
95. The method of any of Claims 83-94, wherein the compounds can be present in the I3-D or I3-L configuration.
96. The method of any of Claims 83-94, wherein the virus is a Coronavirus.
97. The method of Claim 96, wherein the Coronavirus is SARS-CoV2, MERS, SARS, or OC-43.
98. The method of Claim 97, wherein the Coronavirus is SARS-CoV2.
99. The method of any of Claims 83-94, wherein the compound is co-administered with one or more additional active compounds selected from the group consisting of fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, and agents of distinct or unknown mechanism.
100. The method of Claim 99, wherein the compound is administered with remdesivir, N-hydroxy cytidine, or a pharmaceutically-acceptable salt or prodrug thereof
101. The method of Claim 99, wherein the additional active compound is a JAK
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
102. The method of Claim 99, wherein the one or more additional active agents comprise an anticoagulant or a platelet aggregation inhibitor.
103. The method of Claim 99, wherein the one or more additional active agents comprise an ACE-2 inhibitor, a CYP-450 inhibitor, or NOX inhibitor.
104. The use of a compound of any of Claims 83-94 in the preparation of a medicament for use in treating or preventing a Coronaviridae, Flaviviridae, Picornaviridae, Bunyaviridae, or Togaviridae infection.
105. The use of Claim 104, wherein the infection is a Coronaviridae infection.
106. The use of Claim 105, wherein the Coronavirus is SARS-CoV2, MERS, SARS, or OC-43.
107. The use of Claim 106, wherein the Coronavirus is SARS-CoV2.
108. The use of Claim 104, wherein the medicament further comprises one or more additional active compounds selected from the group consisting of fusion inhibitors, entry inhibitors, protease inhibitors, polymerase inhibitors, antiviral nucleosides, viral entry inhibitors, viral maturation inhibitors, JAK inhibitors, angiotensin-converting enzyme 2 (ACE2) inhibitors, SARS-CoV-specific human monoclonal antibodies, including CR3022, and agents of di stinct or unknown m echani sm .
109. The use of Claim 108, wherein the medicament further comprises remdesivir, N-hydroxy cytidine, or a pharmaceutically-acceptable salt or prodrug thereof
110. The use of Claim 108, wherein the medicament further comprises a JAK
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
inhibitor, and the JAK inhibitor is Jakafi, Tofacitinib, or Baricitinib, or a pharmaceutically-acceptable salt or prodrug thereof
111. The use of Claim 108, wherein the medicament further comprises an anticoagulant or a platelet aggregation inhibitor.
112. The use of Claim 108, wherein the medicament further comprises an ACE-2 inhibitor, a CYP-450 inhibitor, or a NOX inhibitor.
113. The use of Claim 108, wherein the medicament is is a transdermal composition or a nanoparti cul ate composition.
114. The method of any of Claims 1-72 or 83-103, wherein the compound is administered in combination with an NS5A inhibitor.
115. The method of Claim 114, wherein the NS5A inhibitor is daclastavir.
116. The use of any of Claims 73-82 or 104-113, wherein the compound is administered in combination with an NS5A inhibitor.
117. The use of Claim 116, wherein the NS5A inhibitor is daclastavir.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163173354P | 2021-04-09 | 2021-04-09 | |
US63/173,354 | 2021-04-09 | ||
US202163175673P | 2021-04-16 | 2021-04-16 | |
US63/175,673 | 2021-04-16 | ||
US202163210246P | 2021-06-14 | 2021-06-14 | |
US63/210,246 | 2021-06-14 | ||
US202163288163P | 2021-12-10 | 2021-12-10 | |
US63/288,163 | 2021-12-10 | ||
US202263298836P | 2022-01-12 | 2022-01-12 | |
US63/298,836 | 2022-01-12 | ||
PCT/US2022/024289 WO2022217154A2 (en) | 2021-04-09 | 2022-04-11 | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3214904A1 true CA3214904A1 (en) | 2022-10-13 |
Family
ID=83546595
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3214904A Pending CA3214904A1 (en) | 2021-04-09 | 2022-04-11 | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses |
CA3214918A Pending CA3214918A1 (en) | 2021-04-09 | 2022-04-11 | Thionucleosides as antiviral agents |
CA3214726A Pending CA3214726A1 (en) | 2021-04-09 | 2022-04-11 | Nucleosides and nucleotides analogs as antiviral agents |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3214918A Pending CA3214918A1 (en) | 2021-04-09 | 2022-04-11 | Thionucleosides as antiviral agents |
CA3214726A Pending CA3214726A1 (en) | 2021-04-09 | 2022-04-11 | Nucleosides and nucleotides analogs as antiviral agents |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP4319762A2 (en) |
JP (2) | JP2024513571A (en) |
KR (2) | KR20230170015A (en) |
AU (2) | AU2022253068A1 (en) |
BR (2) | BR112023020798A2 (en) |
CA (3) | CA3214904A1 (en) |
IL (2) | IL307478A (en) |
WO (3) | WO2022217155A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021154687A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
US20210393653A1 (en) | 2020-05-29 | 2021-12-23 | Gilead Sciences, Inc. | Remdesivir treatment methods |
BR112022026321A2 (en) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | 1'-CYAN NUCLEOSIDE ANALOGS AND USES THEREOF |
US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE74701B1 (en) * | 1989-10-04 | 1997-07-30 | Univ Birmingham | Further antiviral pyrimidine nucleosides |
US5128458A (en) * | 1990-04-20 | 1992-07-07 | Southern Research Institute | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents |
US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
AU2004274021B2 (en) * | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
AU2006210422B2 (en) * | 2005-02-04 | 2012-09-13 | Takeda Pharmaceutical Company Limited | Inhibitors of E1 activating enzymes |
US20110130440A1 (en) * | 2008-03-26 | 2011-06-02 | Alnylam Pharmaceuticals, Inc. | Non-natural ribonucleotides, and methods of use thereof |
EA201391264A1 (en) * | 2011-04-13 | 2014-03-31 | Джилид Сайэнс, Инк. | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGUES FOR ANTI-VIRUS TREATMENT |
EP3004130B1 (en) * | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
-
2022
- 2022-04-11 EP EP22785599.6A patent/EP4319762A2/en active Pending
- 2022-04-11 AU AU2022253068A patent/AU2022253068A1/en active Pending
- 2022-04-11 JP JP2023562229A patent/JP2024513571A/en active Pending
- 2022-04-11 WO PCT/US2022/024290 patent/WO2022217155A2/en active Application Filing
- 2022-04-11 KR KR1020237038196A patent/KR20230170015A/en unknown
- 2022-04-11 EP EP22785600.2A patent/EP4319763A2/en active Pending
- 2022-04-11 CA CA3214904A patent/CA3214904A1/en active Pending
- 2022-04-11 IL IL307478A patent/IL307478A/en unknown
- 2022-04-11 CA CA3214918A patent/CA3214918A1/en active Pending
- 2022-04-11 WO PCT/US2022/024289 patent/WO2022217154A2/en active Application Filing
- 2022-04-11 JP JP2023561740A patent/JP2024514825A/en active Pending
- 2022-04-11 KR KR1020237038195A patent/KR20240006536A/en unknown
- 2022-04-11 AU AU2022254108A patent/AU2022254108A1/en active Pending
- 2022-04-11 EP EP22785601.0A patent/EP4319764A2/en active Pending
- 2022-04-11 CA CA3214726A patent/CA3214726A1/en active Pending
- 2022-04-11 BR BR112023020798A patent/BR112023020798A2/en unknown
- 2022-04-11 WO PCT/US2022/024286 patent/WO2022217153A2/en active Application Filing
- 2022-04-11 BR BR112023020600A patent/BR112023020600A2/en unknown
- 2022-04-11 IL IL307486A patent/IL307486A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023020600A2 (en) | 2023-12-12 |
EP4319762A2 (en) | 2024-02-14 |
KR20230170015A (en) | 2023-12-18 |
AU2022254108A1 (en) | 2023-10-26 |
IL307486A (en) | 2023-12-01 |
WO2022217155A3 (en) | 2022-11-17 |
BR112023020798A2 (en) | 2023-12-19 |
WO2022217155A2 (en) | 2022-10-13 |
JP2024513571A (en) | 2024-03-26 |
KR20240006536A (en) | 2024-01-15 |
JP2024514825A (en) | 2024-04-03 |
AU2022253068A1 (en) | 2023-10-26 |
WO2022217153A3 (en) | 2022-11-17 |
CA3214726A1 (en) | 2022-10-13 |
EP4319764A2 (en) | 2024-02-14 |
IL307478A (en) | 2023-12-01 |
WO2022217153A2 (en) | 2022-10-13 |
CA3214918A1 (en) | 2022-10-13 |
WO2022217154A3 (en) | 2022-11-17 |
WO2022217154A2 (en) | 2022-10-13 |
EP4319763A2 (en) | 2024-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019133712A1 (en) | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents | |
US11207370B2 (en) | Peptidomimetics for the treatment of coronavirus and picornavirus infections | |
CA3214904A1 (en) | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses | |
AU2016244212B2 (en) | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections | |
CA2751458C (en) | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | |
WO2017165489A1 (en) | Antiviral agents for treating zika and dengue virus infections | |
TW202140042A (en) | Highly active compounds against covid-19 | |
CA2984421C (en) | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
WO2022251663A2 (en) | Novel universal anti-rna virus agents | |
EP3134423A1 (en) | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
JP2022106920A (en) | Alkyne-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
JP2023547599A (en) | Phospholipid compounds and their uses | |
US20200206229A1 (en) | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections | |
CN117769427A (en) | Modified nucleosides and nucleotide analogues as antiviral agents for coronaviruses and other viruses | |
US11963972B2 (en) | Antiviral agents and nucleoside analogs for treatment of Zika virus |